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Nomenclature
In general the nomenclature as adopted by Chemical Abstracts has 
been used in this thesis. At times, particularly in the tables, the alphabetic 
order of substituent has been altered for the sake of clarity or emphasis in 
comparing the various structures e.g. under the heading imidazo- 
[l,2-b]pyridazine the terminology: 6-OPh-3-OMe-2-C6H4Cl-p, has been 
used in describing 2-(4'-chlorophenyl)-3-methoxy-2-phenoxyimidazo- 
[l,2-£]pyridazine. Those imidazo[l,2-&]pyridazines which bear potential 
hydroxyl groups are, for simplicity, usually assigned the oxo structures 
without implying predominance of any one tautomeric form.
iv
Summary
Chemical syntheses, receptor binding studies and structure-activity 
correlations of some imidazo[l,2-&]pyridazines, imidazo[l,2-a]pyridines and imidazo- 
[l,2-a]pyrimidines are reported in this thesis. Some physical properties of these 
compounds are also discussed.
Several new series of 6-substituted 3-alkoxy-2-arylimidazo[l,2-b]- 
pyridazine derivatives have been prepared by condensing the appropriately substituted 
pyridazin-3-amines with arylglyoxals followed by methylation. A novel method of 
preparing some imidazo[l,2-£]pyridazin-3(5//)-one derivatives from substituted 
pyridazin-3-amine 2-oxides and bromoacetyl compounds was also used in the 
preparation of some 3-alkoxyimidazo[l,2-Z?]pyridazines.
General synthetic methods for the preparation of some 2,6-disubstituted 3- 
acylaminomethylimidazo[l,2-&]pyridazines from 2,6-disubstituted imidazo[l,2-Z?]- 
pyridazines and A-(hydroxymethyl)acylamino compounds are reported. In addition, 
some 6-substituted 2-aryl-3-dimethylaminomethylimidazo[l,2-h]pyridazines were 
prepared from 6-substituted 2-arylimidazo[l,2-&]pyridazines by the Mannich reaction.
The above compounds were subsequently tested for their ability to bind to 
specific benzodiazepine binding sites in rat brain preparations. The results of the binding 
studies for each series of compounds are presented and discussed within each chapter. 
Some of these compounds which exhibit high binding affinity were examined (by others) 
for in vivo pharmacological activities. Some other in vitro binding properties of these 
compounds are also reported.
Most of the imidazo[l,2-Z?]pyridazines prepared in this work exhibited 
binding affinity at benzodiazepine binding sites. The 2-aryl-6-benzylamino(and 
substituted benzylamino)-3-methoxyimidazo[l,2-£]pyridazines were found to have 
relatively higher binding potency than the 2-aryl-6-halogeno(and aryloxy)-3-methoxy- 
imidazo[l,2-6]pyridazines and the 3-acylaminomethyl(and dimethylaminomethyl)- 
imidazo[l,2-Z?]pyridazines.
3-Methoxy-6-(3'-methoxybenylamino)-2-phenylimidazo[l,2-Z?]pyridazine 
prevented pentylenetetrazole(PTZ)-induced tonic convulsions in rats as well as increasing 
punished responding in the conflict paradigm at which no side-effects were observed. In 
a continuous avoidance performance test in monkeys, no impairment was observed at 10 
or 30 mg/kg p.o.. The dose separation between desired effects (anticonflict, 
anticonvulant) and such side effects as motor impairment, relaxation and sedation also 
generally appeared greater for this compound than for diazepam.
3-Methoxy-6-(3'-methoxybenzyloxy)-2-phenylimidazo[l,2-Z?]pyridazine 
exhibited high in vitro binding activity but was weaker than its 6-(3'-methoxybenzyl- 
amino) analogue in preventing PTZ-induced tonic convulsions in rats. However, 2-(4'- 
fluorophenyl)-3-methoxy-6-(3"-methoxybenzylthio)imidazo[l,2-fr]pyridazine showed no 
biological activity in the above tests.
Hansch-type analyses involving electronic, steric and lipophilic effects of 
substituents have also been performed using a multiple regression analysis. The results 
of these studies suggest that substituent effects on binding affinity may be quantified by 
the electronic, hydrophobicity and steric properties of the substituent.
The conformational preferences of a representative member of 3-alkoxy- 
imidazo[l,2-£]pyridazines were examined with the aid of computer graphics. The results 
of these studies are discussed in comparison with Fryer's proposed model for 
benzodiazepine receptor ligands.
The role of a nitrogen substituent in the six-membered ring of the 
diazaindolizine system as well as the relevance of nitrogen position in binding affinity 
was investigated by screening some 3-alkoxy-2-aryl-6-chloro derivatives of 
imidazo[l,2-fl]pyridine and imidazo[l,2-a]pyrimidine for benzodiazepine receptor 
binding. This study and the preparation of these compounds are described in Chapter 
VII.
The aim of this work is to find novel compounds which may have more 
selective pharmacological actions than have the benzodiazepine class of compounds.
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1CHAPTER I INTRODUCTION
I -1  Pharmacology of benzodiazepines and their receptors 
I -1.1 General Introduction 
i History and use
Throughout history anxiety has been recognised as an inherent part of man's 
being, although its functional significance has not yet been fully comprehended. While 
the definition of anxiety may be as varied as the experience itself, anxiety may be thought 
of as an unpleasant emotional state, characterized by apprehension and a disquietude of 
mind.1 However, milder forms of anxiety may have an adaptive importance in that it can 
provide an impetus to action, increase vigilance and alertness, and motivate better 
performances. Pathological or excessive anxiety however may seem life-threatening and 
be strongly disruptive of normal behaviour and hence is clearly undesirable.
Over the last two or three decades two main classes of "tranquillizing" drugs 
have been used to treat anxiety. These are the substituted propanediols (e.g. 
meprobamate and its congeners) and the benzodiazepines. Prior to their discovery and 
use the only drugs (apart from alcohol, opiates and belladonna) that could be used to 
calm anxious and disturbed patients were sedative-hypnotic compounds which had a 
general depressant action e.g. the barbiturates and compounds such as glutethimide, 
methaqualone and chlormethiazole.
The first centrally acting 1,4-benzodiazepine derivative introduced into 
clinical use was chlordiazepoxide2 (trade name, Librium). Three years later, in 1963, a 
more potent analogue, diazepam, was introduced under the trade name, Valium, followed 
by flurazepam ('Dalmane') in 1970. These three drugs and congeners thereof, soon 
became the most frequently prescribed centrally-active drugs, e.g. in 1972 they 
accounted for 49% of all psychotropic drug prescription within the United States.3 
Flurazepam was specifically marketed as a hypnotic and in 1977 accounted for 53% of all 
hypnotics prescribed.4 By 1983, about 35 benzodiazepine drugs were available for 
therapy5(Fig I - 1). They are widely used in clinical practice as anxiolytics and hypnotics 
and also because of their anticonvulsant and muscle-relaxant action.
NHMe
Diazepam Chlordiazepoxide Flurazepam
Me
Flunitrazepam
Me
Ro 5-4864
Clonazepam
Me
Clobazam Midazolam
Fig. I -1 Some commercially available benzodiazepines
3The benzodiazepines have achieved a world-wide use due to their wide 
spectrum of central nervous activity which made them the drug of choice in the 
pharmacotherapy of anxiety and related emotional disorders, in the treatment of sleep 
disorders, in status epilepticus and other convulsive states, as centrally acting muscle 
relaxants, and for premedication and induction agents in anaesthesiology.6 Moreover, 
benzodiazepines have a wide margin between the tranquilizing and hypnotic doses, and 
their effects on the autonomic, respiratory and cardiovascular system .6 A widely 
recognised attribute of the benzodiazepines is their safety in overdose. It has been 
reported that it is almost impossible for a healthy adult to die from an overdose.6 The 
same cannot be said for the barbiturates which were the cause of many accidental or 
deliberate deaths in the era preceeding the introduction of the benzodiazepines.
ii In vivo pharmacology
The behavioural effects and methods of biological testing in animals have 
been reviewed.7"^  As a generality, in animals, the benzodiazepines appear to be potent in 
preventing seizures {e.g. in animals genetically prone to seizures or with chemically- 
induced seizures), possess anxiolytic/anticonflict activity (e.g. measured by operant 
conditioning methods or by various measures of exploratory activity in novel 
environments) at the same or slightly higher doses, and at yet higher dose levels, they 
produce sedation (measured by dose-related decreases in overall motor activity) and 
ataxia.
The benzodiazepines are effective in preventing pentylenetetrazole (PTZ)- 
induced seizures.10' 12 The relative potencies of various benzodiazepines in protecting 
mice against PTZ-induced seizures correlate with their clinical potencies as anxiolytics. 
Hence, the measurement of seizure activity in mice is commonly used in initial screening 
tests for potential antianxiety agents.13 Benzodiazepines appear to antagonize the action 
of many other convulsants14' 17 although they are somewhat less effective against 
convulsions produced by bicuculline and picrotoxin.8
The administration of a benzodiazepine leads to an increase in behavioural 
response for a rewarding stimulus during conditions of punishment.18 Since the
4neuronal mechanisms which mediate this type of suppression are believed to be 
inhibitory, the benzodiazepines have thus been classified as "inhibitors of suppressed 
behaviour".4 Despite the complexities involved in this type of conflict methodology,7 it 
is generally accepted that the pharmacological activity of the benzodiazepines in this 
"assay" represents a close behavioural corollary to their anxiolytic activity in man 4 More 
recently, simple animal models have been utilized, on the basis that increased exploratory 
behaviour in laboratory rodents is an index for the anxiolytic effects of benzodiazepines 
in laboratory rodents.19 In one such assay, it was shown that clonazepam and 
chlordiazepoxide treated mice made more transitions across a partition between the dark 
and light ends of a novel environment chamber than did untreated mice, in a dose- 
dependent manner.
In the initial behavioural studies of benzodiazepines, it was also observed that 
benzodiazepines produce muscle relaxation in laboratory animals.10 In later studies 
Zbinden and Randall reported an apparent relation between the effective doses of 
benzodiazepines as muscle relaxants in animals and the anxiolytic dose in man.20
The benzodiazepines also display a variety of other behavioural effects, but 
their relationship to anxiolytic activity in man is not well established.21 An example is 
the potent anti-aggression effects of the benzodiazepines. Chlordiazepoxide was first 
shown to produce taming effects in spontaneously aggressive rhesus monkeys10 at doses 
below those required to produce overt behavioural effects. Other members of the series 
also displayed similar effects.22
Nonetheless, like all psychotropic drugs, benzodiazepines can produce 
undesirable side effects. Sedation and ataxia arise from their central nervous system 
depressant effects. Recently, there has been significant concern about the potential to 
produce dependence (both psychological and physical).23 Therefore, a current goal of 
antianxiety research is the discovery of new agents which may not have adverse side 
effects and which may have a lower potential for dependence.
Furthermore, tolerance to some of the desired actions of benzodiazepines can 
occur e.g. clobazam is very active in certain drug-resistant epilepsies but the quite rapid 
development of tolerance means this drug can be of only limited use. The development
5of new molecules with similar actions but which do not lead to tolerance would be of 
value.
I -1 .2  Molecular mechanisms of action 
i Interactions with GABA receptors
The first clues to the possible mechanism of action of the benzodiazepines 
were provided by Schmidt, Vogel and Zimmerman.24 They observed that diazepam was 
able to potentiate presynaptic inhibition in the spinal cord, a process later shown to be 
mediated by the inhibitory neuro transmitter, gamma-aminobutyric acid (GABA).25 
These findings led to the proposal that benzodiazepines may produce their 
pharmacological effects primarily by enhancing GABAergic transmission.14»26
It is now widely accepted that most of the neuropharmacological and 
neurochemical actions of the benzodiazepines may be mediated via a primary action on 
GABA transmission,27»28 by enhancing the effects of GABA at at least a subclass of 
GAB A a receptors3. This belief is supported by several findings such as : (a) 
benzodiazepines potentiate the actions of both synaptically released and exogenously 
administered GABA on mammalian neuronal preparations;34-36 (b) radioligand binding 
studies suggest that specific high-affinity binding sites for benzodiazepines exist in the 
mammalian central nervous system (CNS)37»38 and that benzodiazepine binding to these 
sites is selectively enhanced by GABA and GABA-like drugs;39'42 (c) benzodiazepines 
stimulate GABA binding;43 (d) benzodiazepine receptors have been found to be localized 
in GABAergic synapses44 and; (e) purified GABA /  benzodiazepine receptor complexes 
preserve the binding sites for GABA, chloride channel ligands, benzodiazepine agonists 
and antagonists, and the characteristic interactions between these sites.45*47
Benzodiazepine receptors seem to be coupled to both GAB A a receptors and 
to chloride channels in a GABAA-receptor / benzodiazepine-receptor /  chloride ionophore 
complex.48 The nerve cell membrane is normally impermeable to chloride ions but there 
are channels in the membrane which, when open, allow chloride ions to enter, altering
a It has been reported that there are at least two pharmacologically and functionally distinct receptors for 
GABA in the mammalian CNS.29"31 GABAa  receptors (or a subclass thereof) are taken to be 
coupled to a chloride ion channel /  benzodiazepine binding site complex whereas GAB Aß receptors are 
believed to be coupled to an adenyl cyclase system.30’32»33
6the electrical potential across the membrane and making the cell more difficult to excite. 
The probability of chloride channel opening is markedly increased by GABAA-receptor 
occupancy, and in this way GABA acts as an inhibitory neurotransm itter. 
Benzodiazepines by themselves do not open chloride channels and inhibit neurons but 
when GABA is released near a neuron in the presence of a benzodiazepine agonist3 *, it 
produces a greater chloride flux through the membrane than before the benzodiazepine 
site on the complex was activated. Thus a benzodiazepine agonist enhances the transfer 
of GABA-mediated inhibitory signals in the vertebrate CNS. This potentiating effect 
may involve an increase in the frequency of channel openings.49 Haefely et a /.5 
suggested that benzodiazepines could account for the modulation of channel opening by 
increasing the affinity of GABAA-receptors for GABA or by increasing the coupling 
between GABAA-receptor activation and chloride channel opening. However, they were 
uncertain whether all benzodiazepine agonists produced the same frequency of chloride 
channel opening or whether the relative increase in the frequency of chloride channel 
opening represented the intrinsic activity of benzodiazepine receptor ligands.
Other benzodiazepines which have been called 'inverse agonists'b seem to 
exert the opposite effect to that of the agonists, that is, they reduce the ability of GABA to 
influence chloride channel opening50-52 and when administered in vivo have 
proconvulsant and anxiogenic actions. A third group of benzodiazepine-type compounds 
block the action of the first two types of benzodiazepines;53-55 these are the 
benzodiazepine antagonists.0
The discovery of these three prototype of ligands with differing activities 
(agonist, inverse agonist and antagonist) has led to the proposal that benzodiazepine 
binding sites can exist in two spontaneously interconvertible states, one decreasing the 
gain of the GABAA-receptor / chloride channel function, and the other increasing it.5 
While inverse agonists might stabilize the former state, agonists might bind preferentially 
to the second state and stabilize it. Competitive antagonists would show no preference
3 A drug which combines with a receptor to produce a biological response ("positive" efficacy).
b A drug which combines with a receptor to produce a biological response opposite to that produced by 
a conventional agonist.
c A drug which combines with a receptor but does not produce a biological response. An antagonist 
will compete with an agonist for the binding site and thus 'antagonise' its ability to activate the 
receptor.
7for either state. Another proposal is the three-state hypothesis53 which assumes that the 
two states with opposite functions are induced by the respective ligands, while pure 
antagonists would bind to a neutral "inactive” form. However, the latter proposal 
appears unsatisfactory56 to explain the pharmacological profile of the antagonists.57’58
To complete this discussion on the possible mechanism of action of the 
benzodiazepines via GABAergic transmission, the hypothetical "two-state" model of the 
benzodiazepine-receptor / GABA-receptor / chloride channel complex as proposed by 
Haefely et a/.5’28 will be discussed briefly below.
In this hypothetical model of benzodiazepine-receptor / GABA-receptor / 
chloride channel complex, Haefely et al. assumed that the complex is a tetrameric 
glycoprotein consisting of four identical or similar protomers (subunits) (Fig 1-2,  see 
also Section 1.3c). This quaternary structure therefore enables the formation of an ion 
pore which can close or open in response to small conformational changes in the subunit. 
The subunits are proposed to have at least three domains with different functions. One 
domain forms the "anatomy" of the pore which by subtle conformational changes can 
hold the pore in an ion-impermeable or ion-permeable state. This ionophore-forming 
domain of the four subunits also have binding sites for ligands of very different chemical 
classes (e.g. picrotoxinin, barbiturate, convulsants). On each tetramer unit there is also a 
GABA binding domain. When GABA is bound, this GABA domain is proposed to 
undergo a conformational change, which is transmitted intramolecularly to the adjacent 
ionophore and benzodiazepine binding domains, such that the pore is forced or stabilized 
in an open state. Binding of a benzodiazepine agonist is assumed to induce a 
conformational change of its own domain, which is transmitted to the GABA domain, 
resulting in the GABA binding site being shifted to a higher affinity state and/or that the 
transmission of its GABA-induced conformational change to the ionophore domain is 
increased i.e. an enhancement in the efficiency of coupling between GABA-receptor and 
chloride channel.
This model was also extended to account for the possible mechanisms of the 
effects of benzodiazepine antagonist and inverse agonist as well as other agents such as 
barbiturates, picrotoxinin, and GABAA-receptor blockers.5
81 3
Fig I -1  Hypothetical model of the GABA-receptor/benzodiazepine receptor/chloride channel complex 
(above view from outside of the membrane, below section along the membrane axis). The complex is 
thought to be formed by four monomeric peptide units, labelled 1 to 4. These units contain at least three 
domains with different functions: C is the anion channel-forming part, G the GABA-binding domain and 
B the benzodiazepine-binding site. The binding sites for so-called channel agents, G AB A-receptor ligands 
and the three classes of benzodiazepine receptor ligands on the three domains are indicated on monomer 2. 
On monomer 3 is indicated that GABA-receptor activation results in the opening of the anion channel, 
and that agents interacting with the C and B domains can affect allosterically this gating process. On the 
fourth monomer are indicated by arrows the multiple bidirectional interactions between the three 
domains.(This diagram is reproduced by kind permission of Prof. W. Haefely and his publisher Ref 28).
ii Possible GABA-independent actions
In addition to the strong evidence favouring the interaction of 
benzodiazepines with GABA-receptors, there have been some proposals for an 
alternative or additional actions. Thus some of the effects of benzodiazepines may be due 
to an interaction with adenosine systems viz. they can inhibit adenosine uptake in CNS 
tissue59 (Extracellular adenosine released from stimulated neurons has a strong
9depressant effect on neuronal activity). Other actions of benzodiazepines include their 
involvement with phospholipid methylation,60 regulation of Ca2+ transport in nerve 
terminals,61'63 enhancement of Ca2+-mediated K+-conductance increase,64’65 inhibition 
of calmodulin-induced activation of Ca2+ phophodiesterase66 and inhibition of 
mitochondrial uptake of Ca2+ into isolated brain mitochondria.67
I -1.3 Benzodiazepine binding sites
The initial characterization of benzodiazepine binding sites by radioligand 
binding studies using tritiated diazepam37*38 suggested an homogeneous population of 
benzodiazepine receptors in the mammalian CNS. However, subsequent studies68 
indicated that there were at least two subtypes of benzodiazepine binding sites in the 
CNS. In addition, other benzodiazepine binding sites have been described. At least five 
specific binding sites for benzodiazepines are now recognized and have been classified5 
as follows.
(a) Human serum albumin binding site
All benzodiazepines bind to plasma proteins, of which binding to serum 
albumin is the most extensive.69 This binding is reversible and demonstrates 
stereospecificity and selectivity.70 The association rate constant for diazepam is 
reported71 as 9 .5x l05 M '1 min-1 compared with 6 .8x l07 M_1 m in-1 in the CNS.72 
Binding of [14C]diazepam to human serum albumin is saturable and Scatchard analysis 
gives a straight line.71
This binding is significant in a pharmacokinetic sense as it reduces the 
concentration of benzodiazepines in the blood and slows the clearance of the drug from 
the body.
(b) Benzodiazepines binding sites in Schistosomes
Clonazepam and meclonazepam are potent antischistosomal agents73 
(Schistosome disease is a major problem in developing countries). [14C]Meclonazepam 
has been shown to bind specifically to membrane fragments of the dermis of male 
Schistosoma mansoni and to intact schistosomes.74 This binding is saturable and of low
10
affinity, with Kd of 2x1 O'6 M in S. mansoni. Various benzodiazepines displaced 
[14C]meclonazepam, their potency correlating with their antischistosomal activity.74 It 
was during one of the screening programmes for antischistosomal benzodiazepines 
which would not induce sedation in the patient that a potent benzodiazepine antagonist, 
Ro 15-1788 (Fig. 1 -5 )  was discovered.
(c) Neuronal high-affinity binding site(s)
These binding sites appear to be intimately involved in the anxiolytic and 
other central actions of the benzodiazepines. They are defined by high affinity for 
"classical" benzodiazepines (low nanomolar concentrations) and are coupled to GABAa- 
receptors. In addition, specific benzodiazepine antagonists inhibit the binding of agonists 
to these high affinity sites. These sites have been further differentiated into type 1 
(B ZR i) and type 2 (BZR2) sites by ligands (such as triazolopyridazines, several ß- 
carbolines and the trifluoroethylbenzodiazepine, quazepam) which preferentially act on 
B ZR i sites.75-77 There are regional differences in the density of the two receptor 
subtypes. The prevalence of BZRi sites in the rat brain is as shown in Table I - l .78 
However, it has also been reported that the triazolopyridazine, CL 218,872, loses its 
ability to discriminate benzodiazepine receptor subtypes intraregionally when incubations 
are perform ed at physiological tem peratures.79 Therefore, compared to the 
pharmacologically active benzodiazepines, the unique actions of CL 218,872 (anxiolytic 
activity without the sedative-hypnotic properties common to the benzodiazepines) may be 
related to the lower intrinsic activity of this compound (partial agonism).80
Monoclonal antibodies to the benzodiazepine receptors have been produced. 
The studies show that the benzodiazepine receptors consist of a mixture of a -  and ß- 
subunits with molecular weights 50 and 55 K daltons, respectively. Although there was 
no biochemical or histological evidence for a structural heterogeneity of the receptor 
complexes, the regional heterogeneity with respect to photoaffinity labelling with 
[3H]flunitrazepam has been reported.81 It is suggested that all benzodiazepine receptors 
consist of 2 a -  and 2 ß-subunits.81 This apparent similarity in peptide structures of 
benzodiazepine receptors from all brain regions however does not preclude the existence 
of a conformational heterogeneity or variations in other parts of the receptor which may
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determine affinity as well as efficacy of various ligands for the receptors.82 Recent 
biochemical characterization of benzodiazepine receptors has also provided evidence for 
some kind of heterogeneity within species, as well as across species to support a 
working hypothesis of benzodiazepine heterogeneity arising from only small variations in 
the total composition of the benzodiazepine receptor complex.82
Table I - 1 Prevalance of benzodiazepine type 1 receptors (BZRi) in rat brain. 
(From Braestrup and Nielsenref 78)
Brain region
BZRi
(%  of total benzodiazepine receptor population)3
Cerebullum 100 (definition)
Medial cortex 84+2(4)b
Pons 81±3(5)
Occipital cortex 81±1(4)
Thalamus 78,81(2)
Frontal cortex 78±1(6)
Bulbus olfactorius 78(1)
Corpus striatum 62±3(4)
Hippocampus 59±2(5)
Nucleus accumbens 57±2(4)
Hypothalamus 56,59(2)
Forebrain, whole 69±3(3)
a The term BZRj was suggested for a binding site for which the triazolopyridazine CL218,872 and 
some ß-carbolines have higher affinity than for the assumed BZR2; the percentage of BZRi receptors 
was calculated as the proportion of specific binding of [3H]propyl-ß-carboline carboxylate (PrCC) to 
[3H]flunitrazepam (FNM) multiplied by the cerebellar proportion of [3H]FNM to [3H]-PrCC binding, 
b Mean ± S.E.M. of (N) samples investigated in duplicate assays by the original authors.78
(d) The nonneuronal (or peripheral) type benzodiazepine binding site
These binding sites have been found in various peripheral tissues and organs 
(kidney, heart, liver, ileum, platelets and mast cells83»84) but are also present in low 
levels in the brain (probably neuronal on cerebellar Purkinje cells85"87). The ligand 
specificity of these 'peripheral-type' binding sites is quite different from that of the
12
benzodiazepine binding sites which have been characterized in the CNS.37’38 Thus, 
clonazepam and a number of other potent anxiolytic or hypnotic agents which inhibit 
brain [3H]diazepam binding at low concentrations do not inhibit kidney binding even at 
high concentrations.88 On the other hand, Ro 5-4864 (commonly called chlorodiazepam) 
which is essentially inactive as an anxiolytic or anticonvulsant does not inhibit 
[3H]diazepam binding to brain receptors but inhibits kidney [3H]diazepam binding at 
nanomolar concentrations.89’90 It is fortuitous that diazepam, the first ligand used for 
radiolabelling studies, binds with equally high affinity to both central and peripheral sites; 
otherwise, the 'peripheral-type' site may have remained undiscovered for some time.
These nonneuronal benzodiazepine binding sites do not appear to be coupled 
to GABA receptors i.e. GABA is unable to stimulate binding to these sites;91"95 there is 
also no stimulant effect of chloride ions, barbiturates and convulsants.94 These sites 
which appear to be located on the outer membrane of mitochondria are probably not 
involved in the known clinical effects of benzodiazepines. However, it has been 
reported60 that occupancy of kidney-type benzodiazepine binding sites by Ro 5-4864 and 
to a lesser extent by diazepam, increased membrane phospholipid methylation. The latter 
is associated with changes in the fluidity of membrane lipids.
(e) The low-affinity (micromolar) type benzodiazepine binding site
This binding site has a low affinity for benzodiazepines and a ligand 
specificity which is different from both the neuronal high affinity and the peripheral 
binding sites.96 Bowling and DeLorenzo96 also reported that binding at these sites 
occurs after the high-affinity binding sites are already saturated. Saturation of this low 
affinity binding occurred at about 0.3 mM diazepam. The apparent dissociation constant 
(Kd ) of [3H]diazepam from these sites was reported96 to be 4.5 qM as compared with 
Kd of 3.5 nM for the high affinity sites and Kd of near 40 nM for the peripheral 
benzodiazepine binding sites.83
The presence of a single, homogeneous population of these low-affinity type 
sites was also proposed. However, binding at these sites was not significantly enhanced 
by the addition of GABA or muscimol (a GABA agonist).96
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I -1.4 Bezodiazepines and the development of new drugs
Many thousands of benzodiazepine derivatives have been synthesized and 
screened for pharmacological activity with the aim of finding compounds with more 
selective pharmacological activities as well as different pharmacokinetic and 
physicochemical profiles. One of the first non-benzodiazepine structures discovered 
which interacted with the receptors but showed only part of the pharmacological profile 
of classical benzodiazepines was CL218,872 [3-methyl-6(3-trifluoromethylphenyl)- 
l,2,4-triazolo[4,3-&]pyridazine]97'99 (Fig. I - 3). It is active in a range of animal models 
of anxiety but appears to lack muscle relaxation and sedation properties, (see above under 
Section 1.3c). SR 95195, a positional analogue of CL218,872 (Fig. I - 3) is an inverse 
agonist.100
Another series of non-benzodiazepine type compounds were the 2-substituted 
pyrazolo[4,3-c]quinolin-3(5//)-ones namely, CGS 8216, CGS 9895 and CGS 9896101 
(Fig. I - 3). They have different intrinsic activities at benzodiazepine receptors. Thus, 
CGS 8216 is a potent antagonist of diazepam102 (inverse agonist activity has also been 
reported in some animal studies103), CGS 9896 is an antianxiety agent101’104 and CGS 
9895, a partial agonist.101
The discovery of the first ß-carboline derivatives which could interact with 
benzodiazepine receptors,105*106 viz. BCM (methyl ß-carboline-3-carboxylate) and BCE 
(ethyl ß-carboline-3-caboxylate) (Fig. I - 4), also led to the development of a series of 
unique compounds which led to the concept of bidirectional agonism. The bidirectional 
effects of some ß-carbolines on seizure activity have been studied by Jensen and 
Petersen.107 They reported that agonists, ZK 93423 (ethyl 6-benzyloxy-4- 
methoxymethyl-ß-carboline-3-carboxylate) and ZK 91296 (ethyl 5-benzyloxy-4- 
methoxymethyl-ß-carboline-3-carboxylate) enhanced the threshold level for convulsions 
induced by pentylenetetrazole and picrotoxin (similar to the behavioural profile of 
diazepam), while the inverse agonists FG 7142 (N’-methyl-ß-carboline-3-carboxamide), 
ZK 90886 (ethyl 4-ethyl-5-methoxy-ß-carboline-3-carboxylate) and DMCM (methyl 4- 
ethyl-6,7-dimethoxy-ß-carboline-3-carboxylate) decreased the threshold (i.e. were 
proconvulsant agents). The antagonist, ZK 93426 (ethyl 5-isopropoxy-4-methyl-ß-
14
carboline-3-carboxylate) had no effect in these convulsant tests. Moreover, ß-carbolines 
of the agonist type have anxiolytic properties108 whereas ß-carbolines of the inverse 
agonist type have strong anxiogenic properties in humans.109 Other bidirectional effects 
of ß-carbolines were observed in memory tests110 and barbiturate anaesthesia.107 Thus, 
various ß-carboline derivatives range in activity from agonists (ZK 93423) over 
antagonists (ZK 93426) to full inverse agonists (DMCM), as shown in Table 1-2.
The first specific benzodiazepine antagonist, Ro 15-1788 (trade name 
Flumazenil, Fig. 1 - 5 )  was discovered111 in 1981 (see also Section 3b). It is largely 
devoid of any intrinsic activity in most behavioural and electrophysiological experiments 
but specifically blocks all CNS effects of compounds which act through binding at 
benzodiazepine receptors.112-114
The clinical effects of Ro 15-1788 include reversal of sedation, muscle 
relaxation, sleep and even coma which are induced by some benzodiazepine agonists.115' 
117 A congener of this compound, Ro 15-3505 (Fig. 1 - 5 )  showed a higher potency in 
initial human pharmacological studies.118
Fig 1 -3  Structures of triazolo[4,3-Z?]pyridazine and pyrazolo[4,3-c]quinolin-3(5-//)- 
one derivatives that interacted with benzodiazepine receptors
HBCM 
BCE 
FG 7142
R
COOMe
COOEt
CONHMe
MeO COOMe
DMCM
M e o " ^ ^ N ' ^ N
COOEt
H
R1 R2 R3
ZK 91262 CH2OMe H OCH2Ph
ZK 93423 CH2OMe OCH2Ph H
ZK 93426 Me H OPr
ZK 90886 Et H OMe
Fig. 1 -4  ß-Carboline derivatives that interact with benzodiazepine receptors
Ro 15-3505
Fig. 1 -5  Ro 15-1788 and Ro 15-3505, benzodiazepine antagonists.
Table I - 2 Classification of some ß-carbolines
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Name ß-carboline type Efficacy Actions
Agonist ZK93423 High positive 
efficacy
Anticonvulsant, 
anticonflict, ataxia, 
sedative, amnesic
Partial ZK91296 Low positive Anticonvulsant,
agonist efficacy anticonflict, amnesic
Antagonist ZK93426 No efficacy Antagonise effects of 
agonists and inverse 
agonists
Partial inverse FG 7142 Low negative Proconvulsant,
agonist efficacy proconflict,
nootropic
Inverse ß-CCM High negative Convulsant,
agonists DMCM efficacy proconvulsant,
nootropic
Several other compounds with pharmacological profiles related to activation 
of benzodiazepine receptors have been developed in recent years. Some of these have 
been reviewed by Gardner119 and by Haefely et al.,5 and will be mentioned briefly 
below.
Zopiclone, Suriclone and Suproclone (see Fig. I - 6 for structure), are 
Cyclopyrrolone derivatives.120 Their pharmacological profiles show little difference from 
those of classical benzodiazepines. Another compound, RU 43028 (Fig. I - 6) a member 
of a series of 3,6-disubstituted-4-hydroxyquinolines, posseses partial agonist and 
antagonist properties in v/vo.121
Zolpidem (Fig. 1-6)  has been developed recently and is a potential hypnotic 
agent.122 Moreover, it shows preferential affinity for B Z R i.123 Another imidazo- 
[l,2-fl]pyridine derivative, Alpidem (Fig I - 6) is currently undergoing clinical trials.124 
It has been shown that this compound is an anxiolytic agent with significant therapeutic 
action in various types of acute and chronic anxiety and that it may successfully alleviate
oZopiclone
N =
R
Suriclone R = Me 
Suproclone R = COOEt
OH O
MeO
RU 43028 Zolpidem Me Me Me2  
Alpidem Cl Cl Pro2
O
RU 31719
O
RU 32514
MeO
O
RU 32698
Fig 1 - 6  Some chemical structures that are ligands for benzodiazepine receptors
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anxiety without necessarily inducing sedation or reducing psychomotor or cognitive 
performance.124
Other new drugs which have been developed recently include RU 31719, RU 
32698 and RU 32514 (Fig. I - 6). RU 31719 shows nearly all the pharmacological 
properties of a classical benzodiazepine agonist but has reduced muscle relaxant activity. 
RU 32698 however, has the profile of a partial agonist. While RU 32514 appears to be a 
weak partial agonist at benzodiazepine receptors, it has no CNS depressant properties.125
The rapid advances made in the understanding of neurochemical mechanisms 
responsible for the therapeutic actions of the benzodiazepines will greatly assist in the 
development of new CNS drugs. Moreover they help provide new insights into the 
underlying biochemical mechanisms of action of anxiolytics, anticonvulsants, sedatives 
and centrally-acting muscle relaxants.
I -1.5 Structure-activity relationships and models of benzodiazepine receptor ligands
The clinical introduction of 1,4-benzodiazepines also led to subsequent 
attempts to correlate their structural modifications with biological activity.126427 with  
the advent of receptor-binding techniques in the mid-1970's, studies were initiated in an 
attempt to define the common structural features required for affinity to benzodiazepine 
receptors in vitro.111
Preliminary attempts to establish a common three dimensional feature 
between different structures binding to the same receptor were carried out by Crippen.128 
By distance geometry analyses,129 he deduced a binding site model for a subset of 18 
compounds that consisted of 15 site points and 5 adjustable energy parameters. He 
concluded that five atoms of each ligand could occupy corresponding points in the site 
and that this constituted a possible benzodiazepine pharmacophore.
Studies involving the identification of molecular discriminants of receptor 
affinity and activity of a series of 1,4-benzodiazepines was also carried out by using 
theoretical calculations.130» ^  From these studies, Leow and coworkers131 proposed 
that the electron-withdrawing group at C-7, the C-2 carbonyl group and the imine
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nitrogen atom, N-4, were involved in the interaction with three cationic sites on the 
benzodiazepine binding site.
Me
A 1,4-benzodiazepine derivative
Another model, developed by Gilli and coworkers132 was based on a number 
of X-ray structures of 1,4-benzodiazepines. They proposed that the major determinant of 
activity was the electronegativity of the substituent in the 7-position since it affected the 
strength of potential hydrogen bonds formed at N-l with the receptor site.
Codding and Muir133 further extended the above models131»132 to 
benzodiazepine antagonists to account for the spectrum of responses elicited by receptor 
binding.
However, the above correlations have met with very limited predictive
success.134
More convincing evidence for a conformational recognition of the biological 
binding site by 1,4-benzodiazepines was put forward following the determination of the 
absolute stereochemistry of the active conformation of diazepam by using single crystal 
X-ray comparisons135 and by NMR studies.136 Following on these lines and together 
with in vitro binding data obtained from 1,4-benzodiazepine receptor binding 
assays,37»38 Fryer postulated a three-dimensional molecular model for ligands with five 
possible binding regions.137 This representation was derived by superimposition of the 
com pounds111»128 with the aid of computer graphics analysis. However, later 
refinement of the model based on structural correlations of compounds (both 
benzodiazepines and non-benzodiazepines) which have high affinity for CNS 
benzodiazepine binding sites (Fig. I - 7), led to the proposal134’138 that there are only
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two major sites for binding of ligands at the receptor. One involves an aromatic or 
heteroaromatic ring (called the "A" ring) and the second is a spatially related system 
designated as (Fig. I - 8a). Three auxiliary binding sites namely, a second electron 
enriched region (7t2-system), a double bond and an electron withdrawing substituent, 
were regarded as part of this model but it was reported that these sites are not always 
required and are in fact inconsistent in their effects at the benzodiazepine receptor.134 It 
was proposed that if the "A" ring is placed in the xy plane of a set of cartesian 
coordinates with its centre at (0,0,0), then the proton attracting group for active 
compounds always have positive values for x, y and z-coordinates (Fig. I - 8b).
In addition, a relationship between the in vivo activity of a series of 
compounds and their mid "A" to n \ distance was established.134»138 Thus, the 
approximate range of this distance for agonists is from 3Ä to about 6.5Ä; for antagonists 
the range is from about 6.5 Ä to about 7.45 Ä; and for inverse agonists, the distance 
begins at approximately 7.5 Ä. In addition, it was proposed that possible overlaps 
between the three regions may lead to compounds which have either mixed agonist / 
antagonist or mixed antagonist / inverse agonist activity. Fryer et al. gave a few 
examples to support this proposal.134»138 One such example was the pyrazoloquinoline 
compounds which have pharmacological profiles ranging from agonist, to a mixed (or 
partial) agonist, to an antagonist (CGS 9896, 9895, 8216 respectively). It was 
suggested that the activity of compound CGS 9895 could be rationalized on the basis that 
it was capable of binding to the receptor in more than one way (conformation).
In agreement with this model, new compounds have been designed and 
found to be active.139
Diazepam Midazolam Ro 11-6896
Ro 22-8515 Ro 15-1788 Zopiclone
OEt
I
A
C=5 o
* 1
BCE
Fig. 1 -7  Structures of some compounds used by Fryer138 for correlation studies
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Fig. 1 -8  (a) Schematic representation of model for receptor binding (From 
Fryer et a/.134). A 3-dimensional representation of the five binding sites for 
benzodiazepine ligand-receptor interaction which includes "A" ring, two tc- 
systems, a double bond and substituent X, of which only the "A" ring and 
7ti-system are necessary for receptor interaction to occur.
(b) Cartesian coordinates (x, y, z) derived from single crystal X-ray data. 
Distances are measured from the center of the aromatic ring (Ä) to the center 
of the 7Ui-system (in Ä).
Compound X
Coordinates
y z Mid "A" to  7ii (A )
Midazolam 3.38 2.15 0.60 3.85
Diazepam 4.33 2.10 0.99 4.91
Ro 11-6896 4.47 1.94 0.58 4.91
Ro21-8515 5.72 2.07 1.19 6.20
Ro21-9187 6.38 1.39 1.64 6.73
Rol5-8670 6.38 1.39 1.64 6.73
Rol5-8670 6.36 3.44 0.95 7.29
Rol5-1788 6.19 3.64 1.17 7.29
Zopiclone 5.45 2.52 0.36 6.02
CL218,872 5.67 2.13 0.49 6.07
CGS8216 5.98 1.18 0.61 6.12
CCE 6.50 3.72 0.61 7.51
Average 5.57 2.00 0.90 6.13
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I - 2 Syntheses, reactivities and biological activities of some imidazo[l,2-Z?]- 
pyridazines
1 - 2 . 1  Structure and nomenclature
Imidazo[l,2-&]pyridazine (1,3*2, 4-triazaindene) is a heteroaromatic bicyclic 
system representing a 10 n electron system which consists of a 7t-excessive imidazole 
ring and a 71-deficient pyridazine ring. The orientation of the ring is as shown below ( I . 
1), with the positions numbered according to Chemical Abstracts.
6 X N ----------  3
N 4 
5
I . 1
Imidazo[ 1,2-b]pyridazine
I - 2.2 Syntheses
The first synthesis of compounds belonging to this system was reported by 
Yoneda and coworkers140 in 1964. Since then the chemistry of im idazo[l,2-£]- 
pyridazines has developed rapidly due to theoretical and practical interests. This 
heterocycle is conveniently prepared from suitably substituted pyridazines by completion 
of the five membered ring. The synthesis, and the physical and chemical properties of 
this ring system have been investigated by several research groups with reviews by Tisler 
and Stanovnik141 as well as M aury.142 However, a brief summary of the different 
methods of synthesis including those recently developed will be given in this section.
The parent compound, imidazo[l,2-6]pyridazine (1 .1 ) may be prepared 
in three ways. Armarego143 used 3-methylthiopyridazine (1 .2 )  as starting compound 
and displaced the methylthio group with ethanolamine. Upon treatment with thionyl 
chloride, the 3-(hydroxyethylamino)pyridazine (1 .3 )  cyclized via (1 .4 )  into the 
partially reduced imidazo[l,2-b]pyridazinium chloride (1 .5 ). When oxidized with 
potassium ferricyanide, this afforded the imidazo[l,2-b]pyridazine (1 .6 )  in 5% yield.
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I . 5
NH
CH2
c h 2
Cl
I . 4
The second synthetic approach described by Stanovnik and Tisler144>145 
employed 3-amino-6-chloropyridazine as the starting material. Thus with 
bromacetaldehyde, compound 1 .8  was obtained and when dehalogenated in the presence 
of hydrogen, palladized charcoal and triethylamine, yielded the parent bicycle (1.6) in 
75% yield.
In addition it was shown146 that this ring system can be prepared from 
tetrazolo[l,5-Z?]pyridazines involving valence isomerization. Thus when 6-(2',2'- 
dimethoxyethylaminotetrazolo[l,5-6]pyridazine (1.9) was treated with polyphosphoric 
acid, ring closure to the imidazole occurred with simultaneous opening of the tetrazolo 
ring and formation of an azido group to give 6-azidoimidazo[l,2-£]pyridazine (1 . 10).
25
(MeO)2CHCH2NH
For substituted imidazo[l,2-&]pyridazines, the choice of substituents on the 
pyridazine ring usually depends on the initial substituted 3-aminopyridazine, whereas 
substituents in the imidazole part may be varied with the choice of the appropriate a- 
halogenocarbonyl compound or substituted ethanolamine. In this manner, 3- 
aminopyridazines (1 . 11) and a-halogenoaldehydes such as bromo- 144’147 and chloro- 
acetaldehyde,148d49 gave imidazo[l,2-Z?]pyridazines (1. 12) which were unsubstituted 
in the imidazole ring; and a-haloketones such as phenacyl bromide, 14°d 50-152 
substituted phenacyl bromide, 140,150,153 chloroacetone149’154 ancj. bromoacetone152 
gave those which were unsubstituted in the 3-position (1 . 13); and 3-bromobutan-2- 
one155 gave the 2,3-dimethyl analogues.
I . 14
Condensation of 6-methoxypyridazin-3-amine with ethyl 3-bromopyruvate148 and ethyl 
2-chloroacetoacetate148 gave ethyl 6-methoxyimidazo[l,2-£]pyridazine-2-carboxylate
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and ethyl 6-methoxy-2-methylimidazo[l,2-b]pyridazine-3-carboxylate respectively. The 
bicyclic system can also be formed by employing 1,2-dibromoethane or ethyl 
chloroacetate.156 The reactions with halogeno ketones in most instances were conducted 
in boiling alcohol or 1,2-dialkoxyethane whereas those with halogeno aldehydes were 
carried out at room temperature. In this manner, Yoneda and coworkers,140 starting 
from 6-halogenopyridazin-3-amines (1.11) and substituted phenacyl bromide, prepared 
derivatives of compound type 1 .13 by refluxing the reagents in ethanol.
Though the type of condensations considered above could lead to either 
compound 1 . 17 or 1 . 18 (assuming the formation of C-N bonds exclusively), only 
compound 1 .17 was generally obtained.
I . 15
n h 2
+ x c h 2c o r 2
I . 16
I . 17
I . 18
Hence, it was proposed141 that the more favoured intermediate arises from the attack by a 
ring nitrogen of 1 . 15 on the a-carbon of 1 . 16 rather than attack by the exocyclic 
amino group. This mechanism was substantiated by the isolation of I . 20 in the 
condensation of 3-aminopyridazine 1 .19 and phenacyl bromide.140
r i BrCH2COPh
I . 20
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Stanovnik and Tisler141 also proposed that the initial step of the reaction 
involved the formation of a mixture of N1 and N2-quatemized compounds and only the 
N2-quatemized isomer 1 .20 was then capable of cyclization. This was supported by the 
observation that the yield of the final product was usually not higher than 60%. 
Moreover, the quartemization of some aminopyridazines have been examined by 
others.157»158 Barlin158 reported the reactions of simple monoamino- and diamino- 
pyridazines with iodomethane and showed that in most cases both 1- and 2-methylated 
products were obtained with no evidence of quatemization at the exocyclic nitrogen 
atom.
More recently, Barlin159 and coworkers reported the condensation of 3- 
aminopyridazines (1.21) with pyruvaldehyde dimethyl acetal in methanolic hydrogen 
chloride to give the corresponding 3-methoxy-2-methylimidazo[l,2-£]pyridazines (e . g . I 
. 22). The structure of one such product was established by X-ray analysis159. Again, 
the specificity of the reaction was observed. In the analogous condensations with 
phenylglyoxals160 products formulated as compound type 1 .23 were obtained. These 
were shown to be readily acetylated or alkylated to give the 3-acetoxy160 and 3- 
alkoxy160’161 compounds, respectively.
This diazaindolizine system can also be derived by the intramolecular 
cyclization of pyridazinium dicyanomethylide (1.24) with sodium methoxide.162 In this 
manner, derivatives of 2-cyanoimidazo[l,2-£]pyridazine (1.25) were prepared.162
I . 21
Me
OMe
I . 22
Ph
O
I . 23
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In 1984, Podergajs and coworkers163 reported a new approach for the 
synthesis of 3-acyl derivatives of 1 .1  by treatment of the A^iV-dimethyl-iV'-pyridazinyl 
formamidine (1 .26; R 1=R2=H) and analogous compounds with a-bromoacetyl ketones.
(Me)2NC(OMe)2
N NH2
Nv,
N N =C — N(Me)2
I . 26
Consequently, the C2 and the R2 groups are introduced by the acetal used for the 
preparation of the amidine, while C3 and the CO-R3 groups are contributed by the a- 
bromo ketone used for cyclization.
I - 2.3 Chemical and physical properties
Imidazo[l,2-b]pyridazine represents a stable 10 7t electron system which can 
undergo several transformations. Much work has been done in this area but earlier work 
has been reviewed by Tisler and Stanovnik141 in 1973 and Maury142 in 1977. Hence, 
only a brief summary of the reactivities and physical properties including recent literature 
will be mentioned in this section.
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i Electrophilic reactions
Protonation studies on the parent compound, imidazo[l,2-£>]pyridazine, 
revealed that it is a weak base (pKa 4.4,145 4.57143) and forms stable hydrochloride and 
hydrobromide salts, quaternary salts with iodomethane145’164 and phenacyl halides,165 
and a perchlorate salt.164 The site of protonation and quaternization is at N l ,14^ ’164 as 
concluded from ionization, uv and nmr spectral correlations.
The total and frontier 7t-electron densities for imidazo[l,2-Z?]pyridazines, 
calculated by the simple HMO method164 predicted the position 3 as the most susceptible 
for electrophilic substitutions, whereas positions 6 and 8 should be involved in 
nucleophilic substitutions.
Studies of electrophilic substitutions145 on im idazo[l,2-b]pyridazines 
including halogenation, nitration and sulfonation under mild conditions gave exclusively 
3-substituted products. The susceptibility of the various positions for this type of 
substitution was in v estig a ted 166 by means of chlorination of the nucleus with 
phosphorous pentachloride at elevated temperature. Thus it was established that the 
order of reactivity was; 3>2 and 7>8>6.
In a related reaction, 6-methoxyimidazo[l,2-&]pyridazine and its 2-methyl 
derivative have also been found to undergo Mannich reaction to afford 3-dialkylamino 
derivatives.149’167 However, forcing reaction conditions had to be used in certain cases.
ii Nucleophilic reactions
Nucleophilic attack on halogenoim idazo[l,2-£]pyridazines serves to 
introduce various substituents, namely hydrazino, phenylthio, methoxy and other 
alkoxy, alkylam ino or azido, by the use of hydrazine,144’147’168 sodium 
th io p h e n o la te ,144 sodium  m ethox ide140’152»169 and other a lk o x id e s ,169 
alkylam ines140’151’170 or sodium azide,144’147’151 respectively. These nucleophilic 
substitutions led to the displacement of the halogen at position 6. However, 
attempts144’151 to replace a 6-chloro substituent with an amino or thiol group by direct 
aminolysis or with potassium hydrogen sulphide solution were unsuccessful, as was the 
attempted144 reaction with thiourea.
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Nucleophilic substitutions in perchloroimidazo[l,2-£]pyridazine (1 .28) with 
dimethylamine or sodium methoxide has been reported to take place preferentially at 
position(s) 8, or 6 and 8, respectively.171 The position of nucleophilic substitution rests 
on the n.m.r. spectra of the dehalogenated products 1 .3 0  and 1 .32.
NMe2 OMe
Homolytic phenylation also takes place preferentially at position 8 whereas a lower 
selectivity was reported for position 7 and 3.172
The reduction of this heteroaromatic bicyclic ring with metal hydrides like 
sodium borohydride affords the corresponding 5,6,7,8-tetrahydro derivatives.173’174 
Catalytic reduction in the presence of Pt(>2175 and reduction with sodium and ethanol175 
yielded the same results, in that the six membered ring was reduced.
iii Methylation and methyl group migration
In earlier work,140 methylation of 2-phenylimidazo[l,2-b]pyridazin-6(5//)- 
one was reported to occur at position 5. However, Tisler and coworkers176 repeated the
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experiment and found that the product was a mixture of the corresponding 5-methyl ( I . 
34; 52%) and 6-methoxy (1.35; 40%) derivatives accompanied by a small amount of 
starting material (8%). When 1 .35 was heated at an elevated temperature (240°), 
migration of the methyl group was observed176 whereupon a mixture of three 
compounds was isolated. They were the demethylated compound (1.33) (?), N-methyl 
derivative (1.34) and the anhydro salt (1.36) in the ratio 25 : 61: 14. Therefore, 
migration occurred not only to the neighbouring nitrogen atom (N5), but also to the 
nitrogen in the imidazole ring (Nl).
O N 
H
O N 
I
Me
N .  . Ph
MeO N
I . 35
I . 33 I . 34
Me 
I
I . 35 ------------- - I . 33 + I . 34 +
' O
I . 36
The same workers176 reported that when 6-chloro-l-methyl-2- 
phenylirmdazo[l,2-Z?]pyridazin-4-ium iodide (1.37) was treated with sodium methoxide, 
nucleophilic substitution at position 6 occurred to afford compound 1 .38 whereas a 
similar experiment with aqueous potassium hydroxide resulted in the formation of the 
anhydro salt (I . 39). Upon methylation, this anhydro salt underwent O- and N- 
methylation to give a mixture of the 1,5-dimethyl derivative (1.40) and the 6-methoxy 
compound (1.38), in the ratio 1:5.
By using the deuterated compound (1.41) it was established176 that the 
methyl group migration occurred from the methoxy group. The evidence176 was based 
on n.m.r. spectroscopy which distinguished between the Nl-methyl and N5-methyl 
groups in 1 .40. There was no interchange of methyl groups. It was also reported that
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the migration was most probably intermolecular177 and that the driving force for the OMe 
to NMe rearrangements was the greater stability of the amido structures.17**
The methylation of 2-phenylim idazo[l,2-fr]pyridazin-3(5//)-ones with 
diazomethane has been reported160»161 to yield the corresponding 3-methoxy-2- 
phenylimidazo[ 1,2-Z?]pyridazines only.
Me
I . 37
Me
I
Ph
+ I . 38
I . 40
Me Me
CD3
I . 42
iv Ring formations and transformations
Imidazo[l,2-Z?]pyridazines with appropriate functional groups, such as 
hydrazino ,147»152 alkylidenehydrazino144»152 or benzylidenehydrazino144»152 or 
thiosem icarbazido147»152 attached at position 6 have been shown to cyclize under 
appropriate conditions to afford new polyazaheterocyclic systems179 of the type 1 .43
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and I . 44. An extension of this type of transformation was also reported180 for 
imidazo[l,2-£]pyridazin-8-amine (1.45). The latter when treated with phenacyl bromide 
undergoes a perifusion reaction to give the tetra-aza-acenaphthylene derivative (1.46). 
Moreover, the reaction of 1 .45 with phosgene gave the tetra-azacyclopentidene 
derivative180 (1.47).
I . 44
Ph
I . 46
I . 45
N +
C l  '
I . 47
Despite the well documented fact that the pyridazine part of azolo-pyridazine 
systems is extremely unreactive,141 a facile 1,3-dipolar cycloaddition of 2-diazopropane 
to some 6-substituted imidazo[l,2-6]pyridazines (1.48) across the C7-C8 double bond 
has been observed.181 This produced derivatives of 9//-imidazo[l,2-b]pyrazolo- 
[4,3-d] pyridazine.
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I . 48
a R1 = Cl, R2 = H 
b R1 = Cl, R2 = Ph 
c R1 = OMe, R2 = H
6 N  4
I . 49
I - 2.4 Previous pharmacological and biological studies
In 1965, Nitta and coworkers182 reported pharmacological activities 
associated with some imidazo[l,2-b]pyridazines; this appears to be the first literature 
report of biological activity with this ring system. They disclosed analgesic, sedative and 
antispasmodic activity150’169’182 for compounds of type 1 .50 where R1 and R2 are 
halogeno, alkoxy or hydrogen. In addition, some derivatives (I . 50, R1 is 
dimethylamino, morpholino, piperidino or pyrrolidino; R2 is halogeno, alkoxy or 
hydrogen) were shown to be useful as "inhibitors of central nerves".170
I . 50
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Alm irante and cow orkers153 in 1965 also reported antipyretic and 
hypothermic activity as well as anticonvulsant activity for 6-chloro- and 6-methoxy-2-(p- 
methylsulfonylphenyl)imidazo[l,2-Z?]pyridazine. Several other derivatives of this ring 
system with halogeno or alkoxy at C6, alkyl group at C2 and different Mannich side 
chains at C3 were later prepared by workers149 at Chas Pfizer and Company, in 1969, 
for treatment of hypertension and as potent anti-inflamm atory agents. Other 
groups183*184 have made further variations to substituents in the im idazo[l,2-£]- 
pyridazine ring to elucidate the influence of such groups on analgesic, antipyretic, 
antiulcerogenic183’184 and inflammatory activities.183
More recently (i . e . after the present work commenced), M oran and 
coworkers185 claimed anxiolytic activity in animal models following the administration of 
some 6-(pyrid-3'-yl) or 6-(3'-trifluoromethylphenyl) substituted 2-(or 3-)alkylimidazo- 
[1,2-Z?]pyridazines in amounts ranging from 0.1 mg to 35.0 mg / kg of body weight. In 
1987, Meyer and coworkers186 prepared some imidazopyridazinyl-acrylamides as 
antihypertensives, diuretics and saluretics.
Other biological activities reported for derivatives of this ring system include 
their use as bronchodilators,187 ionotropic agents,188 antithrombotic and cardiovascular 
agents,189 antibiotics,190»191 antibacterial agents,192»193 antimicrobial agents,194»195 
antiprotozoal agents,196-199 herbicides,200'202 pesticides,203»204 and insecticides205 as 
well as their use in the control of foot rot and liver lesions in ruminant animals206 and the 
control of haemorrhagic colitis in swine.207
I - 3 Present work
Chemical syntheses, receptor binding studies and structure-activity 
correlations of some imidazo[l,2-&]pyridazine derivatives have been undertaken in the 
present work. The aim of this work was to find novel compounds which may possibly 
have more selective pharmacological actions in the central nervous system than have the 
benzodiazepine class of compounds. Some physical properties of these compounds were 
studied. Furthermore, conformational preference and substituent effect(s) studies on 
some 3-alkoxyimidazo[l,2-£]pyridazines were also carried out.
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Prior to the commencement of the present work, Davies and coworkers in 
their continued interest in characterizing the interactions of purines with benzodiazepine 
receptors208-210 started a screening programme for novel N -heterocycles which were 
structurally related to the purines. In a collaborative work, Davies and Barlin211 
identified 6-chloro-3-methoxy-2-phenylimidazo[l,2-fr]pyridazine as an inhibitor of 
[3H]diazepam binding37*38 to synaptosomal rat brain preparations. This observation led 
to the preparation of new series of 3-alkoxyimidazo[ 1,2-/?]pyridazine derivatives.161*212
In the present work, several new series of 3-alkoxyimidazo[l,2-ö]pyridazine 
derivatives were prepared by condensing the appropriately substituted pyridazin-3- 
amines with glyoxals followed by methylation. In addition, a novel method of preparing 
some imidazo[l,2-£]pyridazin-3(5//)-one derivatives from substituted pyridazin-3-amine 
2-oxide and bromoacetyl compounds was used in the preparation of some 3- 
alkoxyimidazo[l,2-Z?]pyridazines. These compounds were subsequently tested for their 
ability to bind to specific benzodiazepine binding sites in rat brain preparations. The 
results of these in vitro binding studies were then used to elucidate the structure and 
affinity relationships of these series of compounds. Hansch-type analyses213 involving 
electronic, steric and lipophilic effects of substituents have also been performed using a 
multiple regression analysis. The results of these studies are discussed with respect to 
substituent effects on binding affinity and the possible physical interactions of these 
compounds with benzodiazepine receptors. The conformational preferences of a 
representative member of these compounds were examined with the aid of computer 
graphics.
As an extension of the 3-alkoxyim idazo[l,2-£]pyridazine series, the 
preparation of a new series of 3-acylaminomethyl- and 3-dimethylaminomethyl- 
imidazo[l,2-fr]pyridazines as potential ligands of benzodiazepine receptors was also 
carried out.
The role of a nitrogen substituent in the six-membered ring of the 
diazaindolizine system as well as the relevance of nitrogen position in binding affinity 
were investigated by screening some 3-alkoxy-2-aryl-6-chloro derivatives of 
im idazo[l,2-a]pyrim idine and im idazo[l,2-a]pyridine for benzodiazepine-receptor
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binding. This study and the preparation of these compounds are described in Chapter 
VII.
The compounds prepared in the present work which exhibit high binding 
affinity at benzodiazepine binding sites have undergone some further testing for in vivo 
pharmacological activities by other workers.214 Some work has also been commenced to 
examine the binding properties of these compounds in more detail (Chapter VII - 3).
CHAPTER II
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CHAPTER II Syntheses and binding studies of some 3-alkoxy-2-aryI-6-halogeno- 
imidazo[l,2-Z?]pyridazines
II -1 Introduction
In view of the pharmacological activity in the central nervous system 
observed for some imidazo[l,2-2?]pyridazines (Chapter I - 2.4), and the inhibition of 
[3H]diazepam binding by certain 3-alkoxyimidazo[l,2-2?]pyridazines161 at 
benzodiazepine receptors, it was decided to prepare other derivatives of this heterocyclic 
ring system for evaluation. Preliminary investigation was by way of a systematic study 
of the interactions of this class of compound with benzodiazepine receptors.
In this chapter we report the syntheses of some 6-halogenoimidazo[ 1,2-2?]- 
pyridazines with varying substituents at the 2- and 3-positions. The structures of these 
compounds were readily determined by means of their *H n.m.r. spectra. To establish 
the ionic species present in our biological test system, we determined the ionization 
constant of a representative of this series of compounds viz. 6-fluoro-3-methoxy-2-(4'- 
methylphenyl)imidazo[l,2-2?]pyridazine. The ultraviolet and infrared absorption spectra 
for some of these compounds were also recorded and discussed in comparison with data 
from the literature for closely related compounds; and the mass spectrum of 6-chloro-3- 
methoxy-(4'-methylphenyl)imidazo[l,2-2?]pyridazine (II . 3c) was compared with 
reported fragmentation patterns for other derivatives of the imidazo[ 1,2-Z?]pyridazine 
system.
Binding studies involving the displacement of [3H]diazepam from its specific 
binding sites in rat brain membrane preparations were then undertaken in order to 
determine if there was any interaction by these compounds with benzodiazepine 
receptors. These results are also discussed.
Experimental details for the preparation of the above compounds (which 
include some physical data) and those for the radioligand-receptor binding assay will be 
included at the end of this chapter.
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II - 2 Syntheses
The synthesis of 3-alkoxyimidazo[l,2-fr]pyridazines has been investigated by 
Barlin and coworkers159’160 (see Chapter I - 2.2). They reported the condensation of 3- 
amino-4-methylaminopyridazine with pyruvaldehyde dimethyl acetal in methanolic 
hydrogen chloride under reflux to give 3-methoxy-2-methyl-8-methylamino- 
imidazo[l,2-£]pyridazine in 17% yield.160 Correspondingly, the condensation of 
phenylglyoxal with pyridazin-3-amines was carried out in ethanol in the presence of 
mineral acid. This reaction was performed either by stirring at room temperature over a 
number of days, or at reflux for a few hours, to yield derivatives of 2- 
phenylimidazo[l,2-&]pyridazin-3(5//)-one. These oxo compounds were reported to 
undergo O-alkylation with diazoalkanes to give the alkoxy derivatives in moderate yields.
In the present work the 2-aryl-6-chloro-3-methoxyimidazo[l,2-£]pyridazines 
[ I I . 3(a-j), Scheme I - 1] were prepared from 6-chloropyridazin-3-amine215( I I . 1) by 
condensation with the appropriately substituted glyoxal (R3COCHO) in ethanolic 
hydrochloric acid at reflux to give the intermediate oxo-compounds [ I I . 2(a-j)l, as deep 
red products which are relatively insoluble and unstable to acid and alkali. These 
characteristic properties have also been reported for some closely related compounds.159 
These compounds were therefore usually not purified but instead, they were treated 
directly with diazomethane to give exclusively the 0-methyl derivatives [ I I . 3(a-j)] with 
no evidence of A-methylation. Ethylation of the oxo-compounds with diazoethane 
similarly gave the O-ethyl derivatives. In an analogous methylation with iodomethane 
under slightly basic conditions at room temperature, only O-methylation was observed. 
Although the two ways of methylation gave comparable yields of products, the 
methylation with diazomethane provided a relatively cleaner reaction.
In an analogous manner, starting from 6-fluoropyridazin-3-amine216 ( I I . Ik) 
and 4-nitrophenylglyoxal217 was prepared 6-fluoro-3-methoxy-2-(4'-nitrophenyl) 
imidazo[l,2-Z?]pyridazine ( I I . 3k). The nitro compounds ( I I . 3i, j, k; Scheme II - 2) 
were reduced by iron powder in aqueous hydrochloric to the corresponding amino 
compounds ( I I . 4a, b, c).
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Most of the 3-methoxyimidazo[l,2-£>]pyridazines prepared in this work were 
purified by chromatography and were obtained in moderate yields. They proved difficult 
to recrystallize and yields of recrystallized products were often significantly lower.
The reference compound, 6-chloro-2-phenylimidazo[l,2-b]pyridazine ( I I . 8) 
(see Table II - 3) was prepared from 6-chloropyridazin-3-amine and phenacyl bromide by 
the method of Yoneda and coworkers,140 subsequently developed further by Werbel and 
Zamora,151 and by Almirante and coworkers.153
Scheme II - 1
II . 1 II . 2
II . 3
I I . 1 - II . 3
X = Cl 
R 1
a Me-o
b Me-m
c Me-p
d Me2-(3,4)
e OMe-o
X = Cl 
R1
f OMe-m
g OMe-p
h F-p
i N 02-m
j NOrP
X
k n o 2-/>
Scheme II - 2
n o 2
OMe
II . 3 i X = Cl ; N 02-m 
II . 3j X = C1 ; N 02-p 
I I  . 3 k  X = F ;N 0 2-p
II . 4 a X = Cl ; NH2-m 
II  . 4 b X = Cl ; NH2-p 
II . 4 c X = F ; NH2-p
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II - 3 Physical properties
i Nuclear magnetic resonance spectra
In the *H n.m.r. spectrum of unsubstituted imidazo[l,2-ft]pyridazine,141>145 
the protons attached to the imidazole ring appear as an AB quartet. In 
deuterochloroform, the chemical shifts of these protons were found to be at 5 7.89 and 
7.99 for H 2 and H 3 respectively, with a coupling constant of J23 1.0 Hz. Those on 
the pyridazine moiety appear as an ABX system with long-range coupling across the 
bridgehead atoms. The reported chemical shifts and coupling constants for these protons 
are 5 9.30 (H 6), 7.00 (H 7), 7.95 (H 8), J6,7 4.5, J7,8 10.0, J6,g 2.0 and J3>8 0.8 Hz.
In contrast, the 2,3,6-trisubstituted imidazo[l,2-£]pyridazines prepared in the 
present work show relatively simple AH n.m.r. spectra (Table II - 1). Those of the 3- 
methoxyimidazo[l,2-&]pyridazine derivatives (II. 3 and 4) revealed a signal due to the 
protons of the methoxy group as a sharp singlet in the region 8 3.95-4.24. Progressive 
downfield shifts were observed in this signal with increased electron-withdrawing power 
of the substituent on the 2-phenyl ring (see Table II - 1). This is probably due to 
conjugation across the C 2 and C 3 bond and consequent deshielding of the methoxy 
group.
The protons attached to the pyridazine ring appear as an AB quartet, with 
proton H 8 more deshielded than H 7. The chemical shifts of the protons H 7 and H 8 
occur in the range 8 6.74-7.05 and 8 7.67-7.96, respectively. This is consistent with the 
results reported by Barlin^l for some closely related compounds. In the 6-fluoro- 
compounds (II . 3k and I I . 4c), coupling of the fluorine atom to H 8 is observed. 
Hence, the resonance signal due to H 8 appears as a doublet of doublets, with coupling 
constants of Jh ,f 7 Hz and J7>8 9 Hz.
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Table II -1 :  Some n.m.r. spectral data (5)a for 6-haIogeno-3-methoxy- 
imidazo[l^-^]pyridazines
5
R 1 R2 3-OMe H 7 H 8
Cl Meb 4.09 6.90 7.67
Cl C6H4Me-o 3.95 6.97 7.81
Cl CftHaMe-m 4.15 6.97 7.81
Cl CöHaMe-p 4.16 6.99 7.82
Cl C6H3Me2-(3 ',4 ') 4.14 6.95 7.78
Cl Cf^IfyOMe-o 4.06 6.96 7.82
Cl CöIfyOMe-m 4.16 6.99 7.81
Cl CöFLiOMe-p 4.14 6.97 7.81
Cl C6H4F -p 4.15 6.98 7.79
Cl C6H4NO2-/71 4.24 7.03 7.84
Cl C6H4NO2 -p 4.23 7.05 7.85
Cl C6H4NH 2-m 4.15 6.96 7.79
Cl C6H4NH2 -p 4.12 6.94 7.79
F C6H4NO2 -p 4.22 6.87 7.96
F C6H4NH2-/? 4.10 6.74 7.88
a Reported as parts per million (8) downfield from tetramethylsilane (T.M .S.) as internal standard in
deutrochloroform (CDCI3). 
b Prepared as in reference 140.
The 13C n.m.r. spectrum of 6-chloro-3-methoxy-2-methylimidazo[l,2-Z?]- 
pyridazine, a simple derivative of this series of compounds, was recorded and compared 
with that of the unsubstituted imidazo[l,2-&]pyridazine system218»219 (Table II - 2). The 
assignments of the carbon-13 chemical shifts for this compound were carried out by 
running a fully coupled 13C n.m.r. spectrum and 2-D heteronuclear correlated spectrum. 
The latter was used to determine the C-H connectivities present in the molecule.
Table II - 2 : The chemical shifts (5) of the carbon atoms in 6-chIoro-3- 
methoxy-2-methylimidazo[l,2-£]pyridazine and the parent
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compound.ref218
V »
2
X 6 N 4 
5
3 ^ R 2
X R1 R2 C 2 C 3 C 6 C l C 8 C 8a R1 R2
H H Ha 133.5 116.7 143.8 117.3 125.5 138.4 - -
Cl Me OMeb 129.3 138.9 130.5 116.4 126.9 145.7 12.63 61.32
a Relative to TMS : in DMSO-dö 
b Relative to DMSO : in DMSO-d6
The chemical shift of C 2 in 6-chloro-3-methoxy-2-methylimidazo[l,2-£]- 
pyridazine shows that it is slightly more shielded than in the unsubstituted parent 
compound. This is consistent with substitution by a methyl group on C 2. However, a 
downfield shift is observed for C 3 which suggests the presence of inductive and /or 
conjugative effects. The chemical shifts for C 7 and C 8 of the two compounds remained 
very similar to each other. In addition, a single peak at 5 61.32 also suggests that there is 
no O to N  methyl group migration. The resonance signal due to the carbon of methoxy 
groups in a variety of heterocycles has been reported220 to occur in the range 5 53.20 to 
61.87 while those from the N-methyl groups occur in the range from 34.29 to 49.62.
ii Ionization constants, ultraviolet spectra and infrared spectra
The ionization constant (pKa) of 6-fluoro-3-methoxy-2-(4'-methylphenyl)- 
imidazo[l,2-b]pyridazine, a representative of the 3-alkoxy-2-aryl-6-halogenoimidazo- 
[l,2-&]pyridazines, was determined to be 2.53±0.06. The values for the other 
compounds of this series were not examined because of their relative insolubility in 
aqueous media. 6-Fluoro-3-methoxy-2-(4'-methylphenyl)imidazo[l,2-&]-pyridazine by
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comparison, is a weaker base than the unsubstituted imidazo[l,2-Z?]-pyridazine (pKa 
4.4,145 4.57143; protonation occurs at N 1143,164^ T h is is compatible with the presence 
of a fluoro substituent at position 6 which is electron-withdrawing and lowers the basic 
strength of this molecule relative to the parent compound. The chloro analogue would 
have a comparable pKa value. (The pKa values of 2-chloro- and 3-chloro-pyridine are 
0.49 and 2.84; 2-fluoro- and 3-fluoro-pyridine have very similar pKa values of 0.44 and 
2.97, respectively221).
The ultraviolet spectrum of 2-(4'-aminophenyl)-6-chloro-3-methoxyimidazo- 
[1,2-Z?]pyridazine (II . 4b) was measured at pH 7.0. At this pH it is assumed to be the 
neutral molecule (The pKa of aniline221 is ca. 4.6) and the spectrum consisted of two 
main absorption bands at ca. 267 nm (log e 4.26) and 393 nm (log e 4.16) with a point 
of inflexion at 307nm (log e 3.73). These absorption maxima are at longer wavelengths 
than in the unsubstituted parent compound143 and the bathochromic shifts are due to 
conjugation with the 2-(4'-aminophenyl) substituent.
The infrared spectrum of the crude 6-chloro-2-(4'-methylphenyl)- 
imidazo[l,2-b]pyridazin-3(5H)-one (II . 2c) displayed a strong carbonyl absorption at 
1650 cm-1; the methoxy derivative (II . 3c) showed no such absorption. This is 
consistent with the reported O-methylation of similar compounds.160
iii Mass spectra
Mass spectra of 2-substituted and 2-unsubstituted imidazo[l,2-&]pyridazines 
have been reported.222 In the 2-unsubstituted imidazo[l,2-b]pyridazines, the major 
cleavage involves loss of HCN from the five membered ring and the fragmentation 
pattem is depicted in Scheme II - 3. In the 2-substituted imidazo[l,2-&]-pyridazines, the 
major cleavage involves the loss of RiCN from the six membered ring as shown in 
Scheme II - 4.
In the present work, the mass spectrum of 6-chloro-3-methoxy-2-(4'- 
methylphenyl)imidazo[l,2-Z?]pyridazine (II. 3c) was recorded . The spectrum shows the 
molecular ion peak associated with an M+2 peak with relative intensities of the lines in 
the ratio 3:1. This is characteristic of ions from chlorine containing compounds and is
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engendered by the 35C1 and 37C1 isotopes.223a The spectrum also shows two closely 
associated strong peaks at m/z 230 and 232, and two relatively weak peaks at m/z 258 
and 260, with broad metastable peaks centered at ca. mh 244 and 205. Hence, it can be 
concluded that the molecular ion m/z 273 decomposed by a loss of 15 mass units to the 
daughter ion m/z 258 which further decomposed with a loss of 28 mass units to give the 
subsequent daughter ion 230, as shown in Scheme II - 5. Correspondingly the M+2 
peak decomposes in an analogous manner.
High resolution mass measurement on the ion m/z 230 gave a measured mass 
of 230.0485. The best fit composition was Ci2H935ClN3 with a calculated mass of 
230.0485. This datum confirms the expected composition of the ion m/z 230 as well as 
establishing its origin i.e. it arises from the loss of C2H3O from the molecular ion, most 
likely via the two step loss of CH3* and CO as shown in Scheme II - 5.
In addition, the presence of a peak at m/z 117 (M-CH3C6H4CN) in the mass 
spectrum of this compound is consistent with a 2- rather than a 3-(4'-methylphenyl) 
derivative. A similar observation has been reported160 for 2-phenylimidazo[l,2-Z?]- 
pyridazine-3(5H)-one.
Scheme II - 3 Fragmentations typical of the 5-membered ring( R2 = H)
Scheme II - 4 Fragmentations typical of the 6-membered rings ( R2 * H)
Scheme II - 5 The m ajor fragmentation in 6-chloro-3-methoxy- 
2-(4 -m e th y lp h en y l)im id azo [l,2 -& ]p y rid az in e
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mH 273 , 275
CH3 ‘ *1 m etastable ions (258)2/ 273 = 243.8 
(260)2/ 275 = 245.8
m/z 258 , 260
-CO *2 *2 m etastable ions (230)2/ 258 = 205.0 
(232)2/ 260 = 207.0
C 12H 9N3C1 
m/z 230 ,2 32
II - 4 7« vz/ro binding studies
There is a number of benzodiazepine radioligands available for labelling 
benzodiazepine receptors.78 The characteristics of [3H]flunitrazepam, [3H]diazepam and 
[3H]clonazepam binding to central nervous system receptors are essentially similar and 
permit them to be used interchangeably for in vitro binding studies in the mammalian 
central nervous system. In the present work, [3H]diazepam was used in the preliminary 
screen. Because this ligand also binds to the peripheral-type benzodiazepine receptor 
(e.g. with kidney membrane preparations) it can also be used to detect compounds with 
activity at peripheral-type benzodiazepine binding sites.
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H - 4.1 Biochemical characteristics of [3H]diazepam binding
[3H] Diazepam binds to synaptosomal preparations from rat brain membranes 
with high affinity. The dissociation equilibrium constant for [3H] diazepam at 0° is ca. 
3.2 nM72 (dissociation equilibitgfyn constant Kd = affinity constant = binding constant) 
whereas the association and dissociation rate constants are 6.8 x 107 M' 1 min' 1 and 0.16 
min'1, respectively.72 This specific [3H]diazepam binding to brain membranes has been 
shown to be saturable,37»38 indicating the presence of a limited number of binding sites.
Möhler and Okada224 reported that in the binding assay, equilibrium 
between the specific binding sites and [3H]diazepam was reached within fifteen minutes. 
This binding also displayed a linear dependency on protein (up to 3.0 mg protein using a 
crude extract) with a sharp pH-optimum between pH 7.0 to pH 7.4. Specific binding 
was found to be temperature dependent with the highest amount bound at 40.224 When 
the data from this binding assay were plotted according to the Hill equation, linear plots 
were obtained38»225 which suggested an homogeneous population of non-interactive 
sites. However, later work by Lippa and coworkers68»99»226 showed evidence of at least 
two pharmacologically, biochemically and functionally distinct types of receptors. They 
used a novel series of triazolopyridazines (TPZ) to identify these distinct receptor 
subtypes (and designated the high affinity sites as Type 1 receptors and the low affinity 
sites as Type 2 receptors). The later observation indicates that [3H]diazepam binding 
does not distinguish between these two sub-populations of benzodiazepine binding sites. 
However, [3H]diazepam binding has been found to be stereospecific.37»135
The in vitro binding of the radiolabel (as described above) has also been 
observed to undergo displacement by unlabelled drugs in competitive binding 
studies.37»38»227 A detailed study was carried out by Braestrup and Squires227 who 
were trying to further characterize these binding sites. They reported that "classical" 
benzodiazepines as well as "triazolo" benzodiazepines, "imidazol" benzodiazepine and 2- 
carbamoylmethylene-benzodiazepine displaced [3H]diazepam binding at low 
concentrations (Ki = 1 to 60 nM). More significantly, they observed a good correlation 
between [3H]diazepam displacement potency (Ki values) and ED50 values in several 
pharmacological tests which are predictive of anxiolytic and anticonvulsant activity in
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man. This correlation was also reported by others.37 Today it is known that a number 
of non-benzodiazepine drugs which have a similar spectrum of pharmacological activities 
as the benzodiazepines can compete for these sites (see Chapter I - 1).
Thus, the use of [3H]diazepam and an appropriate brain membrane 
preparation provides a simple and efficient in vitro binding assay to assess the affinity of 
compounds for benzodiazepine receptors. Accordingly this radioligand-receptor-binding 
assay is used in the present work for the examination of structure-activity relationships of 
a series of new compounds for this receptor system. The advantage of using this in vitro 
test system over an in vivo assay (e.g. anticonvulsant action in rodents) is that it provides 
a rapid and efficient testing routine without complications arising from differences in 
drug adsorption and metabolism. Furthermore, only sub-milligram quantities of 
compounds are required cf. larger amounts needed for whole-animal testing. This is an 
important consideration when the synthesis of difficult analogues for structure-activity 
relationship studies is con"templated. Thus this methodology represents an efficient way 
to direct further synthesis and drug design as well as in determining the 
pharmacologically active part of the compounds under study.
II - 4.2 Results of in vitro testing
The 6-halogenoimidazo[l,2-Z?]pyridazines prepared in the present work were 
tested in the competitive [3H]diazepam binding assay.3 The details of this biological test 
is outlined in the Experimental Section II - 5.3. Results are given in Table II - 3 as IC50 
values (the concentration of drug that resulted in 50% displacement of specific 
[3H]diazepam binding in the standard assay) or the percentage displacement at a specified 
concentration. IC50 values are related to Ki app (apparent inhibition constant) where Ki 
app = IC50/(l+C/Kd), where C = concn of [^HJdiazepam (0.7±0.05nM) and Kd = 
apparent dissociation constant of [3 H] diazepam/benzodiazepine receptor complex 
(3.5±0.1nM). Therefore IC50 values assess the affinity of the test compounds for 
benzodiazepine receptors. Unlabelled diazepam was used as a control. For further
a The assays were carried out in collaboration with Dr. L.P. Davies of the Australian National 
University, Research School of Biological Sciences, Canberra, A.C.T. 2601.
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comparison, some data by other workers are also included in Table II - 3, with 
appropriate footnotes.
Table II - 3 : Results of displacement of [3H]diazepam from rat brain membrane
by some substituted imidazo[l,2-Z>]pyridazines
6 ^
N  4 
5
2
3
Formula
number
Compounds and 
substituents
IC50
(nM)a
Displacement (%) at 
concn specified
n . / Imidazo[ 1,2-b]pyridazine
5 6-Cl-3-OMe-2-Phb 772
6 6-Cl-3-OEt-2-Phb 508
7 6Cl-7-Me-3-OMe-2-Phb 23.8% at 1000 nM
8 6-Cl-3-H-2-Ph c
9 6-H-3-OMe-2-Phb c
10 6-Cl-3-OMe-2-Me c
3a 6-Cl-3-OMe-2-C6H4Me-ö 8.9% at 1000 nM
3b 6-Cl-3-OMe-2-C6H4Me-m 1284
3c 6-Cl-3-OMe-2-C6H4Me-p 148
3d 6-Cl-3-OMe-2-C6H3Me2-(3,,4') 813
31 6-Cl-3-OEt-2-C6H4Me-p 83% at 1000 nM
3e 6-Cl-3-0 Me-2-C6H40Me-ö 14.2% at 1000 nM
3f 6-Cl-3-0 Me-2-C6H40Me-m 960
3g 6-Cl-3-0 Me-2-C6H40Me-/? 267
11 6-Cl-3-OMe-2-C6H4Cl-pb 207
12 6-Cl-3-OMe-2-C6H4Br-pb 264
3h 6-Cl-3-OMe-2-C6H4F-/? 462
3i 6-Cl-3-0Me-2-C6H4N02-w 616
3j 6-Cl-3-0Me-2-C6H4N02-p 1116
4a 6-Cl-3-OMe-2-C6H4NH2-m 609
4b 6-Cl-3-OMe-2-C6H4NH2-p 403
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Table II - 3 Continued
Formula
number
Compounds and 
substituents
IC50
(nM)a
Displacement (%) at 
concn specified
I I ./ Imidazo [ 1,2-b] pyridazine
13 6-F-3-OMe-2-Phb 320
3k 6-F-3-OMe-2-C6H4N02-p 148
4c 6-F-3-OMe-2-C6H4NH2-/? 363
14 6-Br-3-OMe-2-Phb 3168
Phthalazine
15 6-Cl-3-OMe-2-Phb d
Diazepam 4.2
a IC50 values (nM) in the presence of 100 jiM y-aminobutyric acid (see Experimental Section for details), 
b Personal communication from Dr G.B. Barlin and Dr L.P. Davies. 
c Not significant at 1000 nM 
d Not significant at 10000 nM
II - 4.3 Discussion of results
The results of the in vitro competitive binding studies revealed that the 
compounds 6-chloro-2-phenylimidazo[l,2-b]pyridazine (II . 8), 3-methoxy-2-phenyl- 
imidazo[l,2-ö]pyridazine (I I . 9) and 6-chloro-3-methoxy-2-methylimidazo[l,2-Z?]- 
pyridazine (II . 10) did not show any significant inhibition of [3H]diazepam binding to 
synaptosomal rat brain membrane preparations at a concentration of 1000 nM. 
Compound II . 5 (IC50 772 nM) the 2-phenyl analogue of (II . 10) however 
demonstrated moderate binding affinity for the benzodiazepine receptors and this affinity 
was maintained with the 3-ethoxy analogue (II. 6, IC50 508 nM ). The presence of a 7- 
methyl group as in 6-chloro-3-methoxy-7-methyl-2-phenylimidazo[l,2-fr]pyridazine (II. 
7) or of a 7,8-fused benzene ring as in compound III . 15 resulted in very low or 
negligible binding.
6-Fluoro-3-methoxy-2-phenylimidazo[l,2-£]pyridazine (II . 13) bound 
approximately twice as effectively as its 6-chloro analogue (II. 5) whereas the 6-bromo
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compound (II . 14) was about fourfold weaker in binding than the 6-chloro analogue.
The presence of electron-donating or electron-withdrawing groups in the 2- 
phenyl substituent provided interesting but sometimes conflicting results. In all these 
cases, the affinity for the receptor was maintained, albeit with some quantitative 
differences. A /7-methyl or p-methoxy substituent increased binding potency whereas in 
the ortho position, both substituents decreased binding, and at the meta position, they 
had little effect. The 2-(3',4'-dimethylphenyl) compound (II . 3d) showed lower binding 
affinity than its 2-(4'-methylphenyl) analogue. The electron-withdrawing groups 
generally increased binding affinity. However, the effect of the nitro group was not 
consistent in that there was an increase in activity with 6-fluoro-3-methoxy-2-(4'- 
nitrophenyl)imidazo[l,2-b]pyridazine (II . 3k) but a decrease in displacement activity 
with 6-chloro-3-methoxy-2-(4'-nitrophenyl)imidazo[l,2-b] pyridazine (II . 3j).
The above results may be rationalized in the light of the known structural 
prerequisites for benzodiazepine receptor binding (Fryer,138 see Chapter I - 1.5). On the 
basis of structure-activity studies on a large number of benzodiazepines and non­
benzodiazepines Fryer138 has proposed a model which invokes the necessity, among 
other factors, of an aromatic or heteroaromatic ring which is spatially related to a proton- 
accepting group to assure effective binding of these molecules to the receptor. The 
aromatic ring is probably involved in 7t-7t stacking interactions with the aromatic rings of 
amino acid side chains within the receptor whereas the proton-accepting group may be 
involved in hydrogen bonding with amino acids containing SH, NH2, OH or imidazo 
NH groups within the receptor.
In my work, compound (II . 10), in which the 2-phenyl group of 6-chloro-3- 
methoxy-2-phenylimidazo[l,2-Z?]pyridazine (II . 5) has been replaced by a methyl group, 
the potential n region in the above model has been removed, resulting in no significant 
binding activity. The significance of this phenyl group is further enhanced by the 
observation that substitutions to this phenyl ring resulted in differences in receptor 
affinity without complete removal of binding affinity. The presence of this 7t-region 
(designated as ring "A" in Fryer's model138) however is a necessary but not sufficient 
condition for binding, as shown by the lack of affinities observed for 6-chloro-2-
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phenylimidazo[l,2-Z?]pyridazine (II . 8) and 3-methoxy-2-phenylimidazo[l,2-fr]- 
pyridazine (II . 9) in which no significant binding was observed at a concentration of 
1000 nM.
In conclusion, the derivatives of the imidazo[l,2-ö]pyridazines (prepared in 
this series) that most effectively inhibit the binding of [3H]diazepam in vitro are 6-chloro- 
3-methoxy-2-(4'-methylphenyl)imidazo[l,2-&]pyridazine (II . 3c, IC50 148 nM) and 6- 
fluoro-3-methoxy-2-(4'-nitrophenyl)imidazo[l,2-Z?]pyridazine (II . 3k, IC50 148 nM), 
both of which maintain the 2-phenyl group (7t-region) and alkoxy group at C-3 of the 
ring system with a halogeno group at C-6. This work is further extended with other 
subtituents at C-6 in the following chapters.
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n - 5  Experimental 
n-5.1 General Topics
i) . Melting points (m.p.s) were taken in Pyrex capillaries with an Electrothermal
melting point apparatus and were uncorrected.
ii) . Infrared (ir) spectra were recorded on a Unicam SP 1050 infrared
spectrophotometer as potassium bromide discs. The following abbreviations were 
adopted : b (broad); s (sharp); w (weak). Assignment of the absorptions were 
attempted if appropriate. The 1602 cm-1 and 1495 cm-1 regions of the ir spectra 
were calibrated by the absorption of polystyrene film.
iii) . Ultraviolet (uv) spectra were recorded on a CARY 219 uv-visible
spectrophotometer in aqueous solution at 20-21° and at the specified pH. The 
wavelengths of absorption maxima (k max) and the extinction coefficients (e) were 
checked on a Perkin-Elmer Lamba I uv-visible spectrophotometer. The buffers 
were of constant ionic strength, I = 0.02.228 Data were presented in the following 
order : pH; wavelength of absorption in nm; log e. The absorption on points of 
inflexion was presented in italics.
iv) . Ionization constants were determined spectrophotometrically using the method of
Albert and Seijeant.229
v) . *H n.m.r. spectra were generally recorded at 90 MHz and 30° with a Jeol FX90Q
fourier-transform spectrometer, with tetramethylsilane (in CDCI3, CD3COCD3 or 
CD3SOCD3) as an internal standard (8 0.0 ppm) (In cases where greater peak 
dispersion was required, spectra were also recorded at 200 or 300 MHz on Varian 
XL200E or XL300 spectrometers). Data were presented in the following order : 
chemical shift (ppm) relative to tetramethylsilane; multiplicity; coupling constant (J) 
in Hz; assignment (if appropriate). The following abbreviations were adopted : s 
(singlet); d (doublet); t (triplet); quart (quartet); quint (quintet); m (multiplet); dd 
(doublet of doublets). Exchangable protons were identified by their disappearance 
upon addition of deuterium oxide.
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vi) . 13C n.m.r. spectra were recorded at 300 MHz and 25° on a Varian XL300
instrument. Samples were run in CDCI3 or CD3SOCD3 . Data were presented in 
the following order : chemical shift (ppm) relative to deuterated solvent peak and 
assignments where appropriate.
vii) . Low resolution electron impact mass spectra (EIMS) were recorded at 70 eV. on
either (a) AEI MS-902 or (b) VG-Micromass 7070E double focussing mass 
spectrometers. Data were presented in the following order : m/z value; relative 
intensity as a percentage of the base peak.
High resolution mass spectra (HRMS) were recorded on either (a) or (b) using 
perfluorokerosene as a reference.
viii) . Microanalyses were conducted by the Australian National University Analytical
Services Unit, Canberra. Solids for analysis were dried at 80-100° and 0.1 mm 
Hg for 4 h unless otherwise specified.
ix) . Analytical thin layer chromatography (t.l.c.) was performed on glass plates
precoated with Merck Kieselgel 60 F254 or Merck aluminium oxide 60 F254 neutral 
(type E) of 0.25 mm thickness. Preparative thin layer chromatography was 
performed on glass plate precoated with Merck aluminium oxide 60 F254 (type E) 
of 1.5 mm thickness. Columns for chromatography were packed using Merck 
aluminium oxide 90 active neutral (0.063-0.200 mm, 70-230 mesh ASTM).
x) . Ethereal diazomethane was prepared from nitrosomethylurea or A-methyl-A-
nitroso-4-toluenesulfonamide (Diazald) according to standard procedures and was 
used on the same day. Ethereal diazoethane was prepared from nitrosoethylurea.
xi) . Reaction temperatures refer to external or bath temperatures, unless otherwise
indicated.
xii) . Where full experimental details are not recorded, percentage yields are given in
brackets from the pyridazin-3-amines or the /V-oxides.
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II - 5.2 Synthetic work
The following compounds were prepared by literature procedures: 6-chloro- 
3-methoxy-2-methylimidazo[ 1,2-Z?]pyridazine160, and 6-chloro-2-phenylimidazo[ 1,2-b]- 
pyridazine.140
6-ChIoro-3-methoxy-2-(2'-methyIphenyl)imidazo[l^-Z>]pyridazine (II. 3a)
A mixture of 6-chloropyridazin-3-amine (0.1 g), (2-methylphenyl)glyoxal230 
(0.12 g) (prepared by selenium dioxide oxidation of 2-methylacetophenone, as described 
for acetophenone230 but for 48 h), ethanol (5.0 ml) and concentrated hydrochloric acid 
(0.2 ml) was refluxed for 17 h. The solvent was evaporated under reduced pressure, the 
residue was mixed with water and evaporated, then the residue was suspended in water, 
chilled and the solid filtered off.
This product was added to ethereal diazomethane (from 2.6 g 
nitrosomethylurea) and the mixture was stirred initially in ice and then at 20° overnight. 
The solvent was evaporated and the product subjected to t.l.c. (alumina; chloroform) to 
give as an oil, 6-chloro-3-methoxy-2-(2'-methylphenyl)imidazo[l,2-b] pyridazine (0.07 
g) (Found : C, 61.5; H, 4.6. C14H12CIN3O requires C, 61.4; H, 4.4%). *H n.m.r. 
(CDCI3) :5 2.41, s, Me; 3.95, s, MeO; 6.97, d, J7>8 9 Hz, H 7; 7.81, d, J7,8 9 Hz, H 8; 
7.31-7.60, complex, H 3',4',5’,6'.
6-Chloro-3-methoxy-2-(2'-methoxyphenyl)imidazo[l,2-Z>]pyridazine (II. 3e)
A mixture of 6-chloropyridazin-3-amine (0.2 g), (2-methoxyphenyl)- 
g lyoxal231»232 (0.28 g) (prepared by selenium dioxide oxidation of 2- 
methoxyacetophenone for 48 h by a method similar to that used for phenylglyoxal230), 
ethanol (8 ml) and concentrated hydrochloric acid (0.2 ml) was refluxed for 8 h. The 
solvent was evaporated under reduced pressure, the residue was diluted with water, and 
the red precipitate (0.25 g) was filtered off, washed with water and dried.
Portion (0.15 g) of this product was stirred with ethereal diazomethane (from 
1.3 g nitrosomethylurea) in ice and then at 20° overnight. It was evaporated to dryness 
and the product subjected to t.l.c. (alumina; chloroform) and recrystallised from
57
cyclohexane to give yellow crystals of 6-chloro-3-methoxy-2-(2'-methoxyphenyl) 
imidazo[ 1,2-b]pyridazine (0.07 g), m.p. 147-150° (Found, for sample dried at 40° and 
0.1 mmHg for 6 h : C, 58.3; H, 4.1; N, 14.5. C14H 12CIN3O2 requires C, 58.0; H, 
4.2; N, 14.5%). n.m.r. (CDCI3) :5 3.90, s, 2’-OMe; 4.06, s, 3-OMe; 6.96, d, J7,8 
9 Hz, H 7; 7.82, d, J7,8 9 Hz, H 8 ; 7.03-7.65, complex, H 3', 4’,5’,6 ’.
6-Chloro-3-methoxy-2-(4'-methoxyphenyl)imidazo[l,2-£]pyridazine (II. 3g)
A mixture of 6-chloropyridazin-3-amine (0.2 g), 4-hydroxyphenylglyoxal233 
(0.26 g), ethanol (8.0 ml) and concentrated hydrochloric acid (0.2 ml) was refluxed for 4 
h, and then chilled. The solid (0.20 g) was filtered off and washed sucessively with 
ethanol, water, ethanol and ether.
This solid (0.19 g) was added to excess ethereal diazomethane and stirred in 
ice and then at 20° overnight. The solvent was evaporated and the product subjected to 
t.l.c. (alumina; chloroform) and recrystallised from cyclohexane to give yellow crystals 
of 6-chloro-3-methoxy-2-(4'-methoxyphenyl)imidazo[l,2-fr]pyridazine (0.06 g), m.p. 
145-146°, with ^  n.m.r. identical with the product of methylation of 6-chloro-2-(4'- 
methoxyphenyl)imidazo[l ,2-£]pyridazin-3(5//)-one described previously.161
6-Chloro-3-methoxy-2-(4,-methylphenyl)imidazo[l,2-£]pyridazine (II. 3c)
A mixture of 6-chloropyridazin-3-amine (0.2 g), 4-methylphenyl- 
glyoxal234 (0.23 g), ethanol (5 ml) and concentrated hydrochloric acid (0.2 ml) was 
refluxed for 4 h. After cooling, the red precipitate was filtered off, washed with ethanol, 
water, ether and dried.
(a). This crude product of 6-chloro-2-(4'-methylphenyl)imidazo[l,2-Z?]pyridazin-3(5//)- 
one (0.15 g) [v max (KBr) 3100 (w), 2940 (w), 1650 (s) (C=0), 1600 (s), 820 (s)] was 
stirred with ethereal diazomethane at 0° and then 20° overnight. The solvent was 
evaporated and the product subjected to t.l.c. (alumina; chloroform) and recrystallised 
from light-petroleum (40-60°) to give yellowish green needles of the title compound 
(0.05 g), m.p. 161-164° (Found : C, 61.1; H, 4.3; N, 15.0. C14H 12CIN3O requires C, 
61.4; H,4.4; N, 15.3%). JH n.m.r. (CDCI3) :5 2.43, s, Me; 4.16, s, MeO; 6.99, d,
58
J7,8 9 Hz, H 7; 7.82, d, J7,8 9 Hz, H 8; 7.32, d, 8.05, d, J2’,3* 9 Hz, H 2’,3’,5’,6’. 
Mass spectrum : m/z 275 (M++2) (11%), 273 (M+) (33%), 260 (3%), 258 (9%), 232 
(31%), 230 (100%), 176 (39%), 161 (29%), 117 (18%), 91 (10%), 77 (8%). 
Measured mass on m/z 230 : 230.0485. Calculated mass for C i2H 935C lN 3 is 
230.0485. v max (KBr) 3060 (w), 2980 (w), 1580 (s), 1530 (s), 1220 (s), 980 (s), 
830 (s). kmax (pH 7.0) 267 nm (log 8 4.26), 307 (3.73), 393 (4.16).
(b). The crude 6-chloro-2-(4'-methylphenyl)imidazo[l,2-Z?]pyridazin-3(5//)-one (0.15 
g), iodomethane (0.13 g) and potassium carbonate (0.08 g) in acetone (12.0 ml) was 
stirred at room temperature for 48 h. To the reaction mixture was added water (30 ml) 
and the product extracted with chloroform. The combined organic extract was washed 
with water, dried over sodium sulphate and evaporated to give a dark residue which was 
subjected to t.l.c. (alumina; toluene) to give a product (0.045 g) with *H n.m.r. identical 
with that from (a).
6-Chloro-3-ethoxy-2-(4'-methyIphenylimidazo[l,2-Z>]pyridazine (II. 31)
The crude 6-chloro-2-(4'-methylphenyl)imidazo[l,2-ö]pyridazin-3(5//)-one 
(0.20 g) was treated with ethereal diazoethane at 0°  and then stirred at 20°  overnight. 
The solvent was evaporated and the darkish residue was subjected to column 
chromatography (alumina; chloroform). The crude product was recrystallised twice from 
light petroleum (b.p. 40-60°) (charcoal) to give fine greenish yellow needles of the title 
compound (0.06 g), m.p. 114-115° (Found : C, 62.4; H, 4.9; N, 14.6. C15H14CIN3O 
requires C, 62.6; H,4.9; N, 14.6%). *H n.m.r. (CDCI3) : 5 1.48, t, J 7 Hz, Me; 2.39, 
s, 4'-Me; 4.40, quart, J 7 Hz, CH2; 6.94, d, J7>8 9 Hz, H 7; 7.28, d, 8.04, d, J2\ 3' 9 
Hz, H 2’,3',5’,6 '; 7.78, d, J7>8 9 Hz, H 8.
In a similar manner from 6-chloropyridazin-3-am ine and 3- 
methylphenylglyoxal, 3,4-dimethylphenylglyoxal (prepared by selenium dioxide 
oxidation of 3,4-dimethylacetophenone as for the preparation of phenylglyoxal ), 3-
9^4 9 'yf.
m ethoxyphenylglyoxal, 4-fluorophenylglyoxal (prepared from the fluoro- 
acetophenone) were prepared the compounds listed below.
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6-Chloro-3-methoxy-2-(3'-methyIphenyl)imidazo[l,2-£]pyridazine (II. 3b) as an
oil (30%) [from t.l.c. (alumina; chloroform)] (Found : C, 61.4; H, 4.3; N, 15.4. 
C14H12CIN3O requires C, 61.4; H, 4.4; N, 15.4%). *H n.m.r. (CDCI3) : 6 2.45, s, 
Me; 4.15, s, MeO; 6.97, d, J7,8 9 Hz, H 7; 7.81, d, J7,8 9 Hz, H 8; 7.12-7.98, 
complex, H 2’,4’,5',6’.
6-Chloro-2-(3',4'-dimethylphenyl)-3-methoxyimidazo[l,2-Z>]pyridazine (II. 3d),
(9%), m.p.l43-144° [from light petroleum (b.p. 60-80°) and cyclohexane] (Found, for 
sample dried at 40° and 0.1 mmHg for 6 h : C, 62.7; H, 5.0; N, 14.6. C15H14CIN3O 
requires C, 62.6; H, 4.9 N, 14.6%). *H n.m.r. (CDCI3) : 6 2.32, s, 2.35, s, 2xMe; 
4.14, s, MeO, 6.95, d, J7,8 9 Hz, H 7; 7.78, d, J7,8 9 Hz, H 8; 7.21-7.91, complex, H 
2 ' ,5 ' ,6 '.
This compound was also prepared by stirring the crude 6-chloro-2-(3',4'- 
dimethylphenyl)imidazo[l,2-Z?]pyridazin-3(5//)-one (0.18g), iodomethane (0.14 g, ca. 
0.06 ml) and potassium carbonate (0.09 g) in acetone (12.0 ml) for 16 h at room 
temperature. Evaporation of the solvent gave a dark residue which was subjected to 
column chromatography (alumina; chloroform). The yellow fraction was further 
subjected to t.l.c. (alumina; toluene, developed twice) to give a product (0.03 g) with *H 
n.m.r. identical with that above.
6-ChIoro-3-methoxy-2-(3'-methoxyphenyl)imidazo[l,2-Z>]pyridazine (II. 3f) as fine 
yellow needles (12%), m.p. 111-115° (from cyclohexane) (Found, for sample dried at 
40° and 0.1 mmHg for 5 h : C, 58.5; H, 4.2; N, 14.3. C14H12CIN3O requires C, 58.0; 
H, 4.2 N, 14.5%). *H n.m.r. (CDCI3) : 5 3.91, s, 3'-OMe; 4.16, s, 3-OMe; 6.99, d, 
J7,8 9 Hz, H 7; 7.81, d, J7,8 9 Hz, H 8; 6.91-7.75, complex, H 2',4’,5’,6'.
6-Chloro-2-(4'-fIuorophenyl)-3-methoxyimidazo[l,2-Z>]pyridazine (II . 3h) as
yellowish green crystals (24%), m.p. 180-182° (from cyclohexane) (Found : C, 56.5; 
H, 3.3; N, 15.2. C13H9CIFN3O requires C, 56.2; H, 3.3; N, 15.1%). ! h  n.m.r.
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n.m.r. (CDCI3) : 5 4.15, s, MeO; 6.98 d, J7>8 9 Hz, H 7; 7.06-8.19, complex, H 
2',3',5',6'; 7.79, d, J7,8 9 Hz, H 8
6-ChIoro-3-methoxy-2-(3'-nitrophenyl)imidazo[l,2-Z>]pyridazine (II. 3i)
A mixture of 6-chloropyridazin-3-amine (0.2 g), 3-nitrophenylglyoxal237 
(0.35 g), concentrated hydrochloric acid (0.12 ml) and ethanol (8.0 ml) was refluxed in 
an oil bath at 85° for 8 h. After cooling, the red precipitate (0.28 g) was collected and 
washed with cold water and ether.
This product was stirred with excess ethereal diazomethane initially at 0° and 
then at 20° overnight. The mixture was then evaporated under reduced pressure and the 
product subjected to chromatoghraphy in chloroform over a column of alumina (30 cm) 
and recrystallised from methanol to give the title compound (0.14 g), m.p. 230-232°. 
(Found : C, 51.5; H, 3.0; N, 18.4. C13H9CIN4O3 requires C, 51.2; H, 3.0; N, 
18.4%). iH n.m.r. (CDCI3) : 5 4.24, s, Me; 7.03, d, J7,8 9 Hz, H 7; 7.55-8.99, 
complex, H 2’,4',5',6’; 7.84, d, J7,8 9 Hz, H 8.
6-ChIoro-3-methoxy-2-(4'-nitrophenyl)imidazo[l,2-£]pyridazine (II. 3j) (31%), 
was prepared in a similar manner to its 3'-nitro isomer. It decomposed at 256-258° 
(from methanol) (Found, for sample dried at 75° and 0.2 mmHg for 5 h: C, 51.4; H, 
3.0; N, 18.1. C13H9CIN4O3 requires C, 51.2; H, 3.0 N, 18.4%). *H n.m.r. (CDCI3) : 
5 4.23, s, MeO; 7.05, d, J7,8 9 Hz, H 7; 7.85, d, J7>8 9 Hz, H 8; 8.3, b, H 2',3',5’,6’.
6-FIuoro-3-methoxy-2-(4'-nitrophenyI)imidazo[l,2-Zdpyridazine (II. 3k)
In a similar manner, this compound was prepared from 6-fluoropyridazin-3- 
amine216 (0.68 g) and 4-nitrophenylglyoxal217 (1.2 g). This product was purified by 
column chromatography (alumina; chloroform) and then t.l.c. (alumina; chloroform : 
cyclohexane, 10:3) and recrystallised from ethanol to give fine yellow needles of the title 
compound (0.06 g), m.p. 224-226° (Found : C, 54.1; H, 3.1; N, 19.4. C13H9FN4O3 
requires C, 54.2; H, 3.1; N, 19.4%). *H n.m.r. (CDCI3) : 6 4.22, s, MeO; 6.87, d, 
J7>8 9 Hz, H 7; 7.96, dd, J7>8 9 Hz, Jh ,f 7 Hz, H 8; 8.30, b, H 2’,3’,5',6’.
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2-(3'-Aminophenyl)-6-chIoro-3-rnethoxyimidazo[l,2-Z>]pyridazine (II. 4a)
A solution of 6-chloro-3-methoxy-2-(3'-nitrophenyl)imidazo[l,2-£]- 
pyridazine (0.1 g) in methanol (30 ml) was added dropwise to a rapidly stirred mixture 
of iron powder (0.45 g, freshly washed with dilute acid), methanol (15.0 ml), water (6.0 
ml) and concentrated hydrochloric acid (0.6 ml) at 80-85° and then maintained at that 
temperature for 2 h. The residual solid was filtered off and washed with hot methanol. 
The combined filtrates were evaporated, the residue diluted with water (10.0 ml) and 
adjusted with M sodium hydroxide to pH 6-7. This solution was extracted with 
chloroform and the extract washed with water and dried (Na2S04). After evaporation of 
the solvent the product was subjected to t.l.c. (alumina; ethyl acetate) and recrystallised 
from toluene-cyclohexane to give orange needles of the title compound (0.03 g), m.p. 
167-169° (Found : C, 56.8; H, 4.0; N, 20.3. C13H11CIN4O requires C, 56.8; H, 4.0; 
N, 20.4%). !h  n.m.r. (CDCI3): 8 3.7, b, NH2; 4.15, s, MeO; 6.63-7.59, complex, H 
2',4',5',6’; 6.96, d, J7>8 9 Hz, H 7; 7.79, d, J7>8 9 Hz, H 8.
2-(4,-AminophenyI)-6-chloro-3-methoxyimidazo[l,2-Z>]pyridazine (II. 4b) was
prepared in a similar manner to its 3'-amino isomer from 6-chloro-3-methoxy-2-(4'- 
nitrophenyl)imidazo[l,2-&]pyridazine (0.03 g). The product was purified by t.l.c. 
(alumina; chloroform) and recrystallised from cyclohexane to give fine orange needles of 
the title compound (0.02 g), m.p. 180-182° (Found : C, 56.9; H, 4.0; N, 20.2. 
C13H11CIN4O requires C, 56.8; H, 4.0; N, 20.4%). 1H n.m.r. (CDCI3) : 5 3.3, b, 
NH2; 4.12, s, MeO; 6.78, d, 7.94, d, J2-,3’ 9 Hz, H 2’,3',5’,6’; 6.94, d, J7,g 9 Hz, H 
7; 7.79, d, J7,8 9 Hz, H 8
2-(4'-AminophenyI)-6-fliioro-3-methoxyimidazo[l,2-Z>]pyridazine (II. 4c)
The title compound was prepared in a similar manner from 6-fluoro-3- 
methoxy-2-(4'-nitrophenyl)imidazo[l,2-Z?]pyridazine (0.035 g). The crude product was 
purified by t.l.c. (alumina; chloroform) and recrystallised from cyclohexane-chloroform 
(5:1) to give light green needles of the title compound (0.025 g), m.p. 173-175° (Found 
: C, 60.7; H, 4.4; N, 21.6. C13H11FN4O requires C, 60.5; H, 4.3; N, 21.7%). >H
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n.m.r. (CDCI3) : 5 3.1, b, NH2; 4.10, s, MeO; 6.74, d, J7,8 9 Hz, H 7; 7.88, dd, J7,g 
9 Hz, Jh,f 7 Hz, H 8 ; 6.78, d, J2’,3' 9 Hz, H 2',3',5’,6 '.
Determination of ionization constant of 6-fluoro-3-methoxy-2-(4'-methyIphenyl)- 
imidazo[l,2-Zdpyridazine
Substance: 6-Fluoro-3-methoxy-2-(4'-methylphenyl)imidazo[l ,2-£>]pyridazine,a 
C14H12FN3O; MW 257.26
Concentration : 2.5xl0‘5 M. Recrystallized compound, m.p. 146-148°, was dried at 
20° and 0.2 mmHg overnight and 0.00324 g was dissolved in 1 ml ethanol and made 
up to 10 ml with 0.1 N HC1 and diluted to 100 ml with glass distilled water. This 
stock solution (1.26x1 O' 4 M compound and 0.009 M in HC1) was diluted five-fold 
with relevant buffers.
Analytical wavelength : 356 nm; cells, 1 cm
Buffers : potassium hydrogen phthalate, HC1 buffer (I = 0.1)
Species : Neutral and cationic species 
Temperature : 21°
Result:
pH measured: 2.20 2.23 2.39 2.58 2.75 2.93 3.17
pKa calc. : 2.58 2.54 2.48 2.55 2.57 2.50 2.47
pKa = 2.53 ± 0.06
II - 5.3 [3H]Diazepam binding assay
Young adult Sprague-Dawley rats were decapitated and their brains removed 
and placed on ice. Washed synaptosomal membranes were prepared from the 'P2 ' 
mitochondrial pellet according to a previously published procedure210 and stored frozen 
until use. On the day of assay, membrane preparations15 were thawed, washed once by 
centrifugation and resuspension in ice-cold distilled water, then resuspended in 50 mM 
Tris-HCl buffer, pH 7.4 at 2°. For the receptor binding assay, aliquots of the membrane
a Kindly prepared by Mr S.J. Ireland.
15 The author is grateful to Professor G.A.R. Johnston and coworkers of the Department of 
Pharmacology, University of Sydney, N.S.W., for the provision of membrane preparations.
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suspension (approx. 0.8 mg protein) were incubated with tritiated diazepam (86.6 
Ci/mmol, 0.70 ± 0.05 nM final concentration) in a final volume of 2 ml of 50 mM tris- 
HC1 buffer containing various concentrations of the test compounds and 100 p.M GABA 
(to stimulate the binding of the ligand to the benzodiazepine receptors in the plasma 
membranes). Three to five separate concentrations of test compounds were always used 
in tests on each compound. Assays were conducted on ice for an incubation period of 35 
minutes. Nonspecific binding was determined in separated tubes by the addition of a 
large excess (10 p.M) of unlabelled diazepam. Membranes were collected by filtration 
under vacuum on glass-fibre filters (Whatman GF/B, 2.5 cm) and washed with 12 ml of 
ice-cold buffer. Filters were placed in scintillation vials with 1 ml of water and 8 ml of 
toluene/Triton X-100 scintillation fluid; bound radioactivity was determined using 
conventional techniques.
The im idazo[l,2-fr]pyridazines were routinely tested at 4 different 
concentrations (spaced logarithmically eg. 30, 100, 300 and 1,000 nM) and within each 
experiment all assays were performed in triplicate. For each concentration of test 
compounds, results were calculated as the percent displacement of specific binding, 
where specific binding was taken as the amount of radioactive diazepam bound in control 
tubes (no inhibitor) less the amount bound in the presence of excess unlabelled 
diazepam. IC50 values (the concentration of the drug causing 50% displacement of 
radioactive diazepam bound to the brain membranes, under standard assay conditions) 
were calculated for each test compound using computer-assisted log-logit analysis. 
When the correlation coefficient of the lines of best-fit to log-logit curves was less than 
0.95 for a test compound, the experiment was repeated.
Compounds were initially dissolved in dimethyl sulphoxide (DMSO) to give 
4 mM stock solutions which were then serially diluted with buffer (or DMS O/buffer) and 
immediately added to the assay tubes. DMSO was also added to control and blank tubes 
so that all tubes contained the same final concentration of DMSO (0.25%)
CHAPTER HI
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CHAPTER HI Syntheses and binding studies of some 3-methoxy-6-phenoxy- 
(substituted phenoxy and naphthyloxy)-2-phenyl(and aryl)- 
imidazo[l,2-Z>]pyridazines
III -1  Introduction
In the work reported in this chapter, we have selected a series of derivatives 
and analogues of 3-m ethoxy-6-phenoxy-2-phenylim idazo[l,2-Z?]pyridazine for 
benzodiazepine-receptor binding studies. In particular, we investigated the effect (a) of 
substitution in a phenoxy or of naphthyloxy groups at C-6, and (b) in a series of 6- 
(methoxy- and methylthio-phenoxy) compounds, the effect of substitution in the phenyl 
group at C-2 and its replacement with naphthyl or pyridyl groups.
The preparation of these compounds will be reported and their *H n.m.r. 
spectral data discussed in relation to the structures. Other physical properties will also be 
presented and compared with related compounds reported in the previous chapter.
The results of the receptor-binding studies of these analogues using the 
[3H]diazepam binding assay will then be reported and discussed. Finally the 
experimental detail of the preparation of the series of aryloxy compounds will be 
reported.
HI - 2 Syntheses
in - 2.1 3-Methoxy-6-phenoxy (substituted phenoxy and naphthy!oxy)-2-phenyI- 
imidazo[l,2-£]pyridazines
These compounds were prepared by two routes (shown in Scheme III - 1) 
which are detailed below and required as intermediates the relevant 6-phenoxy 
(substituted phenoxy or naphthyloxy)pyridazin-3-amines or their 2-oxides.
The starting materials for this preparative programme were prepared from 6- 
chloropyridazin-3-amine215 or its 2-oxide238 by nucleophilic displacement of the chloro 
group. Clark and Taft239 of the American Cyanamid company have reported the 
preparation of some 6-substituted pyridazin-3-amines, including 6-phenoxypyridazin-3-
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amine (no details given), by a general method in which 6-chloropyridazin-3-amine and 
the respective sodium alkoxide or phenoxide were heated in a sealed tube, to afford the 
desired products in low yields (15-16%). This low yield may result from the low 
reactivity of the starting material due to the deactivation of the pyridazine ring by the 
electron-donating amino group (one of the most potent electron donors) and hence the 
displacement of the chloro substituent by nucleophilic reagents does not proceed 
readily.240 Nevertheless, the starting materials were prepared by the reaction of 6- 
chloropyridazin-3-amine ( I I I . 1) or its 2-oxide ( I I I . 2) with the appropriate sodium 
phenoxide or naphthyloxide in a sealed reaction tube within the temperature range 1 SO­
HO0 for ca. 16 h. These reactions proceeded to give the required products [ I I I . 3(a-t) 
and I I I . 4(a-b)] in moderate yields (e.g. 36% for 6-phenoxypyridazin-3-amine).
However, it was not possible to prepare 6-(2'- or 4'-aminophenoxy)- 
pyridazin-3-amine by heating 6-chloropyridazin-3-amine with 2- or 4-aminophenol in 
aqueous alkali at a range of temperatures; and 6-(2'-nitrophenoxy)pyridazin-3-amine 
could not be isolated from heating 6-chloropyridazin-3-amine with 2-nitrophenol in 
aqueous alkali at 135° to 170°. Likewise no reaction product was isolated from heating 
6-chloropyridazin-3-amine 2-oxide with either aqueous alkaline o-nitrophenol at 145- 
160° or with aqueous alkaline p-aminophenol at 130°-
The 6-phenoxy- and 6-aryloxy-imidazo[l,2-6]pyridazines required in the 
present work were mostly prepared via route 1 as shown in Scheme III - 1. Thus, 6- 
phenoxypyridazin-3-amine (II I . 3a) was condensed with phenylglyoxal in ethanol with 
hydrochloric acid at reflux, to give 6-phenoxy-2-phenylimidazo[l,2-6]pyridazin-3(5//)- 
one (III . 5a) (not characterized). Methylation of the latter with diazomethane in ether at 
0° and then at 20° overnight gave 3-methoxy-6-phenoxy-2-phenylimidazo[ 1,2-6]- 
pyridazine (III . 6a). In this manner, compounds (H I. 6b-t) were also prepared.
The second synthesis involved the reaction of 6-aryloxypyridazin-3-amine 2- 
oxide [ I I I . 4(a-b)] with phenacyl bromide to give the oxo compounds [ I I I . 5(b and 
r)]. In this case, the condensation probably proceeded by in situ generation of the 
aldehyde function as reported by Deady and Stanborough241 in the synthesis of 2-
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arylimidazo[l,2-fl]pyridin-3-ols. (It is known that 2-picoline 1-oxide will convert 
phenacyl bromide to phenylglyoxal).242
In the present work, we also prepared the required 6-(3'-aminophenoxy)-3- 
methoxy-2-phenylimidazo[l,2-&]pyridazine (III. 7) by reduction of compound (III. 
6r) with iron powder and hydrochloric acid in aqueous methanol.
Ill - 2.2 2-Aryl-3-methoxy-6-(methoxy- and methylthio-phenoxy)-
imidazo[l,2-Z>]pyridazines
The above compounds were prepared by either of two methods as mentioned 
in Section III - 2.1. The first method was generally employed when the required 
glyoxals could be readily obtained by oxidation of the appropriate acetophenones with 
selenium oxide. Accordingly, compounds III. 3b and III. 3j underwent ring closure 
with the substituted glyoxals to give the corresponding oxo compounds [III. 8(a-g)] 
which were readily methylated with diazomethane to afford the 3-methoxyimidazo- 
[1,2-Z?]pyridazines [III . 9(a-g)]. Methylation with iodomethane afforded the same 
products but in lower yields accompanied by more bye-products. Thus, methylation 
with diazomethane was preferred
The second method was used for the preparation of the 2-(trifluoromethyl- 
phenyl) and 2-(pyridyl) derivatives of 3-methoxy-6-(2'-methoxy-phenoxy)- 
imidazo[l,2-Z?]pyridazines [III. ll(a-e)]. The appropriate bromoacetyl compounds were 
prepared in a similar manner to that reported in the literature.243*244 The ring closure 
reaction was simply carried out by heating an ethanolic solution of the bromoacetyl 
compounds with 6-(2'-methoxyphenoxy)pyridazin-3-amine 2-oxide. When bromo- 
acetylpyridine hydrobromides were employed, sodium hydrogen carbonate was also 
added to the reaction mixture. In cases where insufficient base was used, the product, as 
a hydrobromide salt, sometimes separated from the solution. The free base was usually 
isolated by adjusting the pH of the reaction mixture to 7. However these oxo 
compounds [III. 10(a-e)] were not purified for reasons mentioned in Chapter II - 2.2. 
The crude oxo compounds were treated with ethereal diazomethane to afford the desired
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desired products [ I I I . ll(a-e)] which gave satisfactory analyses and *H n.m.r. spectra. 
Most of the final products proved hard to crystallize, hence the yields of recrystallized 
compounds were generally low.
Scheme III - 1
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ID - 3 Physical properties
The JH n.m.r. data of this series of compounds are consistent with the 
results obtained for the 2-aryl-6-chloro-3-methoxyimidazo[l,2-£]pyridazines reported in 
the Chapter II - 3. In deuterochloroform, the signal due to the protons of the methoxy 
group on C-3 of the heterocyclic system appeared as a sharp singlet in the region 5 3.76- 
4.03. However, the methoxy substituents on the 6-phenoxy group are relatively more 
shielded and occur in the range 8 3.74-3.83. (Table III - 1). The protons on C-7 and C- 
8 appeared as an AB quartet with a coupling constant of J7?8 9 Hz. The chemical shift 
for H 7 occurred in the range 5 6.75-6.90 whereas that for H 8 was slightly downfield, 
with a chemical shift of 5 7.77-7.90. These protons appeared more shielded than the 
corresponding protons in imidazo[l,2-&]pyridazine in which the signals due to H 7 and 
H 8 appear at 8 7.00 and 7.95 respectively.145
The aromatic protons of the phenyl substituents on C-2 and C-6 of the 
imidazo[l,2-fr]pyridazine ring usually appeared complex. However, the assignments for 
these protons were readily carried out for para-substituted phenyl compounds. In this 
case, they occurred as a doublet of doublets with a coupling constant of ca.9 Hz. These 
signals were readily distinguished from that of the AB quartet arising from protons H 7 
and H 8 by their intergral ratio. The ^  n.m.r. spectra of these compounds were 
consistent with existing data.
The ionization constant of 3-methoxy-6-phenoxy-2-phenylimidazo[ 1,2-0]- 
pyridazine (III . 6a) was determined spectrophotometrically and found to have a value of 
3.22±0.05. On comparison with 6-fluoro-3-methoxy-2-(4'-methylphenyl)- 
imidazo[l,2-£]pyridazine, it is a slightly stronger base. However, it is a weaker base 
than the unsubstituted imidazo[l,2-Z?]pyridazine (pKa 4.4,145 4.57143).
The ultraviolet absorption spectrum of 3-methoxy-6-(2'-methoxyphenoxy)-2- 
phenylimidazo[l,2-£]pyridazine ( I I I . 6b) (at pH 7.0), had a broad band at ca. 352 nm 
(log e 3.97) whereas that of 2-(4'-aminophenyl)-3-methoxy-6-(2"-methoxyphenoxy) 
imidazo[l,2-£]pyridazine (III . 7) displayed a similar band at 373 nm (log e 4.17).
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Thus, a para-amino substituent shifted the absorption maxima to longer wavelength by 
21 nm.
6-Phenoxy-2-phenylimidazo[l,2-fr]pyridazin-3(5//)-one (III. 5a) and 6-(2'- 
chlorophenoxy)-2-phenylimidazo[l,2-fr]pyridazin-3(5//)-one (III . 51) (as crude 
products) displayed a strong carbonyl absorption peak (1600 cm-1) as well as a broad 
band at ca. 3300 cm-1 in their infrared spectra. The latter band could have arisen due to 
the presence of the hydroxy tautomer of the above oxo compound, especially as the 
methoxy derivatives of these compounds showed no such absorptions.
In the mass spectrum of 3-methoxy-6-phenoxy-2-phenylimidazo[l,2-£]- 
pyridazine (III. 6a), the major cleavage involved the loss of C2H3O from the molecular 
ion. This fragmentation pattern is consistent with that for 6-chloro-3-methoxy-2-(4'- 
methylphenyl)imidazo[l,2-£]pyridazine (IT. 3c).
Table III -1 Some 1H n. m. r. spectral data3 for 2-ary I-3-methoxy-6-
phenoxy-(substituted phenoxy and naphthyloxy)imidazo[l,2-b]- 
pyridazines
R 10  6
2
3^ OMe
R1 R2 OMe (in R1) 3-OMe H 7 H 8
Ph Ph 3.97 6.79 7.83
C6H4M e-a Ph 3.90 6.81 7.85
C^TUMe-m Ph 3.99 6.78 7.83
CöPLtMe-p Ph 3.92 6.80 7.84
CöPLiOMe-o Ph 3.77 3.89 6.83 7.82
CöH^OMe-m Ph 3.80 4.00 6.79 7.85
CöPUOMe-p Ph 3.83 3.96 6.76 7.79
CöHiOEt-o Ph 3.91 6.82 7.80
CöPLjOEt-p Ph 3.97 6.77 7.82
CöPUSMe-ö Ph 3.94 6.86 7.85
CöIEtSMe-p Ph 3.98 6.78 7.83
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Table III -1  Continued
R 1 R 2 O M e (in R 1) 3-OMe H 7 H 8
C6 H4 CI- 0 Ph 3 .90 6.89 7.87
C 6 H 4 Cl-m Ph 3.99 6.81 7 .86
C6 H4 CI-/? Ph 3.98 6.81 7.85
C 6 H 3 C12-(2’,4 ’) Ph 3.93 6.89 7.89
CöH4 C F 3 -m Ph 3 .96 6.87 7 .90
C6H4NM e2-w Ph 4.03 6.75 7 .79
C6 H4 N O 2 -W Ph 3.96 6 . 8 6 7 .90
C 6 H 4 N H 2-m Ph 4.03 6.76 7 .82
C i0 H 7- a b Ph 3.95 6.87 7.87
C loH v-ß  b Ph 3.76 6.87 7 .84
CöFLtOMe-ö CöFUMe-ö 3.77 3.80 6.81 7 .80
CölTtOM e-o CöFLtMe-m 3.78 3 .90 6.81 7.81
CöFLtOMe-ö C6 H4 M  e-p 3.78 3.89 6.81 7 .80
CöFLtOMe-o C 6 H4 F -/7 3.78 3.89 6.82 7.78
CöH^OMe-ö C 6 H 4N O 2 -P 3 .79 3.95 6.90 7.83
CöFLtOMe-o C 6 H4 N H 2 -P 3.78 3.88 6 .76 7.77
CöFLtOMe-o C6H4CF3-m 3.78 3 .90 6 . 8 6 7.81
CöFLiOMe-o C 6 H4 C F 3-/7 3.78 3.92 6 . 8 6 7.81
C ö ^ O M e -ö C 5 H4 N-OC c 3 .74 3 .94 6 .80 7 .80
C6 H4 OM  e-o C5H4N-ßc 3.78 3.91 6.85 7 .80
CöITtOMe-ö C5H4N-yc 3.77 3.92 6.87 7 .80
a Reported as parts per million (8) downfield from tetramethylsilane as internal standard in 
deuterochloroform. 
b Naphthyl. 
c Pyridyl.
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FH - 4 In vitro binding studies
The compounds prepared in this part of the present work were tested in the 
[3H]diazepam binding assay to study their interaction(s) with benzodiazepine receptors. 
The experimental details of this biological testing are as outlined in Chapter II - 5.3.
I ll - 4.1 Results of [3H]diazepam binding assay
The results of these binding studies are given in Table III - 2 as IC50 values 
or percentage displacement at specified concentrations of the test compounds. The 
results will be presented first for compounds with variation of the substituent at the 6- 
position, and then for variations at the 2-position.
Table III - 2 Results of displacement of [3H]diazepam from rat brain membrane by 
some substituted imidazo[l,2-£]pyridazines
’f V )
N  4 
5
2
3
Formula Substituents IC50 Displacement (%) at
number (nM)a concn specified
in . /
6a 6-OPh-3-OMe-2-Ph 1122
6b 6-OC6H4Me-o-3-OMe-2-Ph 716
6c 6-OC6H4Me-m-3-OMe-2-Ph 1490
6d 6-OC6H4Me-p-3-OMe-2-Ph 816
6e 6-0 C6H4 0 Me-ö-3-0 Me-2-Ph 70
6f 6-0 C6H4 0 Me-m-3-0 Me-2-Ph 461
6g 6-OC6Ü4 0 Me-p-3-OMe-2-Ph 988
6h 6-OC6H4 0 Et-o-3-OMe-2-Ph 50
6i 6-0 C6H4 0 Et-p-3-0 Me-2-Ph 20% at 300 nM
6j 6-OC6H4SMe-ö-3-OMe-2-Ph 112
6k 6-OC6H4SMe-p-3-OMe-2-Ph 1140
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Table HI - 2 Continued.
Form ula
num ber
Substituents icso
(nM )a
Displacem ent ( % )  at 
concn specified
III./
61 6-O C6H 4Cl-o-3-OM e-2-Ph 580
6m 6-O C6H 4Cl-w -3-O M e-2-Ph 1400
6n 6-OC6H4Cl-p-3-OM e-2-Ph 4480
60 6-O C 6H 3C l2-(2 ,,4 ,)-3-O M e-2-Ph >2600
6p 6-O C 6H4CF3-m -3-O M e-2-Ph 1450
6q 6-OC6H4NMe2-w-3-OMe-2-Ph 149
6r 6 -0 C 6H 4N 02-m -3-0M e-2-Ph 2200
7 6-O C 6H4NH2-m -3-OM e-2-Ph 1190
6s 6-O C ioH 7b-a-3-O M e-2-Ph >1000
6t 6-O C ioH 7b-ß-3-O M e-2-Ph 523
9a 6-0C6H40Me-ö-3-0Me-2-C6H4Me-ö 1736
9b 6-OC6H40Me-ö-3-OMe-2-C6H4Me-m 150
9c 6-OC6H40Me-ö-3-OMe-2-C6H4Me-p 64
12 6-OC6H40Me-ö-3-OMe-2-C6H4F-o c 7.5%  at 30 nM
13 6-0 C6H4 0 M e-ö-3-0 M e-2-C6H4F-m c 82
9d 6-OC6H40Me-ö-3-OMe-2-C6H4F-/? 30
11a 6-OC6H40Me-ö-3-OMe-2-C6H4CF3-m 46%  at 1000 nM
l ib 6-OC6H4 0 M e-ö-3-O M e-2 -C6H4CF3-p 59% at 1000 nM
9f 6-0 C6H4 0 M e-ö-3-0 M e-2-C6F[4N 0 2 -p 312
9h 6-0C6H40Me-ö-3-0Me-2-C6H4NH2-/? 115
9e 6-OC6H 4 0 M e-o-3-O M e-2-C ioH 7-ß  b 693
11c 6-OC6H4 0 M e-o-3-O M e-2-C5H4N -a  d 13% at 100 nM
lid 6-OC6H4 0 M e-o-3-O M e-2-C5H4N -ß d 136
l ie 6-OC6H4 0 M e-o-3-O M e-2-C5H4N-Y d 14% at 100 nM
9g 6-OC6H4SM e-ö-3-OM e-2-C6H4F-p 81
a IC50 values (nM) are the concentration required to displace 50% of specific [^H]diazepam binding to rat
brain membrane preparation, 
b Naphthyl.
c Kindly prepared by Mr S J . Ireland, 
d Pyridyl.
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III - 4.2 Discussion of results
The inhibition of [3H]diazepam binding to benzodiazepine receptors by 3- 
methoxy-6-phenoxy-2-phenylimidazo[l,2-Z?]pyridazine (III. 6a, IC50 1122 nM) was 
relatively less effective than its 6-chloro analogue (II . 5, IC 50 772 nM). However, a 
naphth-2-yloxy group (see compound III . 6t; IC50 523nM) in place of the 6-phenoxy 
group of compound II I . 6a proved to be beneficial and gave a twofold increase in 
inhibition. In contrast, the naphth-l'-yloxy isomer (III. 6s) was less active (IC50 >1000 
nM).
Substitutions in the phenoxy group at C-6 had a significant effect on the 
relative receptor-binding affinity of this series of compounds. The effect of electron- 
donating substituents, such as alkoxy groups (as in compounds III. 6 e,f,g, and h) was 
to improve this interaction with the receptors whereas electron-withdrawing groups, such 
as chloro or nitro groups, (compounds II I . 6 m,n,o and r) generally had an adverse 
effect.3 Moreover, an ortho-substituent consistently furnished a more effective binding 
(as in compounds III. 6 b,e,h,i and j) than corresponding substituents at meta- and para- 
positions of the phenoxy group.
The observation that substitution at the ortho position of the phenoxy group 
increases binding affinity allows the inference that a steric factor is also involved in the
1
interaction of this phenyl ring with the receptor. This implied importance of the 
orientation or comformation of this moiety of the compound is consistent with another 
observation : that increasing the "steric bulk"b of the substituent at the ortho position 
increases affinity (see Table III - 2; compounds III. 6b, 6e and 6h). As the size of the 
ortho substituent increases, conformational flexibility of the phenyl ring decreases due to 
loss in flexibility of torsional rotation. Thus, the enhanced affinity of the 2-ethoxy 
analogue (III. 6h) appeares to be partly due to its ability to maintain a more favourable 
orientation of the phenoxy group for receptor interaction.
The effect of various substituents at C-2 was then examined. In this case, a 
6-(2'-methoxyphenoxy) group was chosen as the suitable substituent at C-6 because of
a The a-effect at the 0/7/10-position is usually dominated by the steric effect, 
b This descriptor is based on Hansch's MR factor (Ref 245).
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the low IC50 value of compound I I I . 6e (IC50 70 nM) and convenience in handling. 
Isomeric tolyl groups on the 2-positions (compounds I I I . 9 a,b and c with IC50 values 
of 1736, 150 and 64 nM, respectively) showed a similar trend in binding affinity as their 
corresponding 6-chloro analogues (compounds I I . 3a,b and c, IC50 >1000 nM, 1284 
and 148 nM, respectively). In both series, compounds containing the 2-(2'- 
methylphenyl) group exhibited the highest IC50 values and thus the lowest binding 
affinity. However, a 2-(4'-methylphenyl) group was somewhat less activating in 
compound I II . 9c than in the corresponding 6-chloro analogue (II . 3c).
Substitution with a relatively strong electron-donating substituent such as a p- 
amino group (as in compound III . 9h, IC50 115 nM) resulted in less favourable 
interactions with the receptor Accordingly, strong electron-withdrawing groups on the 
2-phenyl group (as in compounds I I I . 9f, 11a and b) were generally not beneficial. 
However, a small substituent with a weak electron-withdrawing ability, such as a fluoro 
group (as in compound I I I . 9d) improved the receptor-ligand interaction to give an IC50 
value of 30 nM.
Replacement of the 2-phenyl group of compound I I I . 6e with a naphth-2’-yl 
group (compound I I I . 9e) decreased the binding affinity by about tenfold. This result 
appears to suggest that if the 2-phenyl group is indeed the k -region necessary for 
benzodiazepine receptor binding (see Fryer's model, Chapter 1 - 1 . 6  and II - 4.3), then 
the hydrophobic pocket on the receptor, which is involved in this ligand-receptor 
interaction would not accommodate as efficiently, a larger n group .
The results of our studies of this series of 6-phenoxy-3-methoxyimidazo[l,2-£]- 
pyridazines demonstrate that the relative affinity for the benzodiazepine-receptor is partly 
altered by both conformational and electronic properties. This observation was further 
investigated by studying the binding affinities of analogous compounds with other 
substituents on C-6 of this ring system (see Chapters IV - VI).
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DI - 5 Experimental
The general procedure and experimental details for the [3H]diazepam binding 
assay are recorded in Chapter II - 5.1 and 5.3
6-Phenoxypyridazin-3-amine (IH. 3a)
6-Chloropyridazin-3-amine215 (1.0 g) and aqueous sodium phenoxide 
(prepared from 0.6 g sodium hydroxide in 15 ml water with 2.0 g phenol) were heated in 
a screw-top Teflon-lined stainless steel bomb at 170° for 16 h. After cooling, the solid 
was filtered off, washed with 1 M sodium hydroxide and water, dried and recrystallised 
from benzene to give 6-phenoxypyridazin-3-amine (0.5 g), m.p. 155-156° (Found : C, 
63.9; H, 4.9; N, 22.1. C10H9N3O requires C, 64.2; H, 4.8; N, 22.4%). *H n.m.r. 
(CD3COCD3) : 5 7.05-7.47, complex, H 4,5 and Ph.
6-(2'-MethyIphenoxy)pyridazin-3-amine (H I. 3b)
6-Chloropyridazin-3-amine (1.0 g) and aqueous sodium 2-methylphenoxide 
(prepared from 0.6 g sodium hydroxide in 15 ml water with 2.1 g 2-methylphenol) were 
heated in a screw-top bomb at 170° for 16 h. After cooling, the oil was extracted into 
chloroform, the extract washed with 1 M sodium hydroxide and water, and the extract 
dried (Na2S0 4 ). The solvent was evaporated and the product (0.4 g) was recrytallised 
from benzene to give 6-(2'-methylphenoxy)pyridazin-3-amine , m.p. 107-110° (Found : 
C, 65.4; H, 5.6; N, 21.0. C11H 11N3O requires C, 65.6; H, 5.5; N, 20.9%). *H n.m.r. 
(CDCI3) : 5 2.20, s, Me; 4.8, b, NH2; 6.73-7.36, complex, H 4,5,3’,4’,5’,6 '.
6-(2,-Methoxyphenoxy)pyridazin-3-amine (H I. 3e)
A mixture of 6-chloropyridazin-3-amine (1.0 g) and a solution of sodium 
hydroxide (0.8 g) and 2-methoxyphenol (2.5 g) in water (15 ml) was heated in a screw- 
top bomb at 160° for 16 h. After cooling the product was extracted into chloroform and 
then finally recrystallised from toluene to give the title compound (0.35 g), m.p. 132- 
135° (Found, for sample dried at 65° and 0.1 mmHg for 16 h: C, 61.0; H, 5.4; N, 19.2.
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C11H11N3O2 requires C, 60.8; H, 5.1; N, 19.3%). n.m.r. (CDCI3) : 5 3.76, s, Me; 
4.7, b, NH2; 6.75-7.26, complex, H 4, 5, 3’, 4’, 5’, 6 '.
In a similar manner from 6-chloropyridazin-3-amine and 3-methylphenol 
(150°), 4-methylphenol (160°), 3-methoxyphenol (160°), 4-methoxyphenol (150°), 2- 
ethoxyphenol (175°), 4-ethoxyphenol (160°), 2-(methylthio)phenol (165°), 4- 
methylthiophenol (165°), 2-chlorophenol (160°), 3-chlorophenol (165°), 4-chlorophenol 
(165°), 2,4-dichlorophenol (160°), 3-trifluoromethylphenol (170°), 3- 
dimethylaminophenol (160°), 1-naphthol (170°), 2-naphthol (170°) and 3-nitrophenol 
(160°) respectively, were prepared the following compounds :
6-(3'-Methylphenoxy)pyridazin-3-amine ( in . 3c) (16%), m.p. 111-113° (from benzene) 
(Found : C, 65.9; H, 5.5; N, 20.9. C11H 11N3O requires C, 65.7; H, 5.5; N, 20.9%).
1H n.m.r. (CDCI3) : 5 2.33, s, Me; 4.7, b, NH2; 6.77-7.36, complex, H 
4 ,5 ,2’,4’,5’,6 ’.
6-(4'-Methylphenoxy)pyridazin-3-amine (III . 3d) (25%), m.p. 165-168° (from 
benzene) (Found : C, 65.8; H, 5.5; N, 21.0. C11H11N3O requires C, 65.7; H, 5.5; N, 
20.9%). !H n.m.r. (CDCI3) : 5 2.32, s, Me; 4.6, b, NH2; 6.70, d, 7.31; d, J4,5 9 Hz, H
4,5; 6.89, d, 7.07, d, J 4 Hz, H 2',3’,5’,6 '.
6-(3'-Methoxyphenoxy)pyridazin-3-amine (III . 3f) (28%), m.p. 82-83° [from light 
petroleum (b.p. 40-60°)] (Found, for a sample dried at 65° and 0.1 mmHg for 16 h: C, 
60.9; H, 5.2; N, 19.2. C n H n N 3 0 2 requires C, 60.8; H, 5.1; N, 19.3%). *H n.m.r. 
(CDCI3) : 5 3.78, s, Me; 4.6, b, NH2; 6.66-7.34, complex, H 4,5,2’,4’,5’,6’.
6-(4’-Methoxyphenoxy)pyridazin-3-amine (III . 3g) (35%), m.p. 160-164° (from 
methanol) (Found : C, 61.0; H, 5.2; N, 19.3. C n H n N 3 0 2 requires C, 60.8; H, 5.1; 
N, 19.3%). lU n.m.r. (CDCI3) : 5 3.80, s, Me; 4.5, b, NH2; 6.80, d, 7.09, d, J4,5 9 
Hz, H 4,5; 6 .88, d, 9.67, d, J 8 Hz, H 2’,3’,5’,6’.
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6-(2’-Ethoxyphenoxy)pyridazin-3-amine (III . 3h) (38%), m.p. 98-100° (from benzene- 
cyclohexane, then toluene) (Found, for a sample dried at 70° and 0.1 mmHg for 5 h: C, 
62.6; H, 5.7; N, 18.2. C12H 13N3O2 requires C, 62.3; H, 5.7; N, 18.2%). *H n.m.r. 
(CD3SOCD3) : 5 1.08, t, J 7 Hz, CH3; 3.94, quart, J 7 Hz, CH2; 6.0, b, NH2; 6.82- 
7.35, complex, H 4,5,3’,4',5',6 '.
6-(4'-Ethoxyphenoxy)pyridazin-3-amine (III . 3i) (19%), m.p. 155-157° (from ethanol- 
ether) (Found, for a sample dried at 70° for 6 h : C, 62.2; H, 5.9; N, 18.1. 
C12H13N3O2 requires C, 62.3; H, 5.7; N, 18.2%). *H n.m.r. (CD3SOCD3) : 5 1.31, t, 
J 7 Hz, CH3 ; 3.99, quart, J 7 Hz, CH2 ; 6.1, b, NH2 ; 6.83-7.11, complex, H 
4,5,2’,3’,5 ',6 .
6-(2'-Methylthiophenoxy)pyridazin-3-amine (III . 3j) (16%), m.p. 124-126° (from 
toluene) (Found, for a sample dried at 40° and 0.1 mmHg for 6 h: C, 56.4; H, 4.6; N,
17.8. C11H11N3OS requires C, 56.6; H, 4.7; N, 18.0%). JH n.m.r. (CDCI3) : 5 2.39, 
s, Me; 4.8, b, NH2 ; 6.82, d, 6.98, d, 14,5 9 Hz, H 4,5; 7.10-7.27, complex, H 
3 ',4 ’,5 ',6 '.
6-(4'-Methylthiophenoxy)pyridazin-3-amine ( I I I . 3k) (21%), m.p. 178-180° (from 
toluene) (Found, for a sample dried at 50° and 0.1 mmHg for 4 h: C, 56.7; H, 4.7; N,
17.9. C11H11N3OS requires C, 56.6; H, 4.7; N, 18.0%). *H n.m.r. (CDCI3) : 5 2.48, 
s, Me; 4.6, b, NH2; 6.83, d, 7.01, d, J4,5 9 Hz, H 4,5; 7.08, d, 7.30, d, J 8 Hz, H 
2 ' ,3 ' ,5 ' ,6 '.
6-(2’-Chlorophenoxy)pyridazin-3-amine (III . 31) (51%), m.p. 134-135° (from toluene) 
(Found : C, 55.0; H, 3.7; N, 19.2. C ioH8C1N30  requires C, 54.2; H, 3.6; N, 19.0%). 
!H n.m.r. (CDCI3) : 5 4.7, b, NH2; 6.90, d, 7.08, d, J4j5 9 Hz, H 4,5; 6.85-7.48, 
complex, H 3',4',5',6 '.
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6-(3'-Chlorophenoxy)pyridazin-3-amine (HI. 3m) (34%), m.p. 143-145° (from toluene) 
(Found : C, 54.5; H, 3.6; N, 19.0. C ioH8C1N30  requires C, 54.2; H, 3.6; N, 19.0%). 
*H n.m.r. (CDCI3) : 5 4.7, b, NH2; 6.88, d, 7.03, d, J4,5 9 Hz, H 4,5; 6.93-7.31, 
complex, H 2’,4',5',6’.
6-(4'-ChIorophenoxy)pyridazin-3-amine (III. 3n) (40%), m.p. 207-209° (from toluene) 
(Found : C, 54.3 H, 3.6; N, 18.7. CioH8C1N30  requires C, 54.2; H, 3.6; N, 19.0%). 
*H n.m.r. (CDC13) : 5 4.6, b, NH2; 6.86, d, 7.01, d, J4,5 9 Hz, H 4,5; 7.10, d, 7.33, 
d, J 9 Hz, H 2’,3’,5',6'.
6-(2',4'-Dichlorophenoxy)pyridazin-3-amine (III . 3o) (56%), m.p. 135-136° (from 
toluene) (Found : C, 47.1; H, 2.7; N, 16.2. Ci0H7Cl2N3O requires C, 46.9; H, 2.8; N, 
16.4%). *H n.m.r. (CDC13) : 5 4.7, b, NH2; 6.88, d, 7.07, d, J4,5 9 Hz, H 4,5; 7.15- 
7.44, complex, H 3',5',6'.
6-(3'-Trifluoromethylphenoxy)pyridazin-3-amine (HI. 3p) (20%), m.p. 120-122° (from 
benzene) (Found, for sample dried at 40° and 0.1 mmHg for 6 h : C, 51.9; H, 3.1; N, 
16.5. Ch H8F3N30  requires C, 51.8; H, 3.2; N, 16.5%). JH n.m.r. (CDC13) : 5 4.6, 
b, NH2; 6.90, d, 7.06, d, J4,5 9 Hz, H 4,5; 7.37-7.57, complex, H 2',4',5',6’.
6-(3’-Dimethylaminophenoxy)pyridazin-3-amine (III. 3q) (11%), m.p. 128-130° (from 
benzene) (Found, for sample dried at 40° and 0.1 mmHg for 6 h : C, 62.7; H, 6.1; N, 
24.1. C i2H i4N40  requires C, 62.6; H, 6.1; N, 24.3%). *H n.m.r. (CDC13) : 5 2.93, 
s, Me2N; 4.6, b, NH2; 6.80, d, 6.97, d, J4j5 9 Hz, H 4,5; 6.37-7.36, complex, H 
2 ',4 ’,5 ',6 ’.
6-(Naphth-l'-yloxy)pyridazin-3-amine (III. 3s) (21%), m.p. 185-187° (from benzene 
or toluene) (Found : C, 70.8; H, 4.6; N, 17.6. Ci4H n N 30  requires C, 70.9; H, 4.7; 
N, 17.7%). *H n.m.r. (CDC13) : 5 4.6, b, NH2; 6.89, d, 7.07, d, J4j5 9 Hz, H 4,5; 
7.31-7.90, complex, H 2',3',4’,5',6',7’,8'.
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6-(Naphth-2’-yloxy)pyridazin-3-amine (III. 3t) (16%), m.p. 183-184° (from benzene or 
toluene) (Found : C, 70.6; H, 4.8; N, 17.5. C14H11N3O requires C, 70.9; H, 4.7; N, 
17.7%). l H n.m.r. (CDCI3) : 5 4.6, b, NH2; 6 .86 , d, 7.05, d, J4,5 9 Hz, H 4,5; 7.18- 
8.07, complex, H 1’,3',4’,5',6 ',7',8’.
6-(3’-Nitrophenoxy)pyridazin-3-amine (III. 3r) (27%), m.p. 161-162° (from toluene) 
(Found : C, 51.7; H, 3.4; N, 24.1. C ioH8N4C>3 requires C, 51.7; H, 3.5; N, 24.1%). 
!H n.m.r. (CD3SOCD3) : 5 6.2, b, NH2; 6.98, d, 7.22, d, J4j5 9 Hz, H 4,5; 7.59-8.08, 
complex, H 2',4',5',6 '.
6-(3'-Nitrophenoxy)pyridazin-3-amine 2-oxide (III. 4b)
6-Chloropyridazin-3-amine 2-oxide238 (1.0 g) and aqueous sodium 3- 
nitrophenoxide (prepared from 0.56 g sodium hydroxide, 1.82 g 3-nitrophenol and 10 
ml water) were heated in a screw top reaction vessel at 155° for 16 h. After cooling the 
mixture was adjusted to pH 12-13, chilled, and the solid (0.6 g) was filtered off and 
washed with water and ether. The product was recrystallised from a mixture of methanol 
and ethanol to give 6-(3'-nitrophenoxy)pyridazin-3-amine 2-oxide, m.p. 230-232° 
(Found : C, 48.4; H, 3.2; N, 22.4. C i 0H8N4O4 requires C, 48.4; H, 3.2; N, 22.6%). 
lH n.m.r. (CD3SOCD3) : 5 6.72, s, NH2; 7.05, d, 7.39, d, J4>5 9 Hz, H 4,5; 7.66- 
8.33, complex, H 2',4',5',6 '.
6-(2'-Methoxyphenoxy)pyridazin-3-amine 2-oxide (HI. 4a)
2-Methoxyphenol (1.3 g) was dissolved in a solution of sodium hydroxide 
(0.4 g) in water (7.0 ml), 6-chloropyridazin-3-amine 2-oxide (0.6 g) was added and the 
mixture heated in a screw top reaction vessel at 150° for 19 h. The cooled alkaline 
mixture was extracted with chloroform to give an off-white solid (N.B. During the 
extraction a precipitate separated and was collected by filtration). The combined crude 
product was recrystallised from n-propanol/acetone (1:2) to give white needles of the title 
compound (0.21 g), m.p. 198-199° (Found, for sample dried at 40° and 0.2 mmHg for 
12 h : C, 56.8; H, 4.7; N, 18.1. C11H11N3O3 requires C, 56.7; H, 4.7; N, 18.0%). lH
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n.m.r. (CD3SOCD3) : 5 3.68, s, OMe; 6.5, b, NH2; 6.84, d, 7.28, d, J4,5 9 Hz, H 4,5; 
6.8-7.3, complex, H 3',4’,5',6’.
3-Methoxy-6-phenoxy-2-phenylimidazo[l,2-Z>]pyridazine (IQ . 6a)
A mixture of 6-phenoxypyridazin-3-amine (0.37 g), concentrated 
hydrochloric acid (0.15 ml) and ethanol (2.0 ml) was refluxed until all dissolved. Then 
phenylglyoxal230 (0.27 g) in ethanol (1.0 ml) was added and the mixture refluxed for 7 
h. After chilling, the orange solid (0.15 g) was filtered off and washed with water, 
ethanol and ether.
(a) . This solid (0.13 g) [vmax (KBr) 3300 (b) (enolic OH str), 3110 (w), 
2840 (w), 1600 (s) (C=0 str), 1200 (s), 1100 (s), 750 (m)] was added to diazomethane 
in ether (prepared from 2.6 g nitrosomethylurea) and the mixture stirred in ice and at 20° 
overnight. The solvent was evaporated and the product subjected to t.l.c. (alumina; 
chloroform) and recrystallised from light petroleum (b.p. 40-60°) to give 3-methoxy-6- 
phenoxy-2-phenylimidazo[ 1,2-b]pyridazine (0.115 g), m.p. 146-148° (Found : C, 72.0; 
H, 4.8; N, 12.8. C19H15N3O2 requires C, 71.9; H, 4.8; N, 13.2%). l H n.m.r. 
(CDCI3) : 5 3.97, s, Me; 6.79, d, J7j8 9 Hz, H 7; 7.83, d, J7>8 9 Hz, H 8; 7.38-8.15, 
complex, 2xPh. Mass spectrum mlz 317 (M+) (52%), 302 (12%), 274 (100%), 103 
(8%), 93 (27%), 77 (32%), 65 (70%). vmax (KBr) 3100 (w) , 2880 (w), 2840 (w), 
1590 (m), 1580 (m), 710 (s). pKa 3.21±0.05 (at 2.31xl0"5 M and 342 nm at 21° and I 
= 0.01 M). X max (pH 2.0) 212 nm, (log e 4.55), 248, (4.33), 342 (4.25).
(b) . The crude 6-phenoxy-2-phenylimidazo[l,2-£]pyridazin-3(5//)-one (0.13 
g) was stirred with potassium carbonate (0.06 g) and iodomethane (0.092 g, ca 0.04 ml) 
in acetone (12.0 ml) at room temperature overnight. The reaction mixture turned from 
orange to purple and finally greenish brown. Evaporation of acetone gave a light brown 
oil which was subjected to t.l.c. (alumina ; chloroform) to give a product with *H n.m.r. 
identical with that of the above.
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3-Methoxy-6-(3,-methyIphenoxy)-2-phenyIimidazo[l,2-£]pyridazine ( i n . 6c)
Phenylglyoxal (0.067 g) in ethanol (1.0 ml) was added to a warm solution of 
6-(3'-methylphenoxy)pyridazin-3-amine (0.1 g) in ethanol (1.5 ml) containing 
hydrochloric acid (0.1 ml), and the mixture refluxed for 7 h. No precipitate separated on 
cooling. The mixture was evaporated to dryness and the residue washed carefully with 
warm water to give a yellow solid (0.020 g).
This solid (0.020 g) was added to diazomethane in ether (prepared from 2.6 
g nitrosomethylurea) and the mixture stirred in ice and at 20° overnight. The solvent was 
evaporated and the product subjected to t.l.c. (alumina; chloroform) and recrystallised 
from light petroleum (b.p. 40-60°) to give 3-methoxy-6-(3'-methylphenoxy)-2- 
phenylimidazo[ 1,2-bJpyridazine (0.010 g), m.p. 88-90° (Found : C, 72.5; H, 5.2; N, 
12.7. C20H17N3O2 requires C, 72.5; H, 5.2; N, 12.7%). n.m.r. (CDCI3) : 5 2.40, 
s, Me; 3.99, s, MeO; 6.78, d, J7,8 9 Hz, H 7; 7.83, d, J7,8 9 Hz, H 8; 7.05-8.18, 
complex, H 2’,4',5',6' and Ph.
3-Methoxy-6-(2'-methoxyphenoxy)-2-phenylimidazo[I^-Z?])pyridazine ( f f l . 6e)
A solution of phenylglyoxal (0.067 g) in ethanol (1.0 ml) was added to a hot 
solution of 6-(2'-methoxyphenoxy)pyridazin-3-amine (0.1 g) in ethanol (1.5 ml) with 
concentrated hydrochloric acid (4 drops) and the mixture refluxed for 10 h. The ethanol 
was evaporated and the residue evaporated with water, then diluted with water and the 
orange crude oxo compound (0.15 g) was filtered off and washed with water and ether.
This product was stirred with excess ethereal diazomethane at 0° and 20° 
overnight. After removeal of the volatile material the product was subjected to t.l.c. 
(alumina; chloroform) and recrystallised from light petroleum (b.p. 40-60°) to give the 
title compound (0.020 g), m.p. 150-152° (Found, for a sample dried at 50° and 0.1 
mmHg for 6 h : C, 68.9; H, 4.9; N, 12.1. C2oH i7N3C>3 requires C, 69.1; H, 4.9; N, 
12.1%). !H n.m.r. (CDCI3): 5 3.77, s, 2’-OMe; 3.89, s, 3-OMe; 6.83, d, J7j8 9 Hz, H 
7; 7.82, d, J7>8 9 Hz, H 8; 7.01-8.09, complex, H 3’,4',5',6' and Ph. vmax (KBr) 
3020 (w) , 2940 (w), 2820 (w), 1500 (s), 1210 (s), 1110 (s), 740 (s). X max (pH 7.0) 
352 nm (log e 3.97).
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3-Methoxy-6-(2,-methylthiophenoxy)-2-phenylimidazo[l,2-&]pyridazine (H I. 6j)
A mixture of 6-(2'-methylthiophenoxy)pyridazin-3-amine (0.2 g), 
phenylglyoxal (0.12 g), ethanol (10 ml) and concentrated hydrochloric acid (0.15 ml) 
was refluxed for 16 h. The solvent was evaporated under reduced pressure and the 
residue evaporated with water to give a sticky red residue.
This product was mixed with ethereal diazomethane (from 1.3 g 
nitrosomethylurea) and stirred in ice and at 20° for 16 h. The mixture was evaporated to 
dryness and the product subjected to t.l.c. (alumina; chloroform) and recrystallised from 
cyclohexane to give the 3-methoxy-6-(2'-methylthiophenoxy)-2-phenylimidazo[l,2- 
bjpyridazine (0.03 g), m.p. 164-166° (Found: C, 66.0; H, 4.7; N, 11.4. 
C20H17N3O2S requires C, 66.1; H, 4.7; N, 11.5%). *H n.m.r. (CDCI3) : 6 2.46, s, 
MeS; 3.94, s, MeO; 6.86, d, J7,g 9 Hz, H 7; 7.85, d, J7,8 9 Hz, H 8; 7.28-8.12, 
complex, H 3',4',5',6' and Ph.
In a similar manner from phenylglyoxal and 6-(2'-methylphenoxy)pyridazin- 
3-amine, 6-(4'-methylphenoxy)pyridazin-3-amine, 6-(3'-methoxyphenoxy)pyridazin-3- 
amine, 6-(4'-methoxyphenoxy)pyridazin-3-amine, 6-(2'-ethoxyphenoxy)pyridazin-3- 
amine, 6-(4'-ethoxyphenoxy)pyridazin-3-amine, 6-(4'-methylthiophenoxy)pyridazin-3- 
amine, 6-(2'-chlorophenoxy)pyridazin-3-amine, 6-(3'-chlorophenoxy)pyridazin-3- 
amine, 6-(4'-chlorophenoxy)pyridazin-3-amine, 6-(2',4'-dichlorophenoxy)pyridazin-3- 
amine, 6-(3'-trifluoromethylphenoxy)pyridazin-3-amine, 6-(3'-dimethylaminophenoxy)- 
pyridazin-3-amine, 6-(naphth-l'-yloxy)pyridazin-3-amine, 6-(naphth-2'-yloxy)- 
pyridazin-3-amine and 6-(3'-nitrophenoxy)pyridazin-3-amine were prepared the 
following compounds.
3-Methoxy-6-(2'-methyIphenoxy)-2-phenylimidazo[l,2-£]pyridazine (III . 6b)
(20%), m.p. 103-105° [from light petroleum (b.p. 40-60°)] (Found, for a sample dried 
at 25° and 0.1 mmHg for 12 h : C, 72.6; H, 5.2; N, 12.5. C2oH i7N302 requires C, 
72.5; H, 5.2; N, 12.7%). n.m.r. (CDCI3) : 6 2.22, s, Me; 3.90, s, MeO; 6.81, d, 
J7)8 9 Hz, H 7; 7.85, d, J7,8 9 Hz, H 8; 7.12-8.10, complex, H 3’,4',5’,6’ and Ph.
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3-Methoxy-6-(4’-methylphenoxy)-2-phenylimidazo[l,2-£]pyridazine (III. 6d)
(12%), m.p. 99-101° [from light petroleum (b.p. 40-60°)] (Found : C, 72.3; H, 5.3; N, 
12.6. C20H17N3O2 requires C, 72.5; H, 5.2; N, 12.7%). *H n.m.r. (CDCI3) : 5 2.25, 
s, Me; 3.92, s, MeO; 6.80, d, J7,8 9 Hz, H 7; 7.84, d, J7,8 9 Hz, H 8; 7.09-8.18, 
complex, H 2',3',5',6' and Ph.
3-Methoxy-6-(3’-methoxyphenoxy)-2-phenylimidazo[l,2-Zdpyridazine (ID • 6f), as 
an oil (13%) which crystallised. It had m.p. 104-107° (Found, for a sample dried at 50° 
and 0.1 mmHg for 6 h : C, 68.9; H, 5.1; N, 12.1. C2oH i7N303 requires C, 69.1; H, 
4.9; N, 12.1%). JH n.m.r. (CDCI3) : 5 3.80, s, 3'-OMe; 4.00, s, 3-OMe; 6.79, d, J7>8 
9 Hz, H 7; 7.85, d, J7>8 9 Hz, H 8; 6.79-8.11, complex, H 2',4’,5',6' and Ph.
3-Methoxy-6-(4'-methoxyphenoxy)-2-phenyIimidazo[l,2-Z>]pyridazine (III. 6g)
(13%), m.p. 153-154° [from light petroleum (b.p 60-80°)] (Found : C, 69.2; H, 4.8; 
N, 12.0. C20H i 7N3O3 requires C, 69.2; H, 4.9; N, 12.1%). *H n.m.r. (CDCI3) : 6 
3.83, s, 4’-OMe; 3.96, s, 3-OMe; 6.76, d, J7,8 9 Hz, H 7; 6.93, d, 7.18, d, J 9 Hz, H 
2’,3’,5’,6'; 7.79, d, J7,8 9 Hz, H 8; 7.37-8.15, complex, Ph.
6-(2'-Ethoxyphenoxy)-3-methoxy-2-phenylimidazo[l,2-Z>]pyridazine (III. 6h)
(15%), m.p. 135-137° [from light petroleum (b.p. 40-60°)] (Found : C, 70.3; H, 5.7; 
N, 11.4. C21H19N3O3 requires C, 69.8; H, 5.3; N, 11.6%). n.m.r. (CDCI3) : 5 
1.20, t, J 7 Hz, CH3; 3.91, s, 3-OMe; 4.01, quart, J 7 Hz, CH2; 6.82, d, J7,8 9 Hz, H 
7; 6.99-8.14, complex, H 3',4',5’,6’ and Ph; 7,80, d, J7,8 9 Hz, H 8.
6-(4'-Ethoxyphenoxy)-3-methoxy-2-phenylimidazo[l,2-Z>]pyridazine (III. 6i)
(12%), m.p. 134-135° [from light petroleum (b.p. 40-60°)] (Found, for a sample dried 
at 70° and 0.1 mmHg for 4.5 h : C, 69.8; H, 5.6; N, 11.6. C21H19N3O3 requires C, 
69.8; H, 5.3; N, 11.6%). *H n.m.r. (CDCI3) : 5 1.45, t, J 7 Hz, CH3; 3.97, s MeO; 
4.07, quart, J 7 Hz, CH2; 6.77, d, J7>8 9 Hz, H 7; 6.93, d, 7.17, d, J2\3' 9 Hz, H 
2',3’,5',6'; 7.32-8.15, complex, Ph; 7,82, d, J7j8 9 Hz, H 8.
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3-Methoxy-6-(4'-methyIthiophenoxy)-2-phenylimidazo[l,2-b]pyridazine (III. 6k)
(19%), m.p. 106-109° [from light petroleum (b.p. 40-60°)] (Found, for a sample dried 
at 70° and 0.1 mmHg for 9 h : C, 6 6 .6 ; H, 4.7; N, 11.4. C20H 17N3O2S requires C, 
66.1; H, 4.7; N, 11.6%). *H n.m.r. (CDCI3) : 5 2.53, s, MeS; 3.98, s, MeO; 6.78, d, 
J7>8 9 Hz, H 7; 7.83, d, J7,8’ 9 Hz, H 8 ; 7.13-8.15, complex, H 2',3',5',6 ' and Ph.
6-(2'-Chlorophenoxy)-3-methoxy-2-phenylimidazo[l,2-£]pyridazine (III. 61)
(18%), m.p. 99-100° [from light petroleum (b.p. 40-60°)] (Found, for a sample dried at 
70° and 0.1 mmHg for 16 h : C, 65.0; H, 3.9; N, 11.7. C19H 14CIN3O2 requires C, 
64.9; H, 4.0; N, 12.0%). *H n.m.r. (CDCI3) : 5 3.90, s, Me; 6.89, d, J7,8 9 Hz, H 7; 
7.87, d, J7,8 9 Hz, H 8; 7.31-8.10, complex, H 3',4',5',6 ’ and Ph. vmax (KBr) 3100 
(w) , 2940 (w), 1560 (s), 1540 (s), 1480 (s), 1210 (s), 1250 (s), 760 (s).
This compound was also prepared by stirring the crude 6-(2'- 
chlorophenoxy)-2-phenylimidazo[l,2-£]pyridazin-3(5//)-one (0.06 g) with potassium 
carbonate (0.025 g) and iodomethane (0.038 g, ca 0.017 ml) in acetone (7.0 ml) at room 
temperature overnight. This mixture was diluted with water (20 ml) and extracted with 
chloroform (2x30 ml). The combined extract was washed with water (30 ml) and dried 
over sodium sulphate. Evaporation of solvent gave a residue which was subjected to 
t.l.c. (alumina; cyclohexane/chloroform, 1:1, developed twice) to give a product (0.036 
g) with *H n.m.r. identical with that from above.
6-(3'-ChIorophenoxy)-3-methoxy-2-phenyIimidazo[l,2-Z>]pyridazine (III. 6m)
(18%), m.p. 134-135° (from cyclohexane) (Found, for a sample dried at 40° and 0.1 
mmHg for 5 h : C, 65.1; H, 3.9; N, 11.9. C19H14CIN3O2 requires C, 64.9; H, 4.0; N, 
11.9%). *H n.m.r. (CDCI3) : 6 3.99, s, Me; 6.81, d, J7,8 9 Hz, H 7; 7.86, d, J7,8 9 Hz, 
H 8; 7.15-8.12, complex, H 2',4',5',6 ' and Ph.
6-(4'-Chlorophenoxy)-3-methoxy-2-phenylimidazo[l,2-£]pyridazine (H I. 6n)
(18%), m.p. 122-124° (from cyclohexane) (Found, for a sample dried at 40° and 0.1 
mmHg for 5 h : C, 65.1; H, 4.1; N, 11.9. C19H14CIN3O2 requires C, 64.9; H, 4.0; N,
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11.9%). *H n.m.r. (CDCI3) : 6 3.98, s, Me; 6.81, d, J7,8 9 Hz, H 7; 7.85, d, J7>8 9 Hz, 
H 8; 7.19-8.11, complex, H 2’,3’,5',6' and Ph.
6-(2', 4'-Dichlorophenoxy)-3-methoxy-2-phenyIimidazo[l,2-£]pyridazine (HI. 60)
(18%), m.p. 140-142° [from light petroleum (b.p. 40-60°)] (Found, for a sample dried 
at 70° and 0.1 mmHg for 16 h : C, 58.6; H, 3.5; N, 10.3. C19H23CI2N3O2 requires C, 
59.1; H, 3.4; N, 10.9%). lH n.m.r. (CDCI3) : 5 3.93, s, Me; 6.89, d, J7>8 9 Hz, H 7; 
7.89, d, J7,8 9 Hz, H 8; 7.25-8.10, complex, H 3’,5’,6' and Ph.
3-Methoxy-2-phenyl-6-(3'-trifluoromethyIphenoxy)imidazo[l,2-£]pyridazine (HI.
6p) (17%), m.p. 116-119° (from cyclohexane) (Found : C, 62.4; H, 3.6; N, 10.8. 
C20H14F3N3O2 requires C, 62.3; H, 3.7; N, 10.9%). JH n.m.r. (CDCI3) : 6 3.96, s, 
Me; 6.87, d, J7>8 9 Hz, H 7; 7.90, d, J7,8 9 Hz, H 8; 7.38-8.14, complex, H 2’,4',5',6’ 
and Ph.
6-(3,-Dimethylaminophenoxy)-3-methoxy-2-phenylimidazo[l^-Z?]pyridazine (HI.
6q) (18%), m.p. 115-116° (from cyclohexane) (Found, for a sample dried at 40° and 
0.1 mmHg for 6 h : C, 69.9; H, 5.7; N, 15.3. C21H20N4O2 requires C, 70.0; H, 5.6; 
N, 15.5%). *H n.m.r. (CDCI3) : 6 2.96, s, Me2N; 4.03, s, MeO; 6.75, d, J7>8 9 Hz, H 
7; 7.79, d, J7>8 9 Hz, H 8; 6.52-8.12, complex, H 2',4',5',6' and Ph.
3-Methoxy-6-(naphth-l'-yIoxy)-2-phenylimidazo[l,2-Z?]pyridazine (HI. 6s) (17%), 
m.p. 171-173° (from cyclohexane) (Found : C, 75.4; H, 4.8; N, 11.4. C23H i7N302 
requires C, 75.2; H, 4.7; N, 11.4%). *H n.m.r. (CDCI3) : 5 3.95, s, Me; 6.87, d, J7)8 9 
Hz, H 7; 7.87, d, J7,8 9 Hz, H 8; 7.32-8.12, complex, H 2’,3’,4', 5’,6',7',8' and Ph.
3-Methoxy-6-(naphth-2'-yloxy)-2-phenyIimidazo[l,2-Z>]pyridazine (HI. 6t) (18%), 
m.p. 132-134° (from cyclohexane) (Found : C, 75.2; H, 4.7; N, 11.2. C23H i7N302 
requires C, 75.2; H, 4.7; N, 11.4%). *H n.m.r. (CDCI3) : 8 3.76, s, Me; 6.87, d, J7>8 9
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Hz, H 7; 7.84, d, J7,s 9 Hz, H 8; 7.30-8.06, complex, H 1',3’,4’,5’,6’,7’,8’ and Ph.
3-Methoxy-6-(3'-nitrophenoxy)-2-phenylimidazo[l,2-Z>]pyridazine (III. 6r)
(a) . A mixture of 6-(3'-nitrophenoxy)pyridazin-3-amine (0.24 g), 
phenylglyoxal (0.14 g), ethanol (20 ml) and concentrated hydrochloric acid (0.4 ml) was 
refluxed for 9 h. After cooling the red solid (0.15 g) was filtered off and the filtrate was 
evaporated to dryness. The residue was triturated with water and the solid (0.05 g) was 
filtered off and washed with ether.
The combined solid (0.2 g) was then stirred overnight with excess ethereal 
diazomethane at ca 0°. The mixture was evaporated and the residue subjected to t.l.c. 
(alumina; chloroform) and the product (0.02 g) recrystallised from cyclohexane to give 3- 
methoxy-6-(3'-nitrophenoxy)-2-phenylimidazo[ 1,2-b]pyridazine, m.p. 181-182° (Found 
: C, 63.1; H, 3.9; N, 15.6. C19H14N4O4 requires C, 63.0; H, 3.9; N, 15.5%). *H 
n.m.r. (CDCI3) : 6 3.96, s, Me; 6.86, d, J7)8 9 Hz, H 7; 7.30-8.26, complex, H 
2',4’,5’,6' and Ph; 7.90, d, J7>8 9 Hz, H 8.
(b) . A mixture of 6-(3'-nitrophenoxy)pyridazin-3-amine 2-oxide (0.3 g), 
phenacylbromide (0.26 g) and ethanol (12.0 ml) was refluxed for 7 h. The solvent was 
evaporated and the residue methylated with excess ethereal diazomethane as above.After 
t.l.c. it gave the title compound (0.08 g) with *H n.m.r. identical with the product 
isolated in (a).
6-(3,-Aminophenoxy)-3-methoxy-2-phenylimidazo[l,2-Z>]pyridazine (H I. 7)
A solution of 3-methoxy-6-(3'-nitrophenoxy)-2-phenyimidazo[l,2-&]- 
pyridazine (0.08 g) in methanol (20.0 ml) was added over five minutes to a stirred 
mixture of reduced iron powder (0.3 g), methanol (10.0 ml), water (4.0 ml) and 
concentrated hydrochloric acid (0.4 ml) at 80-85°, and maintained at that temperature for 
1.5 h. The mixture was filtered and the solid washed with hot methanol. The filtrate 
was evaporated, the residue diluted with water and adjusted to pH 6-7, and the mixture 
extracted with chloroform. The extract gave a greenish blue residue which was subjected 
to t.l.c. (alumina; chloroform) and recrystallised from cyclohexane to give 6-(3'- 
aminophenoxy)-3-methoxy-2-phenylimidazo[ 1,2-b]pyridazine (0.045 g), m.p. 165-167°
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(Found, for a sample dried at 90° and 1 mmHg for 4 h : C, 68.3; H, 4.9; N, 16.6. 
C19H16N4O2 requires C, 68.7; H, 4.9; N, 16.9%). n.m.r. (CDCI3) : 5 3.4, b, NH2; 
4.03, s, Me; 6.49-8.16, complex, H 2',4’,5’,6 ’ and Ph; 6.76, d, J7,8 9 Hz, H 7; 7.82, 
d, J7,8 9 Hz, H 8.
In a similar manner from 6-(2'-methoxyphenoxy)pyridazin-3-amine and (2- 
methylphenyl)glyoxal (prepared from 2 -methylacetophenone by selenium dioxide 
oxidation similar to that used by Riley & Gray230), 3-methylphenylglyoxal,235 4- 
methylphenylglyoxal hydrate,234 4-fluorophenylglyoxal,236 naphth-2-ylglyoxal,246 4- 
nitrophenylglyoxal hydrate217 (prepared from 4-nitroacetophenone by a method similar 
to that reported by Eastham et a/.235) were prepared the following compounds.
3-Methoxy-6-(2,-methoxyphenoxy)-2-(2"-methyIphenyl)imidazo[l,2-Z>]pyridazine 
(III. 9a) (18%), m.p. 138-140° [from light petroluem (b.p. 40-60°)] (Found, for a 
sample dried at 60° and 0.1 mmHg for 5 h : C, 69.6; H, 5.5; N, 11.6. C21H 19N3O3 
requires C, 69.8; H, 5.3; N, 11.6%). lH n.m.r. (CDCI3) : 5 2.41, s, 2"-Me; 3.77, s, 2'- 
OMe; 3.80, s, 3-OMe; 6.81, d, J7>8 9 Hz, H 7; 6.99-7.65, complex, H 
3’,4’,5',6 ',3",4”,5",6 ”; 7.80, d, J7j8 9 Hz, H 8 .
3-Methoxy-6-(2'-methoxyphenoxy)-2-(3"-methyIphenyl)imidazo[l,2-£]pyridazine 
(III. 9b) (15%), m.p. 116-118° [from light petroluem (b.p. 40-60°)] (Found, for a 
sample dried at 75° and 0.1 mmHg for 5 h : C, 69.4; H, 5.4; N, 11.9. C21H 19N3O3 
requires C, 69.8; H, 5.3; N, 11.6%). JH n.m.r. (CDCI3) : 5 2.42, s, 3"-Me; 3.78, s, 2'- 
OMe; 3.90, s, 3-OMe; 6.81, d, J7>8 9 Hz, H 7; 7.00-7.92, complex, H 
3’,4',5',6 ',2",4",5”,6 "; 7.81, d, J7>8 9 Hz, H 8 .
3-Methoxy-6-(2,-methoxyphenoxy)-2-(4"-methyIphenyl)imidazo[l,2-£]pyridazine 
(III. 9c) (13%), m.p. 149-151° [from light petroluem (b.p. 40-60°)] (Found, for a 
sample dried at 90° and 0.1 mmHg for 6 h : C, 69.8; H, 5.4; N, 11.6. C21H 19N3O3 
requires C, 69.8; H, 5.3; N, 11.6%). lH n.m.r. (CDCI3) : 5 2.38, s, 4"-Me; 3.78, s, 2'-
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OMe; 3.89, s, 3-OMe; 6.81, d, J7,8 9 Hz, H 7; 6.94-8.02, complex, H 
3’,4’,5',6 ’,2",3",5",6"; 7.80, d, J7,8 9 Hz, H 8 . vmax (KBr) 3020 (w) , 2940 (w), 
2820 (w), 1510 (s), 1290 (s), 820 (s), 740 (s).
2- (4,-FIuorophenyl)-3-methoxy-6-(2,,-methoxyphenoxy)imidazo[l,2-Z>]pyridazine
(III. 9d) (15%), m.p. 110-111° [from light petroluem (b.p. 40-60°)] (Found, for a 
sample dried at 40° and 0.1 mmHg for 12 h : C, 65.9; H, 4.4; N, 11.6. C20H16FN3O3 
requires C, 65.8; H, 4.4; N, 11.5%). *H n.m.r. (CDCI3) : 8 3.78, s, 2"-OMe; 3.89, s,
3- OMe; 6.82, d, J7>8 9 Hz, H 7; 7.01-8.13, complex, H 2’,3',5’,6’,3",4",5M,6"; 7.78, 
d, J7,8 9 Hz, H 8.
3-Methoxy-6-(2'-methoxyphenoxy)-2-(naphth-2"-yl)imidazo[l,2-Zdpyridazine (ID.
9e) (20%), m.p. 140-141° (from cyclohexane) (Found, for a sample dried at 85° and 0.1 
mmHg for 6 h : C, 72.5; H, 4.8; N, 10.5. C24H 19N3O3 requires C, 72.5; H, 4.8; N, 
10.6%). *H n.m.r. (CDCI3) : 5 3.78, s, 2’-OMe; 3.96, s, 3-OMe; 6.84, d, J7>8 9 Hz, H 
7; 6.95-8.58, complex, H 3',4',5',6 ' and naphthyl; 7.84, d, J7>8 9 Hz, H 8.
3-Methoxy-6-(2'-methoxyphenoxy)-2-(4"-nitrophenyI)imidazo[l,2-ft]pyridazine (III.
9f) (32%), m.p. 186-188° (from methanol-chloroform) (Found, for a sample dried at 80° 
and 0.1 mmHg for 6 h : C, 61.0; H, 3.9; N, 14.6. C20H 16N4O5 requires C, 61.2; H, 
4.1; N, 14.3%). l H n.m.r. (CDCI3) : 5 3.79, s, 2'-OMe; 3.95, s, 3-OMe; 6.90, d, J7,8 9 
Hz, H 7; 7.00-7.30, complex, H 3',4',5’,6 '; 7.83, d, J7>8 9 Hz, H 8 ; 8.25, b, 
H2",4",5",6". vmax (KBr) 3020 (w) , 2960 (w), 2820 (w), 1600 (s), 1520 (s) (N ^O  
antisymm str),1340 (s) (N—O symm), 850 (s), 750 (s).
2-(4'-Aminophenyl)-3-methoxy-6-(2"-methoxyphenoxy)imidazo[l,2-Zdpyridazine 
(IH. 9h)
A warm solution of 3-methoxy-6-(2'-methoxyphenoxy)-2-(4"- 
nitrophenylimidazo[l,2-£]pyridazine (0.12 g) in methanol (30 ml) was added over 5 min 
to a rapidly stirred mixture of reduced iron powder (0.45 g), methanol (12 ml), water (4
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ml) and concentrated hydrochloric acid (0.5 ml) and the mixture maintained at 80-85° for 
2 h. The mixture was filtered hot and the solid washed with hot methanol. The 
combined filtrates evaporated and the residue dissolved in water and adjusted to pH 7 
with 1 M sodium hydroxide. The product was extracted into chloroform, subjected to 
t.l.c. (alumina; chloroform), and recrystallised from benzene-cyclohexane to give the 
title compound (0.07 g), m.p. 152-154° (Found : C, 66.1; H, 4.9; N, 15.4. 
C20H18N4O3 requires C, 66.3; H, 5.0; N, 15.5%). n.m.r. (CDCI3) : 5 3.2, b, NH2; 
3.78, s, 2"-OMe; 3.88, s, 3-OMe; 6.74, d, 7.88, d, J2\3’ 9 Hz, H 2’,3',5’,6'; 6.76, d, 
J7,8 9 Hz, H 7; 6.89-7.36, complex, H 3",4",5",6"; 7.77, d, J7>8 9 Hz, H 8. X max (pH 
7.0) 266 nm (log 8 4.24), 373 (4.17).
2-(4,-Fluorophenyl)-3-methoxy-6-(2"-methylthiophenoxy)imidazo[l,2-Zd-pyridazine 
( i n . 9g)
This compound was prepared from 6-(2'-methylthiophenoxy)pyridazin-3- 
amine (0.18 g) and 4-fluorophenylglyoxal236 (0.14 g) in a similar manner to the 
reactions reported above. It was subjected to t.l.c. (alumina; chloroform-cyclohexane ; 
1:1), and recrystallised from light petroleum (b.p. 60-80°) to give the title compound 
(0.06 g), m.p. 134-135° (Found, for a sample dried at 85° and 0.1 mmHg for 5 h : C, 
63.2; H, 3.9; N, 10.9. C20H i6FN3O2S requires C, 63.0; H, 4.2; N, 11.0%). *H 
n.m.r. (CDCI3) : 6 2.43, s, MeS; 3.91, s, MeO; 6.83, d, J7>8 9 Hz, H 7; 7.01-8.13, 
complex, H 2’,3',5’,6',3",4",5",6"; 7.81, d, J7,8 9 Hz, H 8.
a-Bromo-3-(and 4-)trifluoromethylacetophenones
These compounds were prepared by bromination of 3(and 4-)-trifluoro- 
methylacetophenone in anhydrous ether in the presence of aluminium chloride by the 
procedure of Cowper and Davidson243 for the preparation of a-bromoacetophenone and 
mentioned247 without detail in ref. 235.
The a-bromo-3-trifluoromethylacetophenone had *H n.m.r.(CDCl3) : 6 
4.47, s, CH2; 7.57-8.38, complex, H 2,4,5,6.
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The a-bromo-4-trifluoromethylacetophenone had *H n.m.r.(CDCl3) : 8 
4.46, s, CH2; 7.77, d, 8.10, d, J2,3 9 Hz, H 2,3,5,6.
3-Methoxy-6-(2'-methoxyphenoxy)-2-(4"-trifluoromethyIphenyl)imidazo[l,2-£]- 
pyridazine (H I. lib )
A solution of a-bromo-4-trifluoromethylacetophenone (0.24 g) in ethanol 
(4.0 ml) was added to a warm solution of 6-(2'-methoxyphenoxy)pyridazin-3-amine 2- 
oxide (0.2 g) in ethanol (6.0 ml) and the mixture refluxed gently (oil bath) with stirring 
for 8 h. After cooling, the mixture was diluted with water, adjusted to pH 6-7 and 
ethanol evaporated (rotary evaporator). After chilling, the crude oxo compound (0.23 g) 
was filtered off and washed with water.
It was methylated with excess ethereal diazomethane at 0° and then at 20° 
overnight. The product was subjected to t.l.c. (alumina; chloroform/toluene, 1:2), and 
recrystallised from cyclohexane-light petroleum (b.p. 40-60°) to give the title compound 
(0.14 g), m.p. 150-151° (Found, for a sample dried at 85° and 0.1 mmHg for 6 h : C, 
61.0; H, 3.9; N, 9.9. QZ1H16F3N3O3 requires C, 60.7; H, 3.9; N, 10.1%). *H n.m.r. 
(CDCI3) : 8 3.78, s, 2'-OMe; 3.92, s, 3-OMe; 6.86, d, J7,8 9 Hz, H 7; 7.01-8.24, 
complex, H 3’,4',5’,6',2",3”,5”,6"; 7.81, d, J7,g 9 Hz, H 8.
3-Methoxy-6-(2,-methoxyphenoxy)-2-(3'-trifluoromethyIphenyl)imidazo[l,2-Z>]- 
pyridazine (HI. 11a)
This compound (25%) was prepared in a similar manner from 6-(2'- 
methoxyphenoxy)pyridazin-3-amine 2-oxide. It had m.p. 145-150° [from cyclohexane- 
light petroleum (b.p. 60-80°), 10:3] (Found, for a sample dried at 85° and 0.2 mmHg 
for 6 h : C, 60.8; H, 3.9; N, 10.1. C2i H i6F3N303 requires C, 60.7; H, 3.9; N, 
10.1%). *H n.m.r. (CDCI3) : 8 3.78, s, 2'-OMe; 3.90, s, 3-OMe; 6.86, d, J7>8 9 Hz, H 
7; 7.01-8.36, complex, H 3’,4',5’,6',2",4",5”,6”; 7.81, d, J7,8 9 Hz, H 8.
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3-(BromoacetyI)pyridine hydrobromide
Bromine (4.3 g) was added dropwise with stirring to a solution of 3- 
acetylpyridine (3.0 g) in 48% hydrogen bromide in acetic acid (28.0 ml) at 0-5°. The 
temperature was then raised to 35-40° for 1.5 h and then 75° for 1 h. The mixture was 
cooled and diluted with ether (100 ml) to complete precipitation and the 3-(a- 
bromoacetyl)pyridine hydrobromide (6.0  g) filtered off and washed with ether and 
acetone and dried in vacuo. The crude product had m.p. 180-185° [lit.244 185-188° 
(dec.)] and was recrystallised from methanol-ether. It had n.m.r. (CD3SOCD3) : 5 
5.05, s, CH2; 7.83-9.37, complex, H 2,4,5,6 .
2- (and 4-)(Bromoacetyl)pyridine hydrobromides
These compounds were prepared by bromination of 2- and 4- acetylpyridine 
respectively as described above for the 3-isomer.
The 2-(bromoacetyl)pyridine hydrobromide was recrystallised from 
methanol-ether and had m.p. 208-211° (lit.248 204-208°) *H n.m.r. (CD3SOCD3) : 8 
5.00, s, CH2; 7.63-8.76, complex, H 3,4,5,6 .
The crude 4-(bromoacetyl)pyridine hydrobromide decomposed at ca 195° 
(lit 248 m.p. 198-201°). n.m.r. (CD3SOCD3) : 8 5.10, s, CH2; 8.32, d, 9.16, d, 
J2,3 7 Hz, H 2,3,5,6 .
3- Methoxy-6-(2'-methoxyphenoxy)-2-(pyrid-2" -yI)imidazo[l,2-Z>]pyridazine (HI •
11c)
The solution from 2-(bromoacetyl)pyridine hydrobromide (0.25 g), sodium 
hydrogen carbonate (0.08 g) and ethanol (4.0 ml) was added to a warm solution of 6-(2'- 
methoxyphenoxy)pyridazin-3-amine 2-oxide (0.2 g) in ethanol (5.0 ml) and the mixture 
refluxed gently (oil bath) with stirring for 8 h. Excess ethereal diazomethane was added 
to the chilled reaction mixture which was stirred at 0° and then at 20° overnight. The 
solvents were then evaporated and the product subjected to t.l.c. (alumina; chloroform). 
The title compoumd (0.07 g) recrystallised from acetone-cyclohexane with addition of 
light petroleum (b.p. 40-60°). It had m.p. 178-180° (Found, for a sample dried at 90°
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and 0.1 mmHg for 5 h : C, 65.8; H, 4.7; N, 16.2. C19H16N4O3 requires C, 65.5; H, 
4.6; N, 16.1%). lH n.m.r. (CDCI3) : 5 3.74, s, 2’-0Me; 3.94, s, 3-OMe; 6.80, d, J7)8 
9 Hz, H 7; 6.93-8.76, complex, H 3',4’,5',6',3",4”,5",6”; 7.80, d, J7,8 9 Hz, H 8.
In a similar manner from 6-(2'-methoxyphenoxy)pyridazin-3-amine 2-oxide 
with 3- and 4-(bromoacetyl)pyridine hydrobromide were prepared the following.
3-Methoxy-6-(2,-methoxyphenoxy)-2-(pyrid“3”-yl)imidazo[l,2-£]pyridazine (H I.
lid )  (13%), m.p. 170° (with prior softening) (from toluene-cyclohexane) (Found, for 
a sample dried at 90° and 0.1 mmHg for 5 h : C, 65.4; H, 4.6; N, 16.1. C19H16N4O3 
requires C, 65.5; H, 4.6; N, 16.1%). *H n.m.r. (CDCI3) : 5 3.78, s, 2'-OMe; 3.91, s, 
3-OMe; 6.85, d, J7>8 9 Hz, H 7; 7.00-9.28, complex, H 3',4’,5’,6’,2",4",5",6"; 7.80, 
d, J7>8 9 Hz, H 8.
3-Methoxy-6-(2'-methoxy phenoxy)-2-(py rid-4"-yl)imidazo[l,2-Z>]pyridazine ( m .
lie )  (12%), m.p. 105-107° (from toluene-cyclohexane) (Found, for a sample dried at 
90° and 0.1 mmHg for 5 h : C, 64.5; H, 4.4; N, 16.0. C19H16N4O3 requires C, 64.4; 
H,4.7; N, 15.8%). lH n.m.r. (CDCI3) : 5 3.77, s, 2’-OMe; 3.92, s, 3-OMe; 6.87, d, 
J7,8 9 Hz, H 7; 6.90-8.68, complex, H 3',4’,5',6',2”,3",5",6"; 7.80, d, J7>8 9 Hz, H 8.
CHAPTER IV
94
CHAPTER IV Syntheses and binding studies of some 3-alkoxy-6-benzylthio-
(substituted benzylthio and pyridylmethylthio)-2-phenyI(and aryl)- 
imidazo[l,2-Z?]pyridazines
IV -1  Introduction
In this chapter some derivatives and analogues of 3-alkoxy-6-benzylthio-2- 
phenylimidazo[l,2-£]pyridazines have been prepared and their ability to displace 
[3H]diazepam from its specific binding sites in rat brain has been examined. The aim of 
this investigation was to determine the structure and activity relationships for this series 
of compounds with the hope of identifying a more potent and selective inhibitor of 
[3H]diazepam binding. Thus, we have studied the effect, firstly of varying substituents 
in the phenyl ring of the benzylthio group at C-6 without altering the substituents at C-2 
and C-3, and then maintain a favourable substituent at C-6 but modify the substituent on 
C-2 and the alkoxy group on C-3, respectively.
The synthetic methods for the preparation of these compounds are discussed. 
These compounds were readily characterized using *H n.m.r. spectroscopy. These 
spectral data will be discussed together with other physical properties viz. ionization 
constants, and the ultraviolet, infrared and mass spectra. In addition, the results of the 
receptor binding studies using the [3H]diazepam binding assay will be reported and 
discussed.
IV - 2 Syntheses
The general methods for the synthesis of compounds described in this 
chapter are as outlined in Scheme IV - 1. Route A involves the preparation of 
6-benzylthiopyridazin-3-amines through 6-aminopyridazine-3-thiol, whereas in route B 
6-chloropyridazin-3-amine is allowed to react directly with the sodium phenylmethane- 
thiolate. The 6-benzylthiopyridazin-3-amines so obtained were then condensed with 
appropriate glyoxals to give imidazo[l,2-Z?]pyridazin-3(5//)-ones which were methylated 
with diazoalkanes to the corresponding 3-alkoxy compounds. Route B has been used for
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the preparation of some 6-alkylthio and 6-arylthio-3-methoxy-2-phenylimidazo[l,2-&]- 
pyridazines by Barlin and Ireland.212 Route C involves the preparation of 6- 
chloropyridazin-3-amine 2-oxide as intermediate and its subsequent conversion with the 
sodium phenylmethanethiolate to the 6-benzylthiopyridazin-3-amine 2-oxide. The latter 
compound with bromoacetyl compounds gives the imidazo[l,2-£]pyridazine-3(5//)-ones 
as above. Route D involves the synthesis of the heteroaromatic bicyclic system followed 
by nucleophilic displacement of the 6-chloro group with sodium methanethiolate. 
Although the reported212 preparation of 3-methoxy-6-methylthio-2-phenylimidazo- 
[l,2-&]pyridazine followed this route, the observed yield was relatively low (the low 
reactivity for the 6-chloro group in this ring system has been reported by others144).
In the present work, the required compounds were prepared via routes A and 
C. Route A was generally employed when the substituted benzyl halide was more 
readily available than the corresponding benzylthio compound. However, route C was 
followed when it was necessary to condense with bromoacetyl compounds.
Scheme IV - 1
Route CRoute A
\  Route DRoute B /
R1CH2S
r *s
R2
OR3N
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IY - 2.1 Preparation of some 3-alkoxy-2-phenyl-6-substituted benzylthio
(pyridylmethylthio and naphthylmethyIthio)imidazo[l,2-Z>]pyridazines 
through pyridazin-3-amines.
The preparation of these compounds generally follows route A as outlined in 
Scheme IV - 1. The starting material for such syntheses was 6-chloropyridazin-3- 
amine 215 It was converted through 3-acetamido-6-chloropyridazine and 6-acetamido- 
pyridazine-3-thiol to 6-aminopyridazine-3-thiol249 (Scheme IV - 2, IY . 1) which was 
then treated in alkaline solution with the appropriate benzyl chloride at room temperature 
to give the 6-benzylthiopyridazin-3-amine [compounds IV . 2(a-l)] in yields ranging from 
50-90%. Analogous reactions with 2-, 3- and 4-pyridylmethyl chlorides and naphth-1- 
ylmethyl chloride gave the corresponding 6-pyridymethylthiopyridazin-3-amines [IV . 
5(a,b and c)] and 6-naphth-r-ylmethylthiopyridazin-3-amine (IV . 5d). The *H 
n.m.r. spectra of these compounds are consistent with their structures.
Although Morren250 had reported the synthesis of 6-aminopyridazine-3-thiol 
via 6-chloropyridazin-3-amine by heating the latter at 140-150° with a molar equivalent 
of sodium hydrogen sulphide in ethanol for 7 h, this reaction could not be repeated in our 
laboratory. The literature also revealed that Kumagai251 had attempted a similar reaction 
with thiourea but later reported249 that this reaction did not give the isothiouronium salt 
due to the strong resonance effect of the amino group.
The 6-substituted pyridazin-3-amines (IV . 2 and IV . 5) were subsequently 
condensed with phenylglyoxals in ethanol containing hydrochloric acid at reflux, to give 
the corresponding oxo compounds (IV . 3 and IV . 6). Alkylation of the latter with a 
diazoalkane in ether at 0° and then 20° overnight gave the alkoxy compounds [Scheme 
IV - 2, IV . 4; R' = Me, Et and IV . 7]. Compounds [IV . 4(j-l)] which contain nitro 
groups were reduced by iron in aqueous methanolic hydrochloric acid at 85-90° to the 
corresponding amino compound [Scheme IV - 3, IV . 8(a-b)].
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IV - 2.2 Preparation of some 3-alkoxy(and unsubstituted)-2-aryl-6-benzylthio(and 3'- 
methoxybenzylthio)imidazo[l,2-6]pyridazines through pyridazin-3-amines
The 3-alkoxy-2-aryl-6-benzylthio(and 3'-methoxybenzylthio)imidazo[l,2-&]- 
pyridazines were readily prepared by condensing 6-benzylthiopyridazin-3-amine 
[prepared via route B (Scheme IV - 1)] or 6-(3'-methoxybenzylthio)pyridazin-3-amine 
(prepared as described in Section 2.1 via route A) with the appropriate phenylglyoxal 
which gave the corresponding oxo compounds (Scheme IV - 4, IV . 10), followed by 
alkylation with diazoalkane as described in the previous section. In this way compounds 
IV . ll(a -m ) were readily prepared. The required substituted phenylglyoxals were 
generally prepared in a similar manner to that reported in the literature230*234 viz. by 
oxidation of appropriate acetophenones with selenium dioxide.
The 3-unsubstituted compound, 6-(3'-methoxybenzylthio)-2-phenylimidazo- 
[l,2-£]pyridazine (IV . 12) was prepared by refluxing a mixture of 6-(3'-methoxy- 
benzylthio)pyridazin-3-amine and phenacyl bromide in ethanol. The free base of the 
product was isolated by adjusting the pH of the final reaction mixture to 7 (Scheme IV - 4).
IV - 2.3 Preparation of some 2-aryl-3-methoxy-6-(3'-methoxybenzylthio)imidazo- 
[1,2-Zdpyridazines through pyridazin-3-amine 2-oxides
The synthesis of this series of compounds followed route C as shown in 
Scheme IV - 1. 6-Chloropyridazin-3-amine215 was readily oxidised using peroxyacetic 
acid in glacial acetic acid to give the known 6-chloropyridazin-3-amine 2-oxide.238 This 
was heated with 3-methoxyphenylmethanethiol in aqueous sodium hydroxide to give 6- 
(3'-methoxybenzylthio)pyridazin-3-amine 2-oxide (Scheme IV - 5, IV . 15) in 69% 
yield. The latter underwent ring closure with bromoacetyl compounds as described in 
Chapter III - 2.1 and III - 2.2, to give the oxo compounds [IV . 16(a-g)] which were 
converted to the corresponding methoxy derivatives [IV . 17(a-g)] by treating with 
ethereal diazomethane.
Scheme IV - 2
R 1
IV . 1
IV . 5
IV . 2
c h 2s
H
IV . 6
r 1c h 2s
Ph
OMe
IV . 7
IV . 5 - IV . 7
R1
a C5H4N-01 *1
b C5H4N-ß *1
c C5H4N-y*l
d CjoHy-a *2
Pyridyl 
*2 Naphthyl
IV . 2 - IV , 4
R2= OMe
R1
R2 = OMe
R1
R2 = OEt 
R1
a Me-o g CF 3-m m OMe-m
b Me-m h NMc2-m
c Me-/? i NMe2-p
d OMe-<? j N 02-o
e OMe-/n k N 0 2-m
f OMe-p 1 N 02-p
Scheme IV - 3
n o 2
c h 2s n OMe
IV . 4j N02-o 
IV . 4k NOr m 
IV . 41 N02-p
IV . 8a NH2-o 
IV . 8b NHr m 
IV . 8c NH2-p
Scheme IV - 4
IV . 11
IV . 10 - IV . 11
R1 = H 
R2 | R3
R1 = OMe ; R3=Me
R2
R1 = OMe ; R3=Me 
R2
a Me-/? Me e Me-o i OMe-m
b Me-/? Et f Me-m j OMe-/?
c N02-m Me g Me-/? k F-m
d NO 2-p Me h OMe-o 1
m
F - P
NO 2-m
Scheme IV - 5
MeO
V j T CH2SY ^ i
o
IV . 14
N NH2
I
o
IV . 15
IV 16 - IV . 17
R1
a C^F-O
b C6H4CF3-o
c C6H4CF3-m
d C6H4CF3-/7
e C5H4N-a*
f CsR^N-ß *
g C5H4N-y *
* Pyridyl IV . 17
IV - 3 Physical properties 
i XH n.m.r. spectra
The 1H n.m.r. spectra of the compounds reported in this chapter are 
consistent with existing data. In deuterochloroform, the signal due to the protons of the 
3-methoxy group appeared in the range 5 4.01-4.16 for the 3-methoxy-2-phenyl-6- 
substituted benzylthio (and pyridylmethylthio)imidazo[l,2-£>]pyridazines (Table IV - 1) 
and 8 3.94-4.17 for the 2-aryl (and pyridyl)-6-benzylthio (and 3'-methoxybenzylthio)-3- 
methoxyimidazo[l,2-Z?]pyridazines (Table IV - 2). In all cases, the chemical shifts for 
the protons of the 3'-methoxy group occurred relatively more upfield ( 8 3.79-3.89) than 
those due to the 3-methoxy group. This is consistent with the n.m.r. spectra 
observed for 3-methoxy-6-phenoxyimidazo[l,2-£]pyridazines (see Chapter HI - 3).
The protons H 7 and H 8 attached to the pyridazine ring appeared as an AB 
quartet with a small chemical shift range of 8 6.75-6.84 for H 7 and 8 7.61-7.69 for H 8, 
with a coupling constant of J7,8 9 Hz. However, for 3-methoxy-6-(naphth-l'- 
ylmethylthio)-2-phenylimidazo[l,2-6]pyridazine (IV . 7d), the signal due to H 8 
occurred relatively downfield at 8 7.98.
An attempt was also made to investigate the presence of a k - k  interaction in 
solution between the phenyl ring of the 6-benzylthio group and the imidazo[ 1,2-0]- 
pyridazine ring using high resolution nuclear magnetic resonance spectroscopy. Nuclear 
Overhauser Effect252 (NOE) studies were carried out to observe the proximity of non- 
bonded protons. But no NOEs were detected between the protons on the phenyl ring of 
the 6-benzylthio group and that on the pyridazine part of the imidazo[l,2-£]pyridazine 
system under appropriate conditions.3
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*
a The author is grateful to Dr. G. Collins of the Australian Defence Force Academy, Duntroon, 
A.C.T., for this part of the work.
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Table IV -1 Some n.m.r. spectral data3 for 3-methoxy-2-phenyl-6-substituted 
benzylthio(and pyridylmethyIthio)imidazo[l,2-Z>]pyridazines
R 1 OMe (in R 1) 3-OMe H 7 H 8
Ph 4.10 6.78 7.65
C6 H4 Me-ob 4.15 6.80 7.66
C^ITtMe-m 4.12 6.79 7.64
C6 H4 M e-p 4.14 6.80 7.65
CöKUOMe-o 3.89 4.16 6.77 7.62
CßFLtOMe-m 3.82 4.12 6.80 7.66
C6 H4 0 Me-pb 3.79 4.14 6.78 7.66
C6 H4 CF3 -W 4.06 6.79 7.66
C6 H4 NMe2 -m 4.14 6.79 7.65
C6H4 NO2 - 0 4.10 6.76 7.64
C6H4N02-m 4.07 6.76 7.64
C6 H4 NO2 -/? 4.07 6.79 7.67
C6 H4 Cl-ob 4.12 6.81 7.69
CöITtCl-m 4.08 6.81 7.67
C6 H4 Cl-pb 4.09 6.77 7.65
C 5H4 N -a c 4.08 6.84 7.66
C5H4N-pc 4.08 6.78 7.65
C5H4 N-YC 4.01 6.78 7.65
C ioH 7-ad 4.12 6.78 7.98
3 Reported as parts per million (5) downfield from T.M.S. as internal standard in deuterochloroform. 
b Kindly provided by Mr. S J. Ireland. 
c Pyridyl. 
d Naphth-l'-yl.
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Table IV - 2 Some n.m.r. spectral data3 for 2-aryl-6-benzylthio(and 3'- 
methylbenzylthio)-3-methoxyimidazo[l,2-£]pyridazines
C H 2S
R1 R2 R1 = OMe 3-OMe H 7 H 8
H CöILtMe-p 4.09 6.76 7.63
H C6H4N02-m 4.16 6.83 7.65
H C6H4NO2-/? 4.15 6.84 7.65
H C6H4NH2-m 4.09 6.78 7.63
H C6H4 NH2-/? 4.07 6.75 7.61
OMe CöILtMe-o 3.80 3.94 6.78 7.63
OMe CöILtMe-m 3.80 4.10 6.78 7.63
OMe CöFLtMe-p 3.80 4.09 6.77 7.63
OMe C^ITtOMe-ö 3.80 4.04 6.75 7.64
OMe C^FUOMe-m 3.81 4.11 6.78 7.64
OMe CöILtOMe-p 3.80 4.09 6.77 7.62
OMe C6H4 F-0 3.79 4.12 6.78 7.62
OMe C6H4 F-W 3.80 4.12 6.78 7.62
OMe C6H4F -p 3.81 4.10 6.81 7.67
OMe C6H4 CF3 - 0 3.80 3.95 6.80 7.65
OMe C6H4CF3-/71 3.79 4.10 6.78 7.65
OMe C6H4 CF3-P 3.80 4.12 6.80 7.63
OMe C6H4N02-m 3.81 4.17 6.83 7.66
OMe C6H4 NH2-m 3.80 4.09 6.78 7.64
OMe C5H4N-ab 3.80 4.20 6.80 7.67
OMe C5H4N-ßb 3.80 4.13 6.80 7.63
OMe 3.80 4.15 6.81 7.62
3 Reported as parts per million (8) downfield from T.M.S as internal standard in deuterochloroform. 
b Pyridyl.
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ii Ionization constants, ultraviolet spectra and infrared spectra.
The ionization constant of 3-methoxy-6-methylthio-2-phenylimidazo[l,2-/?]- 
pyridazinea was found to be 3.40±0.06. It is a stronger base than 6-fluoro-3-methoxy- 
2-(4'-methylphenyl)imidazo[l,2-/?]pyridazine (pKa = 2.5310.06) (Chapter II - 3) and 3- 
methoxy-6-phenoxy-2-phenylimidazo[l,2-&]pyridazine (pKa = 3.2210.05) (Chapter III - 
3). The ultraviolet spectrum of the cationic species of 3-methoxy-6-methylthio-2- 
phenylimidazo[l,2-6]pyridazine (at pH 0.6) revealed two absorption bands at 250 nm 
(log e 4.47) and 353 nm (log e 4.18) whereas the neutral molecules of this compound 
displayed a strong peak at 255 nm (log e 4.45) and a broad band at ca. 365 nm (log e 
4.08). The cationic species of these compounds generally exhibit a shift to longer 
wavelength as compared with those of the neutral molecules.
The infrared absorption spectra of compounds from this series, such as 6- 
benzylthio-3-m ethoxy-2-phenylim idazo[l,2-fr]pyridazine, 2-(4 '-fluorophenyl)-3- 
m ethoxy-6-(3'-m ethoxybenzylthio)im idazo[ 1,2-&]pyridazine and 3-methoxy-6-(4'- 
methylbenzylthio)-2-phenylimidazo[l,2-b]pyridazine revealed the characteristic bands 
due to the C-S str in the range 630-660 cm-1.
iii Mass spectra
The mass spectrum of 3-methoxy-6-(4'-methylbenzylthio)-2-phenylimidazo- 
[l,2-b]pyridazine (IV . 4c), a representative of this series of compounds, showed the 
molecular ion peak associated with an M+2 peak which is characteristic of ions 
containing one sulphur atom.223a The major cleavage appeared to be at the bond between 
the benzyl group and sulphur (benzylic bond) to give the stable substituted benzyl cation 
which explains the intense m/z 105 ion peak. However, the fragmentation involving the 
loss of C2H3O from the molecular ion was also evident. The latter is consistent with the 
spectrum observed for 6-chloro-3-m ethoxy-2-(4 '-m ethylphenyl)im idazo[ 1,2-0]- 
pyridazine (I I . 3c). The mass spectrum of 6-benzylthio-3-methoxy-2-phenylimidazo- 
[l,2-&]pyridazine was found to be consistent with the above observation.
a This compound was kindly provided by Dr. G.B. Barlin.
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IV - 4 In vitro binding studies
The compounds prepared in this chapter were tested in the [3H] diazepam 
binding assay as described in Chapter II - 5.3.
IV - 4.1 Results of [3H]diazepam binding assay
The results of these binding studies are given in Table IV - 3 as IC50 values 
(or % displacement at the concentration specified). The results for compounds with 
varying substitutions at C-6 of the imidazo[l,2-fr]pyridazine system are presented first, 
followed by those which involve variations at C-2 and C-3 for the 6-benzylthio and 6- 
(3'-methoxybenzylthio) derivatives of imidazo[l,2-Z?]pyridazines. For a complete and 
comparative study, some data obtained by others will be incorporated, with appropriate 
footnotes, in Table IV - 3.
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Table IV - 3 Results for displacement of [3H]diazepam from rat brain by some 
substituted imidazo[l,2-&]pyridazines
7 f ^ Y ^ N ' ] i 2
6  XN ------------- 3
N 4
5
Formula Substituents IC50 Displacement (%) at
number (nM)a concn specified
I V . /
18 6-SPh-3-OMe-2-Phb 117
19 6-SCH2Ph-3-OMe-2-Phb 2 2
20 6-SCH2CH2Ph-3-OMe-2-Phb 666
21 6-SCH2CH2CH2Ph-3-OMe-2-Phb 373
7d 6-SCH2CioH 7-a c-3-OMe-2-Ph 1300
4a 6-SCH2C6H5Me-o-3-OMe-2-Ph 70
4b 6-SCH2C6H5Me-w-3-OMe-2-Ph 36
4c 6-SCH2C6H5Me-p-3-OMe-2-Ph 66
4d 6-SCH2C6H5OMe-ö-3-OMe-2-Ph 9
4e 6-SCH2C6H5OMe-m-3-OMe-2-Ph 10
4f 6-SCH2C6H5OMe-p-3-OMe-2-Ph 55
22 6-SCH2C6H5Cl-o-3-OMe-2-Phb 42
23 6-SCH2C6H 5Cl-m-3-OMe-2-Phb 49
24 6-SCH2C6H 5Cl-p-3-OMe-2-Phb 63
4g 6-SCH2C6H5CF3-m-3-OMe-2-Ph 64
4h 6-SCH2C6H5NM e2-m-3-OMe-2-Ph 239
4i 6-SCH2C6H5NM e2-p-3-OMe-2-C6H4Me-p 603
4} 6-SCH2C6H5N 0 2-ö-3-0M e-2-Ph 17
4k 6-SCH2C6H5N 0 2-m-3-0M e-2-Ph 8
41 6-SCH2C6H5N 0 2-p-3-0M e-2-Ph 31
8a 6-SCH2C6H5NH2-o-3-OMe-2-Ph 49
8b 6-SCH2C6H5NH2-m-3-OMe-2-Ph 15
8c 6-SCH2C6H5NH2-p-3-OMe-2-Ph 12
7a 6-SCH2C5H4N-<x d-3-OMe-2-Ph 5
7b 6-SCH2C5H4N-ß d-3-OMe-2-Ph 7
7c 6-SCH2C5H4N-yd-3-OMe-2-Ph 6
7e 6-SCH2C5H4N-a d-3-OMe-2-C6H4Me-p 4
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Table IV - 3 Continued
Formula
number
Substituents IC50
(nM)a
Displacement (%) at 
concn specified
IV ./
7f 6-SCH2C5H 4N -ad-3-OMe-2-C6H4F-p 8
11a 6-SCH2Ph-3-OMe-2-C6Fl4Me-p 19
lib 6-SCH2Ph-3-OEt-2-C6H4Me-p 332
11c 6-SCH2Ph-3-OMe-2-C6H4N02-m >1000
lid 6-SCH2Ph-3-OMe-2-C6H 4N 02-/7 >1000
13a 6-SCH2Ph-3-OM e-2-C6H4NH2-m 22
13b 6-SCH2Ph-3-OM e-2-C6H4NH2-/? 19
l ie 6-SCH2C6H5OMe-m-3-OMe-2-C6H4Me-o 171
I lf 6-SCH2C6H50Me-m-3-0Me-2-C6H4Me-m 42
n g 6-SCH2C6H 5OMe-m-3-OMe-2-C6H4Me-p 17
llh 6- S CH2C6H5 OMe-m-3 - OMe-2- CöHLtOMe-o 407
Hi 6- S CH2C6H50Me-m- 3- 0M e-2-C6H40M e-m 17
u j 6-SCH2C6H5OMe-m-3-OMe-2-C6H4 0 Me-/? 11
17a 6-SCH2C6H5OMe-m-3-OMe-2-C6H4F-ö 8
Ilk 6-SCH2C6H50 Me-m-3-0 M e-2-C6H4F-m 9
111 6-SCH2C6H 5OMe-m-3-OMe-2-C6H4F-p 5
11m 6-SCH2C6H 50 Me-m-3-0 Me-2-C6H4N 0 2-m 21.3% at 3000 nM
13c 6-SCH2C6H5OMe-m-3-OMe-2-C6H4NH2-m 5
17b 6-SCH2C6H5OMe-m-3-OMe-2-C6H4CF3-ö 19.2% at 1000 nM
17c 6-SCH2C6H5OMe-m-3-OMe-2-C6F[4CF3-m 156
17d 6-SCH2C6H 5OMe-m-3-OMe-2-C6H4CF3-p 208
17e 6-SCH2C6H5OMe-m-3-OMe-2-C5H4N-a d 448
17f 6-SCH2C6H5OMe-m-3-OMe-2-C5H4N-ß d 5
17g 6-SCH2C6H50Me-m-3-0Me-2-C5H4N-Y d 37
4m 6-SCH2C6H5OMe-m-3-OEt-2-Ph 62
12 6-SCH2C6H5OMe-m-3-H-2Ph 300
a IC50 values are the concentrations required to displace 50% of specific [^H]diazepam binding to rat brain
membrane preparation.
b Personal communication with Dr. G.B. Barlin and Dr. L.P. Davies. 
c Naphthyl, 
d Pyridyl.
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IV - 4.2 Discussion of results
The binding data observed by others for compounds IV . 18, 19, 20 and 
21 showed that 3-methoxy-2-phenyl-6-phenylthioimidazo[l,2-&]pyridazine (IV . 18, 
IC50 117 nM) was a more effective inhibitor of [3H]diazepam binding than its 6-phenoxy 
analogue (III . 6a, IC50 1122 nM). However its 6-benzylthio analogue (IV . 19) 
demonstrated a very much higher binding affinity for benzodiazepine receptors, with an 
IC50 value of 22 nM. Replacement of the benzylthio group at C-6 with a phenethylthio 
as in compound IV . 20 (IC50 666 nm) resulted in a drastic decrease in binding affinity. 
The 6-phenylpropylthio analogue (IV . 21, IC50 373 nM ) however showed an increase 
of displacement activity by approximately twofold. These results appear to suggest that 
if this phenyl ring is interacting with a hydrophobic cleft on the receptor, then, in the case 
of the benzylthio substituent, this phenyl group is more suitably positioned for binding, 
without adverse effect(s) on the interaction of the rest of the molecule with the receptor 
site. In addition, the binding data for the 6-naphth-l'-ylmethylthio analogue (compound 
IV . 7d, IC50 1300 nM) suggests that this hydrophobic cleft on the receptor would not 
accommodate a bicyclic ring. But while this interaction (between the phenyl ring of the 
benzylthio group and the hydrophobic cleft) appears to regulate the binding affinity of the 
molecule at the receptor, it is not essential for binding as shown by the displacement 
activities observed for the 3-alkoxy-2-aryl-6-halogenoimidazo[l,2-&]pyridazines (see 
Chapter II - 4.2).
To investigate further the binding profile at the apparent accessory binding 
site discussed above, the effect of substitution in the 6-benzylthio group of compound IV 
. 19 (IC50 22nM) was investigated. The results from Table IV - 3 show that such 
substitutions altered the relative binding affinity of this compound [As observed for the 
derivatives of 3-methoxy-6-phenoxy-2-phenylimidazo[l,2-&]pyridazine (see Chapter III 
- 4.2)]without complete removal of binding activity. Thus, substitutions with electron- 
withdrawing groups such as nitro and chloro at the para position, resulted in less 
effective binding (Compounds IV . 41 and IV . 24 had IC50 values of 31 and 63 nM, 
respectively). However, a similar substituent at the meta position revealed that a strong 
electron-withdrawing group like nitro (as in compound IV . 4k, IC50 8 nM) increased
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binding affinity by ca. twofold. In the ortho position, the nitro group was less activating 
as the G-effect at ortho position is dominated by its steric effect.
Subtitutions with electron-donating groups provided an interesting binding 
profile. In this case, a strong electron-donating substituent at the para position such as 
the amino group in compound IV . 8c (IC50 12 nM), was conducive to increased in vitro 
benzodiazepine receptor binding. However, a bulky group like dimethylamino 
(compound IV . 4i, IC50 603 nM) was detrimental. This latter observation is consistent 
with the low activity of compound IV . 7d (naphthylmethylthio group at C-6, IC50 1300 
nM). A similar trend was observed for substitutions with electron-donationg groups at 
the meta position. In compounds with the substituent at the ortho position, the binding 
efficacy was seven times higher in the methoxy compound (IV . 4d) than its methyl 
analogue (compound IV . 4a) (IC50 values were 9 nM and 70 nM, respectively). The 
binding by the o-amino compound (IV . 8a, IC50 49 nM) was less effective than in the 
ö-methoxy compound (IV . 4d). Further analyses of the above results will be attempted 
in Chapter VIII - 2.
It was also apparent from the results for compounds IV . 7 (a, b and c) that a 
pyridylmethylthio group on C-6 was more beneficial than benzylthio by about three- to 
four-fold. However, further substitutions to the 2-phenyl group of these compounds (as 
in compounds IV . 7e and 7f) did not enhance their binding activity.
In the second part of the investigation in this chapter, I examined the effect of 
modifying the substituents in the phenyl ring at C-2 but retained the benzylthio and 3- 
methoxybenzylthio groups as the most suitable substituents at C-6. This was studied in 
the twenty-three compounds (IV . 11a-17f, Table IV - 3). The IC50 values reveal that 
strong electron-with drawing substituents like nitro and trifluoromethyl groups [as in 
compounds IV . 11 (c, d and m) and IV . 17 (b, c and d), respectively] are not 
conducive to binding. However, a small substituent with a relatively weak electron - 
withdrawing property, such as a fluoro group (ap = 0.06),245 improved binding. This 
was more pronounced in the case of para-fluoro substitution (IV . Ill, IC50 5 nM). 
Substitution with electron-donating groups in the 2-phenyl substituent revealed that while 
an amino group at meta position was beneficial as in compound IV . 13c (IC50 5 nM),
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the same substituent had no significant effect in compound IV . 13a (IC50 22 nM) relative 
to 6-benzylthio-3-methoxy-2-phenylimidazo[l,2-Z?]pyridazine (IV . 19, IC50 22 nM).
The replacement of the 2-phenyl group on C-2 of 3-methoxy-6-(3'- 
methoxybenzylthio)-2-phenylimidazo[l,2-Z?]pyridazine (IV . 4e, IC50 10 nM) with a 
pyridyl group showed that a pyrid-3'-yl substituent (as in compound IV . 17f, IC50 5 
nM) increased binding activity. In contrast, a pyrid-2'-yl group (as in compound IV . 
17e) decreased the displacement activity by about forty five-fold, compared to the 2- 
phenyl compound (IV . 4e)
In the third part of this study on the interaction of this series of compounds 
with the benzodiazepine receptor, we examined the effect of modifying the substituent on 
C-3 of 3-methoxy-6-(3'-methoxybenzylthio)-2-phenylimidazo[l,2-£]pyridazine (IV . 4e, 
IC50 lOnM). Replacement of the 3-methoxy group with an ethoxy substituent 
(compound IV . 4m) resulted in ca. sixfold decrease in binding efficiency whereas the 3- 
unsubstituted compound (as in compound IV . 12, IC50 300 nM) showed ca. thirtyfold 
decrease in binding. This result differs from that of the 2-aryl-6-halogeno-3- 
methoxyimidazo[l,2-&]pyridazines (see Table II - 2, compound I I . 8). In compound II 
. 8 (6-chloro-2-phenylimidazo[l,2-&]pyridazine) the absence of the methoxy group at 
C-3 led to no observable binding at a concentration of 1000 nM. It appears that the 
partial retention of binding affinity at the benzodiazepine receptor by compound IV . 12 
viz. 6-(3'-methoxybenzylthio)-2-phenylimidazo[l,2-fr]pyridazine may be due to the 
weak interaction of the 6-(3'-methoxybenzylthio) group with the earlier mentioned 
accessory binding site on the receptor.
The results of our studies on this series of compounds suggest the presence 
of an accessory binding site on the benzodiazepine receptor which may be involved in 
regulating the relative binding affinity of the molecule interacting with the receptor. 
Binding to this site however is not essential as opposed to binding at the hydrophobic site 
mentioned in Chapter II - 4.3. In addition, we found that when a favourable substituent 
was maintained at C-6 [such as 6-(3'-methoxybenzylthio)], a p-fluorophenyl, m- 
aminophenyl or a pyrid-3'-yl group at C-2 (as in compounds IV . Ill,  13c, 17e) was
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beneficial for binding activity. This observation will be further extended with other 
substituents at C-6 in the following chapters.
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IV - 5 Experimental
The general procedure and experimental details for the [3H]diazepam binding 
assay are recorded in Chapter II - 5.1 and 5.3
6-Aminopyridazine-3-thiol (IV . 1)
6-Aminopyridazine-3-thiol was prepared from 6-chloropyridazin-3-amine 
through 3-acetamido-6-chloropyridazine and 6-acetamidopyridazine-3-thiol as described 
by Kumagai and Bando.249
6-(2'-MethylbenzyIthio)pyridazin-3-amine (IV . 2a)
6-Aminopyridazine-3-thiol (0.15 g) was dissolved in a solution of 0.25 M 
sodium hydroxide (6.0 ml) and stirred with 2-methylbenzyl chloride (0.18 g) at 20° for 3 
h. The precipitate was collected and recrystallised from toluene to give 6-(2'~ 
methylbenzylthio)pyridazin-3-amine (0.160 g), m.p. 93-94° (Found, for a sample dried 
at 60° and 0.1 mmHg for 8 h : C, 62.1; H, 6.0; N, 18.3. C12H 13N3S requires C, 62.3; 
H, 5.7; N, 18.2%). *H n.m.r. (CDCI3) : 5 2.41, s, Me; 4.50, s, CH2; 4.6, b, NH2; 
6.63, d, J4 ,5 9 Hz, H 5(4); 7.06, d, J4 ,5 9 Hz, H 4(5); 7.11-7.38, complex, H 
3’,4 ',5 ’,6 '.
6-(2'-Methoxybenzylthio)pyridazin-3-amine (TV. 2d)
2-Methoxybenzyl chloride253 (0.8 g, prepared from 2-methoxybenzyl 
alcohol with thionyl chloride) was shaken with a solution of 6-aminopyridazine-3-thiol 
(0.6 g) in 0.3 M sodium hydroxide (20 ml) for 4 h. The solid was filtered off and 
recrystallised from toluene to give the title compound (0.8 g), m.p. 96-99° (Found : C, 
58.9; H, 5.5; N, 16.7. C i2H i 3N3OS requires C, 58.3; H, 5.3; N, 17.0%). *H n.m.r. 
(CDCI3) : 5 3.85, s, MeO; 4.43, s, CH2; 6.80, d, 7.13, d, J4j5 9 Hz, H 4,5; 6.85-7.43, 
complex, H 3',4',5',6 '.
In a similar manner from 6-aminopyridazine-3-thiol and 3-methylbenzyl 
chloride, 4-methylbenzyl chloride, 3-methoxybenzyl chloride, 3-(trifluoromethyl)benzyl 
chloride and 1-chloromethylnaphthalene were prepared the following compounds.
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6-(3'-Methylbenzylthio)pyridazin-3-amine (IV . 2b) (65%), m.p.102-103° (from 
toluene) (Found, for a sample dried at 60° and 0.1 mmHg for 8 h : C, 62.3; H, 5.6; N,
18.2. C12H 13N3S requires C, 62.3; H, 5.7; N, 18.2%). *H n.m.r. (CDCI3) : 6 2.30, 
s, Me; 4.43, s, CH2; 4.6, b, NH2; 6.61, d, J4,5 9 Hz, H 5(4); 7.05, d, J4,5 9 Hz, H 
4(5); 7.13-7.21, complex, H 2',4',5',6 '.
6-(4'-Methylbenzylthio)pyridazin-3-amine (IV . 2c) (54%), m.p. 125-127° (from 
toluene) (Found, for a sample dried at 30° and 0.1 mmHg for 16 h : C, 62.0; H, 5.8; N,
18.3. Ci2H i3N3S requires C, 62.3; H, 5.7; N, 18.2%). lR n.m.r. (CDCI3) : 5 2.32, 
s, Me; 4.48, s, CH2; 4.60, b, NH2; 6.62, d, J4,5 9 Hz, H 5(4); 7.07, d, J4,5 9 Hz, H 
4(5); 7.03, d, 7.32, d, J 9 Hz, H 2',3’,5’,6’.
6-(3'-MethoxybenzyIthio)pyridazin-3-amine (IV. 2e) (64%), m.p.75-76° (from toluene) 
(Found : C, 58.2; H, 5.3; N, 16.8. Ci2H i 3N3OS requires C, 58.3; H, 5.3; N, 17.0%). 
*H n.m.r. (CDCI3) : 5 3.78, s, MeO; 4.46, s, CH2; 4.7, b, NH2; 6.59, d, J4i5 9 Hz, H 
5(4); 7.05, d, J4,5 9 Hz, H 4(5); 6.70-7.27, complex, H 2’,4’,5’,6 ’.
6-(3'-TrifluoromethyIbenzylthio)pyridazin-3-amine (IV . 2g) (50%), m.p. 102-104° 
(from cyclohexane) (Found : C, 50.4; H, 3.5; N, 14.8. C i 2H ioF3N3S requires C, 
50.5; H, 3.5; N, 14.7%). *H n.m.r. (CDCI3) : 5 4.52, s, CH2; 4.7, b, NH2; 6.63, d, 
7.06, d, J4>5 9 Hz, H 4, 5; 7.38-7.67, complex, H 2',4’,5',6 '.
6-(Naphth-r-ylmethyIthio)pyridazin-3-amine (IV . 5d) (37%), m.p. 145-147° (from 
toluene) (Found : C, 67.5; H, 4.9; N, 15.6. C15H13N3S requires C, 67.4; H, 4.9; N, 
15.7%). lR n.m.r. (CDCI3) : 5 4.6, b, NH2; 4.98, s, CH2; 6.62, d, J4>5 9 Hz, H 5(4); 
7.02, d, J4,5 9 Hz, H 4(5); 7.45-8.21, complex, H 3',4',5',6 ',7’,8 '.
3-DimethylaminobenzyI chloride hydrochloride
This compound was prepared from 3-dimethylaminobenzoic acid through its 
ester and the corresponding benzyl alcohol as follows.
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3- Dimethylaminobenzoic acid (5 g), methanol (30 ml) and concentrated 
sulphuric acid (4.0 ml) were refluxed for 4 h. The alcohol was evaporated, the residue 
diluted with water, made alkaline, and extracted with carbon tetrachloride to give the 
ester (4.5 g).
This ester (2.0 g) in ether (10 ml) was added slowly to lithium aluminium 
hydride (0.6 g) in ether (10.0 ml) with stirring at 0°.Then saturated sodium carbonate 
solution (7.0 ml) was added to the cold mixture and stirring continued for 30 minutes 
until all the grey solid became white. The ether solution was then filtered off, dried, and 
evaporated to give a colourless oil (1.6 g). This oil (1.0 g) with concentrated 
hydrochloric acid (25 ml) in a screw top reaction vessel was heated at 100° for 15 h. 
The volatile material was removed under reduced pressure to yield an oil (1.3 g). *H 
n.m.r. (CDCI3) : 5 3.22, s, Me2N; 4.63, s, CH2; 7.52-7.87, complex, H 2,3,5,6 .
6-(3'-Dimethylaminobenzylthio)pyridazin-3-amine (TV. 2h)
6-Aminopyridazine-3-thiol234 (0.6 g) in 0.25 M sodium hydroxide (40 ml) 
was shaken with 3-dimethylaminobenzyl chloride hydrochloride (0.9 g). The precipitate 
was filtered off and recrystallised from toluene to give the title compound (0.55 g), 
m.p. 120-122° (Found : C, 60.4; H, 6.3; N, 21.4. C13H 16N4S requires C, 60.0; H, 
6.2; N, 21.5%). l H n.m.r. (CDCI3) : 5 7.03, d, J4 ,5 9 Hz, H 4, 5; 6.58-7.26, 
complex, H 2’,4’,5',6 '.
4-Dimethylaminobenzyl chloride hydrochloride
4- Dimethylaminobenzyl alcohol254 (l.Og) and concentrated hydrochloric acid 
(2.5ml) were heated in a screw top bomb at 100° for 15h.255 The volatile material was 
removed on a rotary evaporator to give a yellow oil (1.3g; 96%). *H n.m.r. (CDCI3) : 5 
3.21, s, Me2N; 4.61, s, CH2; 7.56, d, 7.85, d, J2,3 9 Hz, H 2,3,5,6 .
6-(4'-DimethyIaminobenzyIthio)pyridazine (TV. 2i)
This compound was prepared for 6-aminopyridazine-3-thiol249 (0.3 g) and 
4-dimethylaminobenzyl chloride hydrochloride (0.45 g) as described above for the 3-
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dimethylamino-isomer. The product recrystallised from toluene to give yellow crystals 
of the title compound (0.3 g), m.p.157-160° (Found : C, 59.7; H, 6.2; N, 21.3. 
C13H16N4S requires C, 60.0; H, 6.2; N, 21.5%). *H n.m.r. (CDCI3) : 5 2.92, s, 
Me2N; 4.41, s, CH2; 4.6, b, NH2; 6.60, d, 7.04, d, J4,5 9 Hz, H 4,5; 6.66, d, 7.28, 
J2',3' 9 Hz, H 2’,3’,5',6’.
6-(2,-Nitrobenzylthio)pyridazin-3-amine (TV. 2j)
2- Nitrobenzyl chloride (0.85 g) and 6-aminopyridazine-3-thiol (0.6 g) with 
sodium hydroxide (0.24 g) in water (20 ml) gave a precipitate (1.1 g) which 
recrystallised from toluene with C filtration to give greenish yellow crystals of the title 
c o m p o u n d in g ) ,  m.p.100-102° (Found : C, 50.6; H, 3.9; N, 21.5. CnHioN402S 
requires C, 50.4; H, 3.8; N, 21.4%). *H n.m.r. (CD3SOCD3) : 8 4.65, s, CH2; 6.3, b, 
NH2; 6.67, d, 7.16, d, J4,5 9 Hz, H 4,5; 7.39-8.03, complex, H 3',4’,5',6’.
6-(3'-Nitrobenzylthio)pyridazin-3-amine (TV. 2k)
3- Nitrobenzyl chloride (0.85 g) and 6-aminopyridazine-3-thiol (0.6 g) gave a 
precipitate (1.1 g) which recrystallised from toluene with C filtration to give, in a manner 
similar to that described above, 6-(3'-nitrobenzylthio)pyridazin-3-amine (0.95 g) 
m .p.115-117° (from toluene) (Found : C, 50.2; H, 3.8; N, 21.2. C nH ioN 402S 
requires C, 50.4; H, 3.8; N, 21.4%). *H n.m.r. (CDCI3) : 5 4.54, s, CH2; 4.9, b, 
NH2; 6.65, d, 7.07, d, J4,5 9 Hz, H 4,5; 7.34-8.29, complex, H 2',4’,5',6'.
6-(4'-Nitrobenzylthio)pyridazin-3-amine (TV. 21)
6-Aminopyridazine-3-thiol (0.6 g) in 0.3 M sodium hydroxide (20 ml) with
4-nitrobenzylchloride (0.85 g) at room temperature gave a greenish precipitate which was 
chromatographed in chloroform over alumina and the product eluted with methanol and 
recrystallised from toluene to give light yellow crystals of the title compound (0.80 g), 
m.p.156-158° (Found : C, 50.2; H, 3.8; N, 21.1. C nH i0N4O2S requires C, 50.4; H, 
3.8; N, 21.4%). JH n.m.r. (CDCI3) : 5 4.54, s, CH2; 6.65, d, 7.07, d, J4,5 9 Hz, H 
4,5; 7.59, d, 8.13, d, J2-,3- 9 Hz, H 2’,3',5’,6’.
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6-(Pyrid-2'-ylmethylthio)pyridazin-3-amine (IV . 5a)
6-Aminopyridazine-3-thiol249 (0.44 g) in 0.5 M sodium hydroxide (15 ml) 
was shaken with pyrid-2-ylmethyl chloride hydrochloride (0.58 g) for 4 h. The aqueous 
solution was extracted with chloroform, the extract washed with water and dried 
(Na2S0 4 ). Evaporation of the solvent gave a white solid which was recrystallised from 
toluene to give the title compound (0.6 g), m.p.124-1260 (Found : C, 55.3; H, 4.6; N, 
25.5. C10H 10N4S requires C, 55.0; H, 4.6; N, 25.7%). *H n.m.r. (CD3SOCD3) : 6 
4.45, s, CH2; 6.25, s, NH2; 6.69, d, 7.24, d, J4 ,5 9 Hz, H 4,5; 7.16-8.49, complex, H 
3 ',4 ’,5 ’,6 '.
6-(Pyrid-3,-ylmethylthio)pyridazin-3-amine (IV . 5b)
In a similar manner, was prepared the title compound (76%), m.p. 105-107° 
(Found : C, 54.7; H, 4.6; N, 25.4. C10H 10N4S requires C, 55.0; H, 4.6; N, 25.7%). 
*H n.m.r. (CD3SOCD3) : 6 4.37, s, CH2; 6.3, s, NH2; 6 .6 8 , d, 7.20, d, J4,5 9 Hz, H 
4,5; 7.22-8.55, complex, H 2’,4',5',6 ’.
6-(Pyrid-4'-yImethylthio)pyridazin-3-amine (TV. 5c)
The title compound (80%) was prepared similarly. It had m.p.187-1880 
(Found : C, 55.1; H, 4.5; N, 25.6. C10H 10N4S requires C, 55.0; H, 4.6; N, 25.7%). 
*H n.m.r. (CD3SOCD3) : 5 4.36, s, CH2; 6.29, s, NH2; 6.69, d, 7.21, d, J4,5 9 Hz, H 
4,5; 7.35, d, 8.45, d, J2\y  6 Hz, H 2',3’,5',6’.
6-(3’-Methoxybenzylthio)pyridazin-3-amine 2-oxide (IV . 15)
3-Methoxybenzyl chloride (7.0 g) and thiourea (3.5 g) in 95% ethanol (40 
ml) were refluxed for 24 h, then 2 M sodium hydroxide (30 ml) was added and the reflux 
continued for 3h. This mixture was acidified, and extracted with benzene to give crude 3- 
methoxyphenylmethanethiol (6.0 g) as an oil. *H n.m.r. (CD3CI3) : 5 1.67, t, J 7.5 Hz, 
SH; 3.60, d, CH2; 3.69, s, MeO; 6.61-7.23, complex, H 2,4,5,6 .
6-Chloropyridazin-3-amine 2-oxide238 (1.0 g) and crude 3-methoxyphenyl- 
methanethiol (1.3 g) and 0.5 M sodium hydroxide (20 ml) were heated in a sealed
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reaction vessel at 115° for 16 h. The product was extracted into chloroform, washed 
with M sodium hydroxide and water and dried over sodium sulphate. After evaporation 
of the solvent the solid was recrystallised from benzene to give 6-(3'-  
methoxybenzyIthio)pyridazin-3-amine 2-oxide (1.16 g), m.p. 127-128° (Found : C, 
55.0; H, 5.0; N, 15.9. C12H13N3O2S requires C, 54.7; H, 5.0; N, 16.0%). n.m.r. 
(CDCI3): 6 3.78, s, MeO; 4.34, s, CH2; 6.77-7.31, complex, H 4,5,2',4',5’,6'.
3-Methoxy-6-(2'-methoxybenzylthio)-2-phenyIimidazo[l,2-£]pyridazine (IV . 4d)
A solution of phenylglyoxal (0.24 g) in ethanol (2.0 ml) was added to a 
solution of 6-(2'-methoxybenzylthio)pyridazin-3-amine (0.4 g) in ethanol (30 ml)with 
concentrated hydrochloric acid (0.5 ml) and the mixture refluxed for 8 h. The solvent 
was evaporated and the residue evaporated with water to give a sticky product.
This product was stirred with excess ethereal diazomethane overnight, the 
solvent evaporated and the product subjected to t.l.c. (alumina; chloroform) to give an oil 
(0.10 g) which was recrystallised from light petroleum (b.p. 40-60°) to give the title 
compound, m.p. 101-102° (Found : C, 67.1; H, 5.2; N, 11.2. C21H19N3O2S requires 
C, 66.8; H, 5.1; N, 11.0%). lH n.m.r. (CDCI3) : 6 3.89, s, 2'-OMe; 4.16, s, 3-OMe; 
4.52, s, CH2; 6.77, d, J7,8 9 Hz, H 7; 6.86-8.19, complex, H 3',4',5',6' and Ph; 7.62, 
d, J7,g 9 Hz, H 8.
3-Methoxy-6-(3'-methoxybenzylthio)-2-phenylimidazo[l,2-£]pyridazine (IV . 4e)
A mixture of 6-(3'-methoxybenzylthio)pyridazin-3-amine (0.100 g), 
phenylglyoxal (0.067 g), ethanol (9.0 ml) and concentrated hydrochloric acid (0.1 ml) 
was refluxed for 8 h, and the solvent was evaporated. The residue was diluted with 
water, chilled in ice and the orange solid filtered off and washed with water.
This product was stirred with ethereal diazomethane in ice and at 20° 
overnight. The solvent was evaporated and the product subjected to t.l.c. (alumina; 
chloroform) to give a 3-methoxy-6-(y-methoxybenzylthio)-2-phenylimidazo[l ,2-\>]- 
pyridazine as an oil (0.040 g) (Found, for a sample dried at 40° and 0.1 mmHg for 5 h : 
C, 66.9; H, 5.2. C21H19N3O2S requires C, 66.8; H, 5.1%). *H n.m.r. (CD3CI3): 5
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3.82, s, 3'-0Me; 4.12, s, 3-OMe; 4.48, s, CH2; 6.80, d, J7,8 9 Hz, H 7; 7.66, d, J7,g 9 
Hz, H 8; 7.07-8.16, complex, H 2',4',5',6' and Ph.
3-Ethoxy-6-(3'-methoxybenzyIthio)-2-phenylimidazo[l,2-Z>]pyridazine (IV. 4m)
This compound was prepared in a similar manner but alkylation was with 
diazoethane.256 The product was subjected to t.l.c. (alumina; benzene, developed twice 
then alumina; chloroform) to give an oil which eventually crystallised from light 
petroleum (b.p. 40-60°) to give light green crystals of the title compound (10%), m.p. 
68-70° (Found, for a sample dried at 45° and 0.2 mmHg for 4 h : C, 67.3; H, 5.4; N, 
10.6. C22H21N3O2S requires C, 67.5; H, 5.4; N, 10.7%). *H n.m.r. (CDCI3) : 5 
1.46, t, J 7 Hz, CH3CH2; 3.80, s, MeO; 4.35, quart, J 7 Hz, CH3CH2; 4.45, s, CH2; 
6.76, d, J7,8 9 Hz, H 7; 6.78-8.20, complex, H 2’,4’,5’,6’ and Ph; 7.62, d, J7,8 9 Hz, 
H 8.
3-Methoxy-6-(4'-methylbenzylthio)-2-phenylimidazo[l,2-£]pyridazine (TV. 4c)
A mixture of 6-(4'-methylbenzylthio)pyridazin-3-amine (0.30 g), 
phenylglyoxal (0.20 g), ethanol (10.0 ml) and concentrated hydrochloric acid (0.2 ml) 
was refluxed for 7 h. After evaporation of the solvent, the residue was broken up with 
water and fdtered to give a yellow solid (0.20 g).
This solid (0.15 g) was methylated with diazomethane and the product 
subjected to t.l.c. (alumina; chloroform) to give an oil which crystallised. It was 
recrystallised from light petroleum (b.p. 60-80°) to give 3-methoxy-6-(4'~  
methylbenzylthio)-2-phenylimidazo[l,2-b]pyridazine (0.05 g), m.p. 109-112° (Found, 
for a sample dried at 20° and 0.1 mmHg for 16 h : C, 69.9; H, 5.5; N, 11.5. 
C21H19N3OS requires C, 69.8; H, 5.3; N, 11.6%). lH n.m.r. (CDCI3): 5 2.35, s, Me; 
4.14, s, MeO; 4.48, s, CH2; 6.80, d, J7,8 9 Hz, H 7; 7.65, d, J7,8 9 Hz, H 8; 7.14- 
8.16, complex, H 2',3',5',6' and Ph. Mass spectrum : m/z 361 (M+) (61%), 346 
(12%), 318 (58%), 317 (80%), 105% (100%), 77 (24%). v max (KBr) : 3040 (w), 
2940 (w), 2860 (w), 1570 (m), 1530 (m), 1200 (s), 1070 (s), 820 (s), 630 (s).
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In a similar manner from phenylglyoxal and 6-(2'-methylbenzylthio)- 
pyridazin-3-amine, 6-(3'-methylbenzylthio)pyridazin-3-amine, 6-(naphth-l'-ylmethyl- 
thio)pyridazin-3-amine ( reflux with phenylglyoxal for 16 h) and 6(3'-trifluoromethyl- 
benzylthio)pyridazin-3-amine the following compounds were prepared.
3-Methoxy-6-(2'-methyIbenzyIthio)-2-phenylimidazo[l,2-£]pyridazine (IV . 4a)
(18%), m.p. 99-101° [from light petroleum (b.p. 60-80°)] (Found, for a sample dried 
at 30° and 0.1 mmHg for 16 h : C, 69.5; H, 5.5; N, 11.5. C21H 19N3OS requires C, 
69.8; H, 5.3; N, 11.6%). JH n.m.r. (CDCI3) : 5 2.49, s, Me; 4.15, s, MeO; 4.52, s, 
CH2; 6.80, d, J7,8 9 Hz, H 7; 7.66, d, J7,8 9 Hz, H 8 ; 7.22-8.17, complex, H 
3’,4',5’,6 ' and Ph.
3-Methoxy-6-(3'-methyIbenzyIthio)-2-phenylimidazo[l,2-£]pyridazine (IV . 4b)
(20%) as an oil (from t.l.c.) (Found, for a sample dried at 30° and 0.1 mmHg for 16 h : 
C, 70.2; H, 5.6. C21H 19N3OS requires C, 69.8; H, 5.3%). *H n.m.r. (CDCI3) : 5 
2.35, s, Me; 4.12, s, MeO; 4.47, s, CH2; 6.79, d, J7,8 9 Hz, H 7; 7.64, d, J7>8 9 Hz, 
H 8 ; 7.40-8.15, complex, H 2’,4',5’,6 ' and Ph.
3-Methoxy-6-(naphth-l'-ylmethylthio)-2-phenyIimidazo[l,2-ft]pyridazine (IV . 7d)
(15%), m.p. 151-153° [from light petroleum (b.p. 40-60°)] (Found, for a sample dried 
at 40° and 0.1 mmHg for 3 h : C, 72.0; H, 4.8; N, 10.4. C24H 19N3OS requires C, 
72.5; H, 4.8; N, 10.6%). *H n.m.r. (CDCI3) : 5 4.12, s, Me; 4.99, s, CH2; 6.78, d, 
J7>8 9 Hz, H 7; 7.98, d, J7>8 9 Hz, H 8 ; 7.51-8.21, complex, H 2’,3',5',6 ’,7',8 ' and 
Ph.
3-Methoxy-2-phenyl-6-(3,-trifluoromethylbenzylthio)imidazo[l,2-Z>]pyridazine 
(IV . 4g)
In this preparation the phenylglyoxal (0.134 g) and 6-(3'-trifluoro- 
methylbenzylthio)pyridazin-3-amine (0.285 g) were refluxed as above but for 15 h.
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The final product, after t.l.c. (alumina; chloroform and alumina; toluene) was 
an oil which crystallised from light petroleum (b.p. 40-60°) to give green needles of.the 
title compound (15%), m.p. 116-118° (Found : C, 61.0; H, 3.8; N, 10.2. 
C21H 16F3N3OS requires C, 60.7; H, 3.9; N, 10.1%). *H n.m.r. (CDCI3) : 5 4.06, s, 
MeO; 4.52, s, CH2; 6.79, d, J7,g 9 Hz, H 7; 7.32-8.17, complex, H 2’,4',5’,6’ and Ph; 
7.66, d, J7,8 9 Hz, H 8 .
6-(3'-DimethyIaminobenzylthio)-3-methoxy-2-phenylimidazo[l,2-Z>]pyridazine (IV . 4h)
Phenylglyoxal (0.14 g) in ethanol (2.0 ml) was added to a stirred refluxing 
solution of 6-(3'-dimethylaminobenzylthio)pyridazin-3-amine (0.25 g), ethanol (15 ml) 
and concentrated hydrochloric acid (0.3 ml) and the mixture refluxed for 9 h.
After evaporation of the solvent the residue was methylated with ethereal 
diazomethane and the product purified by t.l.c.(alumina; chloroform), and 
recrystallisation from light petroleum (b.p. 40-60°) to give the title compound (0.035 g), 
m.p. 129-130° (Found : C, 67.7; H, 5.8; N, 14.1. C22H22N4OS requires C, 67.7; H, 
5.7; N, 14.3%). *H n.m.r. (CDCI3) : 6 2.96, s, Me2N; 4.14, s, MeO; 4.47, s, CH2; 
6.79, d, J7>8 9 Hz, H 7; 6.64-8.18, complex, H 2’,4’,5’,6 ’ and Ph; 7.65, d, J7,8 9 Hz, 
H 8 .
6-(4'-DimethyIaminobenzyIthio)-3-methoxy-2-(4"-methylphenyI)imidazo[l,2-£]- 
pyridazine (IV . 4i)
This compound was prepared from 6-(4'-dimethylaminobenzylthio)- 
pyridazin-3-amine (0.2 g) and 4-methylphenylglyoxal hydrate230*234 (0.14 g) as 
described above for the reaction with phenylglyoxal. After methylation, t.l.c. (alumina; 
chloroform) gave a yellow oil (0.04 g) which crystallised from a mixture of cyclohexane 
and light petroleum (b.p. 40-60°) to give 6-(4'-dimethylaminobenzylthio)-3-methoxy-2- 
(4"-methylphenyl)imidazo[ 1,2-b]pyridazine, m.p. 170-173° (Found, for a sample dried 
at 75° and 2 mmHg for 5 h : C, 68.5; H, 6.1; N, 13.7. C23H24N4OS requires C, 68.3; 
H, 6.0; N, 13.8%). lH n.m.r. (CDCI3) : 6 2.41, s, 4"-Me; 2.93, s, Me2N; 4.15, s,
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MeO; 4.44, s, CH2; 6.75, d, J7>8 9 Hz, H 7; 6.64-8.11, complex, H 2’,3’,5',6’, 
2”,3",5”,6"; 7.60, d, J7,g 9 Hz, H 8.
3-Methoxy-6-(2'-nitrobenzylthio)-2-phenylimidazo[l,2-Zdpyridazine (TV. 4j)
Phenylglyoxal (0.3 g) in ethanol (3.0 ml) was added to a refluxing solution 
of 6-(2'-nitrobenzylthio)pyridazin-3-amine (0.55 g) in ethanol (50 ml) containing 
concentrated hydrochloric acid (1.2 ml) and the mixture refluxed for 9 h. After 
evaporation of the solvent the crude hydroxy compound was methylated with 
diazomethane in ether as above. The crude product was purified by t.l.c. (alumina; 
chloroform) to give flakey yellow crystals of the title compound (0.060 g), m.p. 153- 
1540 (Found : C, 61.2; H, 4.2; N, 14.4. C20H16N4O3S requires C, 61.2; H, 4.1; N, 
14.3%). *H n.m.r. (CDCI3): 6 4.10, s, MeO; 4.85, s, CH2; 6.76, d, J7,8 9 Hz, H 7; 
7.32-8.17, complex, H 2’,4',5’,6' and Ph; 7.64, d, J7,8 9 Hz, H 8.
3-Methoxy-6-(3'-nitrobenzyIthio)-2-phenylimidazo[l,2-Zdpyridazine (IV . 4k)
6-(3'-Nitrobenzylthio)pyridazin-3-amine (0.42 g) and phenylglyoxal (0.24 g) 
were induced to react as for the 2'-nitro isomer above. After reflux, the reaction mixture 
was diluted with water (10.0 ml) and adjusted to pH 7. The precipitate (0.11 g) was 
methylated as above to give the title compound (0.060 g), m.p. 132-134° (from 
chloroform-cyclohexane) (Found : C, 61.4; H, 4.1; N, 14.3. C2oHi6N403S requires 
C, 61.2; H, 4.1; N, 14.3%). *H n.m.r. (CDCI3) : 5 4.07, s, MeO; 4.52, s, CH2; 6.76, 
d, J7,8 9 Hz, H 7; 7.30-8.39, complex, H 2’,4’,5’,6’ and Ph; 7.64, d, J7j8 9 Hz, H 8.
3-Methoxy-6-(4'-nitrobenzylthio)-2-phenylimidazo[l,2-Zdpyridazine (IV . 41)
6-(4'-Nitrobenzylthio)pyridazin-3-amine (0.42 g) and phenylglyoxal (0.24 g) 
similarly gave the crude oxo compound (0.6 g) which was filtered off, washed with 
water and dried at 100°.
This solid was methylated with ethereal diazomethane as above and the 
product subjected to t.l.c. (alumina; chloroform) to give a yellow solid which was 
recrystallised from cyclohexane, then methanol to give the title compound (0.06 g), m.p.
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172-173° (Found : C, 61.0; H, 4.2; N, 14.1. C20H16N4O3S requires C, 61.2; H, 4.1; 
N, 14.3%). *H n.m.r. (CDCI3) : 5 4.07, s, MeO; 4.55, s, CH2; 6.79, d, J7,8 9 Hz, H 
7; 7.39-8.07, complex, Ph; 7.67, d, J7>8 9 Hz, H 8; 7.70, d, 8.20, d, J2',3’ 9 Hz, H 
2 ’, 3 ’, 5 ’,6 ’.
3-Methoxy-2-phenyI-6-(pyrid-2'-ylmethyIthio)imidazo[l,2-£]pyridazine (TV. 7a)
A mixture of 6-(pyrid-2'-yl)methylthiopyridazin-3-amine (0.24 g), 
phenylglyoxal (0.16 g) and concentrated hydrochloric acid (0.6 ml) in ethanol (10 ml) 
was refluxed with stirring, for 9 h.
After cooling, water (10 ml) was added and the pH was adjusted to 7 with 1 
M sodium hydroxide, and the orange precipitate (0.1 g) was filtered off. This solid was 
stirred with a cold solution of ethereal diazomethane at 0° and then at 20° overnight. The 
crude product was subjected to t.l.c. (alumina; chloroform) to give the title compound as 
an oil (0.05 g) (Found, for a sample dried at 80° for 5 h : C, 64.5; H, 5.1; N, 15.4. 
Ci9Hi6N40 3S requires C, 64.0; H, 4.8; N, 15.7%). *H n.m.r. (CDCI3) : 6 4.08, s, 3- 
OMe; 4.74, s, CH2; 6.84, d, J7,8 9 Hz, H 7; 7.12-8.63, complex, H 2’,3’,5’,6’ and 
Ph; 7.66, d, J7>8 9 Hz, H 8.
In a similar manner from the above 6-(pyridylmethylthio)pyridazin-3-amines 
the following compounds were prepared by reaction with phenylglyoxal, 4- 
methylphenylglyoxal,234 or 4-fluorophenylglyoxal,236 followed by methylation with 
diazomethane.
3-Methoxy-2-(4'-methylphenyl)-6-(pyrid-2"-yImethylthio)imidazo[lr2-Z7]pyridazine 
(IV . 7e)
This compound (12%) was obtained as an oil (Found, for a sample dried at 
80° for 4 h : C, 63.2; H, 5.2; N, 14.4. C20H i8N4OS. 1H20  requires C, 63.1; H, 5.3; 
N, 14.7%). lH n.m.r. (CDCI3) : 6 2.40, s, Me; 4.08, s, 3-OMe; 4.65, s, CH2; 6.84, d, 
J7)8 9 Hz, H 7; 7.19-8.62, complex, H 2',3',5',6' and pyrid-2"-yl; 7.69, d, J7j8 9 Hz, 
H 8.
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3-Methoxy-2-phenyI-6-(pyrid-3'-yImethylthio)imidazo[l,2-Z>]pyridazine (TV. 7b)
The title compound (10%) had m.p. 67-71° [from light petroleum(40-60°)] 
(Found, for a sample dried at 40° and 0.2 mmHg for 4 h : C, 62.5; H, 4.9; N, 15.3. 
C i 9H i6N4OS. 1 H20  requires C, 62.3; H, 5.0; N, 15.3%). !H n.m.r. (CDCI3) : 6 
4.08, s, 3-OMe; 4.47, s, CH2; 6.78, d, J7,g 9 Hz, H 7; 7.31-8.17, complex, H
2',4’,5’,6’ and Ph; 7.65, d, J7,8 9 Hz, H 8. X max (pH 7.0) 244 nm (log e 4.40), 370
(4.02).
3-Methoxy-2-phenyl-6-(pyrid-4'-ylmethyIthio)imidazo[l,2-Zdpyridazine (IV . 7c)
This compound (18%) was an oil. (Found, for a sample dried at 80° for 8 h : 
C, 64.5; H, 5.2; N, 15.4. C19H16N4OS. 0.45 H20  requires C, 64.0; H, 4.8 N, 15.7%). 
lH n.m.r. (CDCI3) : 5 4.01, s, 3-OMe; 4.44, s, CH2; 6.78, d, J7,8 9 Hz, H 7; 7.31-8.16, 
complex, H 2',3',5',6' and Ph; 7.65, d, J7>8 9 Hz, H 8
2-(4,-Fluorophenyl)-3-methoxy-6-(pyrid-4"-ylmethylthio)imidazo[l,2-Z>]pyridazine 
( IV . 7f)
It had m.p. 133-135° (17%) (from cyclohexane) (Found : C, 62.2; H, 4.2; 
N, 15.3. C19H15FN4OS. requires C, 62.3; H, 4.1; N, 15.3%). *H n.m.r. (CDCI3) : 5
3.98, s, 3-OMe; 4.43, s, CH2; 6.70, d, J7>8 9 Hz, H 7; 7.04-8.15, complex, H
2',4',5',6’,2",3",5",6”; 7.64, d, J7>8 9 Hz, H 8.
6-(2'-Aminobenzylthio)-3-methoxy-2-phenyIimidazo[l,2-Z>]pyridazine (TV. 8a)
3-Methoxy-6-(2-nitrobenzythio)-2-phenylimidazo[ 1,2-£]pyridazine (0.02 g) 
was reduced with iron in aqueous methanolic hydrochloric acid as for 6-benzylthio-3- 
methoxy-2-(3’-nitrophenyl)imidazo[l,2-£]pyridazine above. The product was subjected 
to t.l.c. (alumina; chloroform) and recrystallised from chloroform/light petroleum (b.p. 
60-80°) to give the title compound as an oil (0.02 g), m.p. 138-139° (Found : C, 66.3; 
H, 5.2; N, 15.4. C2oHigN40S requires C, 66.3; H, 5.0; N, 15.5%). *H n.m.r. 
(CDCI3) : 6 4.17, s, Me; 4.49, s, CH2; 6.81, d, J7>8 9 Hz, H 7; 6.69-8.18, complex, H 
3',4',5’,6' and Ph; 7.68, d, J7>8 9 Hz, H 8.
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6-(3'-Aminobenzylthio)-3-methoxy-2-phenylimidazo[l,2-/>]pyridazine (IV . 8b)
3-Methoxy-6-(3'-nitrobenzythio)-2-phenylimidazo[ 1,2-Z?]pyridazine (0.04 g) 
was reduced and the product purified as above. It was recrystallised from cyclohexane/ 
light petroleum (b.p. 40-60°) to give the title compound (0.03 g), m.p. 132-136° 
(Found : C, 65.9; H, 5.1; N, 15.2. C20H18N4OS requires C, 66.3; H, 5.0; N, 15.5%). 
*H n.m.r. (CDCI3): 5 3.0, b, NH2; 4.12, s, MeO; 4.40, s, CH2; 6.75, d, J7>8 9 Hz, H 
7; 7.64, d, J7,8 9 Hz, H 8; 6.54-8.18, complex, H 2’,4',5',6' and Ph.
6-(4'-Aminobenzylthio)-3-methoxy-2-phenylimidazo[l,2-Z>]pyridazine (IV . 8c)
3-Methoxy-6-(4'-nitrobenzythio)-2-phenylimidazo[ 1,2-&]pyridazine (0.03 g) 
was reduced with iron powder in aqueous methanolic hydrochloric acid as for the 2'- 
nitro isomer.
The crude product was subjected to t.l.c. (alumina; chloroform) to give 
greenish crystals of the title compound (0.03 g), m.p. 142-144° (Found : C, 66.6; H, 
5.2; N, 15.3. C20H i8N4OS requires C, 66.3; H, 5.0; N, 15.5%). *H n.m.r. (CDCI3) : 
5 4.15, s, MeO; 4.41, s, CH2; 6.64, d, 7.44, d, J2',3- 8 Hz, H 2’,3',5’,6'; 6.77, d, J7,8 
9 Hz, H 7; 7.23-8.19, complex, Ph; 7.64, d, J7,8 9 Hz, H 8
6-Benzylthio-3-methoxy-2-(4,-methylphenyl)imidazo[l^-Z>]pyridazine (IV . 11a)
was prepared in a similar manner from 6-benzylthiopyridazin-3-amine and 4- 
methylphenylglyoxal followed by methylation. The product was recrystallised from 
light petroleum (b.p. 40-60°) to give the title compound (10%), m.p. 120-122° (Found, 
for a sample dried at 20° and 0.1 mmHg for 16 h : C, 69.8; H, 5.4; N, 11.5. 
C2iH i 9N3OS. 1H20  requires C, 69.8; H, 5.3; N, 11.6%). !H n.m.r. (CDCI3) : 5 
2.40, s, Me; 4.09, s, MeO; 4.50, s, CH2; 6.76, d, J7,s 9 Hz, H 7; 7.63, d, J7,8 9 Hz, 
H 8; 7.28, d, 8.02, d, J 8 Hz, H 2',3',5’,6'; 7.35-7.52, complex, Ph.
6-Benzylthio-3-ethoxy-2-(4,-methyIphenyl)imidazo[l,2-/>]pyridazine (IV . lib )
Crude 6-benzylthio-2-(4'-methylphenyl)imidazo[ 1,2-b]pyridazin-3(5//)-one 
(0.25 g) was stirred with excess ethereal diazoethane in ice and at 20° for 24 h. The
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product purified by t.l.c.(alumina; chloroform) and recrystallised from light petroleum 
(b.p. 60-80°) gave 6-benzylthio-3-ethoxy-2-(4'-methylphenyl)imidazo[ 1,2-b]pyridazine 
(0.02 g), m.p. 65-67° (Found, for a sample dried at 30° and 0.1 mmHg for 16 h : C, 
70.6; H, 5.7; N, 11.1. C22H21N3OS requires C, 70.4; H, 5.6; N, 11.2%). *H n.m.r. 
(CDCI3) : 5 1.46, t, J 7 Hz, CH3CH2; 2.40, s, 4'-Me; 4.32, q, J 7 Hz, CH3CH2; 4.49, 
s, CH2S; 6.77, d, J7>8 9 Hz, H 7; 7.62, d, J7,8 9 Hz, H 8 ; 7.27, d, 8.04, d, J 8 Hz, H 
2',3',5',6 '; 7.25-7.51, complex, Ph.
6-BenzyIthio-3-methoxy-2-(3,-nitrophenyl)imidazo[l,2-Z>]pyridazine (TV. 11c)
A solution of 3-nitrophenylglyoxal257 (1.2 g) in ethanol (2.0 ml) was added 
to a warm stirred solution of 6-benzylthiopyridazin-3-amine (0.2 g) in ethanol (50 ml) 
with concentrated hydrochloric acid (1.3 ml) and the mixture refluxed for 11 h. After 
dilution with water (40 ml) and cooling, the solid (1.7 g) was filtered off and washed 
with water.
This solid was methylated with excess ethereal diazomethane as above and 
the crude product was subjected to chromatography in chloroform over alumina (25 cm). 
Portion of the product (0.2 g) was subjected to t.l.c. (alumina; chloroform) and 
recrystallised from benzene to give the title compound (0.10 g), m.p. 200-203° (Found : 
C, 61.3; H, 4.0; N, 14.3. C20H16N4O3S requires C, 61.2; H, 4.1; N, 14.3%). iH 
n.m.r. (CDCI3) : 5 4.16, s, MeO; 4.50, s, CH2; 6.83, d, J7j8 9 Hz, H 7; 7.30-8.96, 
complex, H 2’,4',5',6 ' and Ph; 7.65, d, J7,8 9 Hz, H 8.
6-Benzylthio-3-methoxy-2-(4'-nitrophenyl)imidazo[l,2-£]pyridazine (IV . lid )
This compound was prepared from 6-benzylthiopyridazin-3-amine (0.4 g) 
and 4-nitrophenylglyoxal monohydrate217’257 (0.4 g) by a method similar to that 
described for the 3-nitro isomer. The product was subjected to t.l.c. (alumina; 
chloroform) and recrystallised from cyclohexane to give yellow crystals of the title 
compound (0.06 g), m.p. 180-182° (Found : C, 61.5; H, 4.2; N, 14.4. C20H16N4O3S 
requires C, 61.2; H, 4.1; N, 14.3%). JH n.m.r. (CDCI3) : 5 4.15, s, MeO; 4.50, s,
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CH2; 6.84, d, J7,8 9 Hz, H 7; 7.26-7.50, complex, H 2",3",5",6"; 7.65, d, J7,g 9 Hz, 
H 8; 8.29, s, Ph.
In a similar manner from 6-(3'-methoxybenzylthio)pyridazin-3-amine and 
(2 -methylphenyl)glyoxal230 (prepared by selenium dioxide oxidation of 2-methyl- 
acetophenone as described for acetophenone230 but for 48 h), 3-methylphenyl- 
glyoxal,235 4-methylphenylglyoxal,234 (2-methoxyphenyl)glyoxal,231>232 3-methoxy- 
phenylglyoxal,257 4-hydroxyphenylglyoxal,233 3-fluorophenylglyoxal,258 4-fluoro- 
phenylglyoxal,236 and 3-nitrophenylglyoxal,237 were prepared the following 
compounds.
3-Methoxy-6-(3,-methoxybenzylthio)-2-(2"-methyIphenyl)imidazo[l,2-Z>]pyridazine 
(IV . l ie )
The title compound (38%) was obtained as a light green oil (Found : C, 67.6; 
H, 5.6. C22H21N3O2S requires C, 67.5; H, 5.4%). n.m.r. (CDCI3) : 6 2.43, s, 2”- 
Me; 3.80, s, 3’-OMe; 3.94, s, 3-OMe; 4.47, s, CH2; 6.78, d, J7,8 9 Hz, H 7; 7.10- 
7.89, complex, H 2',4',5',6’,3",4",5",6"; 7.63, d, J7,8 9 Hz, H 8.
3-Methoxy-6-(3'-methoxybenzylthio)-2-(3"-methyIphenyl)imidazo[l,2-Z>]pyridazine 
(IV . Ilf)
It had m.p. 96-98° (21%) [from light petroleum (b.p. 40-60°)] (Found : C, 
67.8; H, 5.5; N, 10.6. C22H21N3O2S requires C, 67.5; H, 5.4; N, 10.6%). *H n.m.r. 
(CDCI3) : 5 2.44, s, 3"-Me; 3.80, s, 3’-OMe; 4.10, s, 3-OMe; 4.47, s, CH2; 6.78, d, 
J7,8 9 Hz, H 7; 7.04-7.95, complex, H 2',4’,5',6 ’,2",4",5",6"; 7.63, d, J7,8 9 Hz, H 
8 .
3-Methoxy-6-(3'-methoxybenzylthio)-2-(4"-methyIphenyI)imidazo[l,2-Z>]pyridazine 
( I V . l lg )
This product (16%) had m.p. 76-78° [from light petroleum (b.p. 40-60°)] 
(Found, for a sample dried at 30° and 0.1 mmHg for 4 h : C, 67.6; H, 5.2; N, 10.3.
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C22H21N3O2S requires C, 67.5; H, 5.4; N, 10.7%). l H n.m.r. (CDCI3) : 5 2.41, s, 
4"-Me; 3.80, s, 3’-OMe; 4.09, s, 3-OMe; 4.47, s, CH2; 6.77, d, J7,8 9 Hz, H 7; 7.63, 
d, J7,8 9 Hz, H 8; 7.00-8.66, complex, H 2',4',5’,6 ',2",3”,5",6 ".
3-Methoxy-6-(3'-methoxybenzylthio)-2-(2"-methoxyphenyl)imidazo[l,2-£]pyridazine 
(IV . l lh )
The title compound (25%) had m.p. 75-77° [from light petroleum (b.p. 60- 
80°)] (Found, for a sample dried at 60° and 0.2 mmHg for 6 h : C, 64.8; H, 5.3; N, 
10.3. C22H21N3O3S requires C, 64.8; H, 5.2; N, 10.3%). *H n.m.r. (CDCI3) : 5 
3.80, s, 3'-OMe; 3.89, s, 2M-OMe; 4.04, s, 3-OMe; 4.47, s, CH2; 6.75, d, J7,8 9 Hz, H 
7; 6.98-7.46, complex, H 2',4’,5’,6 ’,3",4”,5”,6 "; 7.64, d, J7,8 9 Hz, H 8 .
3-Methoxy-6-(3'-methoxybenzylthio)-2-(3',-methoxyphenyl)imidazo[lr2-^]pyridazine 
(IV . H i)
It had m.p. 118-119° (30%) [from light petroleum (b.p. 60-80°)] (Found : 
C, 65.0; H, 5.3; N, 10.1. C22H21N3O3S requires C, 64.8; H, 5.2; N, 10.3%). *H 
n.m.r. (CDCI3) : 6 3.81, s, 3’-OMe; 3.90, s, 3”-OMe; 4.11, s, 3-OMe; 4.47, s, CH2; 
6.78, d, J7)8 9 Hz, H 7; 7.04-7.80, complex, H 2’,4’,5',6 ’,2",4",5",6 "; 7.64, d, J7,8 9 
Hz, H 8 .
3-Methoxy-6-(3,-methoxybenzyIthio)-2-(4"-methoxyphenyl)imidazo[l,2-£]pyridazine
( I V .l l j )
The title compound (24%) had m.p. 106-107° (from cyclohexane) (Found: 
C, 64.9; H, 5.2; N, 10.1. C22H21N3O3S requires C, 64.9; H, 5.2; N, 10.3%). *H 
n.m.r. (CDCI3) : 5 3.80, s, 3’-OMe; 3.86, s, 4"-OMe; 4.09, s, 3-OMe; 4.47, s, CH2; 
6.77, d, J7 ,8 9 Hz, H 7; 7.62, d, J7)8 9 Hz, H 8 ; 6.95-8.11, complex, H 
2 ',4 ’,5 ' ,6 ' ,2",3",5",6”.
129
2-(3,-FluorophenyI)-3-methoxy-6-(3"-methoxybenzyIthio)imidazo[l,2-£]pyridazine 
(IV . Ilk )
This product was purified by t.l.c. (alumina; toluene, developed twice) and 
recrystallised from light petroleum (b.p. 40-60°) to give the title compound (19%), m.p. 
93-94° (Found, for a sample dried at 50° for 4 h : C, 63.7; H, 4.7; N, 10.8. 
C21H18FN3O2S requires C, 63.8; H, 4.6; N, 10.6%). *H n.m.r. (CDCI3) : 5 3.80, s, 
3"-OMe; 4.12, s, 3-OMe; 4.45, s, CH2; 6.78, d, J7,8 9 Hz, H 7; 6.93-7.95, complex, H 
2',4',5',6',2",4",5",6”; 7.62, d, J7,g 9 Hz, H 8.
2- (4'-FluorophenyI)-3-methoxy-6-(3"-methoxybenzyIthio)imidazo[l,2-£]pyridazine 
(IV . I ll)
The crude product was chromatographed (alumina; chloroform) and 
recrystallised from light petroleum (b.p. 40-60°) to give the title compound (21%), m.p. 
129-130° (Found : C, 63.7; H, 4.6; N, 10.7. C21H18FN3O2S requires C, 63.8; H, 
4.6; N, 10.6%). lH n.m.r. (CDCI3) : 5 3.81, s, 3"-OMe; 4.10, s, 3-OMe; 4.47, s, 
CH2; 6.81, d, J7,8 9 Hz, H 7; 6.84-8.18, complex, H 2',3',5’,6',2",4”,5”,6"; 7.67, d, 
J7>8 9 Hz, H 8. v max (KBr) : 3040 (w), 2960 (w), 2820 (w), 1590 (s), 1530 (s), 830 
(s), 790 (s), 710 (s), 660 (s).
3- Methoxy-6-(3'-methoxybenzyIthio)-2-(3"-nitrophenyl)imidazo[l,2-Z?]pyridazine 
(IV . 11m)
In this preparation the crude 3-oxo compound crystallised from the reaction 
mixture. The crude 3-methoxy compound was subjected to column chromatography 
(alumina; chloroform) and recrystallised first from chloroform and then from methanol to 
give yellow crystals of the title compound (16%), m.p. 196-198° (Found : C, 59.9; H, 
4.4; N, 13.3. C21H18N4O4S requires C, 59.7; H, 4.3; N, 13.3%). lH n.m.r. (CDCI3) : 
5 3.81, s, 3'-OMe; 4.17, s, 3-OMe; 4.47, s, CH2; 6.83 b, d, J7,8 9 Hz, H 7; 7.06-8.96, 
complex, H 2’,4',5',6',2",4",5",6"; 7.66, d, J7>8 9 Hz, H 8.
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6-(3,-MethoxybenzyIthio)-2-phenyIimidazo[l^-6]pyridazine (IV . 12)
A mixture of 6-(3'-methoxybenzylthio)pyridazin-3-amine (0.2 g) and 
phenacyl bromide (0.16 g) in ethanol (15 ml) was refluxed for 4 h, then the ethanol 
evaporated. The residue was diluted with water (10 ml) and the mixture adjusted to pH 
6-7 and the solid collected. It was subjected to column chromatography (alumina; 
chloroform) and recrystallised from light petroleum (b.p. 40-60°) to give the title 
compound (0.17 g), m.p. 80-82° (Found , for a sample dried at 70° and 0.2 mmHg for
3 h : C, 68.9; H, 4.9; N, 12.1. C20H17N3OS requires C, 68.9; H, 4.9; N, 12.1%). *H 
n.m.r. (CDCI3) : 6 3.78, s, MeO; 4.39, s, CH2; 6.78, d, J7,8 9 Hz, H 7; 6.94-8.00, 
complex, H 2',4',5',6' and Ph; 7.69, d, J7j8 9 Hz, H 8; 8.15, s, H 3.
2-(3'-Aminophenyl)-6-benzyIthio-3-methoxyimidazo[l,2-Z>]pyridazine (TV. 13a)
A solution of 6-benzylthio-3-methoxy-2-(3'-nitrophenyl)imidazo[l,2- 
bjpyridazine (0.04 g) in methanol (15 ml) was added over 15 minutes to a rapidly stirred 
mixture of iron powder (0.08 g; prewashed with dilute hydrochloric acid), methanol (2.0 
ml), water (1.0 ml) and concentrated hydrochloric acid (2 drops) at 85-90° and 
maintained at this temperature for 1.5 h.
Excess iron powder was filtered off and washed with hot methanol and the 
combined filtrates evaporated. The residue was diluted with water, adjusted to pH 7 
with 0.1 M sodium hydroxide and the product extracted into chloroform. After drying 
(Na2S 04) the solvent was evaporated and the product subjected to t.l.c. (alumina; 
chloroform) and recrystallised from light petroleum (b.p. 60-80°) to give the title 
compound (0.02 g), m.p. 78-80° (Found, for a sample dried at 50° and 0.2 mmHg for
4 h : C, 66.5; H, 5.0; N, 15.3. C2oH i8N4OS requires C, 66.3; H, 5.0; N, 15.5%). lH 
n.m.r. (CDCI3): 5 2.80, b, NH2; 4.09, s, MeO; 4.49, s, CH2; 6.78, d, J7>8 9 Hz, H 7; 
7.16-7.50, complex, H 2',4',5',6' and Ph; 7.63, d, J7>8 9 Hz, H 8.
2-(4'-Aminophenyl)-6-benzylthio-3-methoxyimidazo[l,2-£]pyridazine (IV . 13b)
6-Benzylthio-3-methoxy-2-(4'-nitrophenyl)imidazo[ 1,2-b]pyridazine (0.09 
g) was reduced with iron powder in dilute hydrochloric acid as for the 3'-nitro isomer
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above. After t.l.c. (alumina; chloroform), the product was recrystallised from 
cyclohexane to give the title compound (0.06 g), m.p. 150-154° (Found : C, 66.0; H, 
5.2; N, 15.5. C20H18N4OS requires C, 66.3; H, 5.0; N, 15.5%). *H n.m.r. (CDCI3) : 
5 4.07, s, MeO; 4.49, s, CH2; 6.75, d, J7>8 9 Hz, H 7; 6.78, d, 7.93, d, J2’,3' 9 Hz, H 
2',3',5',6'; 7.29-7.52; complex, Ph; 7.61, d, J7,8 9 Hz, H 8.
2-(3,-Aminophenyl)-3-methoxy-6-(3"-methoxybenzylthio)imidazo[lr2-Z>]pyridazine 
(IV . 13c)
A solution of 3-methoxy-6-(3'-methoxybenzylthio)-2-(3"-nitrophenyl)- 
imidazo[l,2-£]pyridazine (0.042 g) in methanol (20 ml) was added over 5 minutes to a 
rapidly stirred mixture of iron powder (0.080 g; freshly acid washed), methanol (2.0 
ml), water (1.0 ml) and concentrated hydrochloric acid (0.24 ml)) at 85-90° and the 
mixture maintained at that temperature for 3 h.
The mixture was filtered hot, the residue washed with hot methanol, and the 
combined filtrates evaporated. The residue was diluted with water, adjusted to pH 6-7 
and extracted with chloroform. The product was subjected to t.l.c. (alumina; 
chloroform) and recrystallised from a mixture of acetone and cyclohexane to give the title 
compound (0.030 g), m.p. 100-115° (Found, for a sample dried at 70° and 0.2 mmHg 
for 5 h : C, 62.9; H, 5.5; N, 13.7. C21H20N4O2S 0.5 H20  requires C, 62.8; H, 5.3; 
N, 14.0%). *H n.m.r. (CDCI3) : 6 2.60, b, NH2; 3.80, s, 3”-OMe; 4.09, s, 3-OMe; 
4.46, s, CH2; 6.64-7.50; complex, H 2’,4',5’,6’,2",4”,5",6"; 7.64, d, J7,8 9 Hz, H 8.
2-(2,-Fluorophenyl)-3-methoxy-6-(3"-methoxybenzyIthio)imidazo[l,2-&]pyridazine 
(IV . 17a)
A warm solution of 6-(3'-methoxybenzylthio)pyridazin-3-amine 2-oxide 
(0.26 g) in ethanol (6.0 ml) was added to a solution of a-bromo-2-fluoroacetophenone 
(0.24 g) in ethanol (4.0 ml) and the mixture refluxed for 4 h. After cooling, the mixture 
was diluted with water (10 ml), adjusted to pH 6-7, and the orange precipitate (0.28 g) 
filtered off washed with water and ether and dried.
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This product was stirred with excess ethereal diazomethane in ice and at 20° 
overnight. The solvent was evaporated and the product was subjected to t.l.c. (alumina; 
chloroform/cyclohexane, 2:1) and recrystallised from light petroleum (b.p. 40-60°) to 
give 2-(2 '-fluorophenyl )-3-methoxy-6-(3"-methoxybenzylthio )imidazo[l ,2-bjpyridazine 
(0.07 g), m.p. 114-115° (Found : C, 63.9; H, 4.7; N, 10.8. C21H18FN3O2S requires 
C, 63.8; H, 4.6; N, 10.6%). *H n.m.r. (CDCI3) : 5 3.79, s, 3"-OMe; 4.12, s, 3-OMe; 
4.45, s, CH2; 6.78, d, J7,8 9 Hz, H 7; 7.00-8.48, complex, H 3',4’,5’,6',2",4",5",6”; 
7.62, d, J7,8 9 Hz, H 8.
In a similar manner from 6-(3'-methoxybenzylthio)pyridazin-3-amine 2 oxide 
and a-bromo-2-(3- and 4-)trifluoromethylacetophenone (Prepared by bromination of the 
acetophenone-see Chapter III - 5) were prepared the following compounds.
3-Methoxy-6-(3'-methoxybenzyIthio)-2-(2"-trifluoromethylphenyl)imidazo[l,2-Zd- 
pyridazine (IV. 17b)
The product from this preparation was subjected to t.l.c. (alumina; 
cyclohexane/chloroform, 1:1) and developed twice to give the title compound (16%) as 
an oil. (Found, for a sample dried at 100° for 6 h : C, 59.5; H, 4.4; N, 9.1. 
C22H18F3N3O2S requires C, 59.3; H, 4.1; N, 9.4%). *H n.m.r. (CDCI3) : 5 3.80, s, 
3’-OMe; 3.95, s, 3-OMe; 4.46, s, CH2; 6.80, d, J7>8 9 Hz, H7; 7.02-7.85, complex, H 
2’,4’,5’,6’,3",4",5”,6”; 7.64, d, J7,8 9 Hz, H 8.
3-Methoxy-6-(3'-methoxybenzylthio)-2-(3"-trifluoromethylphenyI)imidazo[l,2-Zd- 
pyridazine (IV. 17c)
The title compound (17%) had m.p. 99-100° (Found, for a sample dried at 
70° for 4 h : C, 59.3; H, 4.1; N, 9.5. C22H18F3N3O2S requires C, 59.3; H, 4.1; N, 
9.3%). *H n.m.r. (CDCI3) : 8 3.79, s, 3'-OMe; 4.10, s, 3-OMe; 4.46, s, CH2; 6.78,
d, J7,8 9 Hz, H7; 6.71-9.84, complex, H 2',4',5’,6’,2",4",5",6"; 7.65, d, J7>8 9 Hz, H
8 .
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3-Methoxy-6-(3,-methoxybenzy!thio)-2-(4,,-trifluoroniethyIpheny!)imidazo[l,2-£]- 
pyridazine (IV . 17d)
The product was recrystallised from cyclohexane to give yellow green 
crystals of the title compound (16%), m.p. 146-147°. (Found : C, 59.6; H, 4.1; N, 9.5. 
C22H18F3N4O2S requires C, 59.3; H, 4.1; N, 9.3%). *H n.m.r. (CDCI3): 5 3.80, s, 
3'-OMe; 4.12, s, 3-OMe; 4.46, s, CH2; 6.80, d, J7,8 9 Hz, H7; 7.00-7.35, complex, H 
2',4',5’,6'; 7.63, d, J7>8 9 Hz, H 8; 7.69, d, 8.22, d, J2",3" 9 Hz, H 2",3”,5”,6”.
3-Methoxy-6-(3,-methoxybenzylthio)-2-(pyrid-4"-yl)imidazo[l^-Z?]pyridazine 
(IV . 17g)
A solution of 6-(3'-methoxybenzylthio)pyridazin-3-amine 2-oxide (0.26 g) in 
ethanol (6.0 ml) was added to a suspension of 4-(bromoacetyl)pyridine hydrobromide 
(0.31 g) and sodium hydrogen carbonate (0.09 g) in ethanol (5.0 ml) and the mixture 
refluxed with stirring in an oil bath at 85-90° for 4 h. After cooling a small quantity of 
orange precipitate separated.
The reaction mixture was then stirred with excess ethereal diazomethane in 
ice and at 20° overnight, then evaporated to dryness. The product was subjected to t.l.c. 
(alumina; chloroform, developed twice) and recrystallised from cyclohexane-chloroform 
to give yellow crystals of 3 -methoxy-6-(3'-methoxybenzylthio)-2-(pyrid-4"- 
yl)imidazo[ 1,2-b]pyridazine (0.03 g), m.p. 143-144° (Found, for a sample dried at 75° 
and 0.2 mmHg for 5 h : C, 63.8; H, 4.8; N, 15.0. C20H18N4O2S requires C, 63.5; H, 
4.8; N, 14.8%). *H n.m.r. (CDCI3) : 5 3.80, s, 3'-OMe; 4.15, s, 3-OMe; 4.46, s, 
CH2; 6.81, d, J7,8 9 Hz, H7; 6.96-8.69, complex, H 2',4’,5',6',2",3",5",6"; 7.62, d, 
J7>8 9 Hz, H 8.
In a similar manner were prepared the following compounds from the 
respective bromoacetylpyridine (see Chapter III - 5).
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3-Methoxy-6-(3'-methoxybenzyIthio)-2-(pyrid-2"-yl)imidazo[l,2-£]pyridazine (IV . 17e)
The title compound (16%) had m.p. 127-129° [from light petroleum (b.p. 
40-60°)] (Found, for a sample dried at 75° and 0.2 mmHg for 5 h : C, 63.2; H, 4.9; N, 
14.8. C20H 18N4O2S requires C, 63.5; H, 4.8; N, 14.8%). *H n.m.r. (CDCI3) : 5 
3.80, s, 3'-OMe; 4.20, s, 3-OMe; 4.47, s, CH2; 6.80, d, J7,8 9 Hz, H7; 7.04-8.80, 
complex, H 2',4',5',6',3",4",5",6"; 7.67, d, J7,8 9 Hz, H 8.
3-Methoxy-6-(3,-methoxybenzyIthio)-2-(pyrid-3"-yl)imidazo[l,2-Z>]pyridazine (IV . 17f)
This title compound (10%) crystallised from mixture of cyclohexane and light 
petroleum (b.p. 40-60°) (10:2) as yellow crystals, m.p. 112-113° (Found, for a sample 
dried at 75° and 0.2 mmHg for 5 h : C, 64.0; H, 5.0; N, 15.1. C20H18N4O2S requires 
C, 63.5; H, 4.8; N, 14.8%). *H n.m.r. (CDCI3) : 5 3.80, s, 3'-OMe; 4.13, s, 3-OMe; 
4.46, s, CH2; 6.80, d, J7>8 9 Hz, H7; 6.95-9.36, complex, H 2',4',5’,6’,2",4",5",6"; 
7.63, d, J7,8 9 Hz, H 8.
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CHAPTER V Syntheses and binding studies of some 3-aIkoxy-6-benzyloxy(and 
substituted benzyloxy)-2-phenyl(and aryl)imidazo[l,2-Z>]pyridazines
V -1  Introduction
In order to continue the investigation of the structural requirements for high 
binding affinity at benzodiazepine receptors for the 3-alkoxyimidazo[l,2-£]pyridazines, 
we synthesized some 3-alkoxy-6-benzyloxy (and substituted benzyloxy)-2-phenyl(and 
aryl)im idazo[l,2-& ]pyridazines and tested for in vitro receptor binding. These 
compounds were chosen for synthesis in order to study the effect of : (a) varying 
substituents on C-2 of 6-benzyloxy-3-methoxyimidazo[l,2-b]pyridazine, (b) substitution 
with methoxy groups on the 6-benzyloxy group of 6-benzyloxy-3-methoxy-2- 
phenylimidazo[l,2-&]pyridazine, and (c) maintaining a constant favourable substituent at 
C-6 while modifying substituents on C-2. In addition, these derivatives were chosen 
with the aim of comparing the binding profile of this series of compounds with 
derivatives of 6-benzylthio-3-methoxy-2-phenylimidazo[l,2-&]pyridazine (IV . 19) (see 
Chapter IV - 4.1).
In the first part of this chapter, the synthesis and attempted synthesis of these 
compounds are reported. This also includes a novel synthesis of some 3-benzylamino-6- 
benzyloxypyridazines. In the second part, some physical properties are discussed in 
brief. This is followed by the results of in vitro binding studies. These results are 
compared with the corresponding 6-benzylthio analogues. Experimental details for the 
preparation of compounds (including some physical data) are given at the end of this 
chapter.
V - 2 Syntheses
The synthesis of 2-aryl-6-benzyloxy-3-methoxyimidazo[l,2-&]pyridazines 
was undertaken in a similar manner to that of 2-aryl-3-methoxy-6-phenoxyimidazo- 
[l,2-£]pyridazines (see Chapter III - 2.2). Thus, reaction of 6-benzyloxypyridazin-3- 
amine259 (Scheme V - 1, V . 1) with substituted phenylgyloxals in ethanol and a few 
drops of concentrated hydrochloric acid at reflux yielded the oxo compounds [V . 2 (a-c)]
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c)] (not purified) which were readily methylated with diazomethane to give the methoxy 
derivatives [V . 3 (a-c)]. Catalytic reduction of compounds V . 3b and V . 3c with 
Raney nickel in methanol gave the amino compounds V . 4a and V . 4b (Scheme V - 2).
Attempted synthesis of 3-methoxy-6-(4'-methoxybenzyloxy)-2-phenyl- 
im idazo[l,2-fr]pyridazine (Scheme V - 4, V . 14c) by an analogous route was 
unsuccessful. When 6-(4'-methoxybenzyloxy)pyridazin-3-amine [prepared by the 
reaction of 6-chloropyridazin-3-amine (V 5) and a molar equivalent of soduim 4- 
methoxybenzyl oxide in excess 4-methoxybenzyl alcohol at 120-125° for 4h] (Scheme V - 
3, V . 6) and 4-methylphenylglyoxal were refluxed in ethanolic hydrogen chloride and 
the product methylated with diazomethane, the desired product, 3-methoxy-6-(4'- 
methoxybenzyloxy)-2-phenylimidazo[l,2-Z?]pyridazine was not obtained. The *H n.m.r. 
spectrum of the product which was isolated indicated the loss of the 4-methoxybenzyloxy 
group from C-6. The product was found to be indentical with 3,6-dimethoxy-2-(4'- 
m e th o x y p h en y l)im id azo [l,2 -b ]p y rid az in e  (V . 9) [prepared by refluxing 6- 
m ethoxypyridazin-3-am ine (V . 7) and 4-methylphenylglyoxal in ethanol with 
concentrated hydrochloric acid, followed by methylation (Scheme V - 3)]. It was 
therefore postulated that cleavage of the 4-methoxybenzyl group in compound V . 6 may 
have taken place when it was refluxed with 4'-methylphenylglyxoal and ethanolic 
hydrogen chloride. Attempts to effect the ring closure in the absence of acid were 
unsuccessful. It appears therefore that the presence of the p-m ethoxy group in 
compound V . 6 is sufficient to bring about cleavage of the 6-(4'-methoxybenzyl) group 
under the reaction conditions, whereas compound V . 1 is unaffected.
An alternative route for the preparation of the desired compounds [V . 14 (a- 
h)] was then examined as shown in Scheme V - 4 in which the pyridazin-3-amine 2- 
oxide (V . 12) was condensed with bromoacetyl compounds without the addition of 
concentrated hydrochloric acid. A mechanism for this type of reaction has been proposed 
by Deady and Stanborough24! and mentioned briefly in Chapter III - 2.1. The starting 
material for this synthesis, 6-(2'-methoxybenzyloxy)pyridazin-3-amine 2-oxide238 (V . 
12a) was prepared by heating a mixture of sodium 2-methoxybenzyl oxide in excess 2- 
methoxybenzyl alcohol with 6-chloropyridazin-3-amine 2-oxide (V . 11) in a sealed
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methoxybenzyl alcohol with 6-chloropyridazin-3-amine 2-oxide (V . 11) in a sealed 
reaction vessel at 135° for 16 h. The use of toluene or r-butanol as the solvent for the 
above reaction was not beneficial. The 3'- and 4'-methoxy isomers of compound V . 
12a were prepared similarly. Condensation of compounds V . 12 (a-c) with 
bromoacetyl compounds in ethanol gave the oxo compounds [V . 13 (a-c)] which were 
readily methylated with diazomethane to give the desired compounds V . 14(a-g). 
Ethylation of the appropriate oxo compound gave the ethoxy compound (V . 14h) 
(Scheme V - 4).
As an aside, it is interesting to note that the reaction of 6-chloropyridazin-3- 
amine(V . 5)(Scheme V - 3) and a molar equivalent of sodium 3-methoxybenzyl oxide in 
excess 3-methoxybenzyl alcohol at 160-165° for 15 h yielded the disubstituted 
compound V . 10 (Scheme V - 3). The structure of the latter was confirmed by its 
n.m.r. spectrum and analyses. Although similar compounds have been reported 
previously260 (for the manufacture of antihistamic agents), their synthesis involved the 
preparation of 3-benzylamino-6-chloropyridazine followed by nucleophilic substitution 
with sodium benzyl oxide as shown in Scheme V - 5.
V . 1 V . 2
V . 2 - V . 3 
_  R1
a MQ-p
b N02-m 
c NO 2-p
PhCH20
V . 3
Scheme V - 2
PhCH20
no2
OMe OMe
V . 3b 
OT V . 3c
V . 4
a NH2-m 
b NH2-p
Scheme V - 3
NH2
V . 5
R1
V . 10
a R1 = OMe-m 
b R1 = OMe-p
MeO
Me
V . 6 V . 9
V . 7 V . 8
Scheme V - 4
V . 11
V . 13 - V . 14
R3 = Me
R 1 R2
a OMe-o Ph
b OMe-m Ph
c OMe-p Ph
d OMe-m C6H4F-P
e OMe-m C6H4CF3-m
f OMe-m C J lACF3-p
g OMe-m C5H4N-ß *
R3 = Et
R1 R2
h OMe-m Ph
* Pyridyl
V . 12
a R1 = OMe-o 
b R1 = OMe-m 
c R1 = OMe-p
V . 13
Scheme V - 5
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V - 3 Physical properties
The *H n.m.r. of the 6-benzyloxy(and substituted benzyloxy)-3-methoxy-2- 
phenyl(and aryl)imidazo[l,2-£]pyridazines [V . 3(a-c) and V . 14(a-g)] in 
deuterochloroform showed the methoxy group on C-3 at 5 4.05-4.18 (Table V - 1) and 
should be compared with that of the 3-methoxy-6-benzylthio-2-arylimidazo[l,2-/?]- 
pyridazines (Tables IV - 1 and IV - 2) at 5 3.94-4.17; the 3-methoxy-6-phenoxy-2- 
arylimidazo[l,2-£]pyridazines (Table III - 1) at 5 3.76-4.03; and the 3-methoxy-6- 
chloro-2-arylimidazo[l,2-&]pyridazines (Table II - 1) at 5 3.95-4.24. In addition, the 
chemical shifts for the protons of the methoxy substituent in the 6-(2'-, 3'- and 4'- 
methoxybenxyloxy) groups occurred relatively upfield at 6 3.82-3.89. This is consistent 
with the 6-benzylthio series of compounds (see Chapter IV - 2.3). The protons H 7 and 
H 8 of compounds V . 3 (a-b) and V . 14(a-h) appeared as an AB quartet in their 
respective *H n.m.r. spectra, with a coupling constant of J7s8 9 Hz. The chemical shift 
for H 7 and H 8 occurred in the range 8 6.63-6.74 and 8 7.68-7.77, respectively. On 
comparison with the other series mentioned above, H 7 appears to be relatively more 
shielded. However, the chemical shift for H 8 is consistent with the values observed for 
the corresponding proton in the compounds prepared in our earlier work (Chapters II, III 
and IV).
The ultraviolet absorption spectra for 2-(4'-aminophenyl)-6-benzyloxy-3- 
methoxyimidazo[l,2-£]pyridazine (V . 4b) (at pH 7.0) showed two broad absorption 
bands at ca. 264 nm (log e 4.15) and 365 (4.13). This is similar to the spectrum 
recorded for 2-(4'-aminophenyl)-3-methoxy-6-(2'-methoxyphenoxy)imidazo[ 1,2-0]- 
pyridazine (HI. 4).
The infrared spectrum of 6-benzyloxy-2-phenylimidazo[l,2-fr]pyridazin-3- 
(5//)-one revealed a strong carbonyl absorption peak at 1600 cm-1 and a broad band at 
ca. 3300 cm-1 which typifies that of an enolic hydroxyl group.223b However, the 
methoxy derivative of this compound (and others) prepared in this series showed no such 
absorptions.
The mass spectrum of 3-methoxy-6-(3'-methoxybenzyloxy)-2-phenyl- 
imidazo[l,2-£]pyridazine (V . 14b), a representative of this series of compounds,
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displayed a fragmentation pattern which was similar to that for 3-methoxy-6-(4'-methyl- 
benzylthio)-2-phenylimidazo[l,2-b]pyridazine (IV . 4c) (see Chapter IV - 3) in that the 
major cleavage was observed at the benzylic bond. In addition, fragmentation involving 
the loss of C2 H3O from the molecular ion was also detected.
Table V -1 Some n.m.r. spectral data3 for 6-benzyloxy(and substituted
benzyIoxy)-3-methoxy-2-phenyl(andaryI)imidazo[l,2-&]pyridazines
R1 R2 R1 = OMe 3-OMe H 7 H 8
H Phb - 4.11 6.69 7.76
H C6 H4 M Q-p - 4.09 6 . 6 6 7.71
H C6 H4 NO2 -m - 4.18 6.73 7.74
H C6H4 NO2 -/? - 4.17 6.74 7.74
H C6 H4 NH2-m - 4.09 6.67 7.71
H C6 H4 NH2 -P - 4.07 6.63 7.68
OMe-o Ph 3.89 4.14 6 . 6 8 7.72
OMe-m Ph 3.82 4.10 6 . 6 6 7.71
OMe-p Ph 3.83 4.14 6.65 7.74
OMe-m C6 H4 F-P 3.83 4.10 6.67 7.71
OMe-m C6 H4 CF3 -m 3.84 4.14 6.73 7.77
OMe-m C6 H4 CF3 -P 3.83 4.13 6.71 7.73
OMe-m C6 H4 NH4 - 0 3.84 4.05 6.67 7.68
OMe-m c 5 H4 N-ßc 3.83 4.13 6.71 7.73
3 Reported as parts per million (5) downfield from T.M.S as internal standard in deuterochloroform. 
b Kindly provided by Mr. S J. Ireland. 
c Pyridyl.
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V - 4 In vitro binding studies
The compounds prepared in this chapter were tested in the [3H]diazepam 
binding assay as described in Chapter II - 5.3.
V - 4.1 Results of [3H]diazepam binding assay
The relative potencies of some 6-benzyloxyimidazo[l,2-fr]pyridazines in 
displacing [3H]diazepam from rat brain membrane preparations are summarized in Table
V - 2. The results for the 2-aryl-6-benzyloxy-3-methoxyimidazo[l,2-£]pyridazines will 
be presented first followed by those for the 2-aryl-3-methoxy-6-(3'-methoxybenzyloxy)- 
imidazo[ 1,2-&]pyridazines.
t
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Table V - 2 Results for displacement of [3H]diazepam from its specific binding 
sites in rat brain by some substituted imidazo[l,2-£] pyridazines
6 ^  ---------  3
N 4 
5
Formula
number
Substituents IC50
(nM)a
Displacement ( % )  at 
concn specified
V . /
15 6-OCH2Ph-3-OMe-2-Phb 20
3a 6-OCH2Ph-3-OMe-2-C6H4Me-/? 30
3b 6-0CH2Ph-3-0Me-2-C6H4N02-m 69
3c 6-0CH2Ph-3-0Me-2-C6H4N02-p c -
4b 6-OCH2Ph-3-OMe-2-C6H4NH2-/? 28
14a 6-0 CH2C6H4 0 Me-ö-3-0 Me-2-Ph 7
14b 6-0 CH2C6H4 0 Me-m-3-0 Me-2-Ph 6
14c 6-OCH2C6H4 0 Me-p-3-OMe-2-Ph 44
14d 6-OCH2C6H40Me-m-3-OMe-2-C6H4F-p 2
14e 6-0 CH2C6H4 0 Me-m-3-0 Me-2-C6H4CF3-m 16% at 30 nM
14f 6-0CH2C6H40Me-m-3-0Me-2-C6H4CF3-p 32
16 6-0CH2C6H40Me-m-3-0Me-2-C6H4NH2-ö 10
14g 6-OCH2C6H4OMe-m-3-OMe-2-C5H4N-ßtl 5
14h 6-0 CH2C6H4 0 Me-m-3-0 Et-2-Ph 18
a IC50 values are the concentrations required to displace 50% of specific [3H]diazepam binding to rat
brain membrane preparation, 
b Personal communication from Dr. G.B. Barlin.
c The insolubility of this compound prevented us from determining the IC50 value, 
d Pyridyl.
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V - 4.2 Discussion of results
The binding activity for 6-benzyloxy-3-methoxy-2-phenylimidazo[l,2-fr]- 
pyridazine (V . 15, IC50 20 nM) is similar to that of 6-benzylthio-3-methoxy-2- 
phenylimidazo[l,2-£]pyridazine (IV . 19, IC50 22 nM). However, substitution of the 2- 
phenyl group of compound V . 15 resulted in a different binding profile compared to 
similar substitutions in compound IV . 19. Thus, the electron-donating para-methyl or 
para-amino substituent (as in compounds V . 3a and V . 4b) decreased binding whereas 
compound TV . 11a (IC50 19 nM) with a 2-(p-methylphenyl) group differed little in 
activity from IV . 19. A strong electron-withdrawing meta-nitro group (compound V . 
3b) decreases binding by ca. fourfold as compared with compound V . 15. In contrast, 
the 2-(3'-nitrophenyl) analogue of compound TV . 19 revealed a fortyfivefold decrease in 
binding efficiency as compared with IV . 19.
V . 15 IV . 19
IC50 20nM IC50 22nM
To study the effect of substitution with methoxy groups in the 6-benzyloxy 
substituent of compound V . 15, the 6-(2'-, 3'- and 4'-methoxybenzyloxy) analogues 
(compounds V . 14a, 14b and 14c, respectively) were synthesized. The 2'- and 3'- 
methoxy isomers had IC50 values of 7 and 6 nM, respectively. This represented a ca. 
threefold increase in affinity. In the case of the 4'-methoxy isomer (IC50 44 nM), the 
affinity decreased. These results are consistent with those observed for similar 
substitutions in compound IV . 19 whereby the 6-(2'-, 3'- and 4'-methoxybenzylthio) 
analogues (IV . 4d, 4e and 4f) revealed IC50 values of 9, 10 and 55 nM, respectively).
The effect of substitution in the 2-phenyl substituent was also examined in 3- 
methoxy-6-(3'-methoxybenzyloxy)-2-phenylimidazo[l,2-£]pyridazine (V . 14b). The
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results revealed that the 2-(4'-fluorophenyl) compound V . 14d with IC50 2 nM increased 
binding potency by ca. threefold relative to compound V .15, whereas the 2-(4'- 
trifluoromethylphenyl) group in compound V . 14f decreased binding by more than five­
fold. The 2-(3'-trifluoromethylphenyl) analogue (V . 14e) showed a more significant 
decrease in binding (16% displacement of [3H]diazepam was observed at 30 nM). The 
amino group in the 2-(2 '-aminophenyl) compound V . 16 (IC50 10 nM) had little effect 
on binding relative to compound V .15 (IC50 20 nM).
The results in Table V - 2 show that the 2-(4'-fluorophenyl) compound V . 
14d provides the best interaction with benzodiazepine receptors. This result is consistent 
with the observation that the 6-(3'-methoxybenzylthio) analogue of V . 14b, namely 2- 
(4'-fluorophenyl)-3-methoxy-6-(3"-methoxybenzylthio)imidazo[l,2-Z?]pyridazine (IV . 
I ll ,  IC50 5 nM) was the most potent compound amongst the benzylthio series studied in 
Chapter IV.
When the 2-phenyl group in 3-methoxy-6-(3'-methoxybenzyloxy)-2- 
phenylimidazo[l,2-Z?]pyridazine (V . 14b, IC50 6 nM) was replaced by a 2-(pyrid-3'-yl) 
group (compound V .14g, IC50 5 nM), it had little effect on binding activity. In 
addition, replacement of the 3-methoxy group of compound V . 14b with an ethoxy 
substituent (compound V . 14h) resulted in ca. threefold decrease in activity.
The above comparative study appears to suggest in general a parallel in 
binding activities for derivatives of 3-methoxy-6-(3'-methoxybenzyloxy)-2-phenyl- 
imidazo[l,2-£]pyridazine (V . 14b) and those of 3-methoxy-6-(3'-methoxybenzylthio)-2- 
phenylimidazo[l,2-Z?]pyridazine (IV . 4e). This work is extended with other substituents 
on C-6 in the following chapter.
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V - 5 Experimental
The general procedure and experimental details for the [3H]diazepam binding 
assay are recorded in Chapter II - 5.1 and 5.3
6-Benzyloxy-3-methoxy-2-(4'-methylphenyl)imidazo[l,2-Z>]pyridazine (V . 3a)
A mixture of 6-benzyloxypyridazin-3-amine259 (0.2 g), 4-methylphenyl- 
glyoxal monohydrate234 (0.18 g), ethanol (17 ml) and concentrated hydrochloric acid 
(0.2 ml) was refluxed for 10 h, then the solvent evaporated under reduced pressure. The 
residue was methylated with ethereal diazomethane and the product subjected to t.l.c. 
(alumina; chloroform) to give a yellow residue which was recrystallised from light 
petroleum (b.p. 40-60°) to give the title compound (0.1 g), m.p. 130-132° (Found, for a 
sample dried at 90° and 0.1 mmHg for 6 h : C, 72.9; H, 5.6; N, 12.1. C21H 19N3O2 
requires C, 73.0; H, 5.6; N, 12.2%). *H n.m.r. (CDCI3) : 8 2.40, s, Me; 4.09, s, MeO; 
5.44, s, CH2; 6.66, d, J7>8 9 Hz, H 7; 7.27, d, 8.00, d, J2’,3' 9 Hz, H 2’,3',5',6'; 7.71, 
d, J7i8 9 Hz, H 8; 7.33-7.56, complex, Ph.
6-Benzyloxy-3-methoxy-2-(3'-nitrophenyl)imidazo[l,2-Z>]pyridazine (V . 3b)
Commencing from 3-nitrophenylglyoxal monohydrate237 (0.6 g) and 6- 
benzyloxypyridazin-3-amine (0.5 g) in a reaction as above, was prepared the title 
compound (0.35 g), m.p. 140-143° (from benzene /cyclohexane) (Found : C, 63.8; H, 
4.3; N, 14.9. C20H16N4O4 requires C, 63.9; H, 4.3; N, 15.3%). *H n.m.r. (CDCI3) : 
5 4.18, s, 3-OMe; 5.45, s, CH2; 6.73, d, J7>8 9 Hz, H 7; 7.43-8.97, complex, H 
2’,4',5',6' and Ph; 7.74, d, J7>8 9 Hz, H 8.
6-Benzyloxy-3-methoxy-2-(4,-nitrophenyl)imidazo[l»2-Z>]pyridazine (V . 3c)
This compound (0.76 g) was prepared from 6-benzyloxypyridazin-3-amine 
(1.0 g) and 4-nitrophenylglyoxal monohydrate (1.2 g) followed by methylation with 
diazomethane as above. It had m.p. 202-204° (from toluene) (Found : C, 64.0; H, 4.2; 
N, 14.9. C20H 16N4O4 requires C, 63.8; H, 4.3; N, 14.9%). *H n.m.r. (CDCI3) : 5 
4.17, s, 3-OMe; 5.45, s, CH2; 6.74, d, J7,8 9 Hz, H 7; 7.36-8.32, complex, H 
2',3’,5',6' and Ph; 7.74, d, J7>8 9 Hz, H 8.
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2- (4'-Aminophenyl)-6-benzyIoxy-3-methoxyimidazo[l,2-Z>]pyridazine (V . 4b)
6-Benzyloxy-3-methoxy-6-(4'-nitrophenyl)imidazo[l,2-£]pyridazine (0.1 g) 
was dissolved in methanol (150 ml). To this was added Raney nickel and the reaction 
mixture shaken with hydrogen at room temperature and pressure until uptake (53 ml) 
ceased. The catalyst was filtered off on celite and the filtrate evaporated to give a residue 
which was recrystallized from cyclohexane to give the title compound (0.06 g), m.p. 
159-162° (Found : C, 68.9; H, 5.4; N, 16.1. C20H 18N4O2 requires C, 69.3; H, 5.2; 
N, 16.2%). JH n.m.r. (CDCI3) : 6 3.77, b, NH2; 4.07, s, 3-OMe; 5.43, s, CH2; 6.63, 
d, J7,8 9 Hz, H 7; 6.77, d, 7.90, d, J2',3* 9 Hz, H 2',3’,5’,6’; 7.68, d, J7>8 9 Hz, H 8; 
7.34-7.54, complex, Ph. X max (pH 7.0) 264 nm (log e 4.15), 365 (413).
3- (3'-Methoxybenzylamino)-6-(3"-methoxybenzyloxy)pyridazine (V . 10a)
Sodium (0.11 g) and 3-methoxybenzyl alcohol (4.1 g) were heated gently 
until all the sodium had reacted. To this was added 6-chloropyridazin-3-amine (0.65 g) 
and the temperature maintained at 120-125° (with stirring) for 15 h.
After cooling, the reaction mixture was poured into cold ether and the brown 
precipitate filtered off, washed with water, and ether and dried. It was recrystallised 
from toluene to give the title compound (0.8 g), m.p. 141-143° (Found: C, 68.6; H, 
6.3; N, 12.0. C20H 21N 3O 3 requires C, 68.4; H, 6.0; N, 12.0%). *H n.m.r.
(CD3SOCD3) : 5 3.71, s, 3.74, s, 2xMeO; 4.45, d, Jc h ,NH 5 Hz, CH2N; 5.27, s, 
CH20; 6.75-7.37, complex, H 4,5,2',4’,5’,6 ',2",4",5",6”.
3-(4'-Methoxybenzylamino)-6-(4,,-methoxybenzyloxy)pyridazine (V . 10b)
In a similar manner, the solution from sodium (0.23 g) and 4-methoxybenzyl 
alcohol (8.3 g) was heated with 6-chloropyridazin-3-amine (1.3 g) at 160-165° for 14 h 
in a screw top reaction vessel. The product was recrystallised from toluene to give the 
title compound (1.5 g), m.p. 152-54° (Found : C, 68.7; H, 6.2; N, 12.0. C20H21N3O3 
requires C, 68.4; H, 6.0; N, 12.0%). *H n.m.r. (CD3SOCD3) : 5 3.71, s, 3.74, s, 
2xMeO; 4.39, d, Jc h ,NH 5 Hz, CH2N; 5.22, s, CH20; 6.82-7.42, complex, H
4,5,2', 3’, 5', 6 ', 2", 3", 5", 6 ".
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6-(4'-MethoxybenzyIoxy)pyridazin-3-amine (V . 6)
Sodium (0.22 g) in 4-methoxybenzyl alcohol (4.1 g) was heated gently until 
all the sodium had reacted. The temperature was raised to 120-125°, 6-chloropyridazin- 
3-amine (1.3 g) was added, and the mixture stirred and heated at this temperature for 4 h.
After cooling, cold ether (100 ml) was added and the brown precipitate (0.9 
g) was filtered off, washed with ether and water, and dried. It was recrystallised from 
toluene to give the title compound (0.65 g), m.p. 159-161° (Found : C, 62.6; H, 5.9; 
N, 18.1. C12H13N3O2 requires C, 62.3; H, 5.7; N, 18.2%). iH n.m.r. (CD3SOCD3) : 
5 3.75, s, MeO; 5.23, s, CH2; 5.9, b, NH2; 6.85, d, 6.93, d, J4,5 9 Hz, H 4,5; 6.95, d, 
7.40, d, J2',3’ 9 Hz, H 2',3’,5',6’.
3,6-Dimethoxy-2-(4'-methylphenyl)imidazo[l,2-&]pyridazine (V . 9)
(a) A mixture of 6-methoxypyridazin-3-amine161 (0.42 g), 4-methylphenylglyoxal (0.56 
g), ethanol (15 ml) and concentrated hydrochloric acid (0.2 ml) was refluxed for 11 h. 
The reaction mixture was concentrated and the red precipitate (0.65 g) filtered off. A 
portion of this product (0.15 g) was stirred with a solution of ethereal diazomethane at 0° 
and then at 20° overnight. The solvent was evaporated and the product subjected to t.l.c. 
(alumina; toluene/chloroform, 5:1) and recrystallised from light petroleum (b.p.40-60°) 
to give the title compound (0.04 g), m.p. 135-136° (Found : C, 66.7; H, 5.8; N, 15.8. 
C15H15N3O2 requires C, 66.9; H, 5.6; N, 15.6%). lU n.m.r. (CDCI3) : 5 2.39, s, Me; 
4.05, s, 6-OMe; 4.13, s, 3-OMe, 6.60, d, J7>8 9 Hz, H 7; 7.69, d, J7,8 9 Hz, H 8; 
7.26, d, 7.99, J2\3’ 9 Hz, H 2’,3’,5’,6'.
(b) A mixture of 6-(4'-methoxybenzyloxy)pyridazin-3-amine (0.10 g), 4- 
methylphenylglyoxal monohydrate (0.07 g), ethanol (10 ml) and concentrated 
hydrochloric acid (0.25 ml) was refluxed for 10 h. The solvent was removed, the yellow 
residue suspended in water and filtered off, washed with water and ether. This product 
(0.04 g) was stirred with a solution of ethereal diazomethane at 0° and at 20° overnight. 
Evaporation gave a residue which was subjected to t.l.c. (alumina: chloroform) to give a 
product (0.01 g) with *H n.m.r. identical with that from (a).
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6-(2’-Methoxybenzyloxy)pyridazin-3-amine 2-oxide (V. 12a)
Sodium (0.11 g) in 2-methoxybenzyl alcohol (6.0 g) was heated gently until 
all the sodium had reacted. To this was added 6-chloropyridazin-3-amine 2-oxide238 
(0.65 g) and the mixture heated at 135° for 16 h in a screw top reaction vessel.
After cooling, the reaction mixture was poured into cold ether. The light 
brown precipitate (0.95 g) was filtered off and recrystallised from toluene (charcoal) to 
give the title compound (0.4 g), m.p. 189-192° (Found, for a sample dried at 80° and 
0.2 mmHg for 12 h : C, 57.8; H, 5.2; N, 17.1. C12H 13N3O3 requires C, 58.3; H, 5.3; 
N, 17.0%). *H n.m.r. (CD3SOCD3) : 5 3.80, s, MeO; 5.18, s, CH2; 6.4, b, NH2; 
6.79, d, 7.28, d, J4,5 9 Hz, H 4,5; 6.94-7.43, complex, H 3’,4',5',6 ’.
6-(3'-Methoxybenzyloxy)pyridazin-3 -amine 2-oxide (V. 12b)
This compound was prepared from 3-methoxybenzyl alcohol (6.0 g) and 6- 
chloropyridazin-3-amine 2-oxide (0.65 g) as for the isomer above.
The precipitate (0.83 g) was recrystallised from toluene (charcoal) to give the 
title compound (0.47 g), m.p. 143-144° (Found : C, 58.4; H,5.3; N, 17.3. 
Ci2H i3N30 3 requires C, 58.3; H, 5.3; N, 17.0%). !H n.m.r. (CD3SOCD3) : 5 3.74, 
s, MeO; 5.18, s, CH2; 6.39, b, NH2; 6.80, d, 7.28, d, J4,5 9 Hz, H 4,5; 6.95-7.39, 
complex, H 2',4',5',6 '.
6-(4'-Methoxybenzyloxy)pyridazin-3 -amine 2-oxide (V. 12c)
This compound was prepared from sodium (0.21 g), 4-methoxybenzyl 
alcohol (7.0 g) and 6-chloropyridazin-3-amine 2-oxide (1.3 g) but at 110° with stirring, 
for 4 h.
The brown precipitate (0.7 g) was recrystallised from toluene (charcoal) to 
give the title compound (0.5 g), m.p. 164-166° (Found : C, 58.5; H, 5.5; N, 17.2. 
C i2H i 3N30 3  requires C, 58.3; H, 5.3; N, 17.0%). lH n.m.r. (CD3SOCD3) : 5 3.74, 
s, MeO; 5.12, s, CH2; 6.37, b, NH2; 6.75, d, 7.27, d, J4,5 9 Hz, H 4,5; 6.92, d, 7.37, 
d, J2'}3' 9 Hz, H 2',4',5',6’.
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3-Methoxy-6-(2'-methoxybenzyloxy)-2-phenyIimidazo[l,2-Z>]pyridazine (V . 14a)
6-(2'-Methoxybenzyloxy)pyridazin-3-amine 2-oxide (0.28 g) and phenacyl 
bromide (0.24 g) in ethanol (6 ml) were refluxed with stirring for 1.5 h. Ethanol was 
removed under reduced pressure to give a dark residue which was stirred with ethereal 
diazomethane at 0° and at 20° overnight. The crude product was subjected to t.l.c. 
(alumina; chloroform then toluene) to give an orange solid which was recrystallised from 
light petroleum (b.p.60-80°) to give the title compound (0.04 g), m.p. 157-159° 
(Found : C, 70.1; H, 5.5; N, 11.9. C21H19N3O3 requires C, 69.8; H, 5.3; N, 11.6%). 
lH n.m.r. (CDCI3) : 5 3.89, s, 2’-OMe; 4.14, s, 3-OMe; 5.49, s, CH2; 6 .68 , d, J7,8 9 
Hz, H 7; 6.91-8.16, complex, H 3',4’,5’,6’ and Ph; 7.72, d, J7,8 9 Hz, H 8.
3-Methoxy-6-(3'-methoxybenzyloxy)-2-phenylimidazo[l,2-£]pyridazine (V . 14b)
This compound was prepared from 6-(3'-methoxybenzyloxy)-pyridazin-3- 
amine 2-oxide (0.25 g) and phenacyl bromide (0.2 g) in ethanol (30 ml) as for the 2'- 
methoxy isomer above but it was refluxed at 85° with stirring for 3 h. The crude product 
was subjected to t.l.c. (alumina; chloroform, developed twice) to give a yellow oil which 
was recrystallised from light petroleum (b.p.40-60°) to give fine yellow crystals of the 
title compound (0.05 g), m.p. 112-114° (Found : C, 70.1; H, 5.4; N, 11.5. 
C21H19N3O3 requires C, 69.8; H, 5.3; N, 11.6%). *H n.m.r. (CDCI3) : 5 3.82, s, 3’- 
OMe; 4.10, s, 3-OMe; 5.41, s CFI2; 6 .66, d, J7j8 9 Hz, H 7; 6.82-8.16, complex, H 
2',4’,5’,6’ and Ph; 7.71, d, J7,8 9 Hz, H 8. Mass spectrum : m/z 361 (M+) (28%), 346 
(4%), 318 (31%), 121 (100%), 91 (21%), 77 (9%). v max (KBr) 3040 (w), 2940 (w), 
2810 (w), 1550 (s), 1500 (s), 1210 (s), 1030 (s), 820 (s), 680 (s).
3-Ethoxy-6-(3'-methoxybenzyloxy)-2-phenylimidazo[l,2-Z>]pyridazine (V . 14h)
This compound was prepared as for its 3-methoxy analogue above by 
ethylation of crude 6-(3'-methoxybenzyloxy)-2-phenylimidazo[l,2-£]pyridazin-3(5//)- 
one with diazoethane.256
The crude product was subjected to t.l.c. (alumina: toluene, developed twice) 
and recrystallised from light petroleum (b.p.40-60°) to give green crystals of the title 
compound (24%), m.p. 71-72° (Found, for a sample dried at 25° and 0.2 mmHg for 6
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h : C, 70.6; H, 5.8; N, 11.4. C22H21N3O3 requires C, 70.4; H, 5.6; N, 11.2%). *H 
n.m.r. (CDCI3) : 5 1.47, t, J 7 Hz, CH3CH2; 3.82, s, 3’-OMe; 4.34, quart, J 7 Hz, 
CH3CH2; 5.40, s CH2; 6.65, d, J7>8 9 Hz, H 7; 6.67-8.18, complex, H 2',4',5’,6' and 
Ph; 7.71, d, J7,8 9 Hz, H 8.
3-Methoxy-6-(4'-methoxybenzyloxy)-2-phenylimidazo[l,2-£]pyridazine (Y . 14c)
This compound was prepared from 6-(4'-methoxybenzyloxy)pyridazin-3- 
amine 2-oxide (0.25 g) and phenacyl bromide (0.2 g) in ethanol (20 ml) as for the 3'- 
methoxy isomer above but refluxed with stirring for lh. The crude product was 
subjected to t.l.c. (alumina; chloroform) to give an orange solid which was recrystallised 
from cyclohexane to give dark green crystals of the title compound, (0.02g) m.p. 127- 
129° (Found : C, 70.1; H, 5.3; N, 11.6. C21H19N3O3 requires C, 69.8; H, 5.3; N, 
11.6%). iH n.m.r. (CDCI3) : 6 3.83, s, 4'-OMe; 4.14, s, 3-OMe; 5.38, s, CH2; 6.65, 
d, J7>8 9 Hz, H 7; 6.89-8.17, complex, H 2',3',5’,6' and Ph; 7.74, d, J7,8 9 Hz, H 8.
2- (4’-FIuorophenyl)-3-methoxy-6-(3"-methoxybenzyloxy)imidazo[l,2-£]pyridazine (V . 
14d)
A mixture of 6-(3-methoxybenzyloxy)pyridazin-3-amine 2-oxide (0.25 g) 
and a-bromo-4-fluoroacetophenone261 (0.22 g) in ethanol (11 ml) was refluxed with 
stirring for 4 h.
After cooling, ethereal diazomethane was added to the reaction mixture and it 
was stirred at 0° and then at 20° overnight. The solvents were removed under reduced 
pressure and the crude product subjected to t.l.c. (alumina; cyclohexane/chloroform, 1:1) 
to give a light blue crystalline solid which was recrystallized from cyclohexane to give 
light brown crystals of the title compound (0.06 g), m.p. 113-115° (Found, for a 
sample dried at 85° and 0.2 mmHg for 12 h : C, 66.8; H, 4.8; N, 11.2. C21H18FN3O3 
requires C, 66.5; H, 4.8; N, 11.1%). n.m.r. (CDCI3) : 5 3.83, s, 3'-OMe; 4.10, s,
3- OMe; 5.41, s, CH2; 6.67, d, J7>8 9 Hz, H 7; 6.68-8.15, complex, H 
2’,3',5',6',2",4",5",6"; 7.71, d, J7>8 9 Hz, H 8. v max (KBr) 3060 (w), 2940 (w), 
2810 (w), 1550 (m), 1510 (m), 1210 (s), 1040 (s), 830 (s), 800 (s).680 (s).
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3-Methoxy-6-(3,-methoxybenzyloxy)-2-(3"-trifluoromethylphenyl)imidazo[l,2-£]- 
pyridazine (V. 14e)
Similarly 6-(3'-methoxybenzyloxy)pyridazin-3-amine 2-oxide (0.25 g) and 
a-bromo-3-trifluoromethylacetophenone (0.28 g) in ethanol (10 ml) gave a crude product 
which was subjected to t.l.c. (alumina; cyclohexane/chloroform, 1:2) and recrystallised 
from cyclohexane/light petroleum (b.p. 40-60°) to give yellow crystals of the title 
compound (0.06 g), m.p. 96-97° (Found, for a sample dried at 70° and 0.2 mmHg for 
4.5 h : C, 61.7; H, 4.3; N, 9.7. C22H18F3N3O3 requires C, 61.5; H, 4.2; N, 9.8%). 
lH n.m.r. (CDCI3) : 5 3.84, s, 3'-OMe; 4.14, s, 3-OMe; 5.43, s, CH2; 6.73, d, J7,8 9 
Hz, H 7; 6.86-8.45, complex, H 2',4',5',6',2",4”,5",6"; 7.77, d, J7,8 9 Hz, H 8.
3- Methoxy-6-(3,-methoxybenzyloxy)-2-(4"-trifluoromethylphenyI)imidazo[l,2-Z>]- 
pyridazine (V. 14f)
This compound was prepared in similar manner to its 3’-trifluoromethyl 
isomer from 6-(3’-methoxybenzyloxy)pyridazin-3-amine 2-oxide (0.25 g) and a-bromo-
4- trifluoromethylacetophenone (0.28 g). The product was purified by t.l.c. (alumina; 
chloroform) and recrystallised from cyclohexane/light petroleum (b.p. 40-60°) to give the 
title compound (0.16 g), m.p. 110-112° (Found : C, 61.6; H, 4.2; N, 9.9. 
C22H18F3N3O3 requires C, 61.5; H, 4.2; N, 9.8%). *H n.m.r. (CDCI3) : 6 3.83, s, 3’- 
OMe; 4.13, s, 3-OMe; 5.41, s, CH2; 6.71, d, J7>8 9 Hz, H 7; 6.82-7.43, complex, H 
2’,4’,5',6’; 7.73, d, J7>8 9 Hz H 8; 7.69, d, 8.21, d, J2",3" 9 Hz, H 2",3",5",6".
2-(2,-Aminophenyl)-3-methoxy-6-(3,-methoxybenzyIoxy)imidazo[l,2-£]pyridazine 
(V . 16)
A mixture of 6-(3'-methoxybenzyloxy)pyridazin-3-amine 2-oxide (0.3 g) and 
a-bromo-2-nitroacetophenone262 (0.3 g) in ethanol (30 ml) was refluxed for 4 h. The 
solvent was removed in vacuo to leave a dark residue which was stirred with a cold 
solution of ethereal diazomethane at 0° and 20° overnight. Evaporation of the ether gave 
a crude product which was subjected to t.l.c. (alumina; toluene, developed twice) to give 
a yellow oil (0.04 g).
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This product was dissolved in methanol (10 ml) and added dropwise to a 
rapidly stirred mixture of reduced iron powder (0.12 g), methanol (4 ml), water (3 ml) 
and concentrated hydrochloric acid (0.16 ml). The reaction mixture was maintained at 
85-90° for 2 h. The solid was filtered off, washed with hot methanol, and the combined 
filtrates evaporated to dryness. The residue was diluted with water and the pH adjusted 
to 7 (with lM sodium hydroxide). The product was extracted into chloroform. 
Evaporation gave an orange residue which was subjected to t.l.c. (alumina; chloroform) 
to give a yellowish green residue (0.02 g) which was recrystallised from light petroleum 
(b.p. 40-60°) to give the title compound , m.p. 89-90° (Found, for a sample dried at 
75° and 0.2 mmHg for 4 h : C, 67.5; H, 5.6; N, 14.9. C21H20N4O3 requires C, 67.0; 
H, 5.4; N, 14.9%). n.m.r. (CDCI3) : 5 3.84, s, 3"-OMe; 4.05, s, 3-OMe; 5.43, s, 
CH2; 6.67, d, J7,8 9 Hz, H 7; 6.80-7.91, complex, H 3',4',5',6’,2”,4",5",6"; 7.68 d, 
J7>8 9 Hz, H 8.
3-Methoxy-6-(3'-methoxybenzyIoxy)-2-(pyrid-3"-yl)imidazo[l,2-Z>]pyridazine (V .
14g)
A mixture of 6-(3'-methoxybenzyloxy)pyridazin-3-amine 2-oxide (0.25 g), 
3-(bromoacetyl)pyridine hydrobromide (0.28 g) and sodium hydrogen carbonate (0.084 
g) in ethanol (12 ml) was refluxed with stirring for 5.5 h.
After cooling, a solution of ethereal diazomethane was added the mixture 
stirred at 0° and then at 20° overnight. Evaporation of the solvents gave a residue which 
was subjected to t.l.c. (alumina; chloroform, developed twice) and the product 
recrystallised from cyclohexane and light petroleum (b.p. 40-60°) to give the title 
compound (0.03 g), m.p. 114-116° (Found : C, 66.4; H, 4.9; N, 15.5. C20H18N4O3 
requires C, 66.3; H, 5.0; N, 15.5%). *H n.m.r. (CDCI3): 6 3.83, s, 3'-OMe; 4.13, s, 
3-OMe; 5.42, s, CH2; 6.71, d, J7>8 9 Hz, H 7; 6.82-8.36, complex, H
2’,4’,5',6’,2",4",5",6"; 7.73, d, J7>8 9 Hz, H 8.
CHAPTER VI
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CHAPTER VI Syntheses and binding studies of some 3-alkoxy-6-benzyIamino- 
(anilino, phenethylamino and pyridylmethy!amino)-2-phenyl(and
aryl)imidazo[l,2-£]pyridazines
VI -1 Introduction
The studies on the structure and activity relationships of some imidazo- 
[l,2-&]pyridazines in the previous chapters of this thesis have indicated that an aryl group 
at position 2 (Chapter II - 4.3), an alkoxy substituent at position 3 (Chapter II - 4.3 and 
IV - 4.2) as well as suitable substituents at position 6 (Chapter II - 4.3, III - 4.2 and IV - 
4.2) were required in order to enhance affinity at benzodiazepine receptors. In this 
chapter the binding affinities for derivatives of 6-benzylamino-3-methoxy-2-phenyl- 
im idazo[l,2-£]pyridazine (VI . 9a) and for 6-anilino-3-methoxy-2-phenyl- 
imidazo[l,2-fr]pyridazine (VI. 5) have been investigated. In this, substitution on the 6- 
benzylamino group of compound VI . 9a with methoxy group(s) and variations to 
substituents at position 2 were examined.
Binding activities of 6-anilino-, 6-phenethylamino- and pyridylmethylamino- 
analogues of compound V I. 9a were also determined. The results from this study were 
then compared with binding activities exhibited by derivatives of 3-methoxy-6-phenoxy- 
2-phenylimidazo[l,2-£]pyridazine (III . 6a) and 6-benzylthio-3-methoxy-2- 
phenylimidazo[l,2-Z?]pyridazine (IV . 19).
The synthetic methods for the preparation of compounds required in this 
study are reported first and then some physical properties are discussed. Thereafter 
studies of their binding activity are reported.
VI - 2 Syntheses
The intermediates required for the synthesis of the title compounds were 6- 
chloropyridazin-3-amine, 6-phenylalkylamino(and 6-anilino)pyridazin-3-amine, 6- 
chloropyridazin-3-amine 2-oxide and 6-phenylalkylaminopyridazin-3-amine 2-oxide; and 
the chemistry of such aminopyridazines has been reviewed.249»263
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The reactivity of the halogenopyridazine iV-oxides towards nucleophilic 
substitution has been investigated264 and as expected they were more reactive than the 
corresponding halogenopyridazines. Accordingly when the reqiured 6-phenylalkyl- 
aminopyridazin-3-amines could not be prepared from 6-chloropyridazin-3-amine, the 
corresponding iV-oxide was made. This higher reactivity of the V-oxide is due to greater 
activation by the V-oxide group (compared to the aza group) because of the increased 
contribution of the polarized structures by virtue of the negative mesomeric and inductive 
effects of the V-oxide function.263
In my work, I prepared 6-anilinopyridazin-3-amine (Scheme VI - 1, V I . 3) 
from 3,6-dichloropyridazine through the 3-anilino-6-chloropyridazine which with the 
strong nucleophile hydrazine hydrate at reflux for 5 h gave 3-anilino-6-hydrazino- 
pyridazine (VI . 2). The hydrazino group in the latter was split on catalytic 
hydrogenation in methanol over Raney nickel to give 6-anilinopyridazin-3-amine (VI. 3) 
which was converted to its picrate salt for characterization and analyses. Compound VI. 
3 condensed with 4-methylphenylglyoxal, and the oxo compound (VI . 4) was 
methylated as described for 2-aryl-6-halogeno-3-methoxyimidazo[l,2-b]pyridazines in 
Chapter II - 2.2, to give 6-anilino-3-methoxy-2-(4'-methylphenyl)imidazo[l,2-£]- 
pyridazine (VI . 5) (required as a reference compound for work described in this 
chapter).
A similar approach to the synthesis of 6-benzylaminopyridazin-3-amine met 
with failure. 3,6-Dichloropyridazine and benzylamine gave the known 3-benzylamino-6- 
chloropyridazine260 but attemptes to replace the 6-chloro substituent in an ammonolysis 
reaction (ethanolic ammonia at elevated temperatures) or with hydrazine hydrate at reflux 
failed. An alternative route involving the reaction of 6-chloropyridazin-3-amine with 
benzylamine in a sealed reaction vessel at 170-175° gave only starting materials. In view 
of the low reactivity of the chloro-substituent in the above compounds, I proceeded by 
amination of the more reactive 6-chloropyridazin-3-amine 2-oxide. Thus, 6-chloro- 
pyridazin-3-amine 2-oxide (Scheme VI -2, V I . 6) was allowed to react with excess 
benzylamine at 160° for 20 h in a sealed reaction vessel to give 6-benzylaminopyridazin- 
3-amine 2-oxide (VI. 7a) in 51% yield. In an analogous manner, 6-chloro-pyridazin-3-
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3-amine 2-oxide (VI . 6) reacted with arylalkylamines such as phenethylamine, 2- 
methoxybenzylamine, 3-methoxybenzylamine, 3',4'-dimethoxy-benzylamine and pyrid- 
3'-ylmethylamine to give compounds V . 7(b-f) which were used for the subsequent ring 
cyclization reactions.
In the synthesis of the imidazo[l,2-£>]pyridazines, the appropriate pyridazin-3- 
amine 2-oxide (VI . 7) was heated with phenacyl bromide, or other bromoacetyl 
compounds, in ethanol to give the corresponding 2-phenylimidazo[l,2-£]pyridazin- 
3(5//)-ones (VI . 8). Compounds [VI . 8 (a-w)] are not very soluble in common 
organic solvents and give poorly resolved n.m.r. spectra. These compounds were treated 
directly with etheral diazomethane to give the 0-methyl derivatives [V I. 9(a-w)] which 
gave satisfactory analyses, well resolved *H n.m.r. spectra and mass spectra.
The nitro compounds [VI. 9(m and n)] were readily reduced by iron powder 
in aqueous hydrochloric to the corresponding amino compounds [VI. 10(a and b)].
Scheme VI - 1
/ / \ NH
N NHNH2
VI . 1 VI . 2
NH N
VI . 4 VI . 3
OMe
VI . 5
Scheme VI - 2
R 1CH2NH
N NH2
O
VI . 6
N ^ N / A x NH2
*
o
VI . 7
a R1 = Ph
b R1 = CH2Ph
c R1 = C6H4OMe-o
,1d R 
e R] 
f R1
r x h 2n h
C6H4OMe-m 
C6H3(OMe)2-3,4 
C5H4N-ß *
VI . 8
VI . 8 - VI . 9
OMe
R 1 R2
R1 = C6H4OMe-m 
R 2
R 1 = c6h 4o m
R 2
a Ph Ph h C6H4Me-p r C^H4Mc-p
b CH2Ph Ph i C6H4F-m s C6H4Cl-p
c C^H4OMe-o Ph j C6H4F-p t C6H4F-p
d C6H4OMe-m Ph k C5H4CF3-m u C6H4N 02-m
e C6H3(OMe)2-3,4 Ph l C6H4CF3-/? V C6H4N02-p
f C5H4N-ß * C^FLjMe-/? m C6H4N 02-m w C5H4N-ß *
g C6H4N-ß * C5H4N-ß * n C6H4N02-p
o C5H4N-a *
P C6H4N-ß *
q c 5h 4n -y *
* Pyridyl
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VI - 3 Physical properties
The *H n.m.r. spectra of the series of compounds prepared in this chapter 
[V I. 9(a-w)] are consistent with their structures (Table VI -1) and previous data. The 
chemical shifts for the protons of the benzylic methylene group adjacent to the NH group 
on C-6 appeared as a doublet with a coupling constant of 5.0-6.5 Hz and a chemical shift 
range of 5 4.50-4.59. On addition of deuterium oxide, this doublet collapsed to a 
singlet, confirming coupling between benzylic CH2 and amino proton. 
Correspondingly, the amino proton appeared as a triplet, with a chemical shift of 5 4.7- 
5.4.
The protons on C-7 and C-8 of the above compounds appeared as an AB 
quartet with a coupling constant of 17,8 9 Hz. The chemical shifts of these protons are in 
the range 5 6.31-6.45 and 5 7.42-7.58, respectively. On comparison with the values 
observed for the other series, it is found that the proton on C-7 of the 6-benzylamino 
series is significantly shielded. This is consistent with the electron-donating ability of the 
benzylamino group. In addition, the chemical shifts for the protons of the methoxy 
group on C-3 occured in the range 5 4.00-4.17 whereas those of the methoxy substituent 
in the 6-(methoxybenzylamino) group appeared relatively upfield, as for the 6- 
(methoxybenzylthio) series (see Chapter V - 3).
Table VI -1  Some n.m.r. spectral data3 for 6-benzylamino-3-methoxy-2- 
phenyl(aryl and pyridyl)imidazo[l,2-ft]pyridazines
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R1 R2 R1 = OMe 3-OMe CH2b NH° JCH.NH (Hz) H 7 H 8
H c 6 h 5 - 4.04 4.59 4.8 5.0 6.37 7.53
OMe-ö c 6 h 5 - 4.11 4.59 5.1 5.0 6.35 7.48
OMe-m c 6 h 5 - 4.06 4.58 5.0 5.0 6.36 7.53
3',4'-(OMe)2 C6H5 3.85 4.08 4.50 5.0 5.0 6.36 7.49
OMe-m C6H4Me-/7 3.74 4.01 4.51 5.3 5.5 6.31 7.42
OMe-m C6 H4 F-m 3.84 4.09 4.58 5.1 5.5 6.35 7.45
OMe-m C6 H4 F-/? 3.79 4.04 4.56 4.9 5.0 6.37 7.51
OMe-m C6H4CF3-m 3.79 4.07 4.56 5.0 5.0 6.39 7.53
OMe-m C6 H4 CF3 -P 3.80 4.07 4.57 4.9 5.0 6.41 7.55
OMe-m C()H4 N0 2 -m 3.78 4.11 4.57 5.2 5.5 6.45 7.50
OMe-m C6H4 NO2 -/J 3.81 4.11 4.58 5.2 5.5 6.45 7.57
OMe-m C6 H4 NH2 -W 3.78 4.02 4.54 5.0 6.0 6.34 7.48
OMe-m C5 H4 NH2 -/? 3.77 4.00 4.53 5.1 6 .0 6.33 7.46
OMe-m C5H4 N-ad 3.76 4.10 4.55 5.2 5.5 6.42 7.51
OMe-m C5 H4 N-ßd 3.81 4.08 4.57 4.9 5.5 6.42 7.56
OMe-m C5H4N - / 3.81 4.11 4.58 4.7 5.5 6.43 7.58
OMe-o C6 H4 Me-p 3.82 4.07 4.57 5.2 5.5 6.32 7.45
OMe-ö C6 H4 CI -p 3.81 4.08 4.56 5.2 5.5 6.34 7.42
OMe-o C6 H4 F -p 3.80 4.06 4.57 4.9 5.5 6.39 7.52
OMe-ö C6 H4 N0 2 -m 3.84 4.16 4.58 5.3 5.5 6.42 7.46
OMe-ö C6H4 NO2 -P 3.86 4.17 4.59 5.3 5.5 6.43 7.46
OMe-ö C5H4N-ßd 3.85 4.12 4.59 5.4 5.5 6.41 7.48
a Reported as parts per million (5) downfield from tetramethylsilane as internal standard in
deuterochloroform. 
b Doublet. 
c Broad triplet. 
d Pyridyl.
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The ultraviolet absorption spectrum of 3-methoxy-6-(3'-methoxy- 
benzylamino)-2-phenylimidazo[l,2-fr]pyridazine (V I. 9d) (at pH = 7.0), revealed two 
strong bands at 220 nm (log e 5.23) and 350 (4.94) with a point of inflexion at ca. 270 
nm (log e 4.91). A similar spectrum was recorded for 3-methoxy-6-(3'-methoxy- 
benzylamino)-2-(pyrid-3'-yl)imidazo[l,2-b]pyridazine (V I. 9i).
The infrared absorption spectra of 6-benzylamino-3-methoxy-2-aryl- 
imidazo[l,2-£]pyridazines showed the characteristic band for N-H str in the range vmax 
3250-3380 cm-1. In addition, the out-of-plane C-H def bands223*5 were observed for 
para-substituted phenyl group on C-2 and raera-substituted benzylamino group on C-6.
Mass spectral measurements on 3-methoxy-6-(3'-methoxybenzylamino)-2- 
phenylimidazo[l,2-b]pyridazine (V I. 6c) showed that the major cleavage involved the 
loss of C2H3O from the molecular ion. This fragmentation pattern is consistent with that 
of 6-chloro-3-methoxy-2-(4'-methylphenyl)imidazo[l,2-b]pyridazine (II . 3d) and 3- 
methoxy-6-phenoxy-2-phenylimidazo[l,2-&]pyridazine (III. 6a). In addition, cleavage 
at the benzylic bond was also evident as observed for 3-methoxy-6-(4'- 
methylbenzylthio)-2-phenylimidazo[l,2-Z?]pyridazine (IV . 4d) and 3-methoxy-6-(3'- 
methoxybenzyloxy)-2-phenylimidazo[l,2-Z)]pyridazine (V. 14b).
VI - 4 In vitro binding studies
The binding studies on the compounds prepared in this chapter were carried 
out using the [3H]diazepam binding assay as outlined in Chapter II - 5.3.
VI - 4.1 Results of [3H]diazepam binding assay
The results of the above in vitro displacement studies for compounds V I . 
(5-11) are shown in Table VI - 2 as IC50 values or per cent displacement at the specified 
concentration.
Table VI - 2 Results for displacement of [3H]diazepam from its specific binding 
sites in rat brain by some substituted imidazo[l,2-Z>] pyridazines
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6 ^  ----------  3
N  4 
5
Formula Substituents IC50 Displacement (%)
number (nM)a at concn specified
V I . /
5 6-NHPh-3-OMe-2-C6H4Me-/? b
9a 6-NHCH2Ph-3-OMe-2-Ph 9
9b 6-NHCH2CH2Ph-3-OMe-2-Ph 800
9c 6-NHCH2C6H4 0 Me-ö-3-0 Me-2-Ph 2
9d 6-NHCH2C6H4 0 Me-m-3-0 Me-2-Ph 2.5
9e 6-NHCH2C6H3(OMe)2-(3,,4,)-3-OMe-2-Ph 3.5
9h 6-NHCH2C6H4 0 Me-m-3-0 Me-2-C6H4Me-p 1.5
11 6-NHCH2C6H4 0 Me-m-3-OMe-2-C6H4F-oc 1.5
9i 6-NHCH2C6H4 0 Me-m-3-OMe-2-C6H4F-m 15
9j 6-NHCH2C6H4 0 Me-m-3-0 Me-2-C6H4F-p 1.5
9k 6-NHCH2C6H4 0 Me-m-3-0 Me-2-C6H4CF3-m 55
91 6-NHCH2C6H4 0 Me-m-3-0 Me-2-C6H4CF3-/7 24
9m 6-NHCH2C6H4 0 Me-m-3-0 Me-2-C6H4N0 2 -w 2
9n 6-NHCH2C6FUOMe-m-3-OMe-2-C6H4NC>2-/? 13
10a 6-NHCH2C6H4 0 Me-m-3-0 Me-2-C6H4NH2-w 1.5
10b 6-NHCH2C6H4 0 Me-m-3-0 Me-2-C6H4NH2-p 1
9o 6-NHCH2C6H4 0 Me-m-3-OMe-2-C5H4N-ad 21.7% at 30 nM
9p 6-NHCH2C6H4 0 Me-m-3-0 Me-2-C5H4N-ßd 1.5
9q 6-NHCH2C6H4OMe-m-3-OMe-2-C5H4N-7d 6
9r 6-NHCH2C6H4 0 Me-ö-3-OMe-2-C 6H4Me-p 5.5
9s 6-NHCH2C6H4 0 Me-ö-3-0 Me-2-C 6H4Cl-p 16
9t 6-NHCH2C6H4 0 Me-o-3-OMe-2-C 6H4F-p 2
9u 6-NHCH2C6H4 0 Me-ö-3-OMe-2-C 6H4N0 2 -m 30
9v 6-NHCH2C6H4 0 Me-o-3-OMe-2-C 6H4N0 2 -p 20.6% at 10 nM
9w 6-NHCH2C6H4 0 Me-ö-3-0 Me-2-C5H4N-ßd 3
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Table VI - 2 Continued
Formula Substituents IC50 Displacement (%)
number (nM)a at concn specified
V I ./
9f 6-NHCH2C5H4N-ßd-3-OMe-2-C6H4Me-p 7
9g 6-NHCH2C5H4N-ßd-3-OMe-2-C5H4N-ßd 36
a IC50 values are the concentrations required to displace 50% of specific [^HJdiazepam binding to rat
brain membrane preparation, 
b Not significant at 1000 nM. 
c Kindly prepared by Mr S J. Ireland, 
d Pyridyl.
VI - 4.2 Discussion of binding results
These results in Table VI - 2 reveal that whereas 6-anilino-3-methoxy-2-(4'- 
methylphenyl)imidazo[l,2-£]pyridazine (V I. 5) did not show any displacement of 
[3H]diazepam at a concentration of 1000 nM, its 6-benzylamino analogue (V I. 9a) gave 
50% displacement at 9nM. This displacement activity decreased with the 6-phenethyl- 
amino analogue (V I. 9b, IC50 800 nM).
On comparing these results with other series, the lack of binding activity for 
compound VI . 5 was unexpected. Whereas this compound showed no apparent 
inhibition of [3H]diazepam binding, its 6-chloro and 6-phenoxy analogues ( I I . 3c and 
I I I . 9c) gave IC50 values of 148 and 64 nM, respectively. However, 6-benzylamino-3- 
methoxy-2-phenylimidazo[l,2-&]pyridazine (V I. 9a), the parent compound of this 
series, with an IC50 of 9 nM was slightly more effective in binding than its 6-benzylthio 
and 6-benzyloxy analogues (IV . 19 and V. 10, IC50 22 and 20 nM, respectively).
The effect of substitutions by methoxy groups in the 6-benzylamino 
substituent of the parent compound (V I. 9a) was then investigated. The results for the 
6-(2'- and 3'-methoxybenzylamino) compounds V I . 9c and 9d (IC50 2 and 2.5 nM) 
show that these analogues are more potent inhibitors of [3H] diazepam binding than the 
parent compound (V I. 9a, IC50 9 nM). This observation is consistent with our previous 
studies on the effect of substitution by methoxy groups on the 6-benzylthio and 6-
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6-benzyloxy analogues (VI .19 and V . 10) in that binding activity increases with ortho 
or meta substitutions. The relative increase in binding affinity of the 6-benzylamino 
derivatives (V I. 9c and 9d, IC50 2.0 and 2.5 nM) however is greater than that of the 6- 
benzylthio derivatives (IV . 4d and 4e, IC50 9 and 10 nM) or 6-benzyloxy derivatives (V 
. 8a and 8b, IC50 7 and 6 nM). In addition, the 6-(3',4'-dimethoxybenzylamino) 
analogue (VI . 9e) gave an IC50 value of 3.5 nM). The higher potency for the 6- 
benzylamino derivatives may be attributed to the ability of the benzylamino group to 
maintain a more favourable orientation for interaction with the benzodiazepine receptor 
than the corresponding 6-benzylthio and 6-benzyloxy analogues. However, the 
possibility also exists that secondary interactions of the benzylamino N-H with the 
receptor stabilize the ligand-benzodiazepine receptor complex, resulting in enhanced 
binding activity. Further studies are needed to confirm these hypotheses.
In the second part of our study, the effect of substitutions in the 2-phenyl 
substituent of 3-methoxy-6-(3'-methoxybenzylamino)-2-phenylimidazo[ 1,2-&]pyridazine 
(VI . 9d, Ic5o 2.5 nM) with electron-donating or electron-withdrawing groups was 
examined. Strong electron-withdrawing groups such as para-trifluoromethyl and para- 
nitro (as in compounds V I . 91 and 9n) decreased binding. A para-fluoro substituent 
however as in compound V I. 9j maintained a high binding potency. Likewise, electron- 
donating groups such as methyl or amino substituents at the para-position  (as in 
compounds V I . 9h and 10b) were associated with high activity. At the mera-position, 
the effects of substitutions were not consistent. A high binding activity was observed for 
compounds VI . 9m and V I . 10a which contained a meta-nitto and a meta-amino 
group, respectively. But a lower activity was maintained in compounds V I . 9i and V I. 
9k which contained a meta-fluoro and m^a-trifluoromethyl group, respectively.
This study was extended to the 6-(2'-methoxybenzylamino) analogues 
(compounds V I . 9c, 9r-9w). In the compounds V I . 9r and 9t, substitution with a 
para-methyl or para-fluoro group did not alter binding activity significantly, relative to VI 
. 9c. This is consistent with compounds V I. 9h and V I . 9j. However, substitutions 
in the 2-phenyl group with para-chloro, meta-nitro or para-nitro as in compounds V I. 
9s, 9u and 9v resulted in less effective in vitro binding. These results indicate that
164
indicate that factors other than electronic effects have a significant bearing on the binding 
of derivatives of 3-methoxy-6-(3'-methoxybenzylamino)-2-phenylimidazo[l,2- 
&]pyridazine (VI. 9d) and its 6-(2'-methoxybenzylamino) analogue (VI. 9c).
Replacement of the 2-phenyl group of 3-methoxy-6-(3'- 
methoxybenzylamino)-2-phenylimidazo[l,2-Z?]pyridazine (V I. 9d) with a pyrid-2'-yl 
resulted in a reduction in binding potency whereas the 2-(pyrid-3'-yl) analogue retained a 
high affinity for benzodiazepine receptors (compounds V I. 9o and 9p respectively). In 
addition, 3-methoxy-6-(2'-methoxybenzylamino)-2-(pyrid-3'-yl)imidazo[l,2-Z?]- 
pyridazine (VI .9w) exhibited high binding activity (IC50 3 nM). These observations are 
consistent with results obtained for the 2-(pyridyl) analogues of 3-methoxy-6-(3'- 
methoxybenzylthio)-2-phenylimidazo[l,2-6]pyridazine (IV. 4e).
Finally, the effect of replacing the 6-benzylamino group of 6-benzylamino-3- 
methoxy-2-phenylimidazo[l,2-6]pyridazine (V I. 9a, IC50 9 nM) with a 6-(pyrid-3'- 
ylmethylamino) substituent was examined. The result of in vitro displacement by 
compound VI . 9f (IC50 7 nM) showed high binding activity. Similar results were 
obtained for the benzylthio analogue of compound V I. 9a in that high binding activity 
was observed for the 6-pyridylmethylthio compounds (IV . 7a, 7b and 7c, IC50 5, 7 and 
6 nM, respectively). In 3-methoxy-2-(pyrid-3'yl)-6-(pyrid-3,-ylmethylamino)- 
imidazo[l,2-b]pyridazine (VI. 9g, IC50 36 nM) however, a fivefold decrease in affinity 
was observed compared with its 2-phenyl analogue (V I. 9f, IC50 7 nM).
In summary, it appears that interaction with benzodiazepine receptors by 
derivatives of 6-benzylamino-3-methoxy-2-phenylimidazo[l,2-b]pyridazine (VI. 9a), 6- 
benzylthio-3-methoxy-2-phenylimidazo[l,2-£]pyridazine (IV . 19) and 6-benzyloxy-3- 
methoxy-2-phenylimidazo[l,2-&]pyridazine (V . 10) involve a common binding domain. 
In the case of 6-benzylamino-3-methoxy-2-phenylimidazo[l,2-fr]pyridazine, binding at 
this domain is relatively more effective than its 6-benzylthio and 6-benzyloxy analogues. 
The pharmacological actions mediated by these compounds via the occupation of 
benzodiazepine receptors are investigated in the subsequent in vivo pharmacological 
testing on compounds from these three series of related compounds. (Chapter VIII - 
3.3).
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VI - 5 Experimental
The general procedure and experimental details for the [3H]diazepam binding 
assay are recorded in Chapter II - 5.1 and 5.3
3-AniIino-6-chloropyridazine (V I. 1)
This compound (45%) was prepared from 3,6-dichloropyridazine and aniline 
in ethanol at reflux. It had m.p. 185-186° (from cyclohexane) (lit.265,266 1900, 191.2- 
192°). !H n.m.r. (CDCI3) : 5 7.10, d, J4,5 9 Hz, H 4(5); 7.26, d, J4 ,5 9 Hz, H 5(4); 
7.30-7.50, complex, Ph.
3-Anilino-6-hydrazinopyridazine (V I. 2)
A mixture of 3-anilino-6-chloropyridazine (2.0 g) and hydrazine hydrate (40 
ml) was refluxed for 5 h. The hydrazine was evaporated under reduced pressure and the 
residue suspended in water and the product (0.70 g) collected. It was recrystallised from 
aqueous methanol to give 3 -anilino-6-hydrazinopyridazine (0.50 g), m.p. 204-207° 
(Found, for a sample dried at 40° and 0.1 mmHg for 4 h : C, 59.4; H, 5.7; N, 34.7. 
C 10H 11N5 requires C, 59.7; H, 5.5; N, 34.5%). *H n.m.r. (CD3SOCD3) : 5 4.1, b, 
NH2; 6.78, d, J4,5 9 Hz, H 5(4); 6.95, d, J4,5 9 Hz, H 4(5); 6.98-7.69, complex, Ph; 
7.79, b, NH.
6-Anilinopyridazin-3-amine (picrate) (V I. 3)
3-Anilino-6-hydrazinopyridazine (0.2 g) in methanol (150 ml) with a little 
water was shaken with hydrogen over Raney nickel at room temperature and pressure for 
6 h. The catalyst was filtered off and the filtrate evaporated to give a solid (0.1 g). *H 
n.m.r. (CD3SOCD3) : 5 5.71, b, NH2; 6.77, d, J4,5 9 Hz, H 5(4); 6.97, d, J4,5 9 Hz, H 
4(5); 6.87-7.83, complex, Ph; 8.65, b, NH.
Portion of this product with aqueous picric acid gave a yellow precipitate 
which recrystallised from ethanol to give 6-anilinopyridazin-3-amine picrate, m.p. >250° 
(Found, for a sample dried at 50° and 0.1 mmHg for 6 h : C, 46.5; H, 3.3; N, 23.4. 
CMH13N7O7 requires C, 46.3; H, 3.2; N, 23.6%).
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6-Anilino-3-methoxy-2-(4'methylpheriyl)imidazo[l,2-&]pyridazine (V I. 5)
A mixture of 6-anilinopyridazin-3-amine (0.20 g), 4-methylphenylglyoxal234 
(0.18 g) and concentrated hydrochloric acid (0.3 ml) in ethanol (25 ml) was refluxed for 
4 h. After cooling, the solvent was evaporated to give a dark red residue which was 
stirred with excess ethereal diazomethane at 0° and then at 20° overnight. The mixture 
was evaporated and the residue was subjected to t.l.c. (alumina; chloroform) and the 
band showing light blue fluorescence under the 254 nm lamp at low Rf was collected and 
extracted with chloroform to give the product (0.04 g) which was recrystallised from a 
mixture of methanol and cyclohexane to give the title compound, m.p. 228-230° (Found 
: C, 72.5; H, 5.8; N, 16.5. C2oH i8N40 .1/6 H20  requires C, 72.1; H, 5.5; N, 
16.8%). *H n.m.r. (CDCI3) : 5 2.39, s, Me; 4.14, s, 3-OMe; 6.64, d, J7>8 9 Hz, H 7; 
6.77, b, NH; 7.11-8.03, complex, H 2,,3',5',6'and Ph; 7.65, d, J7,8 9 Hz, H 8 .
6-BenzyIaminopyridazin-3-amine 2-oxide (V I. 7a)
6-Chloropyridazin-3-amine 2-oxide238 (0.2 g) and benzylamine (2.0 g) were 
heated in a screw top reaction vessel at 160° for 20 h. After cooling, chloroform (2 ml) 
was added to the brown residue and the mixture subjected to column chromatography 
(alumina; chloroform) and the product eluted with ethanol and methanol, respectively). 
The light brown residue was precipitated from cold chloroform with ether and the yellow 
precipitate (0.18 g) recrystallised from acetone to give golden brown crystals of the title 
compound (0.15 g), m.p. 189-191° (Found, for a sample dried at 90° and 0.1 mmHg 
for 4 h : C, 61.4; H, 5.7; N, 25.9. C n H i2N40  requires C, 61.1; H, 5.6; N, 25.9%). 
*H n.m.r. (CD3SOCD3) : 5 4.32, d, JCH,NH 6 Hz, CH2; 5.85, b, NH2; 6.52, d, 7.07, 
d, J4,5 9 Hz, H 4,5; 7.30, b, Ph.
6-Phenethylaminopyridazin-3-amine 2-oxide (V I. 7b)
6-Chloropyridazin-3-amine 2-oxide (0.3 g) and phenethylamine (2.4 g) were 
heated in a screw top reaction vessel at 160° for 16 h. The reaction mixture was poured 
into cold ether and the light yellow precipitate filtered off. It was recrystallised from 
chloroform to give yellow crystals of the title compound (0.3 g), m.p. 170-173° (Found :
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C, 62.5; H, 6.1; N, 24.1. C12H 14N4O requires C, 62.6; H, 6.1; N, 24.3%). *H n.m.r. 
(CD3SOCD3) : 5 2.80, t, Jch ,NH 6.5 Hz, CH2Ph; 3.29, multiplet, CH2NH; 5.84, b, 
NH2; 6.45, d, 7.05, d, J4,5 9 Hz, H 4,5; 6.53, bt, Jch,NH 6.5 Hz, NH; 7.25, b, Ph.
6-(2'-Methoxybenzylamino)pyridazin-3-amine 2-oxide (V I. 7c)
This compound was prepared from 6-chloropyridazin-3-amine 2-oxide (0.8 
g) and 2-methoxybenzylamine (4.8 g) as for the benzylamino analogue. The product 
was subjected to column chromatography (alumina; acetone, and the product eluted with 
ethanol and methanol). It was recrystallised from «-propanol and ethyl acetate to give 
yellow crystals of the title compound (0.7 g), m.p. 204-206° (Found : C, 58.9; H, 6.0; 
N, 22.9. Ci 2H i4N40 2 requires C, 58.5; H, 5.7; N, 22.8%). lU n.m.r. (CDCI3) : 5 
3.81, s, MeO; 4.27, d, Jch ,NH 6 Hz, CH2; 5.9, b, NH2; 6.56, d, 7.08, d, J4,5 9 Hz, H 
4,5; 6.74-7.31, complex, H 3',4’,5',6 '.
6-(3,-Methoxybenzylamino)pyridazin-3-amine 2-oxide (V I. 7d)
This product was prepared as for its isomer above and purified by column 
chromatography (alumina; chloroform, and eluted with ethanol) and recrystallised from a 
mixture of «-propanol and acetone to give the title compound (63%), m.p. 161-163° 
(Found : C, 58.7; H, 6.0; N, 23.0. Ci2H i4N40 2 requires C, 58.5; H, 5.7; N, 22.8%). 
lH n.m.r. (CD3SOCD3) : 5 3.72, s, MeO; 4.29, d, Jch ,NH 6 Hz, CH2; 5.8, b, NH2; 
6.52, d, 7.07, d, J4,5 9 Hz, H 4,5; 6.71-7.32, complex, H 2',4',5',6 '.
6-(3',4,-Dimethoxybenzylamino)pyridazin-3-amine 2-oxide (V I. 7e)
In a similar manner from 6-chloropyridazin-3-amine 2-oxide and 3,4- 
dimethoxybenzylamine (160°), was prepared the title compound (34%), m.p. 152-154° 
(from a mixture of acetone and ethyl acetate) (Found : C, 56.7; H, 6.1; N, 20.2. 
C13HK5N4O3 requires C, 56.5; H, 5.8; N, 20.3%). lR  n.m.r. (CD3SOCD3) : 5 3.71, 
s, 3.72, s, 2xOMe; 4.42, d, Jch ,NH 5.5 Hz, CH2; 5.84, b, NH2; 6.50, d, 7.06, d, J4 ,5 
9 Hz, H 4,5; 6.76-6.95, complex, H 2’,5',6 *.
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6-(Pyrid-3'-yImethylamino)pyridazin-3-amine 2-oxide (VI. 7f)
6-Chloropyridazin-3-amine 2-oxide (0.4 g) and pyrid-3-ylmethylamine (3.0 
g) were heated at 160° for 16 h. The reaction mixture was dissolved in ethanol (3.0 ml) 
and applied to a column of alumina (22 cm) and washed with n-propanol/ acetone (1:1) to 
remove excess pyrid-3-ylmethylamine. The product was eluted with methanol and 
precipitated from chloroform with ether. It was recrystallised from «-propanol/ethyl 
acetate to give yellow crystals of the title compound (0.25 g), m.p. 204-206° (Found : 
C, 55.0; H, 5.3; N, 32.0. C i0H n N 5O requires C, 55.3; H, 5.1; N, 32.2%). *H 
n.m.r. (CD3SOCD3) : 5 4.34, d, JCH,NH 5.5 Hz, CH2; 5.9, b, NH2; 6.51, d, 7.08, d, 
J4,5 9 Hz, H 4,5; 6.96-8.55, complex, H 2',4',5',6*.
6-Benzylamino-3-methoxy-2-phenyIimidazo[l,2-£]pyridazine (VI. 9a)
A mixture of 6-benzylaminopyridazin-3-amine 2-oxide (0.08 g), phenacyl 
bromide (0.07 g) and ethanol (6 ml) was refluxed, with stirring for 4 h. The solvent was 
evaporated and the brown residue methylated with excess ethereal diazomethane at 0°, 
then at 20° overnight. The solvent was evaporated and the residue subjected to t.l.c. 
(alumina; chloroform, then ether) and the product (0.03 g) recrystallised from light 
petroleum (b.p. 60-80°) to give the title compound, m.p. 132-134° (Found : C, 73.0; H, 
5.7; N, 16.8. C20H i8N4O requires C, 72.7; H, 5.5; N, 17.0%). n.m.r. (CDCI3) : 5
4.04, s, MeO; 4.59, d, JcH,NH 5 Hz, CH2; 4.8, t, JcH,NH 5 Hz, NH; 6.37, d, J7j8 9 
Hz, H 7; 7.36-8.12, complex, 2xPh; 7.53, d, J7,g 9 Hz, H 8.
In a similar manner were prepared the following compounds.
3-Methoxy-6-phenethyIamino-2-phenylimidazo[l,2-Z>]pyridazine (VI. 9b)
The crude product was subjected to t.l.c. (alumina; chloroform) and 
recrystallised from light petroleum (b.p. 60-80°) to give the title compound (15%), m.p. 
109-111° (Found, for a sample dried at 80° and 0.1 mmHg for 8 h : C, 73.1; H, 5.9; N, 
16.0. C2iH20N4O requires C, 73.2; H, 5.9; N, 16.3%). *H n.m.r. (CDCI3) : 5 2.99, 
t, Jch,NH 6.5 Hz, CH?Ph; 3.69, quart, JcH.NH 6.5 Hz, CH2N; 4.15, s, MeO; 4.50, t,
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JCH,NH 6.5 Hz, NH; 6.27, d, J758 9 Hz, H 7; 7.23-8.15, complex, 2xPh; 7.50, d, J7s8 9 
Hz, H 8.
3-Methoxy-6-(2,-methoxybenzylamino)-2-phenylimidazo[l,2-£]pyridazine (V I. 9c)
The crude product was subjected to t.l.c. (alumina; chloroform) and 
recrystallised from a mixture of chloroform and cyclohexane to give the title compound 
(35%), m.p. 132-134° (Found : C, 69.9; H, 5.7; N, 15.4. C21H20N4O2 requires C, 
70.0; H, 5.6; N, 15.5%). *H n.m.r. (CDCI3) : 5 3.88, s, 2’-OMe; 4.11, s, 3-OMe; 
4.59, d, JcH,NH 6 Hz, CH2; 5.10, t, JcH,NH 6 Hz, NH; 6.35, d, J7?8 9 Hz, H 7; 6.83- 
8.15, complex, H 3',4',5',6' and Ph; 7.48, d, J7,8 9 Hz, H 8.
3-Methoxy-6-(3'-methoxybenzyIamino)-2-phenyIimidazo[l,2-^]pyridazine (V I. 9d)
The crude product was subjected to t.l.c. (alumina; chloroform) and 
recrystallised from cyclohexane and also chloroform/cyclohexane to give the title 
compound (35%), m.p. 157-159° (Found, for a sample dried at 90° and 0.1 mmHg for 
6 h : C, 69.7; H, 5.8; N, 15.3. C21H20N4O2 requires C, 70.0; H, 5.6; N, 15.5%). lH 
n.m.r. (CDCI3) : 8 3.80, s, 3-OMe; 4.06, s, 3-OMe; 4.58, d, Jch ,NH 5 Hz, CH2; 
5.0,t, Jch ,NH 5 Hz, NH; 6.36, d, J7,8 9 Hz, H 7; 6.79-8.14, complex, H 2’,4',5’,6' 
and Ph; 7.53, d, J758 9 Hz, H 8. Mass spectrum : m/z 360 (M+) (64%), 345 (15%), 
317 (100%), 287 (10%), 136% (7%), 121 (41%), 91 (25%), 77 (27%). v max (KBr) : 
3380 (m) (N-H str), 3045 (w), 2940 (w), 2820 (w), 1560 (s), 1490 (s), 1215 (s), 1030 
(s), 810 (s), 690 (s). X max (pH 7.0) 220 (log 8 5.23), 270 (4.91), 350 nm (4.94).
6-(3’, 4'-Dimethoxybenzylamino)-3-methoxy-2-phenylimidazo[l,2-Z>]pyridazine (V I. 9e)
The crude product from this preparation was applied to an alumina t.l.c. plate 
and developed twice with chloroform, and then recrystallised from a mixture of acetone 
and cyclohexane to give off-white crystals of the title compound (48%), m.p. 162-164° 
(Found : C, 67.7; H, 5.7; N, 14.1. C22H22N4O3 requires C, 67.7; H, 5.7; N, 14.3%). 
*H n.m.r. (CDCI3) : 8 3.85, s, 2xOMe; 4.08, s, 3-OMe; 4.50, d, Jch ,NH 5 Hz, CH2;
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5.00, t, Jch,NH 5 Hz, NH; 6.36, d, J7,8 9 Hz, H 7; 6.75-8.13, complex, H 2',5',6’ and 
Ph; 7.49, d, J7,8 9 Hz, H 8.
3-Methoxy-2-(4,-methyIphenyl)-6-(pyrid-3"-yImethylamino)imidazo[l,2-Zf|pyridazine 
(V I. 9f)
To a warm solution of 6-(pyrid-3'-ylmethylamino)pyridazin-3-amine 2-oxide 
(0.24 g) in ethanol (5 ml) was added oc-bromo-4-methylacetophenone247 (0.24 g) and 
the mixture was refluxed for 4.5 h. After cooling, this mixture was added to a excess 
cold ethereal diazomethane and stirred at 0° and then at 20° overnight. The mixture was 
evaporated and the residue subjected to t.l.c. (alumina; chloroform) to give a product 
(0.03 g) which was recrystallised from a mixture of toluene and cyclohexane to give 
brown crystals of the title compound, m.p. 141-143° (Found : C, 69.8; H, 5.6; N, 20.1. 
C20H19N5O requires C, 69.5; H, 5.6; N, 20.3%). *H n.m.r. (CDCI3) : 5 2.37, s, Me; 
3.97, s, 3-OMe; 4.60, d, JcH,NH 5.5 Hz, CH2; 5.30, t, JcH,NH 5.5 Hz, NH; 6.38, d, 
J7,8 9 Hz, H 7; 7.18-8.69, complex, H 2',3’,5’,6',2",4",5",6"; 7.95, d, J7,8 9 Hz, H 8.
3-Methoxy-2-(pyrid-3"-yl)-6-(pyrid-3,-yImethylamino)imidazo[l,2-£]pyridazine 
(V I . 9g)
A mixture of 6-(pyrid-3'-ylmethylamino)pyridazin-3-amine 2-oxide (0.22 g), 
3-(bromoacetyl)pyridine hydro bromide (0.30 g) and sodium hydrogen carbonate (0.09 
g) in ethanol (12 ml) was refluxed for 4 h.
After cooling, a cold ethereal solution of diazomethane was added and the 
solution stirred at 0° and then at 20° overnight. The mixture was evaporated and 
subjected to t.l.c. (alumina; ethyl acetate/acetone, 1:1) and the product (0.01 g) was 
recrystallised from a mixture of toluene and cyclohexane to give the title compound (0.01 
g), m.p. 153-155° (Found, for a sample dried at 80° and 0.1 mmHg for 12 h : C, 63.5; 
H, 4.8; N, 24.4. Ci 8H i6N60 .0.5 H20  requires C, 63.3; H, 5.0; N, 24.6%). *H 
n.m.r. (CDCI3) : 8 4.01, s, MeO; 4.63, d, Jch ,NH 5.5 Hz, CH2; 5.22, t, Jch ,NH 5.5 
Hz, NH; 6.45, d, J7,8 9 Hz, H 7; 7.22-9.29, complex, H 2’,4',5',6',2”,4",5",6”; 7.56, 
d, J7,8 9 Hz, H 8.
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3-Methoxy-6-(3'-methoxyIbenzylamino)-2-(pyrid-2"-yI)irmdazo[l,2-£]pyridazine 
(V I . 9o)
A mixture of 6-(3'-methoxybenzylamino)pyridazin-3-amine 2-oxide (0.25 
g), 2-(bromoacetyl)pyridine hydrobromide and sodium hydrogen carbonate (0.08 g) in 
ethanol (10 ml) was refluxed for 8 h. After cooling, excess cold ethereal diazomethane 
was added and the mixture stirred at 0° and then at 20° overnight. This mixture was 
evaporated and the residue subjected to t.l.c. (alumina; chloroform/acetone, 3:1) and the 
product (0.05 g) recrystallised from a mixture of acetone and cyclohexane to give the title 
compound , m.p. 134-135° (Found : C, 66.8; H, 5.3; N, 19.3. C20H19N5O2 requires 
C, 66.5; H, 5.3; N, 19.4%). lH n.m.r. (CDCI3) : 5 3.76, s, 3’-OMe; 4.10, s, 3-OMe; 
4.55, d, Jch ,NH 5.5 Hz, CH2; 5.16, t, JcH.NH 5.5 Hz, NH; 6.42, d, J7j8 9 Hz, H 7; 
6.64-8.71, complex, H 2',4’,5’,6' and pyrid-2"-yl; 7.51, d, J7,8 9 Hz, H 8.
In a similar manner were prepared the two pyridyl isomers listed below.
3-Methoxy-6-(3,-methoxybenzyIamino)-2-(pyrid-3M-yl)imidazo[l,2-Z>]pyridazine 
(VI.  9p)
The crude product from the reaction of 6-(3'-methoxybenzylamino)pyridazin- 
3-amine 2-oxide and 3-(bromoacetyl)pyridine hydrobromide followed by methylation, 
was subjected to t.l.c. (alumina; chloroform/acetone, 1:1) and recrystallised from 
chloroform/cyclohexane/light petroleum (b.p. 40-60°) to give the title compound (25%), 
m.p. 188-189° (Found : C, 64.6; H, 5.4; N, 18.8. C20H19N5O2.0.5 H20  requires C, 
64.8; H, 5.4; N, 18.9%). *H n.m.r. (CDCI3) : 5 3.81, s, 3’-OMe; 4.08, s, 3-OMe; 
4.57, d, Jc h .NH 5.5 Hz, CH2; 4.9, b, NH; 6.42, d, J7>8 9 Hz, H 7; 6.77-9.31, 
complex, H 2',4',5,,6'and pyrid-3"-yl; 7.56, d, J7)8 9 Hz, H 8. v max (KBr) : 3260 
(m) (N-H str), 3040 (w), 2940 (w), 2820 (w), 1580 (s), 1490 (s), 1260 (s), 1050 (s), 
800 (s), 700 (s). X max (pH 7.0) 222 nm (log e 4.42), 272.5 (4.15), 343 (4.19).
3-Methoxy-6-(3'-methoxybenzylamino)-2-(pyrid-4"-yl)imidazo[l,2-£]pyridazine 
(V I. 9q)
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The product from the reaction of 6-(3'-methoxybenzylamino)pyridazin-3- 
amine 2-oxide and 4-(bromoacetyl)pyridine hydrobromide followed by methylation, was 
subjected to t.l.c. (alumina; chloroform/acetone, 3:1 and alumina; ethyl acetate) and 
recrystallised from acetone/cyclohexane and toluene/cyclohexane to give the title 
compound (32%), m.p. 137-139° (Found, for a sample dried at 80° and 0.1 mmHg for 
6 h : C, 66.5; H, 5.3; N, 19.3. C20H 19N 5O2 requires C, 66.5 H, 5.3; N, 19.4%). *H 
n.m.r. (CDCI3) : 5 3.81, s, 3'-OMe; 4.11, s, 3-OMe; 4.58, d, JcH,NH 5.5 Hz, CH2; 
4.7, b, NH; 6.43, d, J7?8 9 Hz, H 7; 6.78-8.65, complex, H 2',4',5',6'and pyrid-4"-yl; 
7.58, d, J7,8 9 Hz, H 8.
2-(3,-FIuorophenyl)-3-methoxy-6-(3"-methoxybenzyIamino)imidazo[l,2-Zdpyridazine 
(V I. 9i)
oc-Bromo-2-fluoroacetophenone26l (0.22 g) was added to a solution of 6- 
(3'-methoxybenzylamino)pyridazin-3-amine 2-oxide (0.25 g) in ethanol (7.0 ml) and the 
mixture refluxed with stirring for 4 h, then evaporated under reduced pressure.
The residue was dissolved in ethanol (2.0 ml) and ethereal diazomethane 
(from 1.5 g nitrosomethylurea) added and the mixture stirred at 0° and at 20° overnight. 
The solvent was evaporated and the product subjected to t.l.c. (alumina; chloroform, 
developed twice) and recrystallised from toluene/cyclohexane to give the title compound 
as light yellow needles (0.10 g), m.p. 159-161° (Found, for a sample dried at 90° and 
0.2 mmHg for 5 h : C, 66.7; H, 5.3; N, 14.7. C21H 19FN4O2 requires C, 66.7; H, 5.1; 
N, 14.8%). *H n.m.r. (CDCI3) : 5 3.80, s, 3"-OMe; 4.06, s, 3-OMe; 4.07, d, Jc h ,NH 
5.5 Hz, CH2; 4.88, t, Jc h ,NH 5.5 Hz, NH; 6.39, d, J7,8 9 Hz, H 7; 6.76-7.91, 
complex, H 2’,4',5',6',2",4”,5”,6"; 7.52, d, J7,8 9 Hz, H 8.
In a similar manner the following compounds were prepared.
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2- (4'-Fluorophenyl)-3-methoxy-6-(3"-methoxybenzylamino)imidazo[l,2-&]pyridazine 
(VI. 9j)
The crude product from 6-(3'-methoxybenzylamino)pyridazin-3-amine 2- 
oxide (0.2 g) and oc-bromo-4-fluoroacetophenone261 followed by methylation gave, after 
t.l.c.(alumina; chloroform) and recrystallisation from toluene/cyclohexane, the title 
compound (0.05 g), m.p. 161-163° (Found, for a sample dried at 80° and 0.1 mmHg 
for 12 h : C, 67.2; H, 5.1; N, 14.5. C21H 19FN4O2 requires C, 66.7; H, 5.1; N, 
14.8%). n.m.r. (CDCI3) : 5 3.79, s, 3”-OMe; 4.04, s, 3-OMe; 4.56, d, Jch,NH 5 
Hz, CH2; 4.91, t, Jch ,NH 5 Hz, NH; 6.37, d, J7,8 9 Hz, H 7; 6.76-8.12, complex, H 
2',3’,5’,6 ',2",4",5",6 "; 7.51, d, J7,8 9 Hz, H 8. v max (KBr) : 3380 (m) (N-H str), 
3040 (w), 2940 (w), 2820 (w), 1560 (s), 1500 (s), 1210 (s), 1030 (s), 830 (s), 810 
(s),690 (s).
3- Methoxy-6-(3,-methoxybenzylamino)-2-(3"-trifluoromethylphenyl)imidazo[l,2-Z>]- 
pyridazine (VI. 9k)
6-(3'-Methoxybenzylamino)pyridazin-3-amine 2-oxide (0.25 g) and a- 
bromo-3-trifluoromethylacetophenone247 (0.28 g) as above eventually gave the yellow 
crystals of title compound (0.12 g), m.p. 144-145° (from toluene/cyclohexane) (Found : 
C, 62.0; H, 4.6; N, 13.0. C22H 19F3N4O2 requires C, 61.7; H, 4.5; N, 13.1%). !H 
n.m.r. (CDCI3) : 5 3.79, s, 3'-OMe; 4.07, s, 3-OMe; 4.56, d, Jch,NH 5 Hz, CH2; 4.95, 
t, JCH,NH 5 Hz, NH; 6.39, d, J7 ,8 9 Hz, H 7; 6.75-8.44, complex, H 2',4’,5’,6 ’, 
2",4",5",6 "; 7.53, d, J7j8 9 Hz, H 8 .
3-Methoxy-6-(3,-methoxybenzylamino)-2-(4"-trifluoromethylphenyl)imidazo[l,2-&]- 
pyridazine (VI. 91)
In a similar manner, from 6-(3'-methoxybenzylamino)pyridazin-3-amine 2- 
oxide (0.23 g) and oc-bromo-4-trifluoromethylacetophenone247 was prepared the title 
compound  (0.140g), m.p. 151-152° (Found : C, 61.9; H, 4.6; N, 13.0. 
C22H19F3N4O2 requires C, 61.7; H, 4.5; N, 13.3%). *H n.m.r. (CDCI3) : 8 3.80, s, 
3'-OMe; 4.07, s, 3-OMe; 4.57, d, Jch ,NH 5.5 Hz, CH2; 4.86, t, Jch ,NH 5.5 Hz, NH;
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6.41, d, J7,8 9 Hz, H 7; 6.77-7.38, complex, H 2',4’,5',6'; 7.55, d, J7,g 9 Hz, H 8; 
7.65, d, 8.19, d, J2",3" 9 Hz, H 2",3”,5",6".
3-Methoxy-6-(3'-methoxybenzylamino)-2-(4"-methylphenyl)imidazo[l,2-£]pyridazine 
(V I. 9h)
A mixture of 6-(3'-methoxybenzylamino)pyridazin-3-amine 2-oxide (0.25 g) 
and oc-bromo-4-methylacetophenone247 (0.22 g) in ethanol (10 ml) was refluxed for 5 h. 
After cooling, the orange precipitate (0.23 g) was filtered off, washed with water and 
ether, and dried in vacuo.
This solid was stirred overnight with excess ethereal diazomethane at 0° and 
then at 20°. The mixture was evaporated and the residue subjected to t.l.c. (alumina; 
chloroform) and the product was recrystallised from a mixture of toluene and 
cyclohexane to give light brown crystals of the title compound (0.09 g), m.p. 148-150° 
(Found : C, 70.9; H, 6.1; N, 14.9. C22H22N4O2 requires C, 70.6; H, 5.9; N, 15.0%). 
*H n.m.r. (CDCI3) : 5 2.35, s, Me; 3.74, s, 3'-OMe; 4.01, s, 3-OMe; 4.51, d, Jch ,NH 
5.5 Hz, CH2; 5.29, t, Jc h ,NH 5.5 Hz, NH; 6.31, d, J7>8 9 Hz, H 7; 6.75-8.01, 
complex, H 2’,4’,5',6',2",3”,5",6"; 7.42, d, J7>8 9 Hz, H 8.
oc-Bromo-3(and 4)-nitroacetophenone
3 (and 4)-Nitroacetophenone were brominated with bromine in acetic acid by 
a method similar to that reported in Ref. 267. The oc-bromo-3-nitroacetophenone was 
recrystallised from acetic acid and had m.p. 88-90° [*H n.m.r. (CDCI3) : 5 4.50, s, 
CH2; 7.66-8.81, complex, H 2,4,5,6].
The oc-bromo-4-nitroacetophenone was recrystallised from glacial acetic acid 
and had m.p. 95-97° [lU n.m.r. (CDCI3) : 5 4.48, s, CH2; 8.16, d, 8.36, d, J2,3 9 Hz, 
H 2,3,5,6].
3-Methoxy-6-(3,-methoxybenzylamino)-2-(3”-nitrophenyI)imidazo[l,2-£]pyridazine 
(V I. 9m)
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A mixture of 6-(3'-methoxybenzylamino)pyridazin-3-amine 2-oxide (0.37 g) 
and a-bromo-3-nitroacetophenone (0.42 g) in ethanol (15 ml) was refluxed for 0.5 h. 
After cooling to room temperature, sodium hydrogen carbonate (0.07 g) was added. 
After effervescence ceased, the mixture was brought to reflux for 3.5 h.
After cooling, water (10 ml) was added and the pH adjusted to 7. After 
chilling in ice, the brown precipitate (0.5 g) was filtered off, washed with water, ether 
and dried. This solid was added to a cold solution of ethereal diazomethane and the 
mixture stirred at 0° and 20° overnight. The crude product was subjected to column 
chromatography (alumina; chloroform) and the product (0.1 g) recrystallised from 
methanol to give yellow crystals of the title compound (0.095 g), m.p. 186-188° (Found 
: C, 61.9; H, 4.6; N, 17.1. C21H 19N5O4 requires C, 62.2; H, 4.7; N, 17.3%). *H 
n.m.r. (CDCI3) : 5 3.78, s, 3'-OMe; 4.11, s, 3-OMe; 4.57, d, JcH,NH 5.5 Hz, CH2; 
5.20, t, JcH.NH 5.5 Hz, NH; 6.45, d, J7j8 9 Hz, H 7; 6.76-8.88, complex, H 
2’,4',5',6',2",4",5",6”; 7.50, d, J7,g 9 Hz, H 8.
In a similar manner were prepared the following compounds.
3-Methoxy-6-(3'-methoxybenzylamino)-2-(4"-nitrophenyl)imidazo[l,2-£]pyridazine 
(V I . 9n)
The title compound (13%) was obtained as orange crystals, m.p. 208-210° 
(from chloroform/methanol) (Found : C, 62.4; H, 4.5; N, 17.2. C21H 19N5O4 requires 
C, 62.2; H, 4.7; N, 17.3%). lH n.m.r. (CDCI3) : 5 3.81, s, 3’-OMe; 4.11, s, 3-OMe;
4.58, d, Jch ,NH 5.5 Hz, CH2; 5.20, t, Jch ,NH 5.5 Hz, NH; 6.45, d, J7,8 9 Hz, H 7; 
6.81-7.38, complex, H 2',4’,5’,6 ’; 7.57, d, J7,8 9 Hz, H 8; 8.24, b, H 2",3",5",6”.
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3-Methoxy-6-(2,-methoxybenzyIamino)-2-(4"-methylphenyl)imidazo[l,2-£]pyridazine 
(V I. 9r)
The crude product from 6-(2'-methoxybenzylamino)pyridazin-3-amine 2- 
oxide (0.25 g) and a-bromo-4-methylacetophenone (0.22 g) followed by methylation 
gave, after t.l.c. (chloroform/cyclohexane, 3:7) and recrystallisation from toluene/light 
petroleum (b.p. 40-60°), the title compound (0.04 g), m.p. 136-138° (Found, for a 
sample dried at 90° and 0.2 mmHg for 8 h : C, 70.8; H, 5.8; N, 15.0. C22H22N4O2 
requires C, 70.6; H, 5.9; N, 15.0%). n.m.r. (CDCI3) : 5 2.36, s, CH3; 3.82, s, 2'- 
OMe; 4.07, s, 3-OMe; 4.57, d, JcH,NH 5.5 Hz, CH2; 5.16, t, JcH ,NH 5.5 Hz, NH; 
6.32, d, J7,8 9 Hz, H 7; 6.81-8.02, complex, H 3',4',5',6’,2",3”,5",6 "; 7.45, d, J7,g 9 
Hz, H 8 .
2- (4,-Chlorophenyl)-3-methoxy-6-(2"-methoxybenzyIamino)imidazo[l,2-Zdpyridazine 
(V I . 9s)
The title compound was obtained from 6-(2'-methoxybenzylamino)pyridazin-
3- amine (0.25 g) and oc-bromo-4-chloroacetophenone (0.24 g)(followed by methylation) 
as a white solid (0.1 g), m.p. 131-133° (from toluene/cyclohexane) (Found : C, 63.7; 
H, 4.9; N, 13.9. C21H 19N4CIO2 requires C, 63.8; H, 4.9; N, 14.2%). *H n.m.r. 
(CDCI3) : 8 3.81, s,2"-OMe; 4.08, s, 3-OMe; 4.56, d, JCH,NH 5.5 Hz, CH2; 5.22, t, 
JCH,NH 5.5 Hz, NH; 6.34, d, J7,8 9 Hz, H 7; 6.80-7.32, complex, H 3’,4’,5',6 ’; 7.42, 
d, J7,8 9 Hz, H 8; 7.35, d, 7.99, d, J2",3" 9 Hz, H 2",3",5",6 ”.
2-(4'-FluorophenyI)-3-methoxy-6-(2M-methoxybenzyIamino)imidazo[l,2-Zdpyridazine 
(VI. 9t)
6-(2'-Methoxybenzylamino)pyridazin-3-amine 2-oxide (0.25 g) and a- 
bromo-4-fluoroacetophenone (0.22 g) as above gave the title compound (0.05 g) which 
had m.p. 135-136° (from toluene/cyclohexane) (Found : C, 66.3; H, 5.3; N, 14.6. 
C21H 19FN4O2 requires C, 66 .6 ; H, 5.1; N, 14.8%). !H n.m.r. (CDCI3) : 8 3.84, s, 
2"-OMe; 4.09, s, 3-OMe; 4.58, d, Jc h ,NH 5.5 Hz, CH2; 5.13, t, Jc h ,NH 5.5 Hz, NH;
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6.35, d, J7,8 9 Hz, H 7; 6.82-8.12, complex, H 2',3',5’,6',3",4",5",6"; 7.45, d, J7,8 9 
Hz, H 8.
3-Methoxy-6-(2'-methoxybenzylamino)-2-(3"-nitrophenyl)imidazo[l,2-£]pyridazine 
(VI. 9u)
The crude product from 6-(2'-methoxybenzylamino)pyridazin-3-amine 2- 
oxide (0.49 g) and a-bromo-3-nitroacetophenone (0.54 g) followed by methylation 
gave, after t.l.c. (alumina; chloroform) and recrystallisation from ethanol/light petroleum 
(b.p. 40-60°), 2:1, yellow crystals of the title compound (0.075 g), m.p. 174-176° 
(Found : C, 62.1; H, 5.0; N, 17.3. C21H19N5O4 requires C, 62.2; H, 4.7; N, 17.3%). 
!H n.m.r. (CDCI3) : 5 3.84, s, 2'-OMe; 4.17, s, 3-OMe; 4.58, d, Jch ,nh 5.5 Hz, CH2; 
5.25, t, Jc h ,NH 5.5 Hz, NH; 6.42, d, J7>8 9 Hz, H 7; 6.83-8.89, complex, H 
3',4 ',5’,6’,2",4”,5”,6".
3-Methoxy-6-(2'-methoxybenzylamino)-2-(4"-nitrophenyl)imidazo[l,2-Zdpyridazine 
(VI. 9v)
In a similar manner, was prepared the title compound (25%), m.p. 163-165° 
[from ethanol/light petroleum (b.p. 40-60°), 3:1] (Found : C, 62.3; H, 4.7; N, 17.3. 
C21H19N5O4 requires C, 62.2; H, 4.7; N, 17.3%). *H n.m.r. (CDCI3) : 5 3.86, s, 2'-
OMe; 4.16, s, 3-OMe; 4.59, d, Jch ,NH 5.5 Hz, CH2; 5.26, t, JcH,NH 5.5 Hz, NH;
6.43, d, J7,8 9 Hz, H 7; 6.85-7.32, complex, H 3',4’,5',6’; 7.46, d, J7,8 9 Hz, H 8; 
8.2, b, H 2”,3",5",6”.
3-Methoxy-6-(2'-methoxybenzylamino)-2-(pyrid-3"-yl)imidazo[l,2-£]pyridazine 
(VI. 9w)
When 6-(2'-methoxybenzylamino)pyridazin-3-amine 2-oxide (0.37 g) was 
condensed with 3-(bromoacetyl)pyridine hydrobromide (0.42 g) as above, subsequent 
methylation gave the title compound (0.06 g), m.p. 170-171° (from toluene/cyclohexane) 
(Found, for a sample dried at 80° and 0.1 mmHg for 6 h : C, 66.3; H, 5.4; N, 19.3.
C20H19N5O2 requires C, 66.5; H, 5.3; N, 19.4%). n.m.r. (CDCI3) : 5 3.85, s, 2’-
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OMe; 4.12, s, 3-OMe; 4.59, d, Jch ,NH 5.5 Hz, CH2; 5.35, t, Jch ,NH 5.5 Hz, NH; 
6.41, d, J7,8 9 Hz, H 7; 6.83-9.31, complex, H 3',4’,5',6’,2",4”,5",6 "; 7.48, d, J7,8 9 
Hz, H 8 .
2- (3'-Aminophenyl)-3-methoxy-6-(3"-methoxybenzylamino)imidazo[l,2-Z>]pyridazine 
(V I . 10a)
To a rapidly stirred mixture of reduced iron powder (0.08 g), methanol (5 
ml), water (1ml) and concentrated hydrochloric acid (0.24 ml), was added a solution of
3- methoxy-6-(3,-methoxybenzylamino)-2-(3"-nitrophenyl)imidazo[l,2-£]pyridazine 
(0.05 g) in methanol (20 ml), while the temperature was maintained at 85-90°. After 
stirring at the same temperature for 3 h, the mixture was filtered and the solid washed 
with hot methanol. The combined filtrates were evaporated, the residue diluted with 
water and adjusted to pH 7, and the mixture extracted with chloroform. The extract gave 
an orange residue which was subjected to t.l.c. (alumina; chloroform) to give a brown 
product (0.03 g) which was recrystallised from toluene to give yellow crystals of the title 
compound (0.015 g), m.p. 84-86° (Found, for a sample dried at 60° and 0.1 mmHg for 
12 h : C, 65.7; H, 5.6; N, 18.3. C21H21N5O2 .0.5 H20  requires C, 65.6; H, 5.8; N, 
18.2%). iH n.m.r. (CDCI3) : 5 3.4, b, NH2; 3.78 s, 3"-OMe; 4.02, s, 3-OMe; 4.54, d,
JCH,NH 6 Hz, CH2; 5.00, t, Jch ,nh 6 Hz, NH; 6.34, d, J7>8 9 Hz, H 7; 6.53-7.45, 
complex, H 2’,4',5',6 ’,2",4",5",6 "; 7.48, d, J7,8 9 Hz, H 8 .
2-(4,-Aminophenyl)-3-methoxy-6-(3"-methoxybenzylamino)imidazo[l,2-Z?]pyridazine 
(V I . 10b)
In a similar manner to its isomer above was prepared the title compound 
(0.020 g) as dark brown crystals, m.p. 70-77° (from toluene/cyclohexane) (Found, for 
a sample dried at 60° and 0.1 mmHg for 6 h : C, 66.4; H, 6.0; N, 18.2. C21H21N5O2 . 
0.25 H20  requires C, 66.4; H, 5.7; N, 18.4%). lH n.m.r. (CDCI3) : 5 3.4, b, NH2;
3.77 s, 3"-OMe; 4.00, s, 3-OMe; 4.53, d, JcH.NH 6 Hz, CH2; 5.06, t, JcH,NH 6 Hz, 
NH; 6.33, d, J7>8 9 Hz, H 7; 6.73, d, 7.86, d, J2",3" 9 Hz, H 2’,3',5',6 '; 6.65-7.34, 
complex, H 2",4”,5",6 "; 7.46, d, J7,8 9 Hz, H 8 .
CHAPTER VII
CHAPTER VII Syntheses and binding studies of some 3-dimethyIaminomethyl- 
(and acylaminomethyl)-2-phenyl(and substituted phenyl)imidazo- 
[1,2-Z>]pyridazines and some 3-aIkoxy-2-aryl- derivatives of 
imidazo[l,2-fl]pyrimidine and imidazo[l,2-a]pyridine
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VII -1 Introduction
In previous chapters, a series of 3-alkoxy-2,6-disubstituted-imidazo[l,2-/?]- 
pyridazines have been synthesized and found to exhibit in vitro binding at specific 
benzodiazepine binding sites. In this chapter, some imidazo[l,2-ö]pyridazines 
containing a different substituent at C-3 namely some 3-dimethylaminomethyl (and 
acylaminomethyl) imidazo[l,2-&]pyridazines [VII. 3(a-b) and V II. 4(a-f)] have been 
prepared and examined for their ability to bind at benzodiazepine receptors. Also the 
binding of some substituted imidazo[l,2-a]pyrimidines [VII. 6(a-b); which contain the 
isomeric pyrimidine ring in place of the pyridazine ring and to which I shall refer as "ring 
isomers"] and the substituted imidazo[l,2-a]pyridine (VII. 9; which is a deaza analogue 
of the imidazo[l,2-£]pyridazine I I . 3c) have been investigated. This last segment of 
work was undertaken to examine the role of a nitrogen substituent in the six-membered 
ring and the relevance of nitrogen position in binding activity. Accordingly, 6-chloro-3- 
methoxy-2-(4'-methylphenyl)imidazo[l,2-fl]pyrimidine (VII. 6a), its 3-ethoxy analogue 
(VII. 6b) and 6-chloro-3-methoxy-2-(4'-methylphenyl)imidazo[l,2-a]pyridine (VII. 
9) were synthesized and screened for in vitro binding.
The preparation of these compounds is discussed first and the results of the 
competitive binding studies are then given. These are compared with previous results 
and their relationship to Fryer's proposed model138 for benzodiazepine receptor ligands 
is examined. Finally, the experimental details (and some physical data) are reported.
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VH - 2 3-DimethyIaminomethyl(and acylaminomethyl)-2-phenyI(and substituted 
phenyl)imidazo[l,2-Z?]pyridazines
The starting materials required for the preparation of these compounds were 
the appropriately substituted 2-arylimidazo[l,2-ö]pyridazines (Scheme VII - 1, V II . 2). 
These were readily prepared by literature procedures140 by condensation of 6- 
chloropyridazin-3-amine or other 6-substituted pyridazin-3-amines, with bromoacetyl 
compounds.
The method employed for the preparation of 2-aryl-3-dimethylamino- 
methylimidazo[l,2-&]pyridazines (V II . 3) involved reacting the appropriate 2-aryl- 
im idazo[l,2-£>]pyridazine (VII . 2) with a combination of formaldehyde and 
dimethylamine in glacial acetic acid (Mannich reaction) at elevated temperatures, under 
conditions modified from those described by Lombardino167 for the preparation of 3- 
piperidinomethyl-6-methoxyimidazo[ 1,2-fr]pyridazine from 6-methoxyimidazo[ 1,2-b]- 
pyridazine with piperidine and formaldehyde. In this way, 6-chloro-2-(4'-chloro- 
phenyl)-3-dimethylaminomethylimidazo[l,2-Z?]pyridazine (V II. 3a) was readily prepared 
from  6 -ch lo ro -2 -(4 '-ch lo ropheny l)im idazo[ 1,2-b]pyridazine (VII . 2b) with 
dimethylamine and formaldehyde. Likewise, 6-benzylthio-3-dimethylaminomethyl-2- 
phenylim idazo[l,2-fr]pyridazine (VII . 3b) was prepared from 6-benzylthio-2- 
phenylimidazo[l,2-£]pyridazine (V II. 2d).
The 3-acylaminomethylimidazo[l,2-&]pyridazines were prepared by a 
method similar to that described for the preparation of 3-acylaminomethylimidazo[l,2-<2]- 
pyridine.268 In this, 6-chloro-2-phenylimidazo[l,2-£]pyridazine (V II. 2a) was allowed 
to react with V-(hydroxymethyl)benzamide269 in galcial acetic acid with a catalytic 
amount of concentrated sulphuric acid at reflux to yield 3-benzamidomethyl-6-chloro-2- 
phenylimidazo[l,2-fr]pyridazine (V II. 4a). The product was isolated as a free base by 
adjusting the pH to 10 with ammonia solution. In an analogous manner, compounds VII 
. 4b to V II . 4f were prepared from the appropriate starting materials (Scheme VII - 1).
The 1H n.m .r. spectra o f the 3-dim ethylam inom ethylim idazo- 
[l,2-£>]pyridazines (V II. 3a and 3b) and 3-acylaminomethylimidazo[l,2-Z?]pyridazines 
[VII . 4(a-f)] are consistent with their structures. Protons H 7 and H 8 of these
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compounds appeared as an AB quartet with a coupling constant of 9 Hz and chemical 
shifts of 8 6.77-7.09 and 5 7.88-8.01, respectively. The chemical shift for H 7 is 
generally dependent on the relative electronic character of the group on C-6. Thus, for 
the compounds (VII. 4a,b and c) containing the electron-withdrawing 6-chloro or 6- 
fluoro substituent, the chemical shifts for H 7 are downfield relative to those with the 
electron-donating 6-benzylthio group at C-6. In addition, the 3-acylaminomethyl 
compounds [V II. 4(a-f)] showed the methylene protons on C-3 as a doublet with a 
coupling constant of Jch.nh 5.5 Hz and a chemical shift range of 8 4.63-5.23, whereas 
those of 3-dimethylaminomethyl compounds (VII. 3a and b) are relatively shielded by 
the adjacent dimethylamino group and appeared at ca. 8 3.90-3.95.
Scheme VII - 1
R
^ C H 2N(Me) 2
VII . 1 VII .2 VII . 3
a R1 = Cl, R2 = H 
b R1 = Cl, R2 = Cl-p 
c R1 = F, R2 = Me-p 
d R1 = SCH2Ph, R2 = H 
e R1 = OC6H4OMe-o, R2 = H
a R1 = Cl, R2 = Cl-p 
b R1 = SCH2PH, R2 = H
R N CH2NHCOR3
VII . 4
a R1 = Cl, R2 = H, R3 = Ph
b R1 = Cl, R2 = H, R3 = CH3
c R1 = F, R2 = Me-p, R3 = Ph 
d R1 = SCH2Ph, R2 = H, R3 = Ph
e R1 = SCH2Ph, R2 = H, R3 = CH3
f R1 = OC6H4OMe-o, R2 = H, R3 = Ph
Scheme VII - 2
VII . 5 VII . 6
a R1 = Me 
b R1 = Et
Scheme VII - 3
VII . 9
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VII - 3 Some 3-alkoxy-2-aryl derivatives of imidazo[l,2-a]pyrimidine and 
imidazo[l,2-a]pyridine
The 6-chloro-3-alkoxyimidazo[l,2-&]pyrimidines (Scheme VII - 2, V II. 6) 
were prepared from 5-chloropyrimidin-2-amine (VII. 5) (obtained by chlorination of 
pyrimidin-2-amine with iV-chlorosuccinamide-70) by cyclisation with phenylglyoxals. 
Structural symmetry in 5-chloropyrimidin-2-amine (VII. 5) ensured the identity of N-l 
and N-3, and the formation of one product only. Thus 5-chloropyrimidin-2-amine with 
4-methylphenylglyoxal in anhydrous methanolic hydrogen chloride under reflux gave 
compound VII . 6a. These are similar reaction conditions to those used for the 
preparation of 3-methoxy-2-methyl-8-methylaminoimidazo[l,2-b]pyridazine.159
The 3-ethoxy analogue (VII . 6b) however was obtained when 5- 
chloropyrimidin-2-amine with 4-methylphenylglyoxal in ethanol containing concentrated 
hydrochloric acid were refluxed for 11 h. These reaction conditions, when applied to 6- 
chloropyridazin-3-amine and phenylglyoxal, gave 6-chloro-2-phenylimidazo[l,2-£>]- 
pyridazin-3(5//)-one.160
The products of these condensation reactions (Scheme VII - 2, V II. 6a and 
b) were readily characterized by their *H n.m.r. spectra. The protons at C-5 and C-7 
appeared as a doublet of doublets with a meta coupling constant of ca. 2.5 Hz and a 
chemical shift range of 5 8.25-8.40. For compound V II. 6a, the proton resonance for 
the methoxy group at C-3 occurred at 5 3.99 which is within the chemical shift range 
observed for the corresponding protons in the 3-alkoxyimidazo[l,2-&]pyridazines 
(Chapter II - 3i). In addition, the general fragmentation pattern depicted in the mass 
spectra of compounds VII . 6(a-b), closely resemble those for the 3-alkoxyimidazo- 
[1,2-Z?]pyridazines (see Chapter II - 3iii).
5-Chloro-3-methoxy-2-phenylimidazo[l,2-fl]pyridine (Scheme VII - 3, VII. 
9) was prepared from the commercially available 5-chloropyridin-2-am ine. 
Condensation of 5-chloropyridin-3-amine (VII . 7) with p-methylphenylglyoxal in 
ethanol and hydrochloric acid, in a similar manner to that described for the preparation of 
compound V II. 6b however did not give the anticipated 3-ethoxy product viz. 6-chloro- 
3-ethoxy-2-(4'-m ethylphenyl)im idazo[l,2-a]pyridine. The product that was
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isolated exhibited similar physical characteristics to the 2-arylimidazo[l,2-£]pyridazin- 
3(5//)-ones160 and the 2-arylimidazo[l,2-a]pyridin-3-ols.241 Methylation of this crude 
product with diazomethane gave the 3-methoxy compound V II. 8. The structure of this 
compound was confirmed by its n.m.r. and mass spectra, as well as analyses.
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VII - 4 In vitro binding studies
The compounds prepared in this chapter were screened for their ability to 
bind at specific benzodiazepine binding sites in rat brain preparations using the 
[3H]diazepam binding assay as outlined in Chapter II - 5.3.
VII - 4.1 Results of [3H]diazepam binding assay
The in vitro competitive binding results are shown in Table VII - 1 as IC50 
values or percent displacement at the specified concentration.
Table VII -1 Results for the displacement of [3H]diazepam from its specific
binding sites in rat brain by some substituted azaindolizines
8 1
6 ^  ✓ N 
Y ^
5
Formula
number
Ring systems and 
substituents
IC50
(nM)a
Displacement^) 
at concn specified
v n ./
3a
Imidazo[l,2-Z?]pyridazine (X=CH, Y=N) 
6-Cl-3-CH2NMe2-2-C6H4Cl-/? 1370
3b 6-SCH2Ph-3-CH2NMe2-2-Ph 58
4a 6-Cl-3-CH2NHCOPh-2-Ph 140
4b 6-Cl-3-CH2NHCOMe-2Ph 474
4c 6-F-3-CH2NHCOPh-2-C6H4Me-p 8
4d 6-SCH2Ph-3-CH2NHCOPh-2-Ph 445
4e 6-SCH2Ph-3-CH2NHCOMe-2-Ph 55
4f 6-OC6H4 0 Me-o-3-CH2NHCOPh-2-Ph 445 b
6a
Imidazo[l,2-fl]pyrimidine (X=N, Y=CH) 
6-Cl-3-OMe-2-C6H4Me-/? 18% at 3000 nM
6b 6-Cl-3-OEt-2-C6H4Me-/? 31% at 3000 nM
9
Imidazo[ 1,2-fl]pyridine(X=Y=CH) 
6-Cl-3-OMe-2-C6H4Me-/? 146
a IC5 0  values are the concentrations required to displace 50% of specific [3H]diazepam binding to rat brain
membrane preparations, 
b Not significant at 1000 nM.
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VII - 4.2 Discussion of binding results
The results shown in Table VII - 1 for the in vitro binding by the imidazo- 
[l,2-/?]pyridazines reveal that 6-chloro-2-(4'-chlorophenyl)-3-dimethylaminomethyl- 
imidazo[l,2-&]pyridazine (V II. 3a, IC50 1370 nM) has a lower binding potency than its 
3-methoxy analogue (II . II, IC50 207 nM). Likewise, compound V II. 3b showed a 
ca. threefold decrease in binding activity as compared with its corresponding 3-methoxy 
analogue (IV . 19, IC50 22 nM) but V II. 3b was significantly more active than V II.
3a. These results may be rationalized in terms of the structural requirements postulated 
for the binding of some 3-alkoxyimidazo[l,2-Z?]pyridazines (see Chapter II - 4.3 and IV - 
4.2). Structure-activity relationship studies on these compounds indicated to me that a 2- 
phenyl or 2-aryl group (7t-region) was necessary for binding (Chapter II - 4.3) and that 
binding at an apparent accessory site by a second aryl ring would facilitate binding 
affinity (Chapter IV - 4.2). In addition, the 3-alkoxy substituent appeared to regulate 
binding but it is not an essential group if binding at the accessory binding site is already 
maintained (Chapter IV - 4.2). In compound V II . 3a the 2-aryl group is present but the 
molecule does not contain a second phenyl ring for binding at the proposed accessory 
binding site on the receptor. In compound V II. 3b, both these parts are present in the 
molecule viz. 2-phenyl and 6-benzylthio substituents. Therefore, compound V II. 3b can 
attain a more effective binding at the receptor than compound VII . 3a. Both these 
compounds however exhibit a lower affinity than their corresponding 3-methoxy 
analogues [compounds I I . 11 (IC50 207 nM) and IV . 9 (IC50 22 nM)] indicating a 3- 
dimethylaminomethyl substituent is less favourable than a 3-methoxy group for binding 
activity.
VII . 3a VII . 3b
IC50 1370 nM IC50 58 nM
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3-Benzamidomethyl-6-chloro-2-phenylimidazo[l,2-fr]pyridazine (VII. 4a, 
IC50 140 nM) exhibited an increase in binding activity by ca. sixfold compared to its 3- 
methoxy analogue (II . 5, IC50 772 nM). However, the 3-acetamidomethyl analogue 
(VII . 4b, IC50 474 nM) showed a lower activity than compound VII . 4a. In 
compound V II . 4a (as shown below) the substituents to the imidazo[l,2-&]pyridazine 
system are the 2-phenyl ("A" ring) 3-benzamidomethyl ("B" ring) and 6-chloro groups.
VII . 4a VII . 4b
IC50 140 nM IC50 474 nM
II . 12
IC50 7 72 nM
Therefore, a second phenyl ring ("B" ring) is incorporated into compound V II. 4a by 
means of a benzamidomethyl group at C-3. It appears that the rotational flexibility in this 
substituent may allow the phenyl group to interact with the accessory binding site 
mentioned for compound V II. 3b (see also Chapter IV - 4.2), thereby giving enhanced 
binding affinity compared to 6-chloro-3-methoxy-2-phenylimidazo[l,2-fr]pyridazine (II. 
5) and compound VII . 4b. In compounds I I . 5 and VII . 4b there is only one 
phenyl substituent ("A" ring) and hence binding at the accessory binding site can not be 
attained by these molecules.
The above considerations prompted me to synthesize 3-benzamidomethyl-6- 
fluoro-2-(4'-methylphenyl)imidazo[l,2-£]pyridazine (VII . 4c) because the 6-fluoro 
analogue of 6-chloro-3-m ethoxy-2-phenylim idazo[l,2-& ]pyridazine (II . 5) had
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demonstrated a higher binding activity than compound II .5 (as in compound I I . 13, 
IC50 320 nM). As anticipated, compound V II. 4c exhibited high binding potency (IC50 
8 nM).
VII . 4c
IC50 8 nM
In the second part of my study on the binding of 3-acylaminomethyl- 
imidazo[l,2-Z?]pyridazines to benzodiazepine receptors, 6-benzylthio-3-benzamido- 
methyl-2-phenylimidazo[l,2-&]pyridazine (VII . 4d), which contained three phenyl 
groups, was synthesized.
VII . 4e
IC50 55 nM
Compound VII .4d gave an IC50 value of 445 nM. However, its 3-acetamidomethyl 
analogue, VII . 4e gave an IC50 value of 55 nM which is similar to the 3- 
dimethylaminomethyl analogue (VII. 3b, IC50 58 nM). The result for compound V II. 
4d appears to suggest that the presence of a third phenyl group is detrimental to binding
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activity (as compared to its 6-chloro analogue, V II. 4a). This may be rationalized by the 
'steric bulk' present in compound VII . 4d which prevents this molecule from 
maintaining an effective interaction with the receptor. This is consistent with another 
obervation : reducing the 'steric bulk' on the molecule as in compound V II. 4e increased 
binding activity, relative to compound V II. 4d.
The binding results also indicate that the 3-benzamidomethyl group in 
compound VII . 4a is beneficial relative to the 3-methoxy compound (II . 5), but 
detrimental in compound V II . 4d relative to IV . 19. In addition, interaction of the 
second phenyl ring with the accessory binding site appears to be more favourably 
maintained by compound VII . 4e than VII . 4a (see structural feature of these 
compounds).
The binding results shown by the deaza analogue of the imidazo[l,2-fr]- 
pyridazine viz. 6-chloro-3-methoxy-2-(4'-methylphenyl)imidazo[l,2-a]pyridine (VII. 9, 
IC50 146 nM), correlate with that found for 6-chloro-3-methoxy-2-(4'-methylphenyl)- 
im idazo[l,2-b]pyridazine (II . 3c, IC50 148 nM). This parallel was however not 
observed between compound II . 3c and its "ring isomer" (VII . 6a). The latter 
compound exhibited very low binding affinity at 3000 nM. Thus, when N5 of the 
pyridazine ring is removed (as in the deaza analogue V II . 9) little change in binding 
activity was observed, whereas relocating the nitrogen atom (as in the "ring isomer") 
resulted in diminished affinity. This result appears to suggest that while a nitrogen 
substituent in the six-membered ring of the bicyclic heteroaromatic system is not 
necessary for binding at the benzodiazepine receptor, the relevant position of this nitrogen 
atom (if present) is important in determining binding affinity.
The above results may be compared with Fryer's model138 for binding of 
ligands at benzodiazepine receptors. However, I will briefly discuss the basic 
pharmacophore of benzodiazepine receptor site as proposed by Fryer138 before 
comparing this model to the type of compounds I have prepared.
Based on structure-activity relationship studies134’137 on benzodiazepine and 
non-benzodiazepine type compounds which have IC50 values in the nM range, Fryer138 
postulated that there are two major sites for binding of ligands at the benzodiazepine
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recepter viz. an aromatic or heteroaromatic ring (which he called "A") and is spatially 
related to a proton accepting group (designated 7t]) (see also Chapter I - 1.5). In this 
model, 7ii is proposed to lay above the plane of the aromatic nucleus "A" whereas the 
relative distance (measured in Ä) from the centre of the "A" ring to the proton accepting 
group 7C] can change (Fig 1).
variable distance of 
ca. 3 Ä to 8.5 Ä
distance above the plane of "A"
Fig. 1: Basic pharmacophore of benzodiazepine receptor site proposed by Fryer
Fryer related the variability in distance ("A" to 7ti) to in vitro activity in that as this 
distance increases the in vitro activity profile shifts from agonist to antagonist to inverse 
agonist, and when the distance overlaps, compounds may exist as either mixed agonist / 
antagonist or mixed antagonist / inverse agonist activity.138
In my work, compound II . 3c, viz. 6-chloro-3-methoxy-2-(4'-methyl- 
phenyl)imidazo[l,2-fr]pyridazine, has been shown to bind at specific benzodiazepine 
sites (IC50 148 nM, see Chapter II - 4.3). It was also proposed that the 2-aryl group of 
this compound was essential for binding. If this 2-aryl group corresponds to ring "A” of 
Fryer's model then the proton accepting group (Tti) of this same model could be N5 of 
the pyridazine part of the imidazo[l,2-&]pyridazine compound viz. I I . 3c or its imidazole 
nitrogen atom Nl.However, when N5 of compound I I . 3c was removed (as in the deaza 
analogue V II. 9) there was little change in binding affinity. This suggests that N5 was 
not essential for the binding of compound I I . 3c to benzodiazepine receptors. Hence, 
N5 would not correspond to n\ of Fryer's model.
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II . 3c
IC50 1 48 nM
VII . 9
IC50 146 nM
A /)—Me
OMe
VII . 6a
(18% displacement of [3H]diazepam 
at 3000 nM of Compound V II . 6a)
The other possibility was that the imidazole nitrogen atom, N l, may be the 
proton accepting group (7ti) portrayed in Fryer's model. If this is so, then the ability of 
N l to act as a proton accepting group in its proposed interaction with the NH2, SH, OH 
or imidazo NH groups on amino acid side chains within the receptor site should decrease 
if the electron-density of N l is decreased. In compound V I I . 6a, the "ring isomer" of 
the imidazo[l,2-£]pyridazine I I . 3c, the electron density on N l may be smaller cf. the 
nitrogen atom N l of compound I I . 3c or V I I . 9. Compound V I I . 6a exhibited very 
low binding affinity when compared to compounds I I . 3c and V I I . 9. This result 
suggests that the imidazole nitrogen atom, N l of derivatives of imidazo[l,2-Z?]- 
pyridazines prepared in this work may be involved in hydrogen bonding with the 
receptor and hence contributes to low IC50 values.
In conclusion, the binding equivalence (at benzodiazepine receptors) of 
imidazo[l,2-a]pyridine with imidazo[l,2-£]pyridazine is demonstrated. Further, it is 
found that 3-benzamidomethyl-6-fluoro-2-(4'-methylphenyl)imidazo[ 1,2-fr]pyridazine 
(VH . 4c, IC50 8 nM) exhibits high binding potency.
VII - 5 Experimental
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The general procedure and experimental details for the [3H]diazepam binding 
assay are recorded in Chapter II - 5.1 and 5.3
The following compounds were prepared by literature procedures : 6-chloro- 
2-phenylimidazo[l,2-£]pyridazine140 and 6-chloro-2-(4'-chlorophenyl)imidazo[ 1,2-5]- 
pyridazine.140
6-Fluoro-2-(4”-methylphenyI)imidazo[l,2-Z?]pyridazine (VII. 2c)
A mixture of 6-fluoropyridazin-3amine216 (1.13 g) and oc-bromo-4- 
methylacetophenone247 (2.13 g) in ethanol (50 ml) was refluxed for 2 h. After cooling 
to room temperature, sodium hydrogen carbonate (0.42 g) was added. The reflux was 
contained for a further 20 h.
The reaction mixture was concentrated and chilled. The yellow precipitate 
was filtered off, washed with water and dried. It was recrystallised from toluene to give 
the title compound (1.55 g), m.p. 211-213° (Found : C, 68.9; H, 4.3; N, 18.4. 
C13H10FN3 requires C, 68.7; H, 4.4; N, 18.5%). *H n.m.r. (CD3SOCD3) : 5 2.33, s, 
Me; 7.23, d, J7,8 9 Hz, H 7; 7.25, d, 7.90, J2\3' 9 Hz, H 2’,3’,5',6’; 8.29, dd, J7,8 9 
Hz, Jh8,F 10 Hz, H 8; 8.74, s, H 3.
6-Benzylthio-2-phenyIimidazo[I,2-£]pyridazine (VII. 2d)
A mixture of 6-benzylthiopyridazin-3-aminea (2.17 g) and phenacyl bromide 
(2.0 g) in ethanol (50 ml) was refluxed for 2 h. After cooling, sodium hydrogen 
carbonate (0.42 g) was added. After effervescence had ceased, the reaction mixture was 
further refluxed for 8 h. After chilling in ice, the precipitate was filtered off and the 
filtrate concentrated to give a second crop. The combined product was washed with 
water and dried. It was recrystallised from ethanol to give the title compound (1.5 g), 
m.p. 155-157° (Found : C, 72.3; H, 4.9; N, 13.5. C19H15N3S requires C, 71.9; H, 
4.8; N, 13.2%). !H n.m.r. (CDCI3) : 5 4.43, s, CH2; 6.80, d, J7,8 9 Hz, H 7; 7.29- 
8.00, complex, 2xPh; 7.71, d, J7,8 9 Hz, H 8; 8.17, s, H 3.
a Kindly prepared by Mr S.J. Ireland.
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6-(2'-Methoxyphenoxy)-2-phenylimidazo[l,2-£]pyridazine (VII. 2e)
In a similar manner to that reported above 6-(2'-methoxyphenoxy)pyridazin- 
3-amine (1.08 g) and phenacyl bromide (1.0 g) gave 6-(2'-methoxyphenoxy)-2- 
phenylimidazo[l ,2-b]pyridazine (0.7 g), m.p. 132-134° (from toluene) (Found : C, 
71.6; H, 4.5; N, 13.2. C19H 15N3O2 requires C, 71.9; H, 4.8; N, 13.2%). *H n.m.r. 
(CDCI3) : 5 3.73, s, MeO; 6 .86, d, J7,8 9 Hz, H 7; 6.88-7.91, complex, H 3',4',5',6’ 
and Ph; 7.86, d, J7,8 9 Hz, H 8; 7.90, s, H 3.
6-ChIoro-2-(4'-chIorophenyl)-3-(dimethyIaminomethyI)imidazo[l,2-&]pyridazine 
(VH. 3a)
To a solution of 6-chloro-2-(4'-chlorophenyl)imidazo[l,2-£]pyridazine140 
(7.3 g) in glacial acetic acid (80 ml) was added a solution of 33% ethanolic 
dimethylamine (4.2 g) and 37% formaldehyde (2.4 g). The reaction mixture was stirred 
at room temperature for 2h and the temperature raised to 50° for 9 h, and then 90° for 16 
h. After cooling to room temperature, more 33% ethanolic dimethylamine (4.2 g) and 
37% formaldehyde (2.4 g) was added and stirring was maintained for 16 h and the 
temperature was raised to 95° for 18 h.
After cooling, the solution was made strongly basic with 10% sodium 
hydroxide. The off-white solid was filtered off, washed with excess water and dried. 
This product was dissolved in chloroform (100 ml) and extracted twice with an aqueous 
solution which was adjusted with hydrochloric acid to pH 2 (2x100 ml). The aqueous 
extract was basified (pH ca. 12) and the white precipitate filtered off. It was 
recrystallised from cyclohexane to give the title compound (3.5 g), m.p. 144-146° 
(Found : C, 56.1; H, 4.3; N, 17.3. C15H 14CI2N4 requires C, 56.1; H, 4.4; N, 
17.4%). *H n.m.r. (CDCI3) : 5 2.31, s, 2xMe; 3.93, s, CH2; 7.05, d, J7,8 9 Hz, H 7; 
7.45, d, 8.08, d, J2\3’ 9 Hz, H 2’,3',5',6 '; 7.89, d, J7>8 9 Hz, H 8 .
6-BenzyIthio-3-dimethyIaminomethyI-2-phenylimidazo[l,2-Z(|pridazine (VH. 3b)
6-Benzylthio-2-phenylimidazo[l,2-£>]pyridazine (0.8 g), 33% ethanolic 
dimethylamine (0.34 g + 0.34 g) and 37% formaldehyde (0.2 g + 0.2 g) as above gave
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the title compound (0.55 g), m.p. 102-104° [from cyclohexane/light petroleum (b.p. 40- 
60°)] (Found : C, 70.9; H, 6.0; N, 14.9. C22H22N4S requires C, 70.6; H, 5.9; N, 
15.0%). *H n.m.r. (CDCI3) : 6 2.30, s, 2xMe; 3.95, s, CH2N; 4.51, s, CH2S; 6.85, d, 
J7j8 9 Hz, H 7; 7.25-8.12, complex, 2xPh; 7.74, d, J7i8 9 Hz, H 8.
3-BenzamidomethyI-6-chloro-2-phenyIimidazo[l,2-Z>]pyridazine (VII. 4a)
A solution of A-(hydroxymethyl)benzamide269 (0.57 g) in glacial acetic acid 
(7 ml) with concentrated sulphuric acid (0.25 g) was heated at 50° for 15 minutes. 6- 
Chloro-2-phenylimidazo[l,2-b]pyridazine140(0.57 g) was added and the reaction mixture 
refluxed for 6 h. Evaporation gave a yellow residue which was mixed with water, and 
ammonia solution added to pH 10. The precipitate was crushed, filtered, washed with 
water, ether and dried. It was recrystallised from methanol to give fine yellow crystals of 
the title compound (0.6 g), m.p. 207-210° (Found : C, 65.9; H, 4.2; N, 15.5. 
C20H15CIN4O requires C, 66.2; H, 4.2; N, 15.4%). *H n.m.r. (CDCI3) : 5 5.23, d, J 
5.5 Hz, CH2; 7.09, d, J7,8 9 Hz, H 7; 7.37-8.07, complex, 2xPh; 7.91, d, J7,8 9 Hz, H 
8 .
3-Acetamidomethyl-6-chloro-2-phenylimidazo[l,2-Z>]pyridazine (VII. 4b)
In a similar manner, from 6-chloro-2-phenylimidazo[l,2-£]pyridazine (0.57 
g) andiV-(hydroxymethyl)acetamide269 (0.33 g) was prepared the title compound , m.p. 
257-259° (from toluene) (Found, for a sample dried at 85° and 0.2 mmHg for 6 h : C, 
60.2; H, 4.4; N, 18.5. C15H13CIN4O requires C, 59.9; H, 4.4; N, 18.6%). *H n.m.r. 
(CDCI3) : 5 2.03, s, Me; 5.02, d, J 5.5 Hz CH2; 7.09, d, J7>8 9 Hz, H 7; 7.39-8.02, 
complex, Ph; 7.92, d, J7>8 9 Hz, H 8. Mass spectrum m/z 300 (M+) (30%), 257 
(100%), 223 (44%), 103 (6%).
3-Benzamidomethyl-6-fluoro-2-(4'-methyIphenyI)imidazo[l,2-Z?]pyridazine (VH . 4c)
A solution of N-(hydroxymethyl)benzamide269 (0.33 g) in glacial acetic acid (6 
ml) and concentrated sulphuric acid (0.2 g) was heated in 50° for 15 minutes. 6-Fluoro-2- 
phenylimidazo[l,2-fr]pyridazine (0.43 g) was added and the reaction mixture refluxed for 6
195
h. Evaporation gave a yellow residue which was dissolved in water and ammonia solution 
added to pH 10. The precipitate was crushed finely, filtered, washed with water, ether and 
dried. This product was subjected to column chromatography (alumina; ether and then 
chloroform) and recrystallised from toluene to give the title compound (0.36 g), m.p. 236- 
238° (Found : C, 70.2; H, 4.8; N, 15.4. C21H 17FN4O requires C, 70.0; H, 4.8; N, 
15.5%). !H n.m.r. (CDCI3) : 5 2.40, s, Me; 5.18, d, J 5.5 Hz, CH2NH; 6 .88 , d, J7,8 9 
Hz, H 7; 7.35-7.92, complex, H 2’,3’,5',6 ’ and Ph; 8.01, dd, J7,g 9 Hz, JH8,F 10 Hz, H 
8. X max (pH 7.0) 344 nm (log £ 3.60). Mass spectrum mlz 360 (M+) (14%), 255 
(100%), 105 (26%), 77 (18%).
In a similar manner to the reactions reported above were prepared the 
folowing compounds.
3-Benzamidometliyl-6-benzyIthio-2-phenylimidazo[l,2-Zdpyridazine (VH . 4d)
iV-(Hydroxymethyl)benzamide269 (0.37 g) and 6-benzylthio-2-phenyl- 
imidazo[l,2-b]pyridazine (0.52 g) gave the title compound (0.3 g), m.p. 187-189° (from 
toluene/cyclohexane) (Found : C, 72.4; H, 4.8. C27H22N4 0 S requires C, 72.0; H, 
4.9%). *H n.m.r. (CDCI3) : 5 4.39, s, CH2S; 5.00, t, J 5.5 Hz, NH; 5.18, d, J 5.5 Hz; 
CH2NH; 6.77, d, J7)8 9 Hz, H 7; 7.12-7.89, complex, H 8 and 3xPh. Mass spectrum 
m/z 388 (M+) (24%), 345 (100%), 255 (41%), 223 (61%), 103 (3%), 91 (33%).
3-Acetamido-6-benzylthio-2-phenylimidazo[l,2-Z>]pyridazine (VII. 4e)
V-Hydroxymethylacetamide269 (0.22 g) and 6-benzylthio-2-phenylimidazo- 
[l,2-&]pyridazine (0.52 g) gave the title compound (0.42 g), m.p. 240-242° (from 
ethanol) (Found : C, 68.0; H, 5.3; N, 14.3. C22H20N4OS requires C, 68.0; H, 5.2; 
N, 14.4%). !H n.m.r. (CDCI3) : 5 1.93, s, Me; 4.46, s, CH2 S; 4.97, d, J 5.5 Hz, 
CH2NH; 6.89, d, J7>8 9 Hz, H 7; 7.29-7.92, complex, 2xPh; 7.67, d, J7j8 9 Hz, H 8 .
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3-Benzamidomethyl-6-(2'-methoxyphenoxy)-2-phenyIimidazo[l,2-Z>]pyridazine 
(V II. 4f)
A-(Hydroxymethyl)benzamide269 (0.37 g) and 6-(2'-methoxyphenoxy)-2- 
phenylimidazo[l,2-£]pyridazine (0.52 g) gave the title compound (0.3 g), m.p. 190- 
192° (from toluene) (Found : C, 72.3; H, 4.9; N, 12.1. C27H22N4O3 requires C, 
72.0; H, 4.9; N, 12.4%). *H n.m.r. (CDCI3) : 5 3.77, s, MeO; 4.63, d, J 5.5 Hz, 
CH2NH; 6 .88, d, J7,8 9 Hz, H 7; 7.04-7.94, complex, H 3',4',5',6’ and 2xPh; 7.88, d, 
J7,8 9 Hz, H 8 .
6-ChIoro-3-ethoxy-2-(4'-methylphenyl)imidazo[l,2-a]pyrimidine (VII. 6b)
A mixture of 2-amino-5-chloropyrimidine270 (0.26 g), 4-methylphenyl- 
glyoxal hydrate234 (0.33 g), ethanol (10 ml) and concentrated hydrochloric acid (0.4 ml) 
was refluxed for 11 h, then evaporated under reduced pressure. The residue was diluted 
with water (15 ml) and adjusted to pH 7 (with M sodium hydroxide) and the product 
extracted into chloroform. The extract was dried (Na2SC>4) and evaporated to give a 
residue which was subjected to t.l.c. (alumina; chloroform) and recrystallised from light 
petroleum (b.p. 40-60°) to give light green needles of the title compound (0.04 g), m.p. 
157-159° (Found, for a sample dried at 85° and 0.2 mmHg for 1 h : C, 63.1; H, 5.1;
N, 14.5. C15H14CIN3O requires C, 62.6; H, 4.9; N, 14.6%). *H n.m.r. (CDCI3) : 6 
1.45, t, J 7 Hz, CH3CH2; 2.40, s, Me; 4.18, quart, J 7 Hz, CH3CH2; 7.28, d, 8 .02 , d, 
J2’,3’ 9 Hz, H 2',3',5',6 '; 8.24, d, 8.35, d, J 2.5 Hz, H 5,7. Mass spectrum mlz 287 
(M+) (48%), 258 (56%), 230 (100%), 113 (52%), 103 (1.3%).
6-ChIoro-3-methoxy-2-(4'-methylphenyl)imidazo[l,2-fl]pyrimidine (VII. 6a)
A solution of 2-amino-5-chloropyrimidine270 (0.26 g), 4-methylphenyl- 
glyoxal hydrate234 (0.33 g), in methanolic hydrogen chloride (15 ml; 6 M) was refluxed 
for 10 h. The reaction was worked up exactly as above for the 3-ethoxy analogue, to 
give the title compound (0.02 g), m.p. 142-144° (Found, for a sample dried at 85° and
O. 2 mmHg for 2 h : C, 61.5; H, 4.4; N, 15.0. C14H12CIN3O requires C, 61.4; H, 4.4; 
N, 15.3%). *H n.m.r. (CDCI3) : 5 2.41, s, Me; 3.99, s, MeO; 7.28, d, 7.02, d, J2,3 9
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Hz, H 2',3',5',6'; 8.28, d, 8.39, d, J 2.5 Hz, H 5,6. Mass spectrum ra/z 273 (M+) 
(65%), 258 (26%), 230 (100%), 142 (25%), 119 (32%), 113 (49%), 91 (18%), 83 
(39%).
6-Chloro-3-methoxy-2-(4'-methylphenyl)imidazo[l,2-ö]pyridine (V II. 9)
To a warm solution of 2-amino-5-chloropyridine (0.51 g) in ethanol (20 ml) 
was added 4-methylphenylglyoxal hydrate234 (0.76 g) and concentrated hydrochloric 
acid (0.6 ml). The mixture was refluxed for 8 h. The solvent was removed to give a 
yellow residue. To this was added water (15 ml) and it was adjusted to pH 7. The 
precipitate (0.16 g) was filtered off, washed with water and ether and dried. This 
product was stirred with a cold solution of ethereal diazomethane at 0° and then at 20° 
overnight. Evaporation gave a solid (0.05 g) which was recrystallised from light 
petroleum (40-60°) to give light yellow needles of the title compound, m.p. 133-135° 
(Found, for a sample dried at 70° and 0.2 mmHg for 3 h : C, 65.8; H, 4.9; N, 10.2. 
C15H13CIN2O requires C, 66.1; H, 4.8; N, 10.3%). *H n.m.r. (CDCI3) : 5 2.40, s, 
Me; 3.95, s, MeO; 7.06, dd, J7,8 9 Hz, J5/7 2 Hz, H 7; 7.27, d, 7.47, d, J2’,3’ 9 Hz, H 
2’,3’,5’,6'; 7.95, d, J7,8 9 Hz, H 8; 7.98, d, J5,7 2 Hz, H 5. Mass spectrum m/z 272 
(M+) (38%), 257 (28%), 229 (100%), 112 (31%), 83 (36%).
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CHAPTER Vin Conformational analysis, structure-activity-relationship studies and 
pharmacological evaluation of some imidazo[l,2-Z?]pyridazines
V m  -1  Conformational analysis 
V m  -1.1 General introduction
The majority of central nervous system(CNS) active drugs exert their primary 
effect by binding in a preferred conformation at pre- or post-synaptic receptor 
sites.271»272 Many studies273-275 have led to the proposals of receptor requirements for 
separate CNS classes. However, Andrew and Lloyd276 postulated that although these 
requirements vary in detail, there is a common structural basis for CNS drugs and their 
receptors, viz. an aromatic group and a nitrogen atom, are the primary binding groups 
whose topographical arrangement is fundamental to the activity of these drug classes. 
Moreover, they proposed that it was the nature and placement of secondary binding 
groups that determined different classes of CNS drug activity.276 Therefore, provided 
the right chemical groups are present in the correct spatial configuration for binding, the 
molecular conformation seems to be the most likely factor influencing the activity of these 
compounds.
In this study, the conformational profiles of 6-benzylthio-3-methoxy-2-phenyl- 
imidazo[l,2-6]pyridazine was investigated by computer assisted modelling.3 In 
particular, the conformational preferences in this molecule were compared to Fryer's 
model138 for benzodiazepine receptor ligands.
V m  -1.2  Conformational analysis by computer assisted modelling
The molecular dynamics of 6-benzylthio-3-methoxy-2-phenylimidazo[l,2-&]- 
pyridazine (VIII. 1), a representative of the 3-alkoxyimidazo[l,2-Z?]pyridazines, was 
studied using the Chem-Xb computer graphics package. The conformational energy 
calculations are based on molecular mechanics calculations277’278 which give a first
a This work was carried out in The Chemistry Department, La Trobe University, Bundoora, Victoria.
6 Chem-X, created by E.K. Davies, Chemical Crystallography Laboratory, Oxford University, 
developed and distributed by Chemical Design Ltd.
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calculations are based on molecular mechanics calculations277’278 which give a first 
approximation to the energies of the various conformers. These approximations however 
have no effect on the qualitative nature of the results.
1. Molecular geometries for the imidazo[l,2-&]pyridazine bicyclic ring system 
were obtained from the crystal structure of 3-methoxy-2-methyl-8-methylaminoimidazo- 
[l,2-b]pyridazine.159 Substituents to this system was then built using the standard bond 
lengths and angles within the molecular building option, the torsion angles were 
minimized and finally the structure optimized using the various facilities within Chem-X. 
Bonds around which rotations are considered are shown in Fig. 1.
Fig. 1 Bonds around which rotations are considered for compound V II I . 1
2. The labelling of the structure of 6-benzylthio-3-methoxy-2-phenylimidazo- 
[1,2-Z?]pyridazine (VIII . 1) by Chem-X programme is shown in Figure 2 and used 
throughout this work.
Method :
V III . 1
Fig. 2 The labelling of the structure of compound V1H . 1 by the Chem-X programme.
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3. The "calculate conformations" facility of Chem-X enables calculation of the 
energy of a molecule while simultaneously rotating around one or several bonds. The 
calculation performed is based on molecular mechanics and gives an approximation to the 
energies of the various conformers.
A minimum of two variable torsion anglesa has been taken into account. Each 
torsion angle was varied, in 30° increments through 360° to give the conformational 
energy picture for the molecule. The calculated relative energies for rotations of xi and X2 
in compound V III . 1 are given in the form of a contour map in Figure 3. Low-energy 
conformations are taken as all conformations within 10 kcal mol"1 of the global minimum 
conformation. The global minimum conformation is taken as the lowest energy 
conformation located by molecular mechanics calculations.
From Figure 3, it is apparent that conformations with xi between 0° and 
360°, X2 between 85° and 110° or X2 between 210° and 260°, all fall within 10 kcal 
mol'1 of the global minimum. The barrier to rotation around Xi is high (>26 kcal mol"1) 
at X2 = 180±30° or X2 = 340±20. These calculations show that provided the lone pair 
electrons on the oxygen atom (021), and the methyl group of the 3-methoxy substituent 
are suitably orientated (Fig. 4), then the 2-phenyl substituent of V III . 1 is free to rotate 
about C8 - C l3. However, it should be noted that the phenyl ring would probably lie 
approximately in the same plane as the imidazo[l,2-b]pyridazine bicyclic system due to 
conjugation.
a The torsion angle is measured by viewing down the axis formed from atoms 2 and 3 and rotating 
counterclockwise from the axis formed by atoms 1 and 2 to the axis formed by atoms 3 and 4.
Fig. 3 The energy contour plot of two torsion angles rotating around C 14-C 13-C 8- 
C9 (ii) and C l3 - C14 - 021 - C22 (X2) of 6-benzythio-3-methoxy-2-phenyl- 
imidazo[l,2-b]pyridazine (VIII . 1). The area of high (white) and low (dark 
blue) conformational energies are labelled, 14 contours are plotted, each being 2 
kcal mol'1 apart.
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Fig. 4 Rotation around Xi is not restricted when X2 is between 85° and 110° (a), and 
when 1 2  is between 210° and 260° (b).
4. The corresponding energies for rotations of X3 , X4 and T5 are given in the 
two-dimension energy plot (Figure 5, 6 and 7) which show the energy conformation on 
the y-axis versus the torsion angle of the rotated bond. Each asterick (*) corresponds to a 
particular conformation varying from T3 to X5 (with Xi and X2 fixed in one of its low 
energy conformations). Thus, there are more than one conformer in each turn of X3 (in 
increments of 30°) due to the energy account for rotations of X4 and X5 (in increments of 
30°).
Figures 8 and 9 show the energy as contours while simultaneously rotating three 
angles X3, X4 and 1 5 . The area of high (H) and low (L) conformational energies are 
labelled, 14 contours are plotted each being 2 kcal mol"1 apart.
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CHEM-X
Torsion angle C18 - C17 - S41 - C39 (x3)
Fig. 5 Plot of conformational energy versus torsion angle (T3) with 14  and T5 in 30° 
increments (and Ti= 60°, Z 2 -  96°) in 6-benzylthio-3-methoxy-2-phenyl- 
imidazo[l,2-&]pyridazine (V III. 1).
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CHEM-X
$0 .0 0 0
Torsion angle C17 - S41 - C39 - C31 (x4)
Fig. 6 Plot of conformational energy versus torsion angle (T4) with T3 and 15 in 30° 
increments (and X\  =  60°, T2 = 96°) in 6-benzylthio-3-methoxy-2-phenyl- 
imidazo[l,2-Z?]pyridazine (V III. 1).
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Torsion angle S41 - C39 - C31 - C40 (x5)
Fig. 7 Plot of conformational energy versus torsion angle (T5) with T3 and 14 in 30°
increments (and X \ =  60°, X2 = 96°) in 6-benzylthio-3-methoxy-2-phenyl- 
imidazo[l,2-£]pyridazine (V III. 1).
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CHEM-X
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90.00
0.00
-90.00 -
-180.00
-180.00 -90.00 0.00 90.00
Torsion angle C18 - C17 - S41 - C39 (x3)
180.00
Fig. 8 The energy contour plot of two torsion angles rotating around the C l8 - C17 - 
S41 - C39 (t3) and C17 - S41 - C39 - C31 (t4) of compound V III. 1. The area 
of high (H) and low (L) conformational energies are indicated, 14 contours are 
plotted, each being 2 kcal mol'1 apart.
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Torsion angle S41 - C39 - C31 - C40 (t5)
180.00
Fig.9 The energy contour plot of two torsion angles rotating around the C l7 - S41 - 
C39 - C31 (14) and S41 - C39 - C31 - C40 (15) of compound V III. 1. The area 
of high (H) and low (L) conformational energies are indicated, 14 contours are 
plotted, each being 2 kcal mol' 1 apart.
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The energy graphs (Fig. 5, 6 and 7) predict that there are several low energy 
conformations available to compound V III. 1 as depicted by the large number of points 
laying within 10 kcal mol'1 of the minima.
The corresponding energies for rotations of X3 and X4 in V III. 1 are given in 
Fig. 8. It predicts that the barrier to rotation of X3 is high (>26 kcal mol'1) when X3 = 
0±45° and X4 = 0±90°; and when X3 = 200±50° and 14 = 0±50°. However, rotation 
around X4 is free when X3 = 90±30° and X3 = 280±20°. Figure 9 also shows that rotation 
of X5 is restricted, with an energy barrier of more than 26 kcal mol'1 when X5 = 0±50° 
and X4 = 0±80°; and when X5 = 180±50° and X4 = 0±70°. Moreover, rotation around X4 
is free when X5 = 90±30° and X5 = 270±30°.
Some general conclusions concerning the conformations of V III. 1 may be 
drawn from the preceeding analysis :
1. Several alternative low-energy confomiations are available to compound V III. 1.
2. Substantial barriers to rotation exist between some alternative conformations.
These data do not indicate which conformation is the "biologically active conformation" 
since interaction with the receptor may equally involve modest binding by a low-energy 
conformation or tighter binding by a higher energy alternative. However, any 
conformation within resonable range of the global minimum may be the active species. 
Figure 10 shows the structure of one of the low-energy conformation of compound V III. 1 
which is related to one of the low-energy points on the energy graph as shown in Figure 6. 
One of the alternative low-energy conformation is shown in Figure 11. The structure 
shown in Figure 10 is also presented in space-filling mode, one of the display options 
within Chem-X.
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Fig. 10 The structure of one of the low-energy conformations of compound V III . 1. 
The torsion angles are :
C18 - C17 - S41 - C39 (x3), 90°;
C17 - S41 - C39 - C31 (x4), -40°;
S41-C 39-C 31-C 40 (x5), 93°;
C 14-C 13-C 8-C 9 (Ti), 60°;
C13 - C14 - 021 - C22 (x2), 97°.
Fig. 11 The structure of one of the low-energy conformations of compound VIII . 1 
which is less than 1 kcal mol"1 higher in energy compared to the conformation in 
Figure 10. The torsion angles are :
C 18-C 17-S41-C 39 (x3), -90°;
C17-S41 -C39-C31 (x4), 20°;
S41 - C39 - C31 - C40 (x5), -87°;
C 14-C 13-C 8-C 9 (xi), 600;
C13 - C14 - 021 - C22 (x2), 97°.
Fig. 12 Space-filling model of one of the low-energy conformation of compound V I I I . 1.
The torsion angles are the same as the structure shown in Figure 10.
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The conformational analysis of 6-benzyloxy-3-methoxy-2-phenyl- 
imidazo[l,2-fr]pyridazine and 6-benzylamino-3-methoxy-2-phenylimidazo[l,2-fr]- 
pyridazine showed very similar conformational profiles to that of compound VIII. 1. 
The above conformational analysis was also compared with results obtained by classical 
potential energy calculations whereby the conformational energies were calculated by 
using CONES (a three-torsion-angle version of the programme COMOL280) on the 
Cyber 73 computer at the Royal Melbourne Institute of Technology.3 The programme 
calculates classical conformational energies by pairwise summation of the Van der Waals 
interactions between nonbonded atoms, together with the electrostatic and torsion 
potentials. The parameterization, which was developed by Giglio281 on the basis of a 
series of hydrocarbon and amide structures, had been used to study a number of 
biological systems.282 It was found that the energy contour plots from calculation 
performed on the programme CONES, were consistent with the results obtained from 
molecular mechanics calculation.
VIII -1.3 Relevance of conformational preference to Fryer's model for benzodiazepine 
receptor ligands
In Chapter VII - 4.2, it was proposed that the 2-phenyl group on the 
imidazo[l,2-fr]pyridazines prepared in this work may correspond to the "A" ring in 
Fryer's model138 for benzodiazepine receptor ligands. In addition, the imidazole 
nitrogen atom, N1 of these compounds was postulated to be involved in hydrogen 
bonding with the receptor (corresponds to the 7ti region in Fryer's model138). By using 
computer assisted modelling the geometry of these sites was examined in relation to the 
proposed model.
Fryer138 postulated that the "A" ring is spatially related to the proton 
accepting group (tci) in that n\ lay above the plane of the aromatic nucleus A whereas the 
relative distance from the centre of "A" ring to 7ti can change (see Chapter VII - 4.2, 
Figure 1).
a The author is grateful to Dr. M.G. Wong of Victorian College of Pharmacy, Melbourne, Victoria, for 
this part of the work.
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The structure of one of the low-energy conformation of 6-benzylthio-3- 
methoxy-2-phenylimidazo[l,2-&]pyridazine (V U I. 1, Figure 10) was used in this study. 
Figure 13 shows the potential proton accepting centre, N12 below the plane of the 2- 
phenyl group. Moreover, N15, N16 and 021 are above the plane of this 2-phenyl ring. 
Rotation about the C l4 - C13 - C8 - C9 (n )  torsion angle however revealed that the 
barrier to this rotation is low (<10 kcal mol'1) (by using the real-time energy scanning 
capability of the Chem-X programme which monitors changes in the Van der Waals 
repulsion energy of a molecule as a bond within it is rotated). This observation is 
consistent with the energy contour plot shown in Section 1.2, Figure 3, in that rotation 
around Xi is free when X2 is between 85° and 110° or between 210° and 260°. 
Therefore, N12, N15, N16 and 021 will only lie above the plane of the 2-phenyl ring 
when this phenyl ring is rotated away from planarity i.e. when Xi (C14 - C l3 - C8 - C9) 
* 0° or 180°.
Fig. 13 Structure of one of the low energy conformations of compound V III . 1. The 
view above shows tne imidazo[l,2-fc]pyridazine bicyclic ring system almost 
perpendicular to the plane of this page. The 2-phenyl and 3-methoxy groups are 
out of the plane of the page.
213
Fryer138 also proposed that the variability in distance of "A" to the proton 
accepting group (7Ci) is related to in vivo activity, and that compounds that exhibit 
antagonist or inverse agonist activity usually contain a mid "A" to 7ti distance of not less 
than 6 Ä whereas compounds that exhibit agonist activity maintain a shorter mid "A" to 
K\ distance. In compound V III . 1, the distance from the centre of the 2-phenyl ring to 
the pyridazine atom, N16, was measured as 6.1 Ä using the "geometry calculate" 
capability of Chem-X programme. Thus, the potential proton accepting centre, N12 (see 
also Chapter VII - 4.2) is less than 6 Ä from the centre of the 2-phenyl group. This 
observation suggests that compound VIII . 1 may be a potential agonist at the 
benzodiazepine receptors.
214
Vin - 2 Statistical analysis of structure-activity relationships 
V m -2.1 Introduction
The use of model systems to extend our understanding of structure-activity 
relationships (SAR) has come a long way since Meyer and Overton suggested the use of 
oil-water partition coefficients to model the partitioning of simple neutral organic 
compounds into nerve tissues and thus provide a basis for the study of narcotic 
action.283’284 Further advance was made when Hammett formulated the G constants to 
account for the electronic effects of substituents on chemical reactivities and physical 
properties of organic compounds.285’286 This was followed by the formulation of 
constants for the steric effects of substituents in organic reactions by Taft,287’288 and for 
molar refractivity (MR) by Pauling and Pressman289 for the correlation of dispersion 
forces of substituents in biochemical reactions. In 1962, the octanol-water hydrophobic 
parameters were formulated by Hansch and coworkers290’291 who also initiated the 
concept of quantitative structure-activity relationships (QSAR).
Since that time, QSAR analyses by the Hansch approach have been widely 
used292-295 on diverse biologically active compounds. QSAR analysis was shown to be 
an effective tool in the optimization of drug design,296»297 it provided insights into 
molecular mechanisms of action298 and aided the understanding of bioavailability and 
bioconcentration in various fields of pesticide and plant growth regulation research 299 
More recently, it has been applied to the study of ligand-receptor interaction300 and the 
mapping of receptor sites.301
In the present work several imidazo[l,2-b]pyridazine derivatives were 
prepared to test for in vitro binding at benzodiazepine receptors. In the earlier chapters of 
this thesis, a qualitative SAR study was carried out in which substituent effects were 
examined in different series of compounds (Chapter II - VII). It was also proposed that 
factors other than the electron-donating or electron-withdrawing properties of each 
substituent have a bearing on the binding activities of these compounds.258 In this 
chapter is reported, a Hansch-type analysis of substituent effects on binding affinity. 
This was performed to examine factors which may contribute to binding activity. Due to
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the fact that the number of compounds in each subset3 of compounds available for such 
a study was limited, an extensive QSAR study was not possible. Nevertheless, it was 
considered that there were adequate data to identify the contribution of other factors, if 
any, to binding affinity.
VIII - 2.2 A Hansch-type analysis of structure-activity relationships
Although a variety of parameters are now employed to quantify bioactivity, 
the present work is limited to a discussion of the Hammett G constant,285»286 the 
hydrophobic parameter 7t291 and the molar refractivity (MR).245
The Hammett G constant of a substituent is defined by the equation :
G = log Kx - log Kh
where Kh is the ionization constant of benzoic acid in water and Kx is that of a 
substituted benzoic acid.286 A positive sign for g  indicates electron-withdrawal by the 
substituent. The hydrophobic parameter n is defined in terms of the partition coefficient 
P between octanol and water :
K = log Px - log Ph
where Ph is the partition coefficient for benzene and Px is that for a substituted 
benzene.290»291»302 A positive value for n means that, relative to H, the substituent 
favours the octanol phase. Molar refractivity is defined as :
MR = [(n2-1) / (n2+l)] (MW / d) cm3
where n is the index of refraction, MW is molecular weight and d is density. Since n 
does not vary much for organic compounds, MR is a measure of volume. However, 
Hansch also reported300 that the hydrophobic parameters from the MR and the octanol- 
water system give a rough characterization of the polar and hydrophobic areas of a 
receptor surface.
a A subset is defined as a group of similar compounds with subslructural variation at the same position 
on the imidazo[l,2-6]pyridazine.
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The binding affinities of some compounds prepared in the previous chapters 
were examined for correlation using the above parameters. Thus substituent effects in 
the 2-phenyl group of 6-chloro-3-methoxy-2-phenylimidazo[l,2-/?]pyridazine (Table 
VIII - 1, Subsets A and B), 3-methoxy-6-(2'-methoxyphenoxy)-2-phenylimidazo- 
[l,2-&]pyridazine (Subset C), 6-benzythio-3-methoxy-2-phenylimidazo[l,2-fr]pyridazine 
(Subset D) as well as 3-methoxy-6-(3,-methoxybenzylthio)-2-phenylimidazo-[l,2-&]- 
pyridazine (Subsets E and F) were investigated. Data from compounds of other series 
prepared in this work were not included because of the small number of compounds. In 
addition, substituent effects in the 6-phenoxy group of 3-methoxy-6-phenoxy-2- 
phenylimidazo[l,2-ö]pyridazine (Table VIII - 2, Subsets G and H) have been compared 
with similar substructural variations in the 6-benzylthio group of 6-benzylthio-3- 
methoxy-2-phenylimidazo[l,2-Z?]pyridazine (Subsets I and J).
The IC50 values for inhibition of specific binding of [3H]diazepam by these 
compounds (Tables II - 1, III - 1, IV - 1 and IV - 2) were converted to apparent Ki 
values (see Table VIII - 1) according to the equation Ki app = IC50 /  (1+C/Kd), where C 
is the concentration of [3H]diazepam (0.7 nM) and Kd = apparent dissociation constant of 
the [3H]diazepam/benzodiazepine receptor complex (3.5±0.1 nM). Ki app is an 
inhibition constant, a measure of displacing potency. The smaller the value for Ki app the 
higher the binding potency. Therefore, in the following correlation equations, a positive 
coefficient for c values indicates that electron-donating substituents favour binding.
Considering the small number of sample points in each subset, we decided to 
pool the binding data (all 65 sample points) for a regression analysis.a Since our 
binding data were obtained under similar conditions following the same radioligand- 
receptor binding assay, it was considered appropriate that the data be pooled and to fit 
additional parameters to account for systematic differences. The analysis involved model 
formulation, the fitting of the model to the experimental data and checking the model for 
inadequacies. In our case, three test points (out of 65 compounds) were found to be 
inconsistent with all the others, namely, compounds number 33, 34 and 65 (Tables VIII - 
1 and VIII - 2). Hence, they were excluded from subsequent correlation analysis. This
a The author is grateful to Mr R. Cunningham, Statistical Consultant, Statistics Department, 
Australian National University.
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procedure led to a reduction in the residual variance from 0.086 to 0.045. The regression 
model was of the form,
log Ki app = ßo + ß lG + $2K + ßßMR
where the coefficients ßo, ßi, ß2 and ß3 were allowed to differ according to the specific 
series from which the compounds came. The electronic parameter a, the hydrophobic 
parameter n and molar refactivity MR were taken from the aromatic substituent constants 
formulated by Hansch and coworkers.245
Compounds of subsets A, C, D and E (Table VIII - 1) were pooled. The 
regression analysis of log Ki app on a p, k and MR yielded equations 1, 2, 3 and 4, 
respectively.
log Ki app = 2.583 (± 0.145) + 0.543 (± 0.179) a  - 0.306 (± 0.089) n
-  0.034 (± 0.024) MR. ...(1)
log Ki app = 1.424 (± 0.258) + 0.386 (± 0.307) a  - 0.308 (± 0.089) n
+ 0.069 (± 0.048) MR. ...(2)
log Ki app = 0.968 (± 0.286) + 1.151 (± 0.368) a  - 0.306 (± 0.089) n
+ 0.104 (±0.046) MR. ...(3)
log Ki app = 0.534 (± 0.258) + 2.154 (± 0.396) a  - 0.306 (± 0.089) n
+ 0.139 (±0.047) MR. ...(4)
Equations 1, 2, 3 and 4 accounted for 92% of the variance in log Kj app.
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Table VIII -1  The binding activities for some derivatives of 3-methoxy- 
imidazo[l,2-Z>]pyridazinesa
6 N 4
Subset Compound 
number
R 1 R2 Ki app IC50(nM) Equation
used
Obs. Calcb
1 Cl H 2.80 772 424
2 Cl Me-/? 2.09 148 162
3 Cl OMe-/? 2.35 167 180
A 4 Cl CI -p 2.24 207 232 1
5 Cl Br -p 2.34 264 168
6 Cl F -p 2.59 462 418
7 Cl NO 2-p 2.97 1116 838
8 Cl NH2-/? 2.53 403 314
9 Cl H 2.80 772 537
10 Cl Me-m 3.03 1284 562
B 11 Cl OMe-m 2.90 960 562 5
12 Cl F - m 2.68 575 468
13 Cl NO 2-m 2.71 616 398
14 Cl NH2-m 2.70 609 575
15 O C ö^O M e-o H 1.77 70 38
16 OCöH^OMe-o Me-p 1.73 64 45
C 17 OCgICtOMe-o F-p 1.40 30 35 2
18 OCßFL^OMe-o NH2-p 1.98 115 100
19 OCgF^OMe-ö N 0 2-p 2.41 312 250
20° SCH 2Ph H 1.26 22 14
21 SCH 2Ph Me-p 1.20 19 19
D 22 SCH2Ph OMe-p 1.60 48 36 3
23 SCH 2Ph Cl-p 1.60 48 53
24 SCH 2Ph Br-p 2.12 137 94
25 SCH 2Ph NH2-p 1.26 22 17
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Table Vin - 1 Continued
Subset Compound R 1 R2 log Kj app IC5 0 (nM) Equation
number used
Obs. Calcb
26 SCE^CßHqOMe-m H 0.92 1 0 6
27 S CH^C^HqOMe-m Me-p 1.15 17 7
E 28 SCH2 C6 H4 OMe-m OMe-p 0.96 1 1 13 4
29 SCH2 C6 H4 OMe-m F-p 0.64 5 7
30 S Ct^CgH ^O M e-m CF3-p 2.24 208 160
31 SCF^CßH^OMe-z/z Me-m 1.54 42 7
32c SCH^CßH^OMe-m H 0.92 1 0 1 1
3 3 d S CF^CßH^OMe-m OMe-m 1.15 177 -
F 34d SCH2 C6 H4 OMe-m F -m 0 . 8 8 9 - 6
35 SCE^CgF^OM e-m CF 3 -m 2 . 1 1 156 179
36 SCH2 C6 H4 OMe-m N 0 2-m 3.48 3020 1118
37 S CH2 C6 H4  OMe-m NH2-m 0.62 5 4
a IC50 values from Tables II - 1, III - 1, IV - 1 and IV - 2.
b The values for compounds numbered 1-8, 9-14, 15-19, 20-25, 26-30, 31-37 have been calculated 
using equations 1,5,2,3,4,6, respectively.
c Values for the parent compounds from each series are reported more than once for comparison 
purposes.
d These values were excluded for derivation of regression equations because they were inconsistent test 
points observed in the initial pooled analysis of variance.
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Then compounds of subsets B and F (Table VIII - 1) were pooled and the 
regression analysis of log Ki app on Gm, n and MR gave equations 5 and 6, respectively.
log Ki app = 2.732 (± 0.139) - 0.188 (± 0.417) Gm ...(5)
log Ki app = 1.034 (± 0.242) - 2.837 (± 0.714) Gm ...(6)
The two equations above accounted for 89.5% of the variance in log Ki app. MR and n 
are not significant regressers for equations 5 and 6. The standard error mean (s.e.m.) for 
Qm in equation 5 is however relatively larger than the coefficient of <3m.
In a similar manner, compounds of subsets G and I (Table VIII - 2) were 
pooled to yield equations 7 and 8 whereas subsets H and J (Table VIII - 2) gave 
equations 9 and 10.
log Ki app = 2.940 (± 0.168) + 0.894 (± 0.522) op + 0.402 (± 0.125) n
+ 0.015 (±0.021) MR. ...(7)
log Ki app = 0.897 (± 0.284) - 2.174 (± 0.747) Gp + 0.402 (± 0.125) k
+ 0.089 (± 0.036) MR. ...(8)
log Ki app = 3.146 (± 0.168) + 0.563 (± 0.278) Gm - 0.066 (± 0.129) tc
- 0.064 (± 0.020) MR. ...(9)
log Ki app = 1.043 (± 0.718) - 0.688 (± 0.481) Gm + 0.466 (± 0.224) n
- 0.059 (± 0.035) MR. ...(10)
Equations 7 and 8 accounted for 95% of the variance in log Ki app whereas equations 9 
and 10 accounted for 93% of the variance in log Ki app. The s.e.m. for the Gp term in 
equation 8 is relatively large, however this variable is a significant regresser for equation 
8. Likewise the s.e.m. for the k term in equation 9 is a significant regresser.
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Table Vin - 2 The binding activities for some derivatives of 3-methoxy-2- 
phenylimidazo[l,2-£]pyridazinesa
R1
5
Subset Compound R 1
number
log Ki app IC5 0 (nM) 
Obs. Caleb
Equation
used
38 OC5 H4 CI-/7 3.57 4480 2637
39 (Xy^SMe-p 2.98 1140 1146
G 40c OC6 H4 2.97 1 1 2 0 1 0 1 0 7
41 OCöH^OMe-p 2.92 988 449
42 OCfcfTiMe-p 2.83 816 1019
43 c OPh 2.97 1 1 2 0 1443
44 OCgfi^Me-m 3.09 1490 617
45 O C ö^O M e-m 2.58 461 623
H 46 OCy^Cl-m 3.07 1400 1007 9
47 OCßF^CFj-m 3.09 1480 1231
48 OC5 H4 NO 2 -/W 3.26 2 2 0 0 1497
49 OC6 H4 NH2-m 3.00 1190 743
50 2.09 149 138
51 SCH 2 C6 H 4 Cl-p 1.72 63 58
52 SCH 2 C6 H4 Me-jp 1.74 6 6 54
53 SCH2 C6 H4 0 Me-/? 1 . 6 6 55 52
I 54 SCH 2 C6 H 4 N H 2-p 2.70 603 380 8
55 S CH 2 C6 H4 N 0 2-/? 1.41 31 24
56 s c h 2 c 6 h 4 n h 2-/> 1 . 0 0 1 2 1 2
57 SCH 2Ph 1.26 2 2 1 2
58 SCH 2 C 6 H 4 Cl-m 1.61 49 34
59 SCH 2 C6 H4 Me-m 1.48 36 56
J 60 SCH 2 C6 H4 N M e2-m 2.30 239 164
61 SCH 2 C6 H 4 N 0 2-m 0.82 8 9 1 0
62 SCH 2 C6 H 4 N H 2-m 1 . 1 0 15 1 0
63 SCH 2 C 6 H4 C F3-m 1.73 64 33
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Table V III -2 Continued
Subset Compound 
number
R1 log Kj app IC50(nM) Equation
used
Obs. Caleb
J 64 S C^Cgf^OMe-m 0.92 10 15 10
65d SCH2Ph 1.26 22
a IC50 values from Tables III - 1 and IV - 1.
b The values for compounds numbered 38-42,43-50, 50-57, 58-64 have been calculated using equations 
7,9,8,10, respectively.
c Values for the parent compounds from each series are reported twice for comparison purposes. 
d This value was excluded for the derivation of equation 10.
The common feature of equations 1 - 4 is that all the three physical 
parameters, a p, n and MR are required to quantify binding affinity. Moreover, the 
coefficient of n is the same in all four equations. Although the numerical value of the 
coefficient of o is different in equations 1,2,3 and 4, a positive coefficient with a  is 
maintained in all of them. The MR factor is however, relatively less significant in 
equations 1 and 2 than in equations 3 and 4.
The positive coefficient for o shows that electron release by the para 
substituents favours binding of compounds from subsets A, C, D and E. However, the 
coefficient of the 0  term in equation 4 is ca. twice that in equation 3 which is relatively 
larger than that in equations 1 and 2. The latter appears to suggest that the relative order 
of electron-donating power of substituents necessary for enhanced binding affinity is 
different for each subset (or series) of compounds.
In equations 1,2,3 and 4, the negative coefficient for n suggests that 
lipophilic groups are beneficial for binding. The relative significance of the MR factor is 
lower compared to the a  and n terms, however, in equations 3 and 4, the positive 
coefficient of MR appears to imply interaction with a polar surface as well as the fact that 
bulky substituents are detrimintal to binding.
Despite the above analyses, it should be noted that other factors may also be 
involved in determining the binding affinity of these compounds to benzodiazepine
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receptors; the small number of compounds used in determining equations 1 - 4 does not 
provide a fully comprehensive QSAR study.
Equations 5 and 6 appear to suggest that the n and MR terms of meta 
subtituents in compounds from subsets B and F are not significant in determining 
binding activity. The coefficient of Gm is however significantly greater for compounds in 
subset F than in subset B. This suggests that the relative order of electron-donating 
ability necessary for enhanced binding is different in these two subsets. This may be due 
to the fact that compounds from subset F generally exhibit a higher binding activity than 
those of subset B.
From equations 7 and 8, it appears that all the three parameters Gp, n and MR 
are significant regressers for log Ki app. In addition, the coefficient of n is the same in 
these two equations. The positive coefficient for n also suggests that hydrophilic 
substituents on the para position of the aromatic group contribute to enhanced binding 
affinity. However, the relative electron-donating power of the substituent necessary for 
enhanced binding is slightly more significant in subset G than I. Although, the 
coefficient of MR is small, this physical parameter appears to be significant for 
quantifying binding activity.
Equations 9 and 10 which were derived for the meta substitution again 
suggest that the Gm, n and MR terms are significant for binding. However, the signs for 
the Gm terms are different from each other. In addition, the coefficient of the n term is 
less significant in equation 9 than it is in equation 10. The coefficient of MR is small in 
both equations.
As previously stated, the small number of compounds in each subset 
prevents a detailed quantitative SAR analysis. However, within the limits of the data 
available, the above analysis suggests that substituent effects on binding affinity of these 
compounds can be quantified by the electronic, hydrophobicity and molar refractivity(/.e. 
steric) properties of the substituent. This also implies that if the 2-phenyl group in the 
above imidazo[l,2-Z?]pyridazine derivatives binds at the 7t-region proposed by Fryer for 
his aromatic (or heteroaromatic) ring "A" (see Chapter I - 1.5) then the relative binding 
affinity at this receptor domain (cleft) may be dependent on the electronic, hydrophobic
224
and steric bulk of para substituents in the phenyl ring. In addition, if the 6-benzylthio or 
6-phenoxy group is involved with binding at an accessory site (see Chapter IV - 4.2) it 
appears that all the three physical parameters mentioned above are also significant is 
determining relative binding affinities.
The above correlation study of imidazo[l,2-Z?]pyridazine derivatives may be 
extended to include more compounds in a subset and hence improve the correlation 
equations. For example, equation 1 may be used to predict the activity of new 
derivatives (Table V in  - 3) whose substituents are characterized by constants both within 
and outside the range of substituent space span already explored. These compounds can 
then be synthesized, evaluated for binding activities and then incorporated into Subset A 
to derive a better correlation equation for directing the design of new, more active 
compounds. In this way, the formulation of a QSAR for each series of compounds can 
be improved and subsequently can be used to map the binding site(s) for derivatives of 
imidazo[ 1,2-Z?]pyridazines.
Table VTH - 3 The predicted binding activities for some 6-chIoro-3-methoxy- 
imidazo[l,2-£]pyridazines using equation 1.
7 V
" z - 
—
/
C l 6 N 4 3
5
X OMe
R 1 MRa Predicted IC5 0  (nM)
p-OCH2CH2CH3 1.05 -0.25 17.06 42
p-OH -0.67 -0.37 2.85 371
p-NM&2 0.18 -0.83 15.55 42
p-CN -0.57 0 . 6 6 6.33 1048
p-Ph 1.96 -0 . 0 1 25.36 16
P-SO2 CH3 -1.63 0.72 13.49 1240
a The values for these substituent constants were obtained from ref. 245.
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VIH - 3 Further pharmacological testing 
V m -3 .1  Introduction
In this section, further pharmacological testing on some derivatives of 
imidazo[l,2-ö]pyridazine are reported, including in vitro binding studies on the 
regulation by GABA of the binding of imidazo[l,2-Z?]pyridazines. Data on the 
interaction of these compounds with photoaffinity-labelled benzodiazepine receptors as 
well as the displacement of [3H]diazepam from kidney preparations (peripheral-type 
benzodiazepine receptors) are also included in a general discussion (The latter data were 
kindly provided by Dr. L.P. Davies of the Department of Behavioural Biology, Research 
School of Biological Sciences, The Australian National University, Canberra, A.C.T. 
2601). In addition, some preliminary in vivo testing results are given. These in vivo 
tests were performed by pharmacologists at F. Hoffmann La-Roche and Company, 
Basel, Switzerland.
VIII - 3.2 In vitro binding studies on some imidazo[l,2-£]pyridazines 
i Effect of GABA on the binding of imidazo[l,2-£]pyridazines
Benzodiazepines have been observed to enhance low affinity binding of 
radiolabelled GABA in vitro,303 while GABA enhances the binding of radiolabelled 
benzodiazepine agonists.39’41 Both effects arise from apparent changes in binding site 
affinity. Moreover it was also noted that the affinity of benzodiazepine antagonists was 
not altered in the presence of GABA.304’305 Thus, it was suggested306 that an 
experimental in vitro approach, to screen for agonist or antagonist drugs acting at 
benzodiazepine receptors, would be to measure the effect of GABA upon affinities of 
compounds which interact with benzodiazepine receptors. Initial studies306’307 were 
performed using benzodiazepine agonist radioligands but their interpretation was 
complicated by GABA altering the affinity of the radioligand itself, in addition to that of 
the compound under test. However, it was found that by using radiolabelled 
benzodiazepine antagonist ligands which are unaffected by GABA in their binding to 
benzodiazepine receptors (e.g. [3H]Ethyl ß-carboline-3-carboxylate or [3H]Ro 15-1788),
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a simple in vitro test could discriminate between compounds with potential agonist or 
antagonist activity.304»305 Thus, in well-washed brain membrane preparations (largely 
free of endogenous GABA), GABA increases the potency of benzodiazepine agonists as 
displacers of [3H]ethyl ß-carboline-3-carboxylate or [3H]Ro 15-1788 while not altering 
the potency of benzodiazepine antagonists.304’305
The present study reports the effect of GABA on some selected imidazo- 
[l,2-fr]pyridazine compounds as displacers of [3H]Ro 15-1788 from rat brain 
preparations.
Methods
Washed synaptosomal membranes from whole rat brain were isolated and 
prepared as described in Chapter II - 5.3. Binding of [3H]Ro 15-1788 (0.7±0.1 nM) 
(New England Nuclear, 87.5 Ci/mmol) was performed as follows. Resuspended 
membranes (0.6-0.8 mg protein) were incubated with [3H]Ro 15-1788 in Tris-HCl, pH 
7.4 at 2° for 45 minutes, in the presence or absence of 100 pM GABA; incubations were 
performed in triplicate with 4-6 separate concentrations of each test compound. Non­
saturable binding of [3H]Ro 15-1788 was assessed using 10 pM diazepam, and typically 
was only 0.9% of total binding. Membranes were collected by filtration under vacuum 
on glass-fibre filters (Whatman GF/B, 2.5 cm) and washed with 12 ml ice cold buffer. 
Filters were placed in scintillation vials with 1 ml of water and 8 ml of toluene/Triton X- 
100 scintillation fluid; bound radioactivity was determined using conventional 
techniques.
The IC50 values (concentration producing 50% inhibition of binding) were 
calculated as reported in Chapter II - 5.3. In this preliminary screen, IC50 values were 
obtained from one determination using 4-5 concentrations of test compound, each 
concentration being carried out in triplicate. Results are as shown in Table VIII - 4 
(together with literature values for some benzodiazepine agonists and antagonists).
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Table Vin - 4 Inhibitors of [^H]Ro 15-1788 binding by various compounds: effect 
of GABA
6 ^
N 4 
5
Imidazo[l ,2-6]pyridazine
Compounds and substituents
IC50 (nM)
Ratio of IC50
Control +GABA (100 (iM) values
Imidazo[l ,2-6]pyridazine 
3-0Me-6-Cl-2-C6H4N02-m (H . 3i) 2420 660 3.7
3-0 Me-6-SCH2C6H4 0 Me-m-2-C6H4F-p (IV . Ill) 46 16 2.9
3-0 Me-6 -NHCH2C6H4 0 Me-m-2-Ph (V I. 9d) 7 3 2.3
3-CH2NHCOPh-6-F-2-C6H4Me-p (VII. 4c) 42 19 2.2
CL 218 875 230 140 1.6a
Diazepam 8.5±0.2 3.7±0.2 2.3b
Chlordiazepoxide 1440±150 750+50 1.9b
Ethyl ß-carboline-3-carboxylate 2.8±0.1 2.6±0.1 0.93b
a Reference 208 gives 1.7 (PcO.OOl using Student's t-test) from 8 determinations. 
b From reference 208.
Results and discussion
The triazolopyridazine CL 218,872 inhibited [3H]Ro 15-1788 binding, with 
IC50 values of the same order of potency as found for the inhibition of the agonist 
[3H]diazepam. This potency was increased by GABA. This is in accord with results 
showing that GABA can increase the binding of [3H]CL 218,872 to CNS receptors.308
The inhibitory potencies of the selected imidazo[l,2-b]pyridazines upon 
[3H]Ro 15-1788 binding was significantly enhanced by GABA (Table VIII - 4). The 
relative order of enhancement is similar or greater than that reported303 for diazepam. 
This result suggests that these imidazo[l,2-Z?]pyridazine derivatives may be potential 
agonists at benzodiazepine receptors. This is consistent with the earlier prediction 
(Section 1.3) based on the model proposed by Fryer138 for benzodiazepine agonists.
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ii Interaction with photoaffinity-labelled benzodiazepine receptors
Evidence from research on benzodiazepine receptors suggests that synaptic 
membranes contain proteins (or protein complexes) with four benzodiazepine receptor 
sites in close spatial proximity.309'311 Irreversible uv-photoaffinity labelling of one of 
these sites with flunitrazepam appears to induce a conformational change in the 
neighbouring sites which is manifested by a decreased affinity of these remaining sites 
for benzodiazepine receptor agonists but not for antagonist.312"314 Thus, it was forseen 
that by comparing the potency of drugs as displacers of [3H]Ro 15-1788 before and 
after photoaffinity labelling with flunitrazepam, the efficacy of a benzodiazepine receptor 
ligand could be predicted312-314 i.e. it could be ascertained whether a compound had an 
agonist-like or antagonist-like interaction with the receptors.
However, later studies by Brown and Martin315 as well as Davies and 
coworkers316 showed that such a methodology was not a suitable screening method 
since the assay could not distinguish between non-benzodiazepine compounds which 
other assays suggested had agonist- or antagonist-like interactions at benzodiazepine 
receptors. Thus they proposed that changes in the affinity of ligands for the 
benzodiazepine receptor produced by photoaffinity labelling appeared to be related to 
their chemical structure rather than to their pharmacological profile.315
The interaction of two derivatives of imidazo[l,2-£]pyridazine (Table VIII - 
5) with [3H]Ro 15-1788 binding sites in rat brain membrane preparations was examined 
before and after uv-photoaffinity labelling of a proportion of the sites with flunitrazepam. 
The results of this study were kindly provided by Dr. Davies. The procedure is similar 
to that reported in his earlier work.316
The potency of 2-(4'-fluorophenyl)-3-methoxy-6-(3"-methoxybenzylthio)- 
imidazo[l,2-&]pyridazine (IV . Ill) and 3-benzamido-6-fluoro-2-(4'-methylphenyl)- 
imidazo[l,2-b]pyridazine (VII . 4c) and diazepam as inhibitors of [3H]Ro 15-1788 
binding in photolabelled and control membranes is given in Table VIII - 5. Values for 
other compounds obtained from the literature316 are included for comparison. The IC50 
values were determined using 5-6 concentrations of inhibitor and incubations were 
preformed in triplicate. Data are from a single experiment.
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Results and discussion
The benzodiazepine receptor agonist, diazepam, was very much weaker (over 
60 fold) in displacing [3H]Ro 15-1788 from photoaffinity labelled membranes than from 
control membranes. In contrast, the benzodiazepine receptor antagonist compounds 
(propyl ß-carboline-3-carboxylate and Ro 15-1788) were approximately equipotent in 
both control and photolabelled membrane preparations.
The affinity of compound VII. 4c was not altered after photoaffinity labelling 
of the membranes. Similarly, the affinity of compound IV . I ll was not significantly 
altered. As discussed in the previous section (effects of GABA), results from the 
GABA-shift studies provide evidence that compounds IV . Ill and VII. 4c are likely to 
be benzodiazepine receptor agonists since they undergo a significant increase in their 
receptor binding potency in the presence of GABA. The observation of a GABA-shift 
appears to be a common property of benzodiazepine receptor agonists over a wide range 
of chemical classes. However, as discussed in the introduction to this section, the 
usefulness of the photoaffinity-labelling procedure for differentiating benzodiazepine 
receptor agonists and antagonists appears to be confined to the benzodiazepine class of 
drugs and is generally not applicable to different chemical classes which have 
benzodiazepine receptor binding activity. Thus the lack of a significant decrease in the 
potency of IV . I ll and VII . 4c in binding to photoaffinity-labelled membranes as 
compared with control membranes cannot be taken as contradicting the GABA-shift 
results.
It appears that the imidazo[l,2-&]pyridazines may bind to benzodiazepine 
receptors in a somewhat different manner to the 'classical' benzodiazepine agonists e.g. 
diazepam. Thus, there is a possibility that they may have a different pharmacological 
activity profile in vivo.
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Table VTH - 5 Potency of various compounds as inhibitors of [^H]Ro 15-1788
binding in photolabelled and control membranes from rat brain
8 1
7
6 ^  --------
N 4 
5
2
3
Imidazo[ 1,2-6]pyridazine
Compounds and substituents
IC50 (nM)
Ratio of IC50 
valuesControl
Membranes
Photolabelled
membranes
Imidazo[ 1,2-]pyridazine
3-OMe-6-SCH2C6H4OMe-m-2-C6H4F-p (IV . Ill) 40 70 1 .8
3-CH2NHCOPh-6-F-2-C6H4Me-p (VII. 4c) 76 76 1 .0
Diazepam 33 2 2 0 0 66.7
Ro 15-1788a 2.24±0.07 1.75±0.08 0.78
Propyl ß-carboline-3-carboxylatea 1.31±0.06 0.94±0.04 0.72
a From reference 316 where mean values ± S.E.M. are from 3 to 4 separate experiments.
iii Interaction with peripheral-type sites
Braestrup and Squires227 *317found specific high affinity binding of 
[3H]diazepam to peripheral tissues, most markedly in kidney, liver and lung. The 
binding sites on kidney membranes, although possessing a high affinity for 
[3H]diazepam (Kd ~ 40 nM, which is only ten times less than for brain membranes) 
showed fundamentally different pharmacological specificity from the brain as discussed 
in earlier chapters (Chapter I - 1.3).
The results of the displacement of [3H]diazepam from specific binding sites 
in the kidney (mitrochondrial membranes) by some derivatives of imidazo[l,2- 
b]pyridazines are given in Table VIII - 6. These experiments were kindly carried out by 
Dr L.P. Davies. The [3H]diazepam assay conditions are as described in Chapter II - 5.3 
but without the addition of GABA. The IC50 values were determined from one 
experiment using 4-5 concentrations of the test compounds; assays were carried out in
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triplicate. These results are compared with IC 50 values for displacem ent of 
[3H]diazepam from rat brain membranes as determined in earlier studies.
The 3-alkoxyimidazo[l,2-£>]pyridazines (Table VIII - 6) are poor inhibitors 
of specific [3H]diazepam binding to kidney (mitrochondrial membrane preparations), that 
is, to the peripheral type benzodiazepine receptors. Although 3-benzamidomethyl-6- 
fluoro-2-(4'-methylphenyl)imidazo[l,2-£]pyridazine exhibited an IC50 value of 168 nM, 
it is about twentyonefold less potent than observed in the CNS (IC50 8 nM).
The results shown in Table VIII - 6 also indicate that the order of 
displacement potency by the imidazo[l,2-&]pyridazines in peripheral-type sites (kidney) 
differs from that in CNS-type sites (brain).
Table VET - 6 Differential inhibition of [3H]diazepam by some compounds in
brain and kidney
6 ^  --------  3
N 4 
5
Imidazof 1,2-b]pyridazine
Inhibition of specific [3H]-
Compound and substituents diazepam binding, IC5o(nM)
Brain Kidney
Imidazo[ 1,2-b]pyridazine
3-CH2NHCOPh-6-F-2-C6H4Me-p (V II. 4c) 8 168
3-OMe-6-SCH2C6H4OMe-m-2-C6H4F-/? (IV . Ill) 5 1129
3-OMe-6-NHCH2C6H4OMe-m-2-Ph (V I. 9d) 2.5 812
3-OMe-6-OCH2C6H4OMe-m-2-Ph (V . 14b) 6 1082
Ro 5-4864a 163,000 3
Clonazepama 5 4595
a Values obtained from reference 78.
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VIII - 3.3 Results for some in vivo pharmacological tests
The following in vivo tests were carried out by workers at F. Hoffmann La- 
Roche and Company, Basel, Switzerland; results are recorded in Table VIII - 7. The 
pharmacological tests conducted included the measurement of anticonvulsant and of anti­
conflict activities. In the anticonvulsant test, convulsions were induced in the animals by 
administration of pentylenetetrazole10 (PTZ) while the anti-conflict activity was 
determined by recording increases in punished responding in a Geller-Seifter type 
conflict paradigm.318’319 In the preliminary tests, three representative compounds were 
examined, namely, 3-methoxy-6-(3'-methoxybenzylamino)-2-phenylimidazo[l,2-/?]- 
pyridazine (VI . 9d), its 6-(3'-methoxybenzyloxy) analogue (V . 14b) and 2-(4'- 
fhiorophenyl)-3-methoxy-6-(3'-methoxybenzylthio)imidazo[l,2-/?]pyridazine (IV . 111).
Table VTII-7 Preliminary in vivo pharmacological evaluation of some 
derivatives of imidazo[l,2-£]pyridazines
Parameter Com pound V I . 9d Com pound V . 14b C om pound IV . I l l
Free Behavior
O bservation up no effect at no effect at no effect at
to 24 h (m ouse) 30 m g/kg, po 30 m g/kg, po 30 m g/kg, po
Prevention of PTZ-
induced tonic 0/10 at 10 m g/kg, po 0/10 at 10 m g/kg, po 0/8 a t 10 m g/kg, po
convulsions (m ouse) 0/10 a t 10 m g/kg, po 0/10 at 100 m g/kg, po 0/8 a t 100 m g/kg, po
Prevention of PTZ- E D io  = 2.2 m g/kg, po
induced tonic E D 50 = 4.9 m g/kg, po 0/10 at 10 m g/kg, po 0/8 at 10 m g/kg, po
convulsions (rat) ED90 = 10.8 m g/kg, po 5/10 at 100 m g/kg, po 0/8 a t 100 m g/kg, po
C onflict test inactive at inactive at inactive at
(mouse) 3,10,30 m g/kg, po 1,3,10,30 m g/kg, po 1,3,10,30 m g/kg, po
Conflict test active at
(rat) 0 .5 ,1 ,5 ,10 m g/kg,po not tested not tested
(no side-effects seen)
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3-Methoxy-6-(3,-methoxybenzylamino)-2-phenylimidazo[l,2-£]pyridazine 
(VI. 9d) exhibited high in vitro affinity to benzodiazepine receptors (IC50 2.5 nM, from 
earlier test), whereas in the in vivo tests, it showed biological activity in rats (but 
interestingly not in mice!). It also prevented PTZ-induced tonic convulsions and quite 
potently increases punished responding in the conflict paradigm at doses at which no 
side-effects were observed. The second compound, 3-methoxy-6-(3'-methoxy- 
benzyloxy)-2-phenylimidazo[l,2-£]pyridazine (V . 14b, IC50 6 nM) exhibited lower 
affinity to the receptor and was weaker than compound VI . 9d in preventing PTZ- 
induced tonic convulsions in rats. On the other hand, 2-(4'fluorophenyl)-3-methoxy-6- 
(3"-methoxybenzylthio)imidazo[l,2-Z?]pyridazine (IV . Ill, IC50 5 nM) showed no 
biological activity in these preliminary tests.
From the above results, 3-methoxy-6-(3'-methoxybenzylamino)-2-phenyl 
imidazo[l,2-£]pyridazine (VI . 9d) appears to be a lead compound with respect to 
receptor agonist activity. In a continuous avoidance performance test in monkeys, no 
impairment was observed at 10 or 30 mg/kg p.o. of compound VI . 9d. The dose 
separation between desired effects (anticonflict, anticonvulsant) and such side effects and 
motor impairment, relaxation and sedation generally appeared greater for compound V I. 
9d than for diazepam.
In view of the receptor binding potency of compound IV . I ll and evidence 
from in vitro studies of possible agonist activity, it will be of interest to study this 
compound further to see whether it has an unusual pharmacological profile or whether its 
lack of in vivo activity is due to pharmacokinetic reasons, that is, lack of CNS 
penetration or rapid metabolism.
VIII - 3.4 Conclusion
Although all target chemicals synthesized in this work were screened as 
inhibitors of [3H]diazepam from rat brain homogenates, only some of the respresentative 
compounds were tested in in vivo pharmacological tests. Preliminary in vitro binding 
studies (Section 3.2i) however appear to suggest that the imidazo[l,2-£]pyridazines may 
be potential agonists at benzodiazepine receptors.
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Nevertheless, it will be interesting to see the results of other pharmacological 
screening tests on 3-methoxy-6-(3'-methoxybenzylamino)-2-phenylimidazo[l,2-&]- 
pyridazine (V I. 4d). If it shows a useful activity profile in vivo with reduced sedative 
and other side-effects, several derivatives from this series which have been synthesized 
in this work should be submitted to relevant pharmacological testing.
Further work is envisaged to involve the syntheses of azaindolizines with 
varying numbers of nitrogen atom(s) in the 6- and in the 5-membered rings, as the 
heterocyclic nucleus; and carrying suitable substituents found to be beneficial in the 
imidazo[l,2-Z?]pyridazine bicyclic system. It is therefore hoped that by probing for the 
pharmacophore at the benzodiazepine receptors with compounds which lack the 
benzodiazepine structure, a selective activity (e.g. antianxiety) might then be achieved by 
partial intrinsic activity at the receptor complex.
It will also be interesting to further examine the relevance of the distance of 
the nitrogen atom at position one (of the imidazo[l,2-Z?]pyridazine system) from the 
centre of the 2-phenyl group (see Section 1.3) to in vivo activity. Therefore, the 
synthesis of imidazo[l,2-£]pyridazines with variability in the above distance, is 
envisaged. These compounds should then be examined for antagonist or inverse agonist 
activity at benzodiazepine receptors.
Future work will need to investigate the selectivity of these compounds for
BZRi and BZR2 sites in the CNS.
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